<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637869</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-5415</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>COVID-19 hospitalization and mortality in community-dwelling racially and ethnically diverse persons living with dementia.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/jgs.18230</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Community-dwelling persons living with dementia (PLWD) are vulnerable to COVID-19 infection, severity, and mortality due to the high prevalence of comorbidities, reliance on caregivers, and potential inability to employ risk reduction measures, among other factors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used a retrospective cohort of Medicare Fee-For-Service beneficiaries enrolled from January 2018 to September 2020 (n&#xa0;=&#xa0;13,068,583), a comparison cohort from January 2019 to April 2021 (n&#xa0;=&#xa0;13,250,297), and logistic regression to estimate the effect of dementia on COVID-19 hospitalization and mortality in community-dwelling older persons.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">COVID-19 diagnoses were higher among persons living with dementia (PLWD) than those without dementia. Conditional on COVID-19 in the 2020 cohort, White PLWD were at higher risk of hospitalization compared to White persons without dementia (aOR 1.31, 95% CI: 1.26-1.36) and marginal for Black PLWD (aOR 1.10, 95% CI: 1.01-1.20), no significant differences were found within other racial/ethnic groups. PLWD were 1.8 times (aOR 1.78, 95% CI: 1.72-1.84) more likely to die within 30&#x2009;days of COVID-19 on average. Within racial/ethnic groups, the estimate for White PLWD, compared with White persons without dementia, was highest (aOR 2.01, 95% CI: 1.92-2.10), followed by Black PLWD (aOR 1.55, 95% CI: 1.41-1.70), and smallest among Hispanic PLWD (aOR 1.37, 95% CI: 1.24-1.50). PLWD hospitalized with COVID-19 were 1.6 times (aOR 1.59, 95% CI: 1.52-1.67) more likely to die within 30&#x2009;days than similar persons without dementia. Estimates from the 2021 cohort, when vaccines were available to older persons, were similar to those in 2020.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Community-dwelling PLWD experienced worse outcomes after a COVID-19 diagnosis than their counterparts without dementia. Results demonstrating higher mortality, but not hospitalization rates, for all races/ethnicities except White PLWD suggest there may have been differential care/treatment that point to potential health care system inequities that persisted into 2021. Understanding the mechanisms underlying these differences may improve ongoing care for community-dwelling PLWD.</AbstractText><CopyrightInformation>&#xa9; 2023 The American Geriatrics Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thunell</LastName><ForeName>Johanna A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0003-3361-4933</Identifier><AffiliationInfo><Affiliation>Price School of Public Policy, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferido</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zissimopoulos</LastName><ForeName>Julie M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Price School of Public Policy, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AG055401</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24AG045061</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">disparities</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637869</ArticleId><ArticleId IdType="doi">10.1111/jgs.18230</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>CDC updates, expands list of people at risk of severe COVID-19 illness [press release]. June 25, 2020. 2020.</Citation></Reference><Reference><Citation>Areosa Sastre A, Vernooij RW, Gonz&#xe1;lez-Cola&#xe7;o Harmand M, Mart&#xed;nez G. Effect of the treatment of type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev. 2017;6(6):CD003804.</Citation></Reference><Reference><Citation>Bunn F, Burn A-M, Goodman C, et al. Comorbidity and dementia: a scoping review of the literature. BMC Med. 2014;12(1):1-15.</Citation></Reference><Reference><Citation>Brown EE, Kumar S, Rajji TK, Pollock BG, Mulsant BH. Anticipating and mitigating the impact of the COVID-19 pandemic on Alzheimer's disease and related dementias. Am J Geriatr Psychiatry. 2020;28(7):712-721.</Citation></Reference><Reference><Citation>Kuo C-L, Pilling LC, Atkins JL, et al. APOE e4 genotype predicts severe COVID-19 in the UK biobank community cohort. J Gerontol Ser A. 2020;75(11):2231-2232.</Citation></Reference><Reference><Citation>Tousi B. Dementia Care in the Time of COVID-19 pandemic. J Alzheimers Dis. 2020;76(2):475-479.</Citation></Reference><Reference><Citation>Mok VC, Pendlebury S, Wong A, et al. Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future. Alzheimers Dement. 2020;16(11):1571-1581.</Citation></Reference><Reference><Citation>Atkins JL, Masoli JA, Delgado J, et al. Preexisting comorbidities predicting COVID-19 and mortality in the UK biobank community cohort. J Gerontol Ser A. 2020;75(11):2224-2230.</Citation></Reference><Reference><Citation>Wang Q, Davis PB, Gurney ME, Xu R. COVID-19 and dementia: analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement. 2021;17(8):1297-1306.</Citation></Reference><Reference><Citation>Tahira AC, Verjovski-Almeida S, Ferreira STJAs, Dementia. Dementia is an age-independent risk factor for severity and death in COVID-19 inpatients. 2021.</Citation></Reference><Reference><Citation>Hariyanto TI, Putri C, Arisa J, Situmeang RFV, Kurniawan A. Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2021;93:104299.</Citation></Reference><Reference><Citation>Zuin M, Guasti P, Roncon L, Cervellati C, Zuliani G. Dementia and the risk of death in elderly patients with COVID-19 infection: systematic review and meta-analysis. Int J Geriatr Psychiatry. 2021;36(5):697-703.</Citation></Reference><Reference><Citation>Saragih ID, Saragih IS, Batubara SO, Lin C-J. Dementia as a mortality predictor among older adults with COVID-19: a systematic review and meta-analysis of observational study. Geriatr Nurs. 2021;42(5):1230-9.</Citation></Reference><Reference><Citation>Liu N, Sun J, Wang X, Zhao M, Huang Q, Li H. The impact of dementia on the clinical outcome of COVID-19: a systematic review and meta-analysis. J Alzheimers Dis. 2020;78(4):1775-1782.</Citation></Reference><Reference><Citation>Chang M-H, Moonesinghe R, Truman BI. COVID-19 hospitalization by race and ethnicity: association with chronic conditions among Medicare beneficiaries, January 1-September 30. J Racial Ethn Health Disparities. 2020;2021:1-10.</Citation></Reference><Reference><Citation>Izurieta HS, Graham DJ, Jiao Y, et al. Natural history of coronavirus disease 2019: risk factors for hospitalizations and deaths among&gt;&#x2009;26 million US Medicare beneficiaries. J Infect Dis. 2021;223(6):945-956.</Citation></Reference><Reference><Citation>Kim J, Blaum C, Ferris R, et al. Factors associated with hospital admission and severe outcomes for older patients with COVID-19. J Am Geriatr Soc. 2022;70:1906-1917.</Citation></Reference><Reference><Citation>Gilstrap L, Zhou W, Alsan M, Nanda A, Skinner JS. Trends in mortality rates among Medicare enrollees with Alzheimer disease and related dementias before and during the early phase of the COVID-19 pandemic. JAMA Neurol. 2022;79:342-348.</Citation></Reference><Reference><Citation>Faes C, Abrams S, Van Beckhoven D, et al. Time between symptom onset, hospitalisation and recovery or death: statistical analysis of Belgian COVID-19 patients. Int J Environ Res Public Health. 2020;17(20):7560.</Citation></Reference><Reference><Citation>Wilson N, Kvalsvig A, Barnard LT, Baker MG. Case-fatality risk estimates for COVID-19 calculated by using a lag time for fatality. Emerg Infect Dis. 2020;26(6):1339-1441.</Citation></Reference><Reference><Citation>Thunell J, Ferido P, Zissimopoulos J. Measuring Alzheimer's disease and other dementias in diverse populations using medicare claims data. J Alzheimers Dis. 2019;72(1):29-33.</Citation></Reference><Reference><Citation>Chou SH-Y, Beghi E, Helbok R, et al. Global incidence of neurological manifestations among patients hospitalized with COVID-19-a report for the GCS-NeuroCOVID consortium and the ENERGY consortium. JAMA Netw Open. 2021;4(5):e2112131.</Citation></Reference><Reference><Citation>Liu Y-H, Chen Y, Wang Q-H, et al. One-year trajectory of cognitive changes in older survivors of COVID-19 in Wuhan, China: a longitudinal cohort study. JAMA Neurol. 2022;79(5):509-517.</Citation></Reference><Reference><Citation>Chen Y, Tysinger B, Crimmins E, Zissimopoulos JM. Analysis of dementia in the US population using Medicare claims: insights from linked survey and administrative claims data. Alzheimer's Dementia Trans Res Clin Interventions. 2019;5:197-207.</Citation></Reference><Reference><Citation>Centers for Medicare and Medicaid Services, Services M. Assessing the completeness of Medicare claims data for measuring COVID-19 vaccine administration. https://www.cms.gov/files/document/assessing-completeness-medicare-claims-data-measuring-covid-19-vaccine-administration.pdf</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637859</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1935-5548</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Diabetes care</Title><ISOAbbreviation>Diabetes Care</ISOAbbreviation></Journal><ArticleTitle>Incidence, Severity, and Presentation of Type 2 Diabetes in Youth During the First and Second Year of the COVID-19 Pandemic.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">dc221702</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2337/dc22-1702</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe the evolving impact of the coronavirus disease 2019 pandemic on the incidence and presentation of new-onset pediatric type 2 diabetes.</AbstractText><AbstractText Label="RESEARCH DESIGN AND METHODS" NlmCategory="METHODS">Retrospective medical record review of youth with new-onset type 2 diabetes comparing the prepandemic period (1 January 2017-29 February 2020) with the first (1 March 2020-31 December 2020) and second pandemic year (1 January 2021-31 December 2021).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The annualized incidence of type 2 diabetes increased nearly threefold during the pandemic versus prior, with a 61% increase in the 2nd versus 1st year. BMI increased during the pandemic versus prior (129% of 95th percentile vs. 141%, P = 0.02). In the 1st year, patients were younger (12.9 years vs. 14.8, P &lt; 0.001), with higher incidence of diabetic ketoacidosis and/or hyperglycemic hyperosmolar syndrome (20% vs. 3.5%, P = 0.02) versus prior.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Providers should be aware of the escalating incidence of youth-onset type 2 diabetes to avoid delays in diagnosis and inform educational programs to combat the continued impact of the pandemic on health outcomes.</AbstractText><CopyrightInformation>&#xa9; 2023 by the American Diabetes Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sasidharan Pillai</LastName><ForeName>Sabitha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0391-3759</Identifier><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Warren Alpert Medical School of Brown University, Providence, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Has</LastName><ForeName>Phinnara</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Lifespan Biostatistics, Epidemiology and Research Design, Rhode Island Hospital, Providence, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintos</LastName><ForeName>Jose Bernardo</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Warren Alpert Medical School of Brown University, Providence, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano Gonzalez</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Warren Alpert Medical School of Brown University, Providence, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasper</LastName><ForeName>Vania L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>The Warren Alpert Medical School of Brown University, Providence, RI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topor</LastName><ForeName>Lisa Swartz</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0000-0002-1219-9921</Identifier><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Warren Alpert Medical School of Brown University, Providence, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fredette</LastName><ForeName>Meghan E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0001-6674-7447</Identifier><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Warren Alpert Medical School of Brown University, Providence, RI.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Diabetes Care</MedlineTA><NlmUniqueID>7805975</NlmUniqueID><ISSNLinking>0149-5992</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637859</ArticleId><ArticleId IdType="doi">10.2337/dc22-1702</ArticleId><ArticleId IdType="pii">148298</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637858</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-3669</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Telemedicine journal and e-health : the official journal of the American Telemedicine Association</Title><ISOAbbreviation>Telemed J E Health</ISOAbbreviation></Journal><ArticleTitle>Telemedicine Has a Social Impact: An Italian National Study for the Evaluation of the Cost-Opportunity for Patients and Caregivers and the Measurement of Carbon Emission Savings.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1089/tmj.2022.0333</ELocationID><Abstract><AbstractText><b><i>Background:</i></b> <i>Owing to COVID-19, all stakeholders have recognized the advantages of telehealth and they were available for its permanent implementation, both from the normative and economic point of view. It is, therefore, necessary to understand what were the real benefits created in society through telehealth.</i> <b><i>Objective:</i></b> <i>Develop a method to identify a social impact of telemedicine in Italy, considering the reduction on the patient moves with a consequent travel cost, time (opportunity costs), and carbon emission savings.</i> <b><i>Methods:</i></b> <i>Since March 2020, we have conducted a quality improvement study in 17 centers, collecting sociodemographic variables. To assess the social impact, we transform the data into outcome measures. The protocol used "Telemedicina Subito" allows the rapid implementation of telemedicine, using operating manual, structured according Health Technology Assessment approach.</i> <b><i>Results:</i></b> <i>We collected data related to 2,091 televisits, analyzing three different perspectives. First, one patient with a televisit had a saving equal to the median of EUR 97.16 (interquartile range [IQR]: 64.29-159.69), USD 113.88; considering that the median cost for the visit in presence was EUR 105.91 (</i>p<i>-value &lt;0.05) and after the use of telehealth had a median of EUR 0 (mean: EUR 14.70;</i> p<i>-value &lt;0.05). Second, informal caregivers have a median savings of EUR 65.06 (IQR: 55.52-89.21), USD 76.26. Finally, for one single telemedicine visits we can contribute with a median carbon emission savings of &#x223c;13&#x2009;kg (IQR: 6-24).</i> <b><i>Conclusions:</i></b> <i>The evaluation of the social impact on telemedicine facilitated the creation of an important framework for decision-makers.</i></AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Papavero</LastName><ForeName>Sara Consilia</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>ALTEMS: High School of Economics and Management of Health Systems, Catholic University of Sacred Hearth, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fracasso</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALTEMS: High School of Economics and Management of Health Systems, Catholic University of Sacred Hearth, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramaglia</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-4359-9415</Identifier><AffiliationInfo><Affiliation>ALTEMS: High School of Economics and Management of Health Systems, Catholic University of Sacred Hearth, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cicchetti</LastName><ForeName>Americo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALTEMS: High School of Economics and Management of Health Systems, Catholic University of Sacred Hearth, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Belvis</LastName><ForeName>Antonio Giulio</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Hygiene Section, Department of Life Sciences and Public Health, Catholic University of Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrara</LastName><ForeName>Fabrizio Massimo</ForeName><Initials>FM</Initials><Identifier Source="ORCID">0000-0002-8596-7346</Identifier><AffiliationInfo><Affiliation>ALTEMS: High School of Economics and Management of Health Systems, Catholic University of Sacred Hearth, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Telemed J E Health</MedlineTA><NlmUniqueID>100959949</NlmUniqueID><ISSNLinking>1530-5627</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">carbon emission savings</Keyword><Keyword MajorTopicYN="N">caregiver</Keyword><Keyword MajorTopicYN="N">cost-opportunity</Keyword><Keyword MajorTopicYN="N">social impact</Keyword><Keyword MajorTopicYN="N">telemedicine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637858</ArticleId><ArticleId IdType="doi">10.1089/tmj.2022.0333</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637857</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-3669</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Telemedicine journal and e-health : the official journal of the American Telemedicine Association</Title><ISOAbbreviation>Telemed J E Health</ISOAbbreviation></Journal><ArticleTitle>Disparities in Use of Virtual Primary Care During the Early COVID-19 Pandemic.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1089/tmj.2022.0499</ELocationID><Abstract><AbstractText><b><i>Background:</i></b> <i>The COVID-19 pandemic increased the use of virtual health care. However, certain factors may disparately affect some patients' utilization of virtual care. Associations between age, racial categories (White or Black), and socioeconomic disadvantage were evaluated during the early COVID-19 pandemic.</i> <b><i>Methods:</i></b> <i>This cross-sectional retrospective study included adult patients with virtual or in-person primary care encounters at a large, midwestern hospital system with widespread urban and suburban offices between March 1, 2020, and June 30, 2020. Virtual visits included synchronous video and telephone visits and asynchronous patient portal E-visits. Chi-squared tests and multivariable logistic analysis assessed the associations between ages and racial categories, and area deprivation index with the use of virtual versus in-person primary care.</i> <b><i>Results:</i></b> <i>Of 72,153 patient encounters, 43.0% were virtual visits, 54.6% were White patients, and 45.4% were Black. Across equivalent age ranges, black patients were slightly less likely to utilize virtual care than similarly aged White patients, but not consistently across virtual modalities. Women were more likely to use virtual care across all modalities, and individuals &gt;65 years were more likely to use telephone visits and less likely to use video and E-visits, regardless of race. Patients residing in areas with the greatest socioeconomic advantage were more likely to utilize video and E-visits.</i> <b><i>Conclusions:</i></b> <i>Differential patterns of utilization emerged across racial categories and age ranges, suggesting that racial disparities are exacerbated depending upon patient age and mode of utilization.</i></AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cherabuddi</LastName><ForeName>Medha R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0001-5715-4121</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heidemann</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0512-2202</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gwinn</LastName><ForeName>Meghan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0707-4956</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White-Perkins</LastName><ForeName>Denise</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-1868-2161</Identifier><AffiliationInfo><Affiliation>Department of Family Medicine, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willens</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4565-0915</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>Anupama</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1896-5954</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Ed</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3546-3828</Identifier><AffiliationInfo><Affiliation>Public Health Sciences, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jesse</LastName><ForeName>Michelle T</ForeName><Initials>MT</Initials><Identifier Source="ORCID">0000-0003-0847-0368</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transplant Institute, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Telemed J E Health</MedlineTA><NlmUniqueID>100959949</NlmUniqueID><ISSNLinking>1530-5627</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">disparities</Keyword><Keyword MajorTopicYN="N">primary care</Keyword><Keyword MajorTopicYN="N">telehealth</Keyword><Keyword MajorTopicYN="N">telemedicine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637857</ArticleId><ArticleId IdType="doi">10.1089/tmj.2022.0499</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637854</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1931-843X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of women's health (2002)</Title><ISOAbbreviation>J Womens Health (Larchmt)</ISOAbbreviation></Journal><ArticleTitle>Women Authorship Trends in the Highest-Impact Anesthesiology Journals from 2005 to 2021.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1089/jwh.2022.0532</ELocationID><Abstract><AbstractText><b><i>Background:</i></b> Although women and men have matriculated into medical schools in similar proportions since the 1980s, recent data indicate that anesthesiology is lagging in gender equity, especially in academic leadership roles.<sup>1,2</sup> As promotion in academic medicine is strongly influenced by publications, understanding whether a lack of women authorship is contributing to this gender gap is crucial.<sup>3,4</sup> This article aims to assess how woman authorship trends have changed in the last 16 years, including during the COVID-19 pandemic. <b><i>Methods:</i></b> The five highest impact journals in anesthesia were identified as <i>Journal of Clinical Anesthesia, British Journal of Anaesthesia</i>, <i>Anesthesiology</i>, <i>PAIN</i>, and <i>Regional Anesthesia &amp; Pain Medicine</i>. Number of total authors, including women, men, and unknown gender authors as well as incidence of woman first and/or last author, was documented from articles published in 2005, 2010, 2015, 2020, and 2021. <b><i>Results:</i></b> This analysis shows that women are gaining representation in anesthesia publications. Overall, there was a statistically significant increase in the total number of women authors and women first and last authorship. However, as of 2021, women still only represented &#x223c;40% of total and first authors and &#x223c;24% of last authors. In addition, increase in first/last woman authorship was not present in all journals when stratified. <b><i>Conclusion:</i></b> These journal differences may suggest the editorial evaluation process as a potential source of gender bias. There was a statistically significant relationship between women senior authors and articles with 50% or more women authors, indicating that woman mentorship is contributing to closing equity gap. These data present a starting point for further investigations into gender disparities within anesthesia to continue the forward progression for women in academic medicine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keim</LastName><ForeName>Audrey A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Alix School of Medicine, Scottsdale, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelkey</LastName><ForeName>Melissa N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Alix School of Medicine, Scottsdale, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broadfoot</LastName><ForeName>Jourdan E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0003-1479-4828</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Folley</LastName><ForeName>Tarrah A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraus</LastName><ForeName>Molly B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maloney</LastName><ForeName>Jillian A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strand</LastName><ForeName>Natalie H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misra</LastName><ForeName>Lopa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Womens Health (Larchmt)</MedlineTA><NlmUniqueID>101159262</NlmUniqueID><ISSNLinking>1540-9996</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anesthesiology</Keyword><Keyword MajorTopicYN="N">authorship</Keyword><Keyword MajorTopicYN="N">gender equity</Keyword><Keyword MajorTopicYN="N">mentorship</Keyword><Keyword MajorTopicYN="N">women in medicine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637854</ArticleId><ArticleId IdType="doi">10.1089/jwh.2022.0532</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637836</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2379-3961</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>WMJ : official publication of the State Medical Society of Wisconsin</Title><ISOAbbreviation>WMJ</ISOAbbreviation></Journal><ArticleTitle>Increased Alcohol-Related Mortality in Wisconsin Pre-COVID: A Two-Decade Trend.</ArticleTitle><Pagination><StartPage>269</StartPage><EndPage>273</EndPage><MedlinePgn>269-273</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Alcohol-related mortality is increasing nationally, but state-specific trends still need to be explored. This paper reviews the patterning of alcohol-related deaths among Wisconsin residents in the 2 decades prior to the COVID-19 pandemic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data are from death certificates for state residents from 2000 through 2019. We used underlying cause of death codes (ICD-10) to classify deaths as 100% attributable to alcohol (ie, acute, chronic liver, and other chronic). Demographic characteristics were available for the most recent decedents (2015-2019). We assess trends in alcohol-related mortality and used chi-square tests to assess demographic differences compared to deaths from all other causes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The number of alcohol-related deaths more than doubled from 2000 through 2019 in Wisconsin, rising from 394 in 2000 to 857 in 2019. In the 5 most recent years (2015-2019), the populations with significantly higher rates of alcohol-related deaths included men, middle-aged adults, Black residents, and those of Hispanic descent. Education level also was significantly related to alcohol-attributable mortality, as those with the highest and lowest education levels were the least likely to die from this cause.</AbstractText><AbstractText Label="DISCUSSION/CONCLUSIONS" NlmCategory="CONCLUSIONS">Results of these analyses show that the number of deaths due to alcohol-related diseases has risen significantly since 2000, and this trend preceded the COVID-19 pandemic. These rising mortality rates deserve the attention of the medical and public health communities. Our findings show that, in recent years, Hispanic individuals, men, and middle-aged adults are at a higher risk for alcohol-related deaths. Stakeholders may wish to consider interventions targeted to these groups.</AbstractText><CopyrightInformation>Copyright&#xa9; Board of Regents of the University of Wisconsin System and The Medical College of Wisconsin, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cotter</LastName><ForeName>Lynne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Wisconsin School of Journalism and Mass Communication, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bentley</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Bureau of Prevention Treatment and Recovery, Division of Care and Treatment Services, Wisconsin Department of Health Services, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imm</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Wisconsin Population Health Institute, Madison, Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bureau of Community Health Promotion, Wisconsin Department of Health Services, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Creswell</LastName><ForeName>Paul D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, pdcreswell@wisc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bureau of Environmental and Occupational Health, Wisconsin Department of Health Services, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>WMJ</MedlineTA><NlmUniqueID>9716054</NlmUniqueID><ISSNLinking>1098-1861</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637836</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637826</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>03</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Economic Burden of the 2020 COVID-19 Hospitalizations in Spain.</ArticleTitle><Pagination><StartPage>e2250960</StartPage><MedlinePgn>e2250960</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2022.50960</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>&#xc1;lvarez-Del R&#xed;o</LastName><ForeName>Blanca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Pharmacology Department, Faculty of Medicine, University of Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-de Prada</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Cl&#xed;nico Universitario de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Influenza Centre, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvaro-Meca</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Preventive Medicine and Public Health Department, Rey Juan Carlos University, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;n-Fern&#xe1;ndez</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmacology Department, Faculty of Medicine, University of Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvarez</LastName><ForeName>F Javier</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Pharmacology Department, Faculty of Medicine, University of Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Cl&#xed;nico Universitario de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamayo</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pharmacology Department, Faculty of Medicine, University of Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Cl&#xed;nico Universitario de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guti&#xe9;rrez-Abej&#xf3;n</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pharmacology Department, Faculty of Medicine, University of Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacy Directorate, Castilla y Le&#xf3;n Health Council, Valladolid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>This economic evaluation reports the total and per patient costs of inpatient care for COVID-19 in Spain in 2020.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637826</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.50960</ArticleId><ArticleId IdType="pii">2800407</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637818</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>03</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Evaluation of Inequities in Cancer Treatment Delay or Discontinuation Following SARS-CoV-2 Infection.</ArticleTitle><Pagination><StartPage>e2251165</StartPage><MedlinePgn>e2251165</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2022.51165</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">There is a disproportionately greater burden of COVID-19 among Hispanic and non-Hispanic Black individuals, who also experience poorer cancer outcomes. Understanding individual-level and area-level factors contributing to inequities at the intersection of COVID-19 and cancer is critical.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To evaluate associations of individual-level and area-level social determinants of health (SDOH) with delayed or discontinued cancer treatment following SARS-CoV-2 infection.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This retrospective, registry-based cohort study used data from 4768 patients receiving cancer care who had positive test results for SARS-CoV-2 and were enrolled in the American Society for Clinical Oncology COVID-19 Registry. Data were collected from April 1, 2020, to September 26, 2022.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="UNASSIGNED">Race and ethnicity, sex, age, and area-level SDOH based on zip codes of residence at the time of cancer diagnosis.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">Delayed (&#x2265;14 days) or discontinued cancer treatment (any cancer treatment, surgery, pharmacotherapy, or radiotherapy) and time (in days) to restart pharmacotherapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 4768 patients (2756 women [57.8%]; 1558 [32.7%] aged &#x2265;70 years at diagnosis) were included in the analysis. There were 630 Hispanic (13.2%), 196 non-Hispanic Asian American or Pacific Islander (4.1%), 568 non-Hispanic Black (11.9%), and 3173 non-Hispanic White individuals (66.5%). Compared with non-Hispanic White individuals, Hispanic and non-Hispanic Black individuals were more likely to experience a delay of at least 14 days or discontinuation of any treatment and drug-based treatment; only estimates for non-Hispanic Black individuals were statistically significant, with correction for multiple comparisons (risk ratios [RRs], 1.35 [95% CI, 1.22-1.49] and 1.37 [95% CI, 1.23-1.52], respectively). Area-level SDOH (eg, geography, proportion of residents without health insurance or with only a high school education, lower median household income) were associated with delayed or discontinued treatment. In multivariable Cox proportinal hazards regression models, estimates suggested that Hispanic (hazard ratio [HR], 0.87 [95% CI, 0.71-1.05]), non-Hispanic Asian American or Pacific Islander (HR, 0.79 [95% CI, 0.46-1.35]), and non-Hispanic Black individuals (HR, 0.81 [95% CI, 0.67-0.97]) experienced longer delays to restarting pharmacotherapy compared with non-Hispanic White individuals.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">The findings of this cohort study suggest that race and ethnicity and area-level SDOH were associated with delayed or discontinued cancer treatment and longer delays to the restart of drug-based therapies following SARS-CoV-2 infection. Such treatment delays could exacerbate persistent cancer survival inequities in the United States.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Llanos</LastName><ForeName>Adana A M</ForeName><Initials>AAM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashrafi</LastName><ForeName>Adiba</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Nabarun</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsui</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rutgers Cancer Institute of New Jersey, New Brunswick.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Angela J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Rutgers Cancer Institute of New Jersey, New Brunswick.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganesan</LastName><ForeName>Shridar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rutgers Cancer Institute of New Jersey, New Brunswick.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Pharmacology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heckman</LastName><ForeName>Carolyn J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Rutgers Cancer Institute of New Jersey, New Brunswick.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637818</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.51165</ArticleId><ArticleId IdType="pii">2800399</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637810</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2047-2986</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2023</Year><Month>Jan</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of global health</Title><ISOAbbreviation>J Glob Health</ISOAbbreviation></Journal><ArticleTitle>Economic evaluation of COVID-19 vaccination: A systematic review.</ArticleTitle><Pagination><StartPage>06001</StartPage><MedlinePgn>06001</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7189/jogh.13.06001</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Safe and effective vaccination is considered to be the most critical strategy to fight coronavirus disease 2019 (COVID-19), leading to individual and herd immunity protection. We aimed to systematically review the economic evaluation of COVID-19 vaccination globally.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We performed a systematic search to identify relevant studies in two major databases (MEDLINE/PubMed and EBSCO) published until September 8, 2022. After deduplication, two researchers independently screened the study titles and abstracts according to pre-determined inclusion and exclusion criteria. The remaining full-text studies were assessed for eligibility. We assessed their quality of reporting using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 checklist and summarized and narratively presented the results.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We identified 25 studies that assessed the economic evaluation of COVID-19 vaccination worldwide by considering several input parameters, including vaccine cost, vaccine efficacy, utility value, and the size of the targeted population. All studies suggested that COVID-19 vaccination was a cost-effective or cost-saving intervention for mitigating coronavirus transmission and its effect in many countries within certain conditions. Most studies reported vaccine efficacy values ranging from 65% to 75%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Given the favorable cost-effectiveness profile of COVID-19 vaccines and disparities in affordability across countries, considering prioritization has become paramount. This review provides comprehensive insights into the economic evaluation of COVID-19 vaccination that will be useful to policymakers, particularly in highlighting preventive measures and preparedness plans for the next possible pandemic.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 by the Journal of Global Health. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Utami</LastName><ForeName>Auliasari Meita</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rendrayani</LastName><ForeName>Farida</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Khoiry</LastName><ForeName>Qisty Aulia</ForeName><Initials>QA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noviyanti</LastName><ForeName>Dita</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwantika</LastName><ForeName>Auliya A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Postma</LastName><ForeName>Maarten J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Economics, Econometrics &amp; Finance, University of Groningen, Faculty of Economics &amp; Business, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zakiyah</LastName><ForeName>Neily</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Scotland</Country><MedlineTA>J Glob Health</MedlineTA><NlmUniqueID>101578780</NlmUniqueID><ISSNLinking>2047-2978</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and declare the following activities and relationships: MJP reports grants and honoraria from various pharmaceutical companies, also those involved in developing, producing, and marketing COVID-19 vaccines. Also, MJP is a member of the UK&#x2019;s Joint Committee of Vaccination &amp; Immunization. Other author reports no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637810</ArticleId><ArticleId IdType="doi">10.7189/jogh.13.06001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637803</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1941-2703</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of aerosol medicine and pulmonary drug delivery</Title><ISOAbbreviation>J Aerosol Med Pulm Drug Deliv</ISOAbbreviation></Journal><ArticleTitle>Safety, Tolerability, and Pharmacokinetics of Nebulized Hydroxychloroquine: A Pilot Study in Healthy Volunteers.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1089/jamp.2022.0062</ELocationID><Abstract><AbstractText><b><i>Background:</i></b> Early in the coronavirus disease 2019 (COVID-19) pandemic, hydroxychloroquine (HCQ) drew substantial attention as a potential COVID-19 treatment based on its antiviral and immunomodulatory effects <i>in vitro</i>. However, HCQ showed a lack of efficacy <i>in vivo</i>, and different groups of researchers attributed this failure to the insufficient drug concentration in the lung following oral administration (HCQ is only available in the market in the tablet form). Delivering HCQ by inhalation represents a more efficient route of administration to increase HCQ exposure in the lungs while minimizing systemic toxicity. In this pilot study, the safety, tolerability, and pharmacokinetics of HCQ nebulizer solution were evaluated in healthy volunteers. <b><i>Methods:</i></b> Twelve healthy participants were included in this study and were administered 2&#x2009;mL of HCQ01 solution (equivalent to 25&#x2009;mg of HCQ sulfate) through Aerogen<sup>&#xae;</sup> Solo, a vibrating mesh nebulizer. Local tolerability and systemic safety were assessed by forced expiratory volume in the first and second electrocardiograms, clinical laboratory results (e.g., hematology, biochemistry, and urinalysis), vital signs, and physical examinations. Thirteen blood samples were collected to determine HCQ01 systemic exposure before and until 6 hours after inhalation. <b><i>Results:</i></b> The inhalation of HCQ01 was well tolerated in all participants. The mean value of <i>C</i><sub>max</sub> for the 12 participants was 9.66&#x2009;ng/mL. <i>T</i><sub>max</sub> occurred at around 4.8 minutes after inhalation and rapidly decreased thereafter. The reported systemic exposure was very low with a mean value of 5.28 (0.6-15.6) ng&#xb7;h/mL. <b><i>Conclusion:</i></b> The low systemic concentrations of HCQ01 of 9.66&#x2009;ng/mL reported by our study compared with 1&#x2009;&#x3bc;g/mL previously predicted after 200&#x2009;mg BID oral administration, and the safety and tolerability of HCQ01 administered as a single dose through nebulization, support the assessment of its efficacy, safety, and tolerability in further studies for the treatment of COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hawari</LastName><ForeName>Feras</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Office of Minister of Health, Ministry of Health, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodin</LastName><ForeName>Yasmeen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cancer Control Office, King Hussein Cancer Center, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tayyem</LastName><ForeName>Rabab</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ACDIMA Biocenter, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Najjar</LastName><ForeName>Samer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sana Pharmaceutical Industry, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakish</LastName><ForeName>Hanan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Amman Pharmaceutical Industries, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fara</LastName><ForeName>Mohammed Abu</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>ACDIMA Biocenter, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou'bi</LastName><ForeName>Abdullah Al</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>ACDIMA Biocenter, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idkaidek</LastName><ForeName>Nasir</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-3115-4240</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy and Medical Sciences, The University of Petra, Amman, Jordan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Aerosol Med Pulm Drug Deliv</MedlineTA><NlmUniqueID>101475057</NlmUniqueID><ISSNLinking>1941-2711</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">inhalable hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">lung diseases</Keyword><Keyword MajorTopicYN="N">nebulizer</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">phase I study</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637803</ArticleId><ArticleId IdType="doi">10.1089/jamp.2022.0062</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637742</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1970-9366</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Internal and emergency medicine</Title><ISOAbbreviation>Intern Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Effects of COVID-19 vaccination on clinical outcomes in patients hospitalized in Internal Medicine during Omicron variant spreading.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11739-022-03185-5</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Colangeli</LastName><ForeName>Luca</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8603-664X</Identifier><AffiliationInfo><Affiliation>Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy. luca.colangeli.ptv@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Unit and Obesity Center, University Hospital Policlinico Tor Vergata, Rome, Italy. luca.colangeli.ptv@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aprile</LastName><ForeName>Gianna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carcone</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Adamo</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Unit and Obesity Center, University Hospital Policlinico Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medda</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Behavioural Sciences and Mental Health, Istituto Superiore Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sbraccia</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Unit and Obesity Center, University Hospital Policlinico Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guglielmi</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Unit and Obesity Center, University Hospital Policlinico Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Intern Emerg Med</MedlineTA><NlmUniqueID>101263418</NlmUniqueID><ISSNLinking>1828-0447</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Internal Medicine</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword><Keyword MajorTopicYN="N">Variant</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637742</ArticleId><ArticleId IdType="doi">10.1007/s11739-022-03185-5</ArticleId><ArticleId IdType="pii">10.1007/s11739-022-03185-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polack FP et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603&#x2013;2615</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384(5):403&#x2013;416</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J et al (2021) Safety and efficacy of single-dose ad26cov2s vaccine against covid-19. N Engl J Med 384(23):2187&#x2013;2201</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkle LM et al (2022) Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med 386(6):531&#x2013;543</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116185</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohsin M, Mahmud S (2022) Omicron SARS-CoV-2 variant of concern: a review on its transmissibility, immune evasion, reinfection, and severity. Medicine 101(19):e29165</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000029165</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch DH (2022) Covid-19 vaccines - immunity, variants Boosters. N Engl J Med 387(11):1011&#x2013;1020</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2206573</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian D et al (2022) The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. J Med Virol 94(6):2376&#x2013;2383</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27643</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng HF et al (2022) Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med 28(5):1063&#x2013;1071</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01753-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Corradini E et al (2021) Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). Intern Emerg Med 16(4):1005&#x2013;1015</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-021-02742-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmi V et al (2022) Inflammation, underweight, malignancy and a marked catabolic state as predictors for worse outcomes in COVID-19 patients with moderate-to-severe disease admitted to internal medicine unit. PLoS One 17(5):e0268432</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0268432</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenti MV et al (2022) Determinants of COVID-19-related mortality in an internal medicine setting. Intern Emerg Med 17(7):2169&#x2013;2173</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-022-03057-y</ArticleId></ArticleIdList></Reference><Reference><Citation>AIFA. Trattamenti utilizzabili nei pazienti COVID-19 nel setting ospedaliero. 2022 26/NOV/2022]; Available from: https://www.aifa.gov.it/documents/20142/1269602/SOC_ospedaliera_03_06.06.2022.pdf .</Citation></Reference><Reference><Citation>Razonable RR et al (2022) Real-world clinical outcomes of bebtelovimab and sotrovimab treatment of high-risk persons with coronavirus disease 2019 during the omicron epoch. Open Forum Infect Dis 9(10):411</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac411</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghazanfar H et al (2022) Outcomes of monoclonal antibody infusion treatment during delta (B16172) and omicron (B11529) COVID 19 variant surges among vaccinated and unvaccinated patients. Health Serv Insights 15:11786329221127152</Citation></Reference><Reference><Citation>Ward IL et al (2022) Risk of covid-19 related deaths for SARS-CoV-2 omicron (B1.1.529) compared with delta (B.1.617.2): retrospective cohort study. Bmj. 378:e070695</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-070695</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima N, Roshani A, Klausner JD (2022) Duration of COVID-19 PCR positivity for Omicron vs earlier variants. J Clin Virol Plus 2(3):100085</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcvp.2022.100085</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637636</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Mortality in psoriatic arthritis patients, changes over time, and the impact of COVID-19: results from a multicenter Psoriatic Arthritis Registry (PsART-ID).</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-022-06492-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aimed to assess the mortality of PsA before and during the COVID-19 pandemic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From the prospective, multicenter PsART-ID (Psoriatic Arthritis Registry-International Database), patients from Turkey were analyzed by linking the registry to the Turkish Cause of Death Registry. The outcome of interest was death from any cause, pre-pandemic (since the onset of registry-March 2014-March 2020), and during the pandemic (March 2020-May 2021). The crude mortality rate and standardized mortality ratio (SMR) were determined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 1216 PsA patients with a follow-up of 7500 patient-years. Overall, 46 deaths (26 males) were observed. In the pre-pandemic period, SMR for PsA vs the general population was 0.95 (0.61-1.49), being higher in males [1.56 (0.92-2.63)] than females [0.62 (0.33-1.17)]. The crude mortality rate in PsA doubled during the pandemic (pre-pandemic crude mortality rate: 5.07 vs 10.76 during the pandemic) with a higher increase in females (2.9 vs 8.72) than males (9.07 vs 14.73).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The mortality in PsA was found similar to the general population in the pre-pandemic era. The mortality rates in PsA doubled during the pandemic. Whether PsA patients have more risk of mortality than the general population due to COVID-19 needs further studies. Key Points &#x2022; Decrease in mortality in PsA might be expected with the more effective treatment options and better disease control. &#x2022; A crude mortality rate is comparable to the general population and not increased until the pandemic. &#x2022; Currently, there is a 2-fold increase in crude mortality rate possibly due to the COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erden</LastName><ForeName>Abdulsamet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, Ministry of Health Ankara City Hospital, Ankara, 06800, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayan</LastName><ForeName>Gizem</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University Medical School, Sihhiye, Ankara, 06100, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilic</LastName><ForeName>Levent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University Medical School, Sihhiye, Ankara, 06100, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solmaz</LastName><ForeName>Dilek</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir Katip Celebi University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakirci</LastName><ForeName>Sibel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Antalya Training and Research Hospital, Antalya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimyon</LastName><ForeName>Gezmis</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Mustafa Kemal University, Antakya, Hatay, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nal</LastName><ForeName>Esen Kasapoglu</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Medeniyet University, Goztepe Research and Training Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dogru</LastName><ForeName>Atalay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Suleyman Demirel University, Isparta, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayindir</LastName><ForeName>Ozun</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ege University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalkilic</LastName><ForeName>Ediz</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Uludag University, Bursa, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;zisler</LastName><ForeName>Cem</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, Diskapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akar</LastName><ForeName>Servet</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir Katip Celebi University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cetin</LastName><ForeName>G&#xf6;zde Yildirim</ForeName><Initials>GY</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarhan</LastName><ForeName>Emine Figen</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Mugla Sitki Kocman University, Mugla, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;&#xe7;&#xfc;ksahin</LastName><ForeName>Orhan</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara Yildirim Beyazit University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omma</LastName><ForeName>Ahmet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, Ankara Numune Education and Research Hospital, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonullu</LastName><ForeName>Emel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Sakarya University, Sakarya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yildiz</LastName><ForeName>Fatih</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, University of Health Sciences, Van Training and Research Hospital, Van, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ersozlu</LastName><ForeName>Emine Duygu</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, Adana Numune Training and Research Hospital, Adana, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cinar</LastName><ForeName>Muhammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, G&#xfc;lhane Training and Research Hospital, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tufan</LastName><ForeName>Abdurrahman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Gazi University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pehlevan</LastName><ForeName>Seval</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Fatih University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esmen</LastName><ForeName>Serpil Ergulu</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, Konya Education and Research Hospital, Konya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yilmaz</LastName><ForeName>Sema</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Selcuk University, Konya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duruoz</LastName><ForeName>Tuncay</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Marmara University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasifoglu</LastName><ForeName>Timucin</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskisehir Osmangazi University, Eskisehir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaz&#x131;s&#x131;z</LastName><ForeName>Veli</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology,, Akdeniz University, Antalya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aksu</LastName><ForeName>Kenan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ege University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aydin</LastName><ForeName>Sibel Zehra</ForeName><Initials>SZ</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalyoncu</LastName><ForeName>Umut</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-7129-2109</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University Medical School, Sihhiye, Ankara, 06100, Turkey. umut.kalyoncu@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Pandemic</Keyword><Keyword MajorTopicYN="N">Psoriatic arthritis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637636</ArticleId><ArticleId IdType="doi">10.1007/s10067-022-06492-6</ArticleId><ArticleId IdType="pii">10.1007/s10067-022-06492-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gupta S, Syrimi Z, Hughes DM, Zhao SS (2021) Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int 41:275&#x2013;284. https://doi.org/10.1007/s00296-020-04775-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04775-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali Y, Tom BD, Schentag CT, Farewell VT, Gladman D (2007) Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum 56:2708&#x2013;2714. https://doi.org/10.1002/art.22800</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22800</ArticleId></ArticleIdList></Reference><Reference><Citation>Bower H, Frisell T, Di Giuseppe D et al (2021) Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis 80:1086&#x2013;1093. https://doi.org/10.1136/annrheumdis-2021-219845</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-219845</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalyoncu U, Bayindir &#xd6;, Ferhat &#xd6;ks&#xfc;z M et al (2017) The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients. Rheumatology (Oxford) 56:279&#x2013;286. https://doi.org/10.1093/rheumatology/kew375</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew375</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakirci S, Ayan G, Gazel U, Tinazzi I, Solmaz D, Kasapoglu E, Kalyoncu U, Aydin SZ (2021) Patient characteristics and minimal disease activity in psoriatic arthritis: a transcontinental comparison. Clin Rheumatol 40:3169&#x2013;3174. https://doi.org/10.1007/s10067-021-05648-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05648-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF (2011) Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 63:1182&#x2013;1189. https://doi.org/10.1002/art.30277</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30277</ArticleId></ArticleIdList></Reference><Reference><Citation>Aron JM, J (2020) Transatlantic excess mortality comparisons in the pandemic. INET Oxford Working Paper No-18 https://ourworldindata.org/covid.excess.mortality . Accessed 9 Jan 2023</Citation></Reference><Reference><Citation>Morfeld P, Timmermann B, Gro&#xdf; JV, Lewis P, Cocco P, Erren TC (2021) COVID-19: heterogeneous excess mortality and &#x201c;burden of disease&#x201d; in Germany and Italy and their states and regions, January&#x2013;June 2020. Front Public Health 9:663259. https://doi.org/10.3389/fpubh.2021.663259</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.663259</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MMA, Khan MN, Mustagir MG, Rana J, Islam S, Kabir I (2020) Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: a systematic review and meta-analysis. J Glob Health 10:020503. https://doi.org/10.7189/jogh.10.020503</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.10.020503</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637634</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Outcomes of Filipinos with inflammatory rheumatic diseases developing COVID-19 prior to vaccinations and new variants: a historical perspective.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-023-06507-w</ELocationID><Abstract><AbstractText>We described the profile and outcome of Filipino patients with inflammatory rheumatic diseases (IRDs) who developed COVID-19 (IRD-C19) during the onset of the pandemic, prior to vaccinations and variants. We obtained de-identified data of Filipino patients with IRD-C19 from the Global Rheumatology Alliance registry from March 2020 to August 2021. Descriptive statistics and multivariate analyses were applied. Registered were 164 patients (mean age 44&#xa0;years; 70% female). The most common IRDs were systemic lupus erythematosus (SLE, 41.4%), rheumatoid arthritis (RA, 15.2%), and gout (14.6%). Majority were receiving conventional DMARDs (59.1%) and/or glucocorticoid therapy (GC, 51.2%). Half (58.5%) were hospitalized, with risk higher in active IRD (OR 3.7), heart disease&#xa0;(8.52), and hypertension&#xa0;(8.73); and lower in SLE patients (0.15). Among hospitalized patients, 76% needed supplemental oxygen. Heart disease (6.28), hypertension (7.6), and moderate-to-high IRD activity (3.37) were associated with higher odds of requiring oxygen supplementation. Hypertension was associated with mechanical ventilation (8.23).&#xa0;Twenty-four (15%) patients died, with odds lower if on prednisone&#x2009;&#x2265;&#x2009;10&#xa0;mg/day (0.17) and with other autoimmune IRDs aside from SLE and RA (0.05). Among patients with IRD-C19 prior to vaccinations and variants, higher disease activity, hypertension, and heart disease were associated with poorer outcomes. Prednisone&#x2009;&#x2265;&#x2009;10&#xa0;mg/day was associated with lower odds of death. This study provides valuable historical information, emphasizing the need for continued data collection to clarify COVID-19's impact.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zamora-Abrahan</LastName><ForeName>Geraldine Tong</ForeName><Initials>GT</Initials><Identifier Source="ORCID">0000-0003-3125-9114</Identifier><AffiliationInfo><Affiliation>University of the Philippines Manila, Manila, Philippines. gtzamora@up.edu.ph.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salido</LastName><ForeName>Evelyn Osio</ForeName><Initials>EO</Initials><Identifier Source="ORCID">0000-0003-1653-2143</Identifier><AffiliationInfo><Affiliation>University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Asian Hospital and Medical Center, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lichauco</LastName><ForeName>Juan Javier Tayengco</ForeName><Initials>JJT</Initials><AffiliationInfo><Affiliation>St. Luke's Medical Center, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutierrez-Rubio</LastName><ForeName>Anna Kristina Manahan</ForeName><Initials>AKM</Initials><Identifier Source="ORCID">0000-0003-1322-9827</Identifier><AffiliationInfo><Affiliation>Makati Medical Center, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera-Go</LastName><ForeName>Ivy Catherine Talavera</ForeName><Initials>ICT</Initials><AffiliationInfo><Affiliation>Medical Center Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortez</LastName><ForeName>Karen Joy Casta&#xf1;eda</ForeName><Initials>KJC</Initials><AffiliationInfo><Affiliation>Baguio General Hospital and Medical Center, Baguio City, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suilan</LastName><ForeName>Katrina Elys Arada</ForeName><Initials>KEA</Initials><AffiliationInfo><Affiliation>University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villo</LastName><ForeName>Jimmy Gene Bobot</ForeName><Initials>JGB</Initials><AffiliationInfo><Affiliation>East Avenue Medical Center, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Rosario</LastName><ForeName>Adora Gatlabayan</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>East Avenue Medical Center, Manila, Philippines.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 immunopathology</Keyword><Keyword MajorTopicYN="N">Filipino patients</Keyword><Keyword MajorTopicYN="N">Global Rheumatology Alliance</Keyword><Keyword MajorTopicYN="N">Registry</Keyword><Keyword MajorTopicYN="N">Rheumatic disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637634</ArticleId><ArticleId IdType="doi">10.1007/s10067-023-06507-w</ArticleId><ArticleId IdType="pii">10.1007/s10067-023-06507-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grainger R, Machado PM, Robinson PC (2021) Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: epidemiology and outcomes. Clin Rheumatol 35:101657. https://doi.org/10.1016/j.berh.2020.101657</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2020.101657</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79:859&#x2013;866. https://doi.org/10.1136/annrheumdis-2020-217871</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C, Yi Z, Cai R, Chen R, Thong BY, Mu R (2021) Clinical outcomes of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis of global data. Autoimmun Rev 20:102778. https://doi.org/10.1016/j.autrev.2021.102778</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102778</ArticleId></ArticleIdList></Reference><Reference><Citation>Salido EO, Manapat-Reyes H, Dans L (2009) Serum uric acid and its relationship with demographic characteristics among Filipino adults 20 years old and above: results from the NNHeS 2003. Phil J Intern Med 46:273&#x2013;278. https://doi.org/10.3860/pjim.v46i6.888</Citation><ArticleIdList><ArticleId IdType="doi">10.3860/pjim.v46i6.888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigley RD, Manahan L, Muirden KD (1991) Rheumatic disease in a Philippine village II: a WHO-APLAR COPCORD study, phase II and III. Rheumatol Int 11:152&#x2013;161. https://doi.org/10.1007/BF00332554</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00332554</ArticleId></ArticleIdList></Reference><Reference><Citation>Dans LS, Salido EO, Penserga EG, Navarra SV (2006) National Nutrition and Health Survey (NNHeS): prevalence of rheumatic diseases among adult Filipinos. Phil J Intern Med 44:297&#x2013;303</Citation></Reference><Reference><Citation>Salido EO, Tee CA, Reyes PWC, Reyes BHM, Zamora GT, Tee ML (2021) Self-reported symptoms in a cohort of rheumatoid arthritis and lupus erythematosus during the COVID-19 quarantine period. The Open Rheumatol J 15:16&#x2013;23. https://doi.org/10.2174/1874312902115010016</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874312902115010016</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonf&#xe1; E, Gossec L, Isenberg DA, Li Z, Raychaudhuri S (2021) Viewpoint: How COVID-19 is changing rheumatology clinical practice? Nat Rev Rheumatol 17:11&#x2013;15. https://doi.org/10.1038/s41584-020-00527-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-00527-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497&#x2013;506. https://doi.org/10.1016/S0140-6736(20)30183-5pmid:31986264</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5pmid:31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Philippine Society for Microbiology and Infectious Diseases. (n.d.) Interim Guidelines on the Clinical Management of Adult Patients with Suspected or Confirmed Covid-19 Infection. https://pcp.org.ph/index.php/interim-guidelines . Accessed September 24, 2021</Citation></Reference><Reference><Citation>Liu X, Zhang R, He G (2020) Hematological findings in coronavirus disease 2019: indications of progression of disease. Ann Hematol 99:1421&#x2013;1428. https://doi.org/10.1007/s00277-020-04103-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-020-04103-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G et al (2020) Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med 80:1&#x2013;11. https://doi.org/10.1016/j.ejim.2020.07.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2020.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D et al (2021) Risk factors for severe and critically ill COVID-19 patients: a review. Allergy 76:428&#x2013;455. https://doi.org/10.1111/all.14657</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14657</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323:1239&#x2013;1242. https://doi.org/10.1001/jama.2020.2648</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId></ArticleIdList></Reference><Reference><Citation>Topless RK, Phipps-Green A, Leask M, Dalbeth N, Stamp LK, Robinson PC et al (2021) Gout, rheumatoid arthritis and the risk of death from COVID-19: an analysis of the UK Biobank. Open Rheumatol 3:333&#x2013;340. https://doi.org/10.1002/acr2.11252</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11252</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye C, Zhong J, Cai S, Dong L, Li C, Hou X et al (2021) COVID-19 infection in patients with connective tissue disease: a multicity study in Hubei province, China. MedComm 2:82&#x2013;90. https://doi.org/10.1002/mco2.56</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.56</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen KM, Bates BA, Rashidi ES, Olex AL, Mannon RB, Patel RC et al (2022) National COVID Cohort Collaborative Consortium. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet 4:e33&#x2013;e41. https://doi.org/10.1016/S2665-9913(21)00325-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00325-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee CA, Salido EO, Reyes PWC, Ho RC, Tee ML (2020) Psychological state and associated factors during the 2019 coronavirus disease (COVID-19) pandemic among Filipinos with rheumatoid arthritis or systemic lupus erythematosus. Open Access Rheumatol 12:215&#x2013;222. https://doi.org/10.2147/OARRR.S269889</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OARRR.S269889</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637614</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2196-8837</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of racial and ethnic health disparities</Title><ISOAbbreviation>J Racial Ethn Health Disparities</ISOAbbreviation></Journal><ArticleTitle>Racial Disparities in the Clinical Prognosis of Gastrointestinal Cancer Patients with COVID-19: a Retrospective Study in UC CORDS.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40615-023-01512-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cancer patients are highly vulnerable to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Few studies have examined racial disparities of clinical prognosis among gastrointestinal (GI) cancer patients with COVID-19, especially after the approval of COVID-19 vaccines.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective study based on the University of California COVID Research Data Set (UC CORDS). Patients aged&#x2009;&#x2265;&#x2009;18 with GI cancer as well as SARS-CoV-2 infection between March 10, 2020, and May 8, 2022, were included. We examined racial disparities using multivariable logistic regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 1054 GI cancer cases included, 117 (11.1%) patients were Asian and Pacific Islander, 51 (4.8%) were Black patients, 377 (35.8%) were Hispanic patients, 403 (38.2%) were White patients, and 106 (10.1%) belonged to other or unknown races. Fully adjusted logistic models revealed a significantly increased risk of COVID-19-related hospitalization or emergency room visits among the Black (OR&#x2009;=&#x2009;2.26, 95% CI&#x2009;=&#x2009;1.08-4.70), the Hispanic (OR&#x2009;=&#x2009;2.24, 95% CI&#x2009;=&#x2009;1.48-3.39), and the patients of other or unknown races (OR&#x2009;=&#x2009;1.80, 95% CI&#x2009;=&#x2009;1.00-3.26) compared with the White patients. No significant racial disparities in 30-day all-cause mortality and mechanical ventilation rate were found. Vaccination, age, cancer type, recent cancer diagnoses in UC CORDS, metastatic cancer or secondary malignant neoplasm, and Charlson comorbidity index score were associated with the prognosis of GI cancer patients with COVID-19.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">GI cancer patients belonging to racial minorities experience worse COVID-19 outcomes. Vaccination status is a crucial factor associated with GI cancer patients' prognosis among different race/ethnicity groups. Targeted communication in the context of cancer is needed to encourage vaccination uptake in this vulnerable population.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Bingya</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Population Health and Disease Prevention, Program in Public Health, Susan and Henry Samueli College of Health Sciences, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yunxia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Population Health and Disease Prevention, Program in Public Health, Susan and Henry Samueli College of Health Sciences, University of California, Irvine, CA, USA. Yunxia.lu@uci.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Racial Ethn Health Disparities</MedlineTA><NlmUniqueID>101628476</NlmUniqueID><ISSNLinking>2196-8837</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Gastrointestinal cancer</Keyword><Keyword MajorTopicYN="N">Racial groups</Keyword><Keyword MajorTopicYN="N">SARS-COV-2</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637614</ArticleId><ArticleId IdType="doi">10.1007/s40615-023-01512-w</ArticleId><ArticleId IdType="pii">10.1007/s40615-023-01512-w</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157&#x2013;60. https://doi.org/10.23750/abm.v91i1.9397 .</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v91i1.9397</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020;17(3):519&#x2013;27. https://doi.org/10.20892/j.issn.2095-3941.2020.0289 .</Citation><ArticleIdList><ArticleId IdType="doi">10.20892/j.issn.2095-3941.2020.0289</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillmore NR, La J, Szalat RE, et al. Prevalence and outcome of COVID-19 infection in cancer patients: a National Veterans Affairs study. J Natl Cancer Inst. 2021;113(6):691&#x2013;8. https://doi.org/10.1093/jnci/djaa159 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djaa159</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell B, Moss C, Papa S, et al. Factors affecting COVID-19 outcomes in cancer patients: a first report from Guy&#x2019;s Cancer Center in London. Front Oncol. 2020;10:1279. https://doi.org/10.3389/fonc.2020.01279 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.01279</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol. 2021;7(2):220&#x2013;7. https://doi.org/10.1001/jamaoncol.2020.6178 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2020.6178</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu J, Reid SA, French B, et al. Racial disparities in COVID-19 outcomes among Black and White patients wit h cancer. JAMA Netw Open. 2022;5(3):e224304. https://doi.org/10.1001/jamanetworkopen.2022.4304 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.4304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kathuria-Prakash N, Antrim L, Hornstein N, et al. Factors associated with hospitalization among breast cancer patients with COVID-19: a diverse multi-center Los Angeles cohort study. Clin Breast Cancer. 2022;22(4):e558&#x2013;66. https://doi.org/10.1016/j.clbc.2021.12.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clbc.2021.12.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lara OD, Smith MJ, Wang Y, et al. Racial disparities in patients with coronavirus disease 2019 infection and gynecologic malignancy. Cancer. 2021;127(7):1057&#x2013;67. https://doi.org/10.1002/cncr.33335 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.33335</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox TA, Troy-Barnes E, Kirkwood AA, et al. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy. Br J Haematol. 2020;191(2):194&#x2013;206. https://doi.org/10.1111/bjh.17027 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17027</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt AL, Tucker MD, Bakouny Z, et al. Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19. JAMA Netw Open. 2021;4(11):e2134330. https://doi.org/10.1001/jamanetworkopen.2021.34330 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.34330</ArticleId></ArticleIdList></Reference><Reference><Citation>California Population Estimates. United States Census Bureau. Updated July 1, 2021. Accessed July 9, 2022. https://www.census.gov/quickfacts/fact/table/CA/PST045221 .</Citation></Reference><Reference><Citation>Ashktorab H, Kupfer SS, Brim H, Carethers JM. Racial disparity in gastrointestinal cancer risk. Gastroenterology. 2017;153(4):910&#x2013;23. https://doi.org/10.1053/j.gastro.2017.08.018 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.08.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller C, Ihionkhan E, Stoffel EM, Kupfer SS. Disparities in Early-Onset Colorectal Cancer. Cells. 2021;10(5):1018. https://doi.org/10.3390/cells10051018.</Citation></Reference><Reference><Citation>Salvatore M, Jeon J, Meza R. Changing trends in liver cancer incidence by race/ethnicity and sex in the US: 1992&#x2013;2016. Cancer Causes Control. 2019;30(12):1377&#x2013;88. https://doi.org/10.1007/s10552-019-01237-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10552-019-01237-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer J Clin. 2022;72(1):7&#x2013;33. https://doi.org/10.3322/caac.21708 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21708</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb YN. BNT162b2 mRNA COVID-19 Vaccine: first approval. Drugs. 2021;81(4):495&#x2013;501. https://doi.org/10.1007/s40265-021-01480-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01480-7</ArticleId></ArticleIdList></Reference><Reference><Citation>University of California Health creates centralized data set to accelerate COVID-19 research. Univ California Health. Published July 15, 2020. Accessed January 23, 2022. https://www.universityofcalifornia.edu/press-room/university-california-health-creates-centralized-data-set-accelerate-covid-19-research .</Citation></Reference><Reference><Citation>Kim Y, Tian Y, Yang J, et al. Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis. Sci Rep. 2020;10(1):11115. https://doi.org/10.1038/s41598-020-68037-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-68037-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson comorbidity index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019;12(4):188&#x2013;97.</Citation></Reference><Reference><Citation>Variants. CALIFORNIA ALL. Updated May 24, 2022. Accessed April 25, 2022. https://covid19.ca.gov/variants/ .</Citation></Reference><Reference><Citation>Curran T, Sun Z, Gerry B, et al. Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities. Cancer Med. 2021;10(5):1805&#x2013;14. https://doi.org/10.1002/cam4.3753 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.3753</ArticleId></ArticleIdList></Reference><Reference><Citation>Simopoulos AP. Genetic variation, diet, inflammation, and the risk for COVID-19. Lifestyle Genom. 2021;14(2):37&#x2013;42. https://doi.org/10.1159/000513886 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000513886</ArticleId></ArticleIdList></Reference><Reference><Citation>Paremoer L, Nandi S, Serag H, Baum F. Covid-19 pandemic and the social determinants of health. BMJ. 2021;372:n129. Published 2021 Jan 28. https://doi.org/10.1136/bmj.n129.</Citation></Reference><Reference><Citation>Schmidt AL, Bakouny Z, Bhalla S, et al. Cancer care disparities during the COVID-19 pandemic: COVID-19 and cancer outcomes study. Cancer Cell. 2020;38(6):769&#x2013;70. https://doi.org/10.1016/j.ccell.2020.10.023 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2020.10.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis LK, Hsu CH, Arrington AK. Reduction in standard cancer screening in 2020 throughout the U.S. Cancers (Basel). 2021;13(23):5918. https://doi.org/10.3390/cancers13235918.</Citation></Reference><Reference><Citation>Boulware LE. Race Disparities in the COVID-19 pandemic-solutions lie in policy, not biology. JAMA Netw Open. 2020;3(8):e2018696. Published 2020 Aug 3. https://doi.org/10.1001/jamanetworkopen.2020.18696.</Citation></Reference><Reference><Citation>Yearby R, Mohapatra S. Law, structural racism, and the COVID-19 pandemic. J Law Biosci. 2020;7(1):lsaa036. Published 2020 Jun 29. https://doi.org/10.1093/jlb/lsaa036.</Citation></Reference><Reference><Citation>Chowkwanyun M, Reed AL Jr. Racial health disparities and Covid-19 - caution and context. N Engl J Med. 2020;383(3):201&#x2013;3. https://doi.org/10.1056/NEJMp2012910 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2012910</ArticleId></ArticleIdList></Reference><Reference><Citation>Yearby R. Reifying racism in the COVID-19 pandemic response. Am J Bioeth. 2021;21(3):75&#x2013;8. https://doi.org/10.1080/15265161.2020.1870773 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15265161.2020.1870773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon DH, Cadena J, Nguyen S, et al. COVID-19 outcomes in patients with cancer: findings from the University of California health system database. Cancer Med. 2022;11(11):2204&#x2013;15. https://doi.org/10.1002/cam4.4604 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.4604</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833&#x2013;9. https://doi.org/10.1016/j.jiph.2020.07.014 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2020.07.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Klein SL, Garibaldi BT, et al. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev. 2021;65:101205. https://doi.org/10.1016/j.arr.2020.101205 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2020.101205</ArticleId></ArticleIdList></Reference><Reference><Citation>Raza HA, Sen P, Bhatti OA, Gupta L. Sex hormones, autoimmunity and gender disparity in COVID-19. Rheumatol Int. 2021;41(8):1375&#x2013;86. https://doi.org/10.1007/s00296-021-04873-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04873-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907&#x2013;18. https://doi.org/10.1016/S0140-6736(20)31187-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31187-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelo-Branco L, Tsourti Z, Gennatas S, et al. COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE). ESMO Open. 2022;7(3):100499. https://doi.org/10.1016/j.esmoop.2022.100499 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.esmoop.2022.100499</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan SL, Kudo M. Impacts of COVID-19 on liver cancers: during and after the pandemic. Liver Cancer. 2020;9(5):491&#x2013;502. https://doi.org/10.1159/000510765 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000510765</ArticleId></ArticleIdList></Reference><Reference><Citation>Monin L, Laing AG, Mu&#xf1;oz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765&#x2013;78. https://doi.org/10.1016/S1470-2045(21)00213-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(21)00213-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt AL, Labaki C, Hsu CY, et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol. 2022;33(3):340&#x2013;6. https://doi.org/10.1016/j.annonc.2021.12.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2021.12.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Poghosyan H, Dinan MA, Tamamyan G, Nelson L, Jeon S. Racial and ethnic variation in COVID-19 vaccination uptake among Medicare beneficiaries with cancer history [published online ahead of print, 2022 Sep 23]. J Racial Ethn Health Disparities. 2022;1&#x2013;9. https://doi.org/10.1007/s40615-022-01415-2.</Citation></Reference><Reference><Citation>Coronavirus (COVID-19) Vaccinations. Our world in Data. Updated July 4, 2022. Accessed July 5, 2022. https://ourworldindata.org/covid-vaccinations?country=USA .</Citation></Reference><Reference><Citation>MacDonald NE, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015;33(34):4161&#x2013;4. https://doi.org/10.1016/j.vaccine.2015.04.036 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.04.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen M, Bain N, Grech L, et al. COVID&#x2010;19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: a multicenter study. Asia-Pac J Clin Oncol. Published online January 18, 2022. https://doi.org/10.1111/ajco.13754.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637563</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1522-9602</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Bulletin of mathematical biology</Title><ISOAbbreviation>Bull Math Biol</ISOAbbreviation></Journal><ArticleTitle>Modeling and Global Sensitivity Analysis of Strategies to Mitigate Covid-19 Transmission on a Structured College Campus.</ArticleTitle><Pagination><StartPage>13</StartPage><MedlinePgn>13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11538-022-01107-2</ELocationID><Abstract><AbstractText>In response to the COVID-19 pandemic, many higher educational institutions moved their courses on-line in hopes of slowing disease spread. The advent of multiple highly-effective vaccines offers the promise of a return to "normal" in-person operations, but it is not clear if-or for how long-campuses should employ non-pharmaceutical interventions such as requiring masks or capping the size of in-person courses. In this study, we develop and fine-tune a model of COVID-19 spread to UC Merced's student and faculty population. We perform a global sensitivity analysis to consider how both pharmaceutical and non-pharmaceutical interventions impact disease spread. Our work reveals that vaccines alone may not be sufficient to eradicate disease dynamics and that significant contact with an infectious surrounding community will maintain infections on-campus. Our work provides a foundation for higher-education planning allowing campuses to balance the benefits of in-person instruction with the ability to quarantine/isolate infectious individuals.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhao</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Applied Mathematics, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Santiago</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Applied Mathematics, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutter</LastName><ForeName>Erica M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Applied Mathematics, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Sciences Research Institute, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khatri</LastName><ForeName>Shilpa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Applied Mathematics, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Sciences Research Institute, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sindi</LastName><ForeName>Suzanne S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0003-2742-4332</Identifier><AffiliationInfo><Affiliation>Department of Applied Mathematics, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA. ssindi@ucmerced.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Sciences Research Institute, University of California, Merced, 5200 North Lake Rd., Merced, CA, 95343, USA. ssindi@ucmerced.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Bull Math Biol</MedlineTA><NlmUniqueID>0401404</NlmUniqueID><ISSNLinking>0092-8240</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Global sensitivity analysis</Keyword><Keyword MajorTopicYN="N">ODE</Keyword><Keyword MajorTopicYN="N">SEIR</Keyword><Keyword MajorTopicYN="N">Sobol indices</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637563</ArticleId><ArticleId IdType="doi">10.1007/s11538-022-01107-2</ArticleId><ArticleId IdType="pii">10.1007/s11538-022-01107-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Archer G, Saltelli A, Sobol I (1997) Sensitivity measures, ANOVA-like techniques and the use of bootstrap. J Stat Comput Simul 58(2):99&#x2013;120</Citation></Reference><Reference><Citation>Backer JA, Klinkenberg D, Wallinga J (2020) Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20&#x2013;28 January 2020. Eurosurveillance 25(5):2000062</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.5.2000062</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl R, Eikmeier N, Fraser A, Junge M, Keesing F, Nakahata K, Reeves L (2021) Modeling COVID-19 spread in small colleges. PLoS ONE 16(8):e0255654</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255654</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, Liu X, Wei L, Truelove SA, Zhang T et al (2020) Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis 20(8):911&#x2013;919</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30287-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Brlek A, Vidovi&#x10d; &#x160;, Vuzem S, Turk K, Simonovi&#x107; Z (2020) Possible indirect transmission of COVID-19 at a squash court, Slovenia, March 2020: case report. Epidemiol Infect 148</Citation></Reference><Reference><Citation>Buitrago-Garcia D, Ipekci AM, Heron L, Imeri H, Araujo-Chaveron L, Arevalo-Rodriguez I, Ciapponi A, Cevik M, Hauser A, Alam MI et al (2022) Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: update of a living systematic review and meta-analysis. PLoS Med 19(5):e1003987</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003987</ArticleId></ArticleIdList></Reference><Reference><Citation>Callimachi R (2021) For colleges, vaccine mandates often depend on which party is in power. https://www.nytimes.com/2021/05/22/us/college-vaccine-universities.html . Accessed 01 June 2021</Citation></Reference><Reference><Citation>Casey-Bryars M, Griffin J, McAloon C, Byrne A, Madden J, Mc Evoy D, Collins &#xc1;, Hunt K, Barber A, Butler F et al (2021) Presymptomatic transmission of SARS-CoV-2 infection: a secondary analysis using published data. BMJ Open 11(6):e041240</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-041240</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, Piontti APY, Mu K, Rossi L, Sun K et al (2020) The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science 368(6489):395&#x2013;400</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aba9757</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowell G, Brauer F (2009) The basic reproduction number of infectious diseases: computation and estimation using compartmental epidemic models, Mathematical and statistical estimation approaches in epidemiology. Springer, New York, pp 1&#x2013;30</Citation></Reference><Reference><Citation>Ellis L (2020) Colleges hoped for an in-person fall. Now the dream is crumbling. Chron High Educ</Citation></Reference><Reference><Citation>Gatto M, Bertuzzo E, Mari L, Miccoli S, Carraro L, Casagrandi R, Rinaldo A (2020) Spread and dynamics of the COVID-19 epidemic in Italy: effects of emergency containment measures. Proc Natl Acad Sci USA 117(19):10484&#x2013;10491</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2004978117</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert M, Pullano G, Pinotti F, Valdano E, Poletto C, Bo&#xeb;lle PY, d&#x2019;Ortenzio E, Yazdanpanah Y, Eholie SP, Altmann M et al (2020) Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. Lancet 395(10227):871&#x2013;877</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30411-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass LM, Glass RJ (2008) Social contact networks for the spread of pandemic influenza in children and teenagers. BMC Public Health 8(1):1&#x2013;15</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-8-61</ArticleId></ArticleIdList></Reference><Reference><Citation>Gressman PT, Peck JR (2020) Simulating COVID-19 in a university environment. Math Biosci 328:108436</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mbs.2020.108436</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamner L (2020) High SARS-CoV-2 attack rate following exposure at a choir practice&#x2014;Skagit County, Washington, March 2020. Morb Mortal Wkly Rep 69</Citation></Reference><Reference><Citation>Hethcote HW (2000) The mathematics of infectious diseases. SIAM Rev 42(4):599&#x2013;653</Citation><ArticleIdList><ArticleId IdType="doi">10.1137/S0036144500371907</ArticleId></ArticleIdList></Reference><Reference><Citation>Homma T, Saltelli A (1996) Importance measures in global sensitivity analysis of nonlinear models. Reliab Eng Syst Saf 52(1):1&#x2013;17</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0951-8320(96)00002-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard J, Huang A, Li Z, Tufekci Z, Zdimal V, van der Westhuizen HM, von Delft A, Price A, Fridman L, Tang LH, Tang V, Watson GL, Bax CE, Shaikh R, Questier F, Hernandez D, Chu LF, Ramirez CM, Rimoin AW (2021) An evidence review of face masks against COVID-19. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.2014564118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2014564118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivory D, Gebeloff R, Mervosh S (2021) Young people have less Covid-19 risk, but in college towns, deaths rose fast. https://www.nytimes.com/2020/12/12/us/covid-colleges-nursing-homes.html . Accessed 01 June 2021</Citation></Reference><Reference><Citation>Jansen MJ (1999) Analysis of variance designs for model output. Comput Phys Commun 117(1&#x2013;2):35&#x2013;43</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0010-4655(98)00154-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns Hopkins Corona Virus Response Center (2020) Corona virus resource center. COVID-19 Dashboard. https://coronavirus.jhu.edu/map.html . Accessed 13 Oct 2022</Citation></Reference><Reference><Citation>Ke R, Romero-Severson E, Sanche S, Hengartner N (2021) Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination. J Theor Biol 517:110621</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtbi.2021.110621</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucharski AJ, Russell TW, Diamond C, Liu Y, Edmunds J, Funk S, Eggo RM (2020) Centre for mathematical modelling of infectious diseases COVID-19 working group. 2020, May. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect. Dis. 20(5):553&#x2013;558</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30144-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon KS, Park JI, Park YJ, Jung DM, Ryu KW, Lee JH (2020) Evidence of long-distance droplet transmission of SARS-CoV-2 by direct air flow in a restaurant in Korea. J Korean Med Sci 35(46)</Citation></Reference><Reference><Citation>Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J (2020) The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 172(9):577&#x2013;582</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-0504</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A (2021) A global survey of potential acceptance of a COVID-19 vaccine. Nat Med 27(2):225&#x2013;228</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1124-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YH, Hong CM, Kim DH, Lee TH, Lee J (2020) Clinical course of asymptomatic and mildly symptomatic patients with coronavirus disease admitted to community treatment centers, South Korea. Emerg Infect Dis 26(10):2346</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2610.201620</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung K, Jit M, Lau EH, Wu JT (2017) Social contact patterns relevant to the spread of respiratory infectious diseases in Hong Kong. Sci Rep 7(1):1&#x2013;12</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-08241-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J (2020) Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 368(6490):489&#x2013;493</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3221</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Gayle AA, Wilder-Smith A, Rockl&#xf6;v J (2020) The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med</Citation></Reference><Reference><Citation>Lofgren E, Lum K, Horowitz A, Madubuonwu B, Myers K, Fefferman NH (2021) The epidemiological implications of jails for community, corrections officer, and incarcerated population risks from COVID-19. medRxiv. https://doi.org/10.1101/2020.04.08.20058842</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.08.20058842</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopman B, Liu C, Le Guillou A, Handel A, Lash TL, Isakov A, Jenness S (2020) A model of COVID-19 transmission and control on university campuses. medRxiv. https://doi.org/10.1101/2020.06.23.20138677</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.23.20138677</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, Giattino C, Rod&#xe9;s-Guirao L (2021) A global database of COVID-19 vaccinations. Nat Hum Behav 1&#x2013;7</Citation></Reference><Reference><Citation>MathWorks (2020) Statistics and machine learning Toolbox[Formula: see text] R2020a. https://www.mathworks.com/help/stats/</Citation></Reference><Reference><Citation>McCombs A, Kadelka C (2020) A model-based evaluation of the efficacy of COVID-19 social distancing, testing and hospital triage policies. PLoS Comput Biol 16(10):e1008388</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1008388</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizumoto K, Chowell G (2020) Transmission potential of the novel coronavirus (COVID-19) onboard the diamond Princess Cruises Ship, 2020. Infect Dis Model 5:264&#x2013;270</Citation></Reference><Reference><Citation>Moody J (2022) Colleges extend remote instruction. https://www.insidehighered.com/news/2022/01/10/colleges-extend-remote-instruction-period-due-omicron . Accessed 08 Feb 2022</Citation></Reference><Reference><Citation>Muniz-Rodriguez K, Chowell G, Cheung CH, Jia D, Lai PY, Lee Y, Liu M, Ofori SK, Roosa KM, Simonsen L et al (2020) Doubling time of the COVID-19 epidemic by province, China. Emerg Infect Dis 26(8):1912</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2608.200219</ArticleId></ArticleIdList></Reference><Reference><Citation>Nierenberg A, Pasick A (2020) Schools briefing: coronavirus dorms and super spreaders. https://www.nytimes.com/2020/09/09/us/schools-reopening-coronavirus.html . Accessed 01 June 2021</Citation></Reference><Reference><Citation>Nunes-Vaz R (2020) Visualising the doubling time of COVID-19 allows comparison of the success of containment measures. Glob Biosecurity 1(3)</Citation></Reference><Reference><Citation>Oran DP, Topol EJ (2021) The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review. Ann Intern Med 174(5):655&#x2013;662</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-6976</ArticleId></ArticleIdList></Reference><Reference><Citation>Paltiel AD, Zheng A, Walensky RP (2020) Assessment of SARS-CoV-2 screening strategies to permit the safe reopening of college campuses in the United States. JAMA Netw Open 3(7):e2016818&#x2013;e2016818. https://doi.org/10.1001/jamanetworkopen.2020.16818</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.16818</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J, Harb C, Leng W, Marr LC (2021) Inward and outward effectiveness of cloth masks, a surgical mask, and a face shield. Aerosol Sci Technol 55(6):718&#x2013;733</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02786826.2021.1890687</ArticleId></ArticleIdList></Reference><Reference><Citation>Panovska-Griffiths J, Stuart R, Kerr C, Rosenfield K, Mistry D, Waites W, Klein D, Bonell C, Viner R (2022) Modelling the impact of reopening schools in the UK in early 2021 in the presence of the alpha variant and with roll-out of vaccination against SARS-CoV-2. J Math Anal Appl 126050</Citation></Reference><Reference><Citation>Park M, Cook AR, Lim JT, Sun Y, Dickens BL (2020) A systematic review of COVID-19 epidemiology based on current evidence. J Clin Med 9(4):967</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9040967</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SB, Patel P (2020) Doubling time and its interpretation for COVID 19 cases. Natl J Community Med 11:141&#x2013;143</Citation></Reference><Reference><Citation>Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, Singer BH, Galvani AP (2021) Asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. Proc Natl Acad Sci USA 118(34):e2109229118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2109229118</ArticleId></ArticleIdList></Reference><Reference><Citation>Saltelli A, Ratto M, Andres T, Campolongo F, Cariboni J, Gatelli D, Saisana M, Tarantola S (2008) Global sensitivity analysis: the primer. Wiley, New Jersey</Citation></Reference><Reference><Citation>Saltelli A, Annoni P, Azzini I, Campolongo F, Ratto M, Tarantola S (2010) Variance based sensitivity analysis of model output. design and estimator for the total sensitivity index. Comput Phys Commun 181(2):259&#x2013;270</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpc.2009.09.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, Gibbs KW, Erickson HL, Steingrub JS, Smithline HA et al (2020) Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network-United States, March-June 2020. Morb Mortal Wkly Rep 69(30):993&#x2013;998</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend JP, Hassler HB, Sah P, Galvani AP, Dornburg A (2022) The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. Proc Natl Acad Sci USA 119(31):e2204336119</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2204336119</ArticleId></ArticleIdList></Reference><Reference><Citation>Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, Thompson H, Walker PG, Fu H et al (2020) Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 20(6):669&#x2013;677</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30243-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeden KA, Cornwell B (2020) The small-world network of college classes: implications for epidemic spread on a university campus. Sociol Sci 7:222&#x2013;241</Citation><ArticleIdList><ArticleId IdType="doi">10.15195/v7.a9</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization March 11, 2020. WHO Director-General&#x2019;s opening remarks at the media briefing on COVID-19. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 . Accessed 28 June 2020</Citation></Reference><Reference><Citation>Wrighton MS, Lawrence SJ (2020) Reopening colleges and universities during the COVID-19 pandemic. Ann Intern Med 173(8):664&#x2013;665</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-4752</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng-Li S (2021) Origins of SARS-CoV-2: focusing on science. Infect Dis Immun 1(01):3&#x2013;4</Citation></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054&#x2013;1062</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637541</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1076</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>European journal of pediatrics</Title><ISOAbbreviation>Eur J Pediatr</ISOAbbreviation></Journal><ArticleTitle>Efficacy of transcutaneous posterior tibial nerve stimulation in functional constipation.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00431-022-04798-w</ELocationID><Abstract><AbstractText Label="UNLABELLED">Most children with functional constipation (FC) improve with conventional treatments. However, a proportion of children have poor treatment outcomes. Management of intractable FC may include botulinum toxin injections, transanal irrigation, antegrade enemas, colonic resections, and in some cases sacral nerve stimulation (SNS). SNS is surgically placed, not readily available and expensive. Posterior tibial nerve stimulation (PTNS) allows transmission of electronic impulses and retrograde stimulation to the sacral nerve plexus in a portable, simple and non-invasive fashion. To assess the efficacy and safety of transcutaneous PTNS for the treatment of FC in children. Single-center, prospective interventional study. Children 4-14&#xa0;years with Rome IV diagnosis of FC received ten daily PTNS (30&#xa0;min/day) sessions. Electrodes placed over skin of ankle. Strength of stimulus was below pain threshold. Outcomes were assessed during treatment and 7&#xa0;days after. Twenty-three subjects enrolled. Two children excluded (acute gastroenteritis, COVID-19 contact). Twenty completed the study (4-14&#xa0;years), (8.4&#x2009;&#xb1;&#x2009;3.2&#xa0;years, 71.4% female). We found significant improvement in the consistency of bowel movements (BM) (p&#x2009;=&#x2009;0.005), fecal incontinence (FI) (p&#x2009;=&#x2009;0.005), abdominal pain presence (p&#x2009;=&#x2009;&lt;&#x2009;0.001) and intensity (p&#x2009;=&#x2009;0.005), and a significant for improvement in blood in stools (p&#x2009;=&#x2009;0.037). There was 86.3% improvement in abdominal pain. 96.7% reported treatment satisfaction. Only one child required rescue therapy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We found significant improvement in stool consistency, FI, abdominal pain, and hematochezia. This suggests that transcutaneous PTNS could be a promising noninvasive treatment for FC in children. Large studies are needed.</AbstractText><AbstractText Label="WHAT IS KNOWN" NlmCategory="BACKGROUND">&#x2022; Functional constipation is one of the most common disorders in children. &#x2022; Current management of functional constipation consists of an integrative approach that includes medications, diet and behavioral strategies.</AbstractText><AbstractText Label="WHAT IS NEW" NlmCategory="BACKGROUND">&#x2022; Posterior tibial nerve stimulation is a novel noninvasive and easy to use therapy that can improve stool consistency, fecal incontinence and blood in stools.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Velasco-Benitez</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universidad del Valle, Calle 13 # 100-00, Cali Valle Del Cauca, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villamarin</LastName><ForeName>Eder</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Universidad del Valle, Calle 13 # 100-00, Cali Valle Del Cauca, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universidad del Valle, Calle 13 # 100-00, Cali Valle Del Cauca, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linero</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universidad Santiago de Cali, Cl. 5 #No. 62 -00, Cali, Valle del Cauca, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hungria</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Saps</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of Miami, Mailman Center, 1601 NW 12 AVE, Suite 3005A, Miami, FL, 33136, USA. msaps@med.miami.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Pediatr</MedlineTA><NlmUniqueID>7603873</NlmUniqueID><ISSNLinking>0340-6199</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Constipation</Keyword><Keyword MajorTopicYN="N">Fecal incontinence</Keyword><Keyword MajorTopicYN="N">Gastrointestinal motility</Keyword><Keyword MajorTopicYN="N">Posterior tibial nerve</Keyword><Keyword MajorTopicYN="N">Transcutaneous electric nerve stimulation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637541</ArticleId><ArticleId IdType="doi">10.1007/s00431-022-04798-w</ArticleId><ArticleId IdType="pii">10.1007/s00431-022-04798-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koppen IJN, Vriesman MH, Saps M et al (2018) Prevalence of functional defecation disorders in children: a systematic review and meta-analysis. J Pediatr 198:121-130.e6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2018.02.029</ArticleId></ArticleIdList></Reference><Reference><Citation>of the Nourth CG (2006) Evaluation and treatment of constipation in infants and children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 43(3):e1&#x2013;13</Citation></Reference><Reference><Citation>Koppen IJN, Di Lorenzo C, Saps M et al (2016) Childhood Constipation: finally, something is moving! Expert Rev Gastroenterol Hepatol 10(1):141&#x2013;155</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/17474124.2016.1098533</ArticleId></ArticleIdList></Reference><Reference><Citation>Liem O, Harman J, Benninga M et al (2009) Health utilization and cost impact of childhood constipation in the United States. J Pediatr 154(2):258&#x2013;262</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2008.07.060</ArticleId></ArticleIdList></Reference><Reference><Citation>Madani S, Tsang L, Kamat D (2016) Constipation in children: a practical review. Pediatr Ann 1;45(5):e189&#x2013;196</Citation></Reference><Reference><Citation>Tabbers MM, DiLorenzo C, Berger MY et al (2014) Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 58(2):258&#x2013;274</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000000266</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricard J, Qu&#xe9;n&#xe9;herv&#xe9; L, Lefevre C et al (2019) Anterograde Colonic irrigations by percutaneous endoscopic caecostomy in refractory colorectal functional disorders. Int J Colorectal Dis 34(1):169&#x2013;175</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-018-3183-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Vriesman MH, Wang L, Park C et al (2020) Comparison of antegrade continence enema treatment and sacral nerve stimulation for children with severe functional constipation and fecal incontinence. Neurogastroenterol Motil [Internet]. [cited 2020 Dec 6];32(8). Available from: https://onlinelibrary.wiley.com/doi/abs/ , https://doi.org/10.1111/nmo.13809</Citation></Reference><Reference><Citation>Heemskerk SCM, Rotteveel AH, Benninga MA et al (2018) Sacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation: study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysis. Int J Colorectal Dis 33(4):493&#x2013;501</Citation></Reference><Reference><Citation>Lu PL, Koppen IJN, Orsagh-Yentis DK et al (2018) Sacral nerve stimulation for constipation and fecal incontinence in children: long-term outcomes, patient benefit, and parent satisfaction. Neurogastroenterol Motil 30(2):e13184</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13184</ArticleId></ArticleIdList></Reference><Reference><Citation>Vriesman MH, Koppen IJN, Camilleri M et al (2020) Management of functional constipation in children and adults. Nat Rev Gastroenterol Hepatol 17(1):21&#x2013;39</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-019-0222-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco R, Braga A, Disanto G et al (2020) Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients. Mult Scler J 12:135245852097226</Citation></Reference><Reference><Citation>Altunrende B, Sengul N, Arisoy O et al (2013) Transcutaneous electrical posterior tibial nerve stimulation for chronic anal fissure: a preliminary study. Int J Colorectal Dis 28(11):1583&#x2013;1589</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-013-1743-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudaoud N, Binet A, Line A et al (2015) Management of refractory overactive bladder in children by transcutaneous posterior tibial nerve stimulation: a controlled study. J Pediatr Urol 11(3):138.e1-138.e10</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpurol.2014.09.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacic K, Sood MR, Mugie S et al (2015) A multicenter study on childhood constipation and fecal incontinence: effects on quality of life. J Pediatr 166(6):1482-1487.e1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2015.03.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Cushing CC, Martinez-Leo B, Bischoff A et al (2016) Health-Related quality of life and parental stress in children with fecal incontinence: a normative comparison. J Pediatr Gastroenterol Nutr 63(6):633&#x2013;636</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001201</ArticleId></ArticleIdList></Reference><Reference><Citation>Bongers MEJ, van Dijk M, Benninga MA (2009) Health Related quality of life in children with constipation-associated fecal incontinence. J Pediatr 154(5):749-753.e1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2008.11.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lorenzo C, Nurko S, Hyams JS et al (2019) 1151 Linaclotide safety and efficacy in children aged 6 to 17 years with functional constipation. Am J Gastroenterol 114(1):S645&#x2013;S646</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/01.ajg.0000594132.11221.16</ArticleId></ArticleIdList></Reference><Reference><Citation>Mugie SM, Korczowski B, Bodi P et al (2014) Prucalopride is no more effective than placebo for children with functional constipation. Gastroenterology 147(6):1285-1295.e1</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2014.09.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman PE, Di Lorenzo C, Prestridge LL et al (2014) Lubiprostone for the treatment of functional constipation in children: J Pediatr Gastroenterol Nutr 58(3):283&#x2013;291</Citation></Reference><Reference><Citation>Dinning PG, Hunt LM, Arkwright JW et al (2012) Pancolonic motor response to subsensory and suprasensory sacral nerve stimulation in patients with slow-transit constipation. Br J Surg 99(7):1002&#x2013;1010</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.8760</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas GP, Dudding TC, Rahbour G et al (2013) Sacral nerve stimulation for constipation. Br J Surg 100(2):174&#x2013;181</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.8944</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudding TC, Meng Lee E, Faiz O et al (2008) Economic evaluation of sacral nerve stimulation for faecal incontinence. Br J Surg 95(9):115</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.6237</ArticleId></ArticleIdList></Reference><Reference><Citation>Queralto M, Portier G, Cabarrot PH et al (2006) Preliminary results of peripheral transcutaneous neuromodulation in the treatment of idiopathic fecal incontinence. Int J Colorectal Dis 21(7):670&#x2013;672</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-005-0068-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Biemans JMAE, van Balken MR (2013) Efficacy and effectiveness of percutaneous tibial nerve stimulation in the treatment of pelvic organ disorders: a systematic review: PTNS in the treatment of pelvic organ disorders. Neuromodulation Technol Neural Interface 16(1):25&#x2013;34</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1403.2012.00504.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal F, Collins B, Thomas GP et al (2016) Bilateral transcutaneous tibial nerve stimulation for chronic constipation. Colorectal Dis 18(2):173&#x2013;178</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/codi.13105</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lorenzo C, de Jong JR, Benninga MA (2017) Surgical management of children with intractable functional constipation; experience of a single tertiary children&#x2019;s hospital. Neurogastroenterol Motil 29(5):e13005</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637466</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2374-4243</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Infectious diseases (London, England)</Title><ISOAbbreviation>Infect Dis (Lond)</ISOAbbreviation></Journal><ArticleTitle>Novel clinical and immunological features associated with persistent post-acute sequelae of COVID-19 after six months of follow-up: a pilot study.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>12</EndPage><MedlinePgn>1-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/23744235.2022.2158217</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Currently, there is scant information regarding the features associated to the persistence of post-COVID-19 syndrome, which is the main aim of the present study.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A cohort study of 102 COVID-19 patients was conducted. The post-COVID-19 symptoms were assessed by a standardised questionnaire. Lymphocyte immunophenotyping was performed by flow cytometry and chemokines/cytokines, neutrophil extracellular traps, the tripartite motif 63, anti-cellular, and anti-SARS-CoV-2 IgG antibodies were addressed in serum. The primary outcome was the persistence of post-COVID-19 syndrome after six months follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Thirteen patients (12.7%) developed the primary outcome and had a more frequent history of post-COVID-19 syndrome 3&#x2009;months after infection onset (<i>p</i>&#x2009;=&#x2009;.044), increased levels of IL-1&#x3b1; (<i>p</i>&#x2009;=&#x2009;.011) and IP-10 (<i>p</i>&#x2009;=&#x2009;.037) and increased CD57 expression in CD8<sup>+</sup> T cells (<i>p</i>&#x2009;=&#x2009;.003). There was a trend towards higher levels of IFN-&#x3b3; (<i>p</i>&#x2009;=&#x2009;.051), IL-1&#x3b2; (<i>p</i>&#x2009;=&#x2009;.062) and IL-6 (<i>p</i>&#x2009;=&#x2009;.087). The history of post COVID-19 in the previous 3&#x2009;months, obesity, baseline serum MIP-1&#x3b1; and IP-10, and CD57 expression in CD8<sup>+</sup> T cells were independently associated with the persistence of post-COVID-19 syndrome.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Our data suggest an important relationship between a pro-inflammatory state mediated through metabolic pathways related to obesity and increased cellular senescence as a key element in the persistence of post-COVID-19 syndrome at six months of follow-up.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Torres-Ruiz</LastName><ForeName>Jiram</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lomel&#xed;n-Gasc&#xf3;n</LastName><ForeName>Julieta</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Carlos Slim Foundation, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lira Luna</LastName><ForeName>Jaquelin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Secci&#xf3;n de Estudios de Posgrado e Investigaci&#xf3;n Escuela Superior de Medicina-IPN, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas-Castro</LastName><ForeName>Ana Sofia</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Becaria o Becario de la Direcci&#xf3;n General de Calidad y Educaci&#xf3;n en Salud, Secretar&#xed;a de Salud, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Fragoso</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratorio de Inmunoqu&#xed;mica 1, Posgrado en Ciencias Qu&#xed;micobiol&#xf3;gicas, Escuela Nacional de Ciencias Biol&#xf3;gicas, Instituto Polit&#xe9;cnico Nacional.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nu&#xf1;ez-Aguirre</LastName><ForeName>Miroslava</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratorio de Inmunoqu&#xed;mica 1, Posgrado en Ciencias Qu&#xed;micobiol&#xf3;gicas, Escuela Nacional de Ciencias Biol&#xf3;gicas, Instituto Polit&#xe9;cnico Nacional.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcal&#xe1;-Carmona</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratorio de Inmunoqu&#xed;mica 1, Posgrado en Ciencias Qu&#xed;micobiol&#xf3;gicas, Escuela Nacional de Ciencias Biol&#xf3;gicas, Instituto Polit&#xe9;cnico Nacional.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Absal&#xf3;n-Aguilar</LastName><ForeName>Abdiel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balderas-Miranda</LastName><ForeName>Jennifer T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Program of Combined Studies in Medicine, School of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maravillas-Montero</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mej&#xed;a-Dom&#xed;nguez</LastName><ForeName>Nancy R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xfa;&#xf1;ez-&#xc1;lvarez</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llorente</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero-Ram&#xed;rez</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sosa-Hern&#xe1;ndez</LastName><ForeName>Victor Andr&#xe9;s</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervantes-D&#xed;az</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ju&#xe1;rez-Vega</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meza-S&#xe1;nchez</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rull-Gabayet</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Ju&#xe1;rez</LastName><ForeName>Luis Alberto</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Carlos Slim Foundation, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Carlos Slim Foundation, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Temporary COVID-19 Hospital, Hip&#xf3;dromo de las Am&#xe9;ricas, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-L&#xf3;pez</LastName><ForeName>Lizeth Naomi</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Carlos Slim Foundation, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Negrete-Trujillo</LastName><ForeName>Jos&#xe9; Adri&#xe1;n</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Carlos Slim Foundation, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falc&#xf3;n-Lezama</LastName><ForeName>Jorge Abelardo</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Carlos Slim Foundation, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Divisi&#xf3;n Acad&#xe9;mica de Ciencias de la Salud, Universidad Ju&#xe1;rez Aut&#xf3;noma de Tabasco, Villahermosa, Tabasco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valdez-V&#xe1;zquez</LastName><ForeName>Rafael Ricardo</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Temporary COVID-19 Hospital, Hip&#xf3;dromo de las Am&#xe9;ricas, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallardo-Rinc&#xf3;n</LastName><ForeName>H&#xe9;ctor</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tapia-Conyer</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Autonomous University of Mexico, School of Medicine, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Mart&#xed;n</LastName><ForeName>Diana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1807-0045</Identifier><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Red de Apoyo a la Investigaci&#xf3;n, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico e Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Infect Dis (Lond)</MedlineTA><NlmUniqueID>101650235</NlmUniqueID><ISSNLinking>2374-4243</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IP-10</Keyword><Keyword MajorTopicYN="N">MIP-1&#x3b1;</Keyword><Keyword MajorTopicYN="N">Persistent PASC</Keyword><Keyword MajorTopicYN="N">immunoinflamation</Keyword><Keyword MajorTopicYN="N">obesity</Keyword><Keyword MajorTopicYN="N">senescence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637466</ArticleId><ArticleId IdType="doi">10.1080/23744235.2022.2158217</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637405</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-5415</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>The Modified and Extended Hospital Elder Life Program: A remote model of care to expand delirium prevention.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/jgs.18212</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Delirium is a common complication of hospitalization and is associated with poor outcomes. Multicomponent delirium prevention strategies such as the Hospital Elder Life Program (HELP) have proven effective but rely on face-to-face intervention protocols and volunteer staff, which was not possible due to restrictions during the COVID-19 pandemic. We developed the Modified and Extended Hospital Elder Life Program (HELP-ME), an innovative adaptation of HELP for remote and/or physically distanced applications.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">HELP-ME protocols were adapted from well-established multicomponent delirium prevention strategies and were implemented at four expert HELP sites. Each site contributed to the protocol modifications and compilation of a HELP-ME Operations Manual with standardized protocols and training instructions during three expert panel working groups. Implementation was overseen and monitored during seven learning sessions plus four coaching sessions from January 8, 2021, through September 24, 2021. Feasibility of implementing HELP-ME was measured by protocol adherence rates. Focus groups were conducted to evaluate the acceptability, provide feedback, and identify facilitators and barriers to implementation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 106 patients were enrolled across four sites, and data were collected for 214 patient-days. Overall adherence was 82% (1473 completed protocols/1798 patient-days), achieving our feasibility target of &gt;75% overall adherence. Individual adherence rates ranged from 55% to 96% across sites for the individual protocols. Protocols with high adherence rates included the nursing delirium protocol (96%), nursing medication review (96%), vision (89%), hearing (87%), and orientation (88%), whereas lower adherence occurred with fluid repletion (64%) and range-of-motion exercises (55%). Focus group feedback was generally positive for acceptability, with recommendations that an optimal approach would be hybrid, balancing in-person and remote interventions for potency and long-term sustainability.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HELP-ME was fully implemented at four HELP sites, demonstrating feasibility and acceptability. Testing hybrid approaches and evaluating effectiveness is recommended for future work.</AbstractText><CopyrightInformation>&#xa9; 2023 The American Geriatrics Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Tamara G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aging Brain Center, Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albaum</LastName><ForeName>Jason A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Biochemistry Program, Vassar College, Poughkeepsie, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Molly L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, Maine Medical Center, Portland, Maine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Sara G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>California Pacific Medical Center, Sutter Health, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Shauni</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, Primary Care Institute, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Supiano</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-5438-5087</Identifier><AffiliationInfo><Affiliation>Geriatrics Division, University of Utah School of Medicine and University of Utah Center on Aging, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlisides</LastName><ForeName>Philip E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Michigan Medicine, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Consciousness Science, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wade</LastName><ForeName>Harley L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, Maine Medical Center, Portland, Maine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinberg</LastName><ForeName>Lyn</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, Primary Care Institute, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wierman</LastName><ForeName>Heidi R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, Maine Medical Center, Portland, Maine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zachary</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>California Pacific Medical Center, Sutter Health, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inouye</LastName><ForeName>Sharon K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Aging Brain Center, Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>HELP-ME Writing Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R33AG071744</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">delirium</Keyword><Keyword MajorTopicYN="N">delirium prevention</Keyword><Keyword MajorTopicYN="N">multicomponent</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>10</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637405</ArticleId><ArticleId IdType="doi">10.1111/jgs.18212</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Wilson JE, Mart MF, Cunningham C, et al. Delirium. Nat Rev Dis Primers. 2020;6:90.</Citation></Reference><Reference><Citation>Leslie DL, Marcantonio ER, Zhang Y, Leo-Summers L, Inouye SK. One-year health care costs associated with delirium in the elderly population. Arch Intern Med. 2008;168:27-32.</Citation></Reference><Reference><Citation>Hshieh TT, Inouye SK, Oh ES. Delirium in the elderly. Clin Geriatr Med. 2020;36:183-199.</Citation></Reference><Reference><Citation>Hshieh TT, Yue J, Oh E, et al. Effectiveness of multicomponent nonpharmacological delirium interventions: a meta-analysis. JAMA Intern Med. 2015;175:512-520.</Citation></Reference><Reference><Citation>Khan A, Boukrina O, Oh-Park M, Flanagan NA, Singh M, Oldham M. Preventing delirium takes a village: systematic review and meta-analysis of delirium preventive models of care. J Hosp Med. 2019;14:E1-e7.</Citation></Reference><Reference><Citation>Inouye SK, Bogardus ST Jr, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999;340:669-676.</Citation></Reference><Reference><Citation>Hshieh TT, Yang T, Gartaganis SL, Yue J, Inouye SK. Hospital Elder Life Program: systematic review and meta-analysis of effectiveness. Am J Geriatr Psychiatry. 2018;26:1015-1033.</Citation></Reference><Reference><Citation>Inouye SK, Bogardus ST Jr, Baker DI, Leo-Summers L, Cooney LM Jr. The Hospital Elder Life Program: a model of care to prevent cognitive and functional decline in older hospitalized patients. Hospital Elder Life Program. J Am Geriatr Soc. 2000;48:1697-1706.</Citation></Reference><Reference><Citation>Rubin FH, Neal K, Fenlon K, Hassan S, Inouye SK. Sustainability and scalability of the Hospital Elder Life Program at a community hospital. J Am Geriatr Soc. 2011;59:359-365.</Citation></Reference><Reference><Citation>Rubin FH, Williams JT, Lescisin DA, Mook WJ, Hassan S, Inouye SK. Replicating the Hospital Elder Life Program in a community hospital and demonstrating effectiveness using quality improvement methodology. J Am Geriatr Soc. 2006;54:969-974.</Citation></Reference><Reference><Citation>Caplan GA, Harper EL. Recruitment of volunteers to improve vitality in the elderly: the REVIVE study. Intern Med J. 2007;37:95-100.</Citation></Reference><Reference><Citation>Rubin FH, Bellon J, Bilderback A, Urda K, Inouye SK. Effect of the Hospital Elder Life Program on risk of 30-day readmission. J Am Geriatr Soc. 2018;66:145-149.</Citation></Reference><Reference><Citation>Zachary W, Kirupananthan A, Cotter S, Barbara GH, Cooke RC 3rd, Sipho M. The impact of Hospital Elder Life Program interventions, on 30-day readmission rates of older hospitalized patients. Arch Gerontol Geriatr. 2020;86:103963.</Citation></Reference><Reference><Citation>Wang YY, Yue JR, Xie DM, et al. Effect of the tailored, family-involved Hospital Elder Life Program on postoperative delirium and function in older adults: a randomized clinical trial. JAMA Intern Med. 2020;180:17-25.</Citation></Reference><Reference><Citation>Chen CC, Li HC, Liang JT, et al. Effect of a modified Hospital Elder Life Program on delirium and length of hospital stay in patients undergoing abdominal surgery: a cluster randomized clinical trial. JAMA Surg. 2017;152:827-834.</Citation></Reference><Reference><Citation>Simpson M, Macias Tejada J, Driscoll A, Singh M, Klein M, Malone M. The bundled Hospital Elder Life Program-HELP and HELP in home care-and its association with clinical outcomes among older adults discharged to home healthcare. J Am Geriatr Soc. 2019;67:1730-1736.</Citation></Reference><Reference><Citation>Boockvar KS, Judon KM, Eimicke JP, Teresi JA, Inouye SK. Hospital Elder Life Program in long-term care (HELP-LTC): a cluster randomized controlled trial. J Am Geriatr Soc. 2020;68:2329-2335.</Citation></Reference><Reference><Citation>Boockvar KS, Teresi JA, Inouye SK. Preliminary data: an adapted Hospital Elder Life Program to prevent delirium and reduce complications of acute illness in long-term care delivered by certified nursing assistants. J Am Geriatr Soc. 2016;64:1108-1113.</Citation></Reference><Reference><Citation>Huson K, Stolee P, Pearce N, Bradfield C, Heckman GA. Examining the Hospital Elder Life Program in a rehabilitation setting: a pilot feasibility study. BMC Geriatr. 2016;16:140.</Citation></Reference><Reference><Citation>Kojaie-Bidgoli A, Sharifi F, Maghsoud F, Alizadeh-Khoei M, Jafari F, Sadeghi F. The modified Hospital Elder Life Program (HELP) in geriatric hospitalized patients in internal wards: a double-blind randomized control trial. BMC Geriatr. 2021;21:599.</Citation></Reference><Reference><Citation>Gan JM, Kho J, Akhunbay-Fudge M, et al. Atypical presentation of COVID-19 in hospitalised older adults. Ir J Med Sci. 2021;190:469-474.</Citation></Reference><Reference><Citation>O'Hanlon S, Inouye SK. Delirium: a missing piece in the COVID-19 pandemic puzzle. Age Ageing. 2020;49:497-498.</Citation></Reference><Reference><Citation>Ward CF, Figiel GS, McDonald WM. Altered mental status as a novel initial clinical presentation for COVID-19 infection in the elderly. Am J Geriatr Psychiatry. 2020;28:808-811.</Citation></Reference><Reference><Citation>Dalkey N, Helmer O. An experimental application of the DELPHI method to the use of experts. Manag Sci. 1963;9:458-467.</Citation></Reference><Reference><Citation>Inouye SK. The importance of delirium and delirium prevention in older adults during lockdowns. JAMA. 2021;325:1779-1780.</Citation></Reference><Reference><Citation>Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990;113:941-948.</Citation></Reference><Reference><Citation>Fick DM, Inouye SK, Guess J, et al. Preliminary development of an ultrabrief two-item bedside test for delirium. J Hosp Med. 2015;10:645-650.</Citation></Reference><Reference><Citation>Fick DM, Inouye SK, McDermott C, et al. Pilot study of a two-step delirium detection protocol administered by certified nursing assistants, physicians, and registered nurses. J Gerontol Nurs. 2018;44:18-24.</Citation></Reference><Reference><Citation>Husser EK, Fick DM, Boltz M, et al. Implementing a rapid, two-step delirium screening protocol in acute care: barriers and facilitators. J Am Geriatr Soc. 2021;69:1349-1356.</Citation></Reference><Reference><Citation>Motyl CM, Ngo L, Zhou W, et al. Comparative accuracy and efficiency of four delirium screening protocols. J Am Geriatr Soc. 2020;68:2572-2578.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637383</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2463-0225</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>Revista colombiana de obstetricia y ginecologia</Title><ISOAbbreviation>Rev Colomb Obstet Ginecol</ISOAbbreviation></Journal><ArticleTitle>[Not Available].</ArticleTitle><Pagination><StartPage>408</StartPage><EndPage>409</EndPage><MedlinePgn>408-409</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18597/rcog.3978</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fl&#xf3;rez-Victoria</LastName><ForeName>Orlando Javier</ForeName><Initials>OJ</Initials><AffiliationInfo><Affiliation>Federaci&#xf3;n Colombiana de Obstetricia y Ginecolog&#xed;a, Bogot&#xe1; (Colombia). fecolsog@fecolsog.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Carta al editor en relaci&#xf3;n con el art&#xed;culo titulado: Reflexiones acerca del desempe&#xf1;o del ministro de Salud de Colombia en el manejo de la pandemia de COVID-19, la salud sexual y reproductiva, y la salud p&#xfa;blica.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Colombia</Country><MedlineTA>Rev Colomb Obstet Ginecol</MedlineTA><NlmUniqueID>0404263</NlmUniqueID><ISSNLinking>0034-7434</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637383</ArticleId><ArticleId IdType="doi">10.18597/rcog.3978</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637379</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1931-7913</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>CBE life sciences education</Title><ISOAbbreviation>CBE Life Sci Educ</ISOAbbreviation></Journal><ArticleTitle>Costs and Benefits of Undergraduates Revealing Depression to Online Science Instructors.</ArticleTitle><Pagination><StartPage>ar9</StartPage><MedlinePgn>ar9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1187/cbe.22-05-0088</ELocationID><Abstract><AbstractText>Depression is one of the leading mental health concerns among science undergraduates, and rates of student depression increased during the COVID-19 pandemic. Revealing one's depression in an academic science environment can be helpful, because it can result in increased support from others. However, depression is considered a concealable stigmatized identity, meaning that it can be kept hidden and may carry a stigma. A national pivot to online learning owing to COVID-19 not only increased the need to bolster student mental health, but also presented a novel learning environment. However, it is unclear to what extent students revealed their depression in science courses and why. We surveyed 1179 undergraduates with depression at a research-intensive institution about whether they had revealed their depression to an online college science instructor. Very few undergraduates (5.9%) had revealed their depression to online science instructors; students who identify as LGBTQ+, have lower grade point averages, or experience more severe depression were more likely to reveal their depression to an instructor. Undergraduates reported potential benefits from doing so, including building a connection with the instructor and receiving accommodations. This work provides insight into steps science instructors can take to foster inclusive course environments for students with depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Busch</LastName><ForeName>Carly A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Research for Inclusive STEM Education Center, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammed</LastName><ForeName>Tasneem F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Research for Inclusive STEM Education Center, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadile</LastName><ForeName>Erika M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witt</LastName><ForeName>Madison L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas</LastName><ForeName>Cindy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Missy</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Joseph Gazing</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Research for Inclusive STEM Education Center, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brister</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biology Education Research Course, School of Life Sciences, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Katelyn M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Research for Inclusive STEM Education Center, Arizona State University, Tempe, AZ 85287.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CBE Life Sci Educ</MedlineTA><NlmUniqueID>101269039</NlmUniqueID><ISSNLinking>1931-7913</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637379</ArticleId><ArticleId IdType="doi">10.1187/cbe.22-05-0088</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637356</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1122-0643</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace</Title><ISOAbbreviation>Monaldi Arch Chest Dis</ISOAbbreviation></Journal><ArticleTitle>Acute myocardial infarction during late COVID-19 era: patient characteristics, presentation and outcomes.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4081/monaldi.2023.2502</ELocationID><Abstract><AbstractText>COVID-19 pandemic has unquestionably influenced care of acute myocardial infarction (AMI). Still, its impact on patients (pts) characteristics, presentation, treatment, and outcomes remains not well established in late pandemic times. To address this issue, we performed a prospective study of type-1 AMI pts admitted in a tertiary care hospital. Pts were enrolled during 6-months in 2019 (n=122; pre-COVID-19 (PC) group) and in 2021 (n=196; late-COVID-19 (C) group). Data was based on pts interview and review of medical records. Age and gender distribution, as well as ST/Non-ST-Elevation Myocardial Infarction (STEMI/NSTEMI) proportion and access to coronariography and revascularization were similar between groups. C pts presented more pre-existing established cardiovascular disease (CVD) (43% vs 30%; p=0,03); more frequent description of typical chest pain (94% vs 84%; p=0,002); higher levels of pain intensity, in a 0-10 scale (8&#xb1;2 vs 7&#xb1;2; p=0,02); higher frequencies of AMI complications (27% vs 15%; p=0,01) and worse Killip (K) class evolution (K&#x2265;2 in 22% C vs 13% PC pts; p=0,05). In conclusion, late pandemic AMI pts presented worse in-hospital outcomes in our study, though pre-hospital and hospital care were comparable to pre-pandemic times. Covid pts had a higher burden of pre-existing established CVD and a more typical and intense symptom presentation. Therefore, it can be hypothesized that "sicker" pts continued to look for help when presenting AMI symptoms, while "less sick" pts and the ones with less typical and intense symptoms possibly avoided contact with health care services during late pandemic period.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marques</LastName><ForeName>Catarina Amaral</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto. catarinamarques5@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabrita</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto. afocabrita@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ara&#xfa;jo</LastName><ForeName>Paulo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto. pauloamfa@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proen&#xe7;a</LastName><ForeName>T&#xe2;nia</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto. taniagproenca@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto. ricardojrapinto@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto. jmiguelmartinscarvalho@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Catarina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto. catarinamarcosta@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amador</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto. a.filipa.amador@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calv&#xe3;o</LastName><ForeName>Jo&#xe3;o</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto. joaocalvao1@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto. mcristina.cruz66@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Monaldi Arch Chest Dis</MedlineTA><NlmUniqueID>9307314</NlmUniqueID><ISSNLinking>1122-0643</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637356</ArticleId><ArticleId IdType="doi">10.4081/monaldi.2023.2502</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637221</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1550-6606</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>11</Day></PubDate></JournalIssue><Title>Journal of immunology (Baltimore, Md. : 1950)</Title><ISOAbbreviation>J Immunol</ISOAbbreviation></Journal><ArticleTitle>Soluble Signal Inhibitory Receptor on Leukocytes-1 Is Released from Activated Neutrophils by Proteinase 3 Cleavage.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ji2200169</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.2200169</ELocationID><Abstract><AbstractText>Signal inhibitory receptor on leukocytes-1 (SIRL-1) is an immune inhibitory receptor expressed on human granulocytes and monocytes that dampens antimicrobial functions. We previously showed that sputum neutrophils from infants with severe respiratory syncytial virus (RSV) bronchiolitis have decreased SIRL-1 surface expression compared with blood neutrophils and that SIRL-1 surface expression is rapidly lost from in&#xa0;vitro activated neutrophils. This led us to hypothesize that activated neutrophils lose SIRL-1 by ectodomain shedding. Here, we developed an ELISA and measured the concentration of soluble SIRL-1 (sSIRL-1) in patients with RSV bronchiolitis and hospitalized patients with COVID-19, which are both characterized by neutrophilic inflammation. In line with our hypothesis, sSIRL-1 concentration was increased in sputum compared with plasma of patients with RSV bronchiolitis and in serum of hospitalized patients with COVID-19 compared with control serum. In addition, we show that in&#xa0;vitro activated neutrophils release sSIRL-1 by proteolytic cleavage and that this diminishes the ability to inhibit neutrophilic reactive oxygen species production via SIRL-1. Finally, we found that SIRL-1 shedding is prevented by proteinase 3 inhibition and by extracellular adherence protein from Staphylococcus aureus. Notably, we recently showed that SIRL-1 is activated by PSM&#x3b1;3 from S. aureus, suggesting that S. aureus may counteract SIRL-1 shedding to benefit from preserved inhibitory function of SIRL-1. In conclusion, we report that SIRL-1 is released from activated neutrophils by proteinase 3 cleavage and that endogenous sSIRL-1 protein is present in&#xa0;vivo.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 by The American Association of Immunologists, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>von Richthofen</LastName><ForeName>Helen J</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0002-2062-5986</Identifier><AffiliationInfo><Affiliation>Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oncode Institute, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westerlaken</LastName><ForeName>Geertje H A</ForeName><Initials>GHA</Initials><AffiliationInfo><Affiliation>Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oncode Institute, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gollnast</LastName><ForeName>Doron</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oncode Institute, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besteman</LastName><ForeName>Sjanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delemarre</LastName><ForeName>Eveline M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodenburg</LastName><ForeName>Karlijn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moerer</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stapels</LastName><ForeName>Daphne A C</ForeName><Initials>DAC</Initials><Identifier Source="ORCID">0000-0001-7058-541X</Identifier><AffiliationInfo><Affiliation>Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andiappan</LastName><ForeName>Anand K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0002-8442-1544</Identifier><AffiliationInfo><Affiliation>Singapore Immunology Network, Agency for Science, Technology and Research, Singapore; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xf6;tzschke</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Singapore Immunology Network, Agency for Science, Technology and Research, Singapore; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nierkens</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leavis</LastName><ForeName>Helen L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bont</LastName><ForeName>Louis J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rooijakkers</LastName><ForeName>Suzan H M</ForeName><Initials>SHM</Initials><Identifier Source="ORCID">0000-0003-4102-0377</Identifier><AffiliationInfo><Affiliation>Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyaard</LastName><ForeName>Linde</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0707-4793</Identifier><AffiliationInfo><Affiliation>Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oncode Institute, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Immunol</MedlineTA><NlmUniqueID>2985117R</NlmUniqueID><ISSNLinking>0022-1767</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>8</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637221</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.2200169</ArticleId><ArticleId IdType="pii">237652</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637213</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1445-2197</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>ANZ journal of surgery</Title><ISOAbbreviation>ANZ J Surg</ISOAbbreviation></Journal><ArticleTitle>Same day discharge for robot-assisted radical prostatectomy: a prospective cohort study documenting an Australian approach.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/ans.18198</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The introduction of robotic surgical systems has significantly impacted urological surgery, arguably more so than other surgical disciplines. The focus of our study was length of hospital stay - patients have traditionally been discharged day 1 post-robot-assisted radical prostatectomy (RARP), however, during the ongoing COVID-19 pandemic and consequential resource limitations, our centre has facilitated a cohort of same-day discharges with initial success.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a prospective tertiary single-centre cohort study of a series of all patients (n&#xa0;=&#x2009;28) - undergoing RARP between January and April 2021. All patients were considered for a day zero discharge pathway which consisted of strict inclusion criteria. At follow-up, each patient's perspective on their experience was assessed using a validated post-operative satisfaction questionnaire. Data were reviewed retrospectively for all those undergoing RARP over the study period, with day zero patients compared to overnight patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 28 patients 20 (71%) fulfilled the objective criteria for day zero discharge. Eleven patients (55%) agreed pre-operatively to day zero discharge and all were successfully discharged on the same day as their procedure. There was no statistically significant difference in age, BMI, ASA, Charlson score or disease volume. All patients indicated a high level of satisfaction with their procedure. Median time from completion of surgery to discharge was 426&#x2009;min (7.1&#xa0;h) in the day zero discharge cohort.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Day zero discharge for RARP appears to deliver high satisfaction, oncological and safety outcomes. Therefore, our study demonstrates early success with unsupported same-day discharge in carefully selected and pre-counselled patients.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. ANZ Journal of Surgery published by John Wiley &amp; Sons Australia, Ltd on behalf of Royal Australasian College of Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mulholland</LastName><ForeName>Clancy</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2093-2775</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soliman</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Urology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furrer</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Urology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Royal Melbourne Hospital, University of Melbourne, The Australian Medical Robotics Academy, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sathianathen</LastName><ForeName>Niranjan</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-3710-014X</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcoran</LastName><ForeName>Niall M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Urology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schramm</LastName><ForeName>Belinda</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mertens</LastName><ForeName>Evie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Urology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Royal Melbourne Hospital, University of Melbourne, The Australian Medical Robotics Academy, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costello</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3083-1799</Identifier><AffiliationInfo><Affiliation>Department of Urology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Royal Melbourne Hospital, University of Melbourne, The Australian Medical Robotics Academy, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawrentschuk</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Urology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dundee</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Urology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Royal Melbourne Hospital, University of Melbourne, The Australian Medical Robotics Academy, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Urology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Royal Melbourne Hospital, University of Melbourne, The Australian Medical Robotics Academy, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>ANZ J Surg</MedlineTA><NlmUniqueID>101086634</NlmUniqueID><ISSNLinking>1445-1433</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ERAS</Keyword><Keyword MajorTopicYN="N">RARP</Keyword><Keyword MajorTopicYN="N">prostate cancer</Keyword><Keyword MajorTopicYN="N">prostatectomy</Keyword><Keyword MajorTopicYN="N">robotic</Keyword><Keyword MajorTopicYN="N">surgical oncology</Keyword><Keyword MajorTopicYN="N">urology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>8</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637213</ArticleId><ArticleId IdType="doi">10.1111/ans.18198</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Ilic D, Evans SM, Allan CA, Jung JH, Murphy D, Frydenberg M. Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer. Cochrane Database Syst. Rev. 2017; 9.</Citation></Reference><Reference><Citation>Basto M, Sathianathen N, Te Marvelde L et al. Patterns-of-care and health economic analysis of robot-assisted radical prostatectomy in the Australian public health system. BJU Int. 2016; 117: 930-9.</Citation></Reference><Reference><Citation>Rosenberg JE, Jung JH, Edgerton Z et al. Retzius-sparing versus standard robot-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer. BJU Int. 2021; 128: 12-20.</Citation></Reference><Reference><Citation>McBride K, Steffens D, Stanislaus C et al. Detailed cost of robotic-assisted surgery in the Australian public health sector: from implementation to a multi-specialty caseload. BMC Health Serv. Res. 2021; 21: 108.</Citation></Reference><Reference><Citation>Abaza R, Martinez O, Ferroni MC, Bsatee A, Gerhard RS. Same day discharge after robotic radical prostatectomy. J. Urol. 2019; 202: 959-63.</Citation></Reference><Reference><Citation>Banapour P, Elliott P, Jabaji R et al. Safety and feasibility of outpatient robot-assisted radical prostatectomy. J. Robot. Surg. 2019; 13: 261-5.</Citation></Reference><Reference><Citation>Berger AK, Chopra S, Desai MM, Aron M, Gill IS. Outpatient robotic radical prostatectomy: matched-pair comparison with inpatient surgery. J. Endourol. 2016; 30: S52-6.</Citation></Reference><Reference><Citation>Dobbs RW, Nguyen TT, Shahait M et al. Outpatient robot-assisted radical prostatectomy: are patients ready for same-day discharge? J. Endourol. 2020; 34: 450-5.</Citation></Reference><Reference><Citation>Khalil MI, Bhandari NR, Payakachat N, Davis R, Raheem OA, Kamel MH. Perioperative mortality and morbidity of outpatient versus inpatient robot-assisted radical prostatectomy: a propensity matched analysis. Urol. Oncol. 2020; 38: 3.e1-6.</Citation></Reference><Reference><Citation>Ploussard G, Almeras C, Beauval J-B et al. Same-day discharge surgery for robot-assisted radical prostatectomy in the era of ERAS and prehabilitation pathways: a contemporary, comparative, feasibility study. World J. Urol. 2020; 204: 956-61.</Citation></Reference><Reference><Citation>Wolboldt M, Saltzman B, Tenbrink P, Shahrour K, Jain S. Same-day discharge for patients undergoing robot-assisted laparoscopic radical prostatectomy is safe and feasible: results of a pilot study. J. Endourol. 2016; 30: 1296-300.</Citation></Reference><Reference><Citation>Martin AD, Nunez RN, Andrews JR, Martin GL, Andrews PE, Castle EP. Outpatient prostatectomy: too much too soon or just what the patient ordered. Urology 2010; 75: 421-4.</Citation></Reference><Reference><Citation>Reynolds BR, Bulsara C, Zeps N et al. Exploring pathways towards improving patient experience of robot-assisted radical prostatectomy (RARP): assessing patient satisfaction and attitudes. BJU Int. 2018; 121: 33-9.</Citation></Reference><Reference><Citation>Hall RM, Linklater N, Coughlin G. Robotic and open radical prostatectomy in the public health sector: cost comparison. ANZ J. Surg. 2014; 84: 477-80.</Citation></Reference><Reference><Citation>Moschovas MC, Bhat S, Rogers T et al. Managing patients with prostate cancer during COVID-19 pandemic: the experience of a high-volume robotic surgery center. J. Endourol. 2020; 35: 305-11.</Citation></Reference><Reference><Citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 2004; 240: 205-13.</Citation></Reference><Reference><Citation>Furrer MA, Abgottspon J, Huber M et al. Perioperative continuation of aspirin, oral anticoagulants or bridging with therapeutic low-molecular weight heparin does not increase intraoperative blood loss and blood transfusion rate in cystectomy patients: an observational cohort study. BJU Int. 2021; 129: 512-23.</Citation></Reference><Reference><Citation>Sighinolfi MC, Eissa A, Spandri V et al. Positive surgical margin during radical prostatectomy: overview of sampling methods for frozen sections and techniques for the secondary resection of the neurovascular bundles. BJU Int. 2020; 125: 656-63.</Citation></Reference><Reference><Citation>Murphy DG, Kerger M, Crowe H, Peters JS, Costello AJ. Operative details and oncological and functional outcome of robotic-assisted laparoscopic radical prostatectomy: 400 cases with a minimum of 12 months follow-up. Eur. Urol. 2009; 55: 1358-66.</Citation></Reference><Reference><Citation>Haff RE, Stoltzfus J, Lucente VR, Murphy M. The surgical satisfaction questionnaire (SSQ-8): a validated tool for assessment of patient satisfaction following surgery to correct prolapse and/or incontinence. J. Minim. Invasive Gynecol. 2011; 18: S49-50.</Citation></Reference><Reference><Citation>No&#xeb;l J, Moschovas MC, Sandri M et al. Patient surgical satisfaction after da Vinci&#xae; single-port and multi-port robotic-assisted radical prostatectomy: propensity score-matched analysis. J. Robot. Surg. 2021; 16: 473-81.</Citation></Reference><Reference><Citation>Carter B, Collins JT, Barlow-Pay F et al. Nosocomial COVID-19 infection: examining the risk of mortality. The COPE-nosocomial study (COVID in older people). J. Hosp. Infect. 2020; 106: 376-84.</Citation></Reference><Reference><Citation>Moschovas MC, Sighinolfi MC, Rocco B et al. Balancing the effects of COVID-19 against potential progression and mortality in high-risk prostate cancer. Eur. Urol. 2020; 78: e14-e5.</Citation></Reference><Reference><Citation>Obek C, Doganca T, Argun OB, Kural AR. Management of prostate cancer patients during COVID-19 pandemic. Prostate Cancer Prostatic Dis. 2020; 23: 398-406.</Citation></Reference><Reference><Citation>Hughes D, Camp C, O'Hara J, Adshead J. Health resource use after robot-assisted surgery vs open and conventional laparoscopic techniques in oncology: analysis of English secondary care data for radical prostatectomy and partial nephrectomy. BJU Int. 2016; 117: 940-7.</Citation></Reference><Reference><Citation>Tandogdu Z, Collins J, Shaw G et al. Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID-19) pandemic: an international accelerated consensus statement. BJU Int. 2021; 127: 729-41.</Citation></Reference><Reference><Citation>Dirie J, Mahesan T, Hart E et al. Delivering safe and timely cancer care during COVID-19: lessons and successes from the transition period. BJU Int. 2021; 127: 633-5.</Citation></Reference><Reference><Citation>Uimonen M, Kuitunen I, Seikkula H, Mattila VM, Ponkilainen V. Healthcare lockdown resulted in a treatment backlog in elective urological surgery during COVID-19. BJU Int. 2021; 128: 33-5.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637209</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1462-0332</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Rheumatology (Oxford, England)</Title><ISOAbbreviation>Rheumatology (Oxford)</ISOAbbreviation></Journal><ArticleTitle>A Phase II randomised controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">kead012</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/rheumatology/kead012</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Although the painful and disabling features of early diffuse cutaneous systemic sclerosis (dcSSc) have an inflammatory basis and could respond to corticosteroids, corticosteroids are a risk factor for scleroderma renal crisis. Whether or not they should be prescribed is therefore highly contentious. Our aim was to examine safety and efficacy of moderate dose prednisolone in early dcSSc.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PRedSS set out as a Phase II, multicentre, double-blind randomised controlled trial, converted to open-label during the Covid-19 pandemic. Patients were randomised to receive either prednisolone (&#x223c;0.3&#x2009;mg/kg) or matching placebo (or no treatment during open-label) for 6&#x2009;months. Co-primary endpoints were the Health Assessment Questionnaire Disability Index (HAQ-DI) and modified Rodnan skin core (mRSS) at 3&#x2009;months. Over 20 secondary endpoints included patient reported outcome measures reflecting pain, itch, fatigue, anxiety and depression, and helplessness. Target recruitment was 72 patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-five patients were randomised (17 prednisolone, 18 placebo/control). The adjusted mean difference between treatment groups at 3&#x2009;months in HAQ-DI score was -0.10 (97.5% CI -0.29-0.10), p= 0.254, and in mRSS -3.90 (97.5% CI -8.83-1.03), p= 0.070, both favouring prednisolone but not significantly. Patients in the prednisolone group experienced significantly less pain (p= 0.027), anxiety (p= 0.018) and helplessness (p= 0.040) than control patients at 3&#x2009;months. There were no renal crises, but sample size was small.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PRedSS was terminated early primarily due to the Covid-19 pandemic, and so was underpowered. Therefore, interpretation must be cautious and results considered inconclusive, indicating the need for a further randomised trial.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov, https://clinicaltrials.gov, NCT03708718.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Griffiths-Jones</LastName><ForeName>Deborah J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Yvonne Sylvestre</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Manchester Clinical Trials Unit, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryder</LastName><ForeName>W David</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Manchester Clinical Trials Unit, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pauling</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Royal United Hospitals Bath NHS Trust, Bath, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Frances</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanyon</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Nottingham University Hospitals NHS Trust, and Lifespan and Population Health, School of Medicine, University of Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhat</LastName><ForeName>Smita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Ninewells Hospital and Medical School, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douglas</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Dudley Group NHSFT, Dudley, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunawardena</LastName><ForeName>Harsha</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Rheumatology Department, North Bristol NHS Trust, and Academic Rheumatology, University of, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akil</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust, Glossop Road, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Lancaster Medical School, Faculty of Health and Medicine, Lancaster University, Lancaster and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffiths</LastName><ForeName>Bridget</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Galdo</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre and Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youssef</LastName><ForeName>Hazem</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Aberdeen Royal Infirmary, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madhok</LastName><ForeName>Rajan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Rheumatic Diseases, Glasgow Royal Infirmary, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arthurs</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buch</LastName><ForeName>Maya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fligelstone</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Royal Free Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zubair</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Governance and Integrity, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Justin C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denton</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Centre for Rheumatology, UCL Division of Medicine, Royal Free Campus, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrick</LastName><ForeName>Ariane L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0003-4941-7926</Identifier><AffiliationInfo><Affiliation>Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03708718</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rheumatology (Oxford)</MedlineTA><NlmUniqueID>100883501</NlmUniqueID><ISSNLinking>1462-0324</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Systemic sclerosis</Keyword><Keyword MajorTopicYN="N">corticosteroids</Keyword><Keyword MajorTopicYN="N">disability</Keyword><Keyword MajorTopicYN="N">pain</Keyword><Keyword MajorTopicYN="N">randomised controlled trial</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>8</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637209</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/kead012</ArticleId><ArticleId IdType="pii">6986975</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637174</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1764-1489</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>European annals of allergy and clinical immunology</Title><ISOAbbreviation>Eur Ann Allergy Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>Skin Atrophy after diagnostic tests with corticosteroids for the diagnosis of SARS-CoV-2 vaccine excipients hypersensitivity.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.23822/EurAnnACI.1764-1489.282</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fabbri</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Allergy and Clinical Immunology Unit, ASST FBF-Sacco, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortolani</LastName><ForeName>V G R</ForeName><Initials>VGR</Initials><AffiliationInfo><Affiliation>Allergy and Clinical Immunology Unit, ASST FBF-Sacco, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caron</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Allergy and Clinical Immunology Unit, ASST FBF-Sacco, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bono</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Allergy and Clinical Immunology Unit, ASST FBF-Sacco, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratti</LastName><ForeName>C P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Allergy and Clinical Immunology Unit, ASST FBF-Sacco, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iemoli</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Allergy and Clinical Immunology Unit, ASST FBF-Sacco, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Eur Ann Allergy Clin Immunol</MedlineTA><NlmUniqueID>101466614</NlmUniqueID><ISSNLinking>1764-1489</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atrophy</Keyword><Keyword MajorTopicYN="N">Hypersensitivity</Keyword><Keyword MajorTopicYN="N">corticosteroids</Keyword><Keyword MajorTopicYN="N">excipients</Keyword><Keyword MajorTopicYN="N">vaccine anti SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637174</ArticleId><ArticleId IdType="doi">10.23822/EurAnnACI.1764-1489.282</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637102</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2133</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>The British journal of dermatology</Title><ISOAbbreviation>Br J Dermatol</ISOAbbreviation></Journal><ArticleTitle>A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ljac045</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/bjd/ljac045</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Immunogenicity and reactogenicity of COVID-19 vaccines have been established in various groups of immunosuppressed patients; however, studies involving patients with immune-mediated dermatological diseases (IMDDs) are scarce.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the influence of IMDDs on the development of SARS-CoV-2-specific immunity and side-effects following ChAdOx1-S[recombinant] vaccination.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This prospective cohort study included 127 patients with IMDDs and 97 participants without immune-mediated diseases who received ChAdOx1-S[recombinant]. SARS-CoV-2-specific immunity and side-effect profiles were assessed at 1 month postvaccination and compared between groups. Immunological (primary) outcomes were the percentages of participants who tested positive for neutralizing antibodies [seroconversion rate (SR)] and those who developed T-cell-mediated immunity demonstrated by an interferon-&#x3b3;-releasing assay (IGRA) [positive IGRA rate (+IGRA)]. Reactogenicity-related (secondary) outcomes were the unsolicited adverse reactions and worsening of IMDD activity reflected by the uptitration of immunosuppressants during and within 1 month of vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, the SR for the IMDD group was similar to that of participants without immune-mediated conditions (75&#xb7;6 vs. 84&#xb7;5, P = 0&#xb7;101), whereas + IGRA was lower (72&#xb7;4 vs. 88&#xb7;7, P = 0&#xb7;003). Reactogenicity was similar between groups. No severe adverse reaction was reported. By stratifying the participants in the IMDD group according to individual disease, the immunogenicity of the vaccine was lowest in patients with autoimmune bullous diseases (AIBD) (SR 64&#xb7;5%, +IGRA 62&#xb7;9%) and highest in patients with psoriasis (SR 87&#xb7;7%, +IGRA 80&#xb7;7%). The reverse trend was found for vaccine-related reactions. Immunosuppressants were uptitrated in 15&#xb7;8% of cases; 75% of these were patients with AIBD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Among participants with IMDDs, ChAdOx1-S[recombinant] showed good immunogenicity among patients with psoriasis, but demonstrated lower levels of immunogenicity for patients with AIBD. Some patients, especially patients with AIBD, should be closely monitored as they may require treatment escalation within 1 month postvaccination.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chanprapaph</LastName><ForeName>Kumutnart</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-7931-3816</Identifier><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, Faculty of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seree-Aphinan</LastName><ForeName>Chutima</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8244-0098</Identifier><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, Faculty of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rattanakaemakorn</LastName><ForeName>Ploysyne</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-8336-1834</Identifier><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, Faculty of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pomsoong</LastName><ForeName>Cherrin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, Faculty of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratanapokasatit</LastName><ForeName>Yanisa</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, Faculty of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Setthaudom</LastName><ForeName>Chavachol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Immunology Laboratory, Department of Pathology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thitithanyanont</LastName><ForeName>Arunee</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suriyo</LastName><ForeName>Aphinyaphiwat</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Immunology Laboratory, Department of Pathology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suangtamai</LastName><ForeName>Thanitta</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Ratchathewi, Bangkok, 10400, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchonwanit</LastName><ForeName>P</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9723-0563</Identifier><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, Faculty of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVIDVAC-DERM study group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Dermatol</MedlineTA><NlmUniqueID>0004041</NlmUniqueID><ISSNLinking>0007-0963</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>7</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637102</ArticleId><ArticleId IdType="doi">10.1093/bjd/ljac045</ArticleId><ArticleId IdType="pii">6765233</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637085</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2151-2396</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Crisis</Title><ISOAbbreviation>Crisis</ISOAbbreviation></Journal><ArticleTitle>Psychiatric Emergencies and Suicide Attempts Before and During COVID-19 Lockdown in Spain.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1027/0227-5910/a000896</ELocationID><Abstract><AbstractText><b/><i>Background:</i> The COVID-19 pandemic had a significant impact on the mental health of the population. The lockdown period in Spain - from March 14 to June 21, 2020 - was particularly stressful. This study aims to examine the differences in visits to the emergency department for psychiatric reasons before and during the lockdown period in a hospital in the province of Lleida (Catalonia, Spain), which has a catchment area of 431,183 inhabitants. We hope that this study can contribute to the understanding of this difficult period in our recent history and help us to be prepared in case of new social emergencies that may affect the mental health of the general population. <i>Aims:</i> This study aims to examine the differences in ER visits due to psychiatric reasons before and during the COVID-19 lockdown period in a province hospital in Spain. <i>Methods:</i> We compared the <i>n</i> = 1,599 visits to the emergency room and their characteristics before (June 13 to March 13, 2020) and during (March 14 to June 21, 2020) the lockdown period in the province of Lerida, Spain. Data were obtained from the electronic health records. Information collected included sociodemographic variables, reason for consultation, previous diagnosis, and characteristics of suicidal ideation and attempts - including history of previous suicidal behavior, method, days spent in the ER, suicide reattempts at 6-month follow-up. <i>Results:</i> Before lockdown, there were an average of 11.2 psychiatric emergencies per day compared with 9.2 psychiatric emergencies per day during lockdown. Regarding suicidal behavior, before lockdown, there were an average of 0.9 suicide attempts before lockdown compared with 0.7 attempts per day during lockdown. <i>Limitations:</i> Since the data came from the electronic health records, we have relied on the clinical diagnosis made by different psychiatrists. Also, we did not record psychiatric comorbidities, but instead only registered one main Axis I diagnosis and one main Axis II diagnosis. <i>Conclusions:</i> We observed a decrease in the number of visits to the ER in general, as well as a lower frequency of patients with suicidal behavior during the first and only lockdown period in Spain, which occurred during the initial months of the pandemic. This is consistent with previous studies showing a reduction of suicidal behavior during periods of social emergency. However, this decrease could be only temporary, and several authors predict an increase of suicidal behavior in the aftermath of the COVID-19 crisis. Ensuring access to mental healthcare during periods of crisis is crucial for the population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Irigoyen-Oti&#xf1;ano</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5326-0928</Identifier><AffiliationInfo><Affiliation>Psychiatry Service, Santa Maria de Lleida University Hospital, Lleida, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRB Lleida, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatry Service, Vithas L&#xe9;rida, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porras-Segovia</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Psychiatry Service, Imperial College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vega-S&#xe1;nchez</LastName><ForeName>Diego de la</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-6038-7257</Identifier><AffiliationInfo><Affiliation>Psychiatry Service, Virgen Macarena University Hospital, Seville, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arenas-Pijoan</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Psychiatry Service, Santa Maria de Lleida University Hospital, Lleida, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agraz-Bota</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Psychiatry Service, Santa Maria de Lleida University Hospital, Lleida, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torterolo</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6906-8175</Identifier><AffiliationInfo><Affiliation>Psychiatry Service, Santa Maria de Lleida University Hospital, Lleida, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Cazalilla</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6552-0427</Identifier><AffiliationInfo><Affiliation>Psychiatry Service, Santa Maria de Lleida University Hospital, Lleida, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuentes-Casany</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Children's Mental Health Center of the Selva Mar&#xed;tima (Blanes), Girona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adrados-P&#xe9;rez</LastName><ForeName>Marina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2924-0396</Identifier><AffiliationInfo><Affiliation>Psychiatry Service, Santa Maria de Lleida University Hospital, Lleida, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puigdevall-Ruestes</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Psychiatry Service, Vithas L&#xe9;rida, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Crisis</MedlineTA><NlmUniqueID>8218602</NlmUniqueID><ISSNLinking>0227-5910</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">emergency room</Keyword><Keyword MajorTopicYN="N">suicidal ideation</Keyword><Keyword MajorTopicYN="N">suicide</Keyword><Keyword MajorTopicYN="N">suicide attempt</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>7</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637085</ArticleId><ArticleId IdType="doi">10.1027/0227-5910/a000896</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36637082</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1754</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of paediatrics and child health</Title><ISOAbbreviation>J Paediatr Child Health</ISOAbbreviation></Journal><ArticleTitle>Parents' COVID-19 vaccine intentions for children under 5&#x2009;years: Brief reflections from a qualitative study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/jpc.16312</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Australian authorities made COVID-19 vaccines available for children aged under 5&#x2009;years old with serious comorbidities in August 2022. There is presently no universal programme for young children, but crucial to any rollout's success is whether parents are motivated and able to vaccinate. By examining parents' vaccine intentions, this study aims to inform current and future COVID-19 vaccine roll-outs for children aged under 5 years.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">As part of the mixed methods project 'Coronavax: Preparing Community and Government' we interviewed 18 Western Australian parents of young children about their intentions in late 2021.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two thirds intended to vaccinate if and when they could, with one third intending to delay for reasons including risk and safety perceptions, fears about side effects and influence from their social networks. However, even those choosing to delay were waiting rather than refusing.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">To improve uptake, targeted messaging should emphasise that COVID-19 can be a serious disease in young children, with such messaging drawing on the reputability and esteem of scientific and technical authorities. Such messaging should be oriented towards parents of children with serious comorbidities at the present time. It will be important to emphasise that government vaccine recommendations are based on supporting families to protect their children and keep them healthy.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Journal of Paediatrics and Child Health published by John Wiley &amp; Sons Australia, Ltd on behalf of Paediatrics and Child Health Division (The Royal Australasian College of Physicians).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Attwell</LastName><ForeName>Katie</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0366-2160</Identifier><AffiliationInfo><Affiliation>School of Social Sciences, The University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKenzie</LastName><ForeName>Lara</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6625-0956</Identifier><AffiliationInfo><Affiliation>School of Social Sciences, The University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomkinson</LastName><ForeName>Sian</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8292-106X</Identifier><AffiliationInfo><Affiliation>School of Social Sciences, The University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Samantha J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-4362-7730</Identifier><AffiliationInfo><Affiliation>School of Social Sciences, The University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blyth</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0003-2017-0683</Identifier><AffiliationInfo><Affiliation>Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>J Paediatr Child Health</MedlineTA><NlmUniqueID>9005421</NlmUniqueID><ISSNLinking>1034-4810</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">child health</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>7</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637082</ArticleId><ArticleId IdType="doi">10.1111/jpc.16312</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Australian Government: Department of Health and Aged Care. ATAGI Recommendations on COVID-19 Vaccine Use in Children Aged 6 Months to &lt;5&#x2009;Years [Internet]; 3 August 2022 [cited 2022 Oct 25]. Available from: https://www.health.gov.au/news/atagi-recommendations-on-covid-19-vaccine-use-in-children-aged-6-months-to</Citation></Reference><Reference><Citation>Australian Government Department of Health and Aged Care. ATAGI Recommendations on Use of the Pfizer COVID-19 Vaccine for Children Aged 6 Months to 4&#x2009;Years. Canberra, Australia: Australian Government; 2022. Available from: https://www.health.gov.au/news/atagi-recommendations-on-use-of-the-pfizer-covid-19-vaccine-for-children-aged-6-months-to-4-years#:~:text=ATAGI%20recommends%20the%20Pfizer%206,significant%20or%20complex%20health%20needs</Citation></Reference><Reference><Citation>Tanne JH. Covid-19: CDC and FDA approve Pfizer and Moderna vaccines for under 5&#x2009;s. BMJ 2022; 377: o1507.</Citation></Reference><Reference><Citation>Health Canada. Health Canada Authorizes Use of Moderna COVID-19 Vaccine in Children 6 Months to 5&#x2009;Years of Age [Internet]; 14 July 2022 [cited 2022 Oct 25]. Available from: https://www.canada.ca/en/health-canada/news/2022/07/health-canada-authorizes-use-of-moderna-covid-19-vaccine-in-children-6-months-to-5-years-of-age.html</Citation></Reference><Reference><Citation>Leask J, Chow MYK, King C, Booy R. Caregivers' intentions regarding pandemic (H1N1) 2009 influenza vaccination for their children. Med. J. Aust. 2010; 193: 485-6.</Citation></Reference><Reference><Citation>National Centre for Immunisation Research and Surveillance. Increasing COVID-19 Vaccine Uptake in Children Aged 5-11&#x2009;Years: Behavioural Insights From the Field [Internet]; 3 March 2022 [cited 2022 Oct 25]. Available from: https://www.ncirs.org.au/sites/default/files/2022-03/Increasing%20COVID-19%20vaccine%20uptake%20in%20children_open%20forum_summary%20report_21%20March%202022_Final.pdf</Citation></Reference><Reference><Citation>Attwell K, Seth R, Beard F, Hendry A, Lawrence D. Financial interventions to increase vaccine coverage. Pediatrics 2020; 146: e20200724.</Citation></Reference><Reference><Citation>Carlson SJ, Blyth CC, Beard FH et al. Influenza disease and vaccination in children in Australia. Med. J. Aust. 2021; 215: 64-67.e1.</Citation></Reference><Reference><Citation>Attwell K, Carlson SJ, Tchilingirian J et al. Coronavax: Preparing community and government for COVID-19 vaccination: A research protocol for a mixed methods social research project. BMJ Open 2021; 11: e049356.</Citation></Reference><Reference><Citation>Carlson SJ, McKenzie L, Roberts L, Blyth CC, Attwell K. Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation. Vaccine 2022; 40: 594-600.</Citation></Reference><Reference><Citation>Bedford H, Attwell K, Danchin M, Marshall H, Corben P, Leask J. Vaccine hesitancy, refusal and access barriers: The need for clarity in terminology. Vaccine 2018; 36: 6556-8.</Citation></Reference><Reference><Citation>Hilton S, Petticrew M, Hunt K. Combined vaccines are like a sudden onslaught to the body's immune system': Parental concerns about vaccine &#x2018;overload&#x2019; and &#x2018;immune-vulnerability&#x2019;. Vaccine 2006; 24: 4321-7.</Citation></Reference><Reference><Citation>Harmsen IA, Mollema L, Ruiter RAC, Paulussen TGW, de Melker HE, Kok G. Why parents refuse childhood vaccination: A qualitative study using online focus groups. BMC Public Health 2013; 13: 1183.</Citation></Reference><Reference><Citation>Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes toward a potential SARS-CoV-2 vaccine: A survey of U.S. adults. Ann. Intern. Med. 2020; 173: 964-73.</Citation></Reference><Reference><Citation>Fadda M, Suggs LS, Albanese E. Willingness to vaccinate against Covid-19: A qualitative study involving older adults from southern Switzerland. Vaccine X 2021; 8: 100108.</Citation></Reference><Reference><Citation>Lockyer B, Islam S, Rahman A et al. Understanding COVID-19 misinformation and vaccine hesitancy in context: Findings from a qualitative study involving citizens in Bradford, UK. Health Expect. 2021; 24: 1158-67.</Citation></Reference><Reference><Citation>Kaufman J, Bagot KL, Tuckerman J et al. Qualitative exploration of intentions, concerns and information needs of vaccine-hesitant adults initially prioritised to receive COVID-19 vaccines in Australia. Aust. N. Z. J. Public Health 2022; 46: 16-24.</Citation></Reference><Reference><Citation>Leask J, Kinnersley P, Jackson C, Cheater F, Bedford H, Rowles G. Communicating with parents about vaccination: A framework for health professionals. BMC Pediatr. 2012; 12: 154.</Citation></Reference><Reference><Citation>Royal Australian College of General Practitioners. Doctors Lead International &#x2018;Most Trusted&#x2019; Profession Poll [Internet]; 13 October 2021 [cited 2022 Oct 25]. Available from: https://www1.racgp.org.au/newsgp/professional/doctors-lead-international-most-trusted-profession</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636994</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1938-2715</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>The American journal of hospice &amp; palliative care</Title><ISOAbbreviation>Am J Hosp Palliat Care</ISOAbbreviation></Journal><ArticleTitle>Perceptions of Palliative Care Program Viability During the Pandemic: Qualitative Results From a National Survey.</ArticleTitle><Pagination><StartPage>10499091231152610</StartPage><MedlinePgn>10499091231152610</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/10499091231152610</ELocationID><Abstract><AbstractText><b>Background:</b> Palliative care programs have played a significant role during the COVID-19 pandemic. However, the financial impact of the pandemic and operational challenges for palliative care programs have raised concerns for their future viability. <b>Objectives:</b> To explore palliative care program leaders' perceptions of the future viability of their programs in the context of the pandemic and inform future educational and program development. <b>Methods:</b> Surveys were sent to 1430 specialist palliative care program leaders, identified through the Center to Advance Palliative Care's contact lists, via email in May 2020 and January 2021. Leaders were asked why they were or were not concerned about the viability of their palliative care programs. Qualitative content analysis was applied to determine themes. <b>Results:</b> We received 440 responses. Most programs served hospital settings and were geographically located across all US regions. We identified four themes: 1) The importance of being valued by organizational leadership and peers, 2) The importance of adequate and supported palliative care staff, 3) The pandemic validated and accelerated the need for palliative care, and 4) The pandemic perpetuated organizational financial concerns. <b>Conclusion:</b> Findings provide insights about palliative care program viability from the perspective of program leaders during a global pandemic. Technical assistance to support palliative care teams and their relationships with stakeholders, methods to measure the impact of peer support, efforts to educate administrators about the value of palliative care, and efforts to reduce burnout are needed to sustain palliative care programs into the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Maggie</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0049-2987</Identifier><AffiliationInfo><Affiliation>Center to Advance Palliative Care at the Brookdale Department of Geriatrics and Palliative Medicine, 5925Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heitner</LastName><ForeName>Rachael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center to Advance Palliative Care at the Brookdale Department of Geriatrics and Palliative Medicine, 5925Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frydman</LastName><ForeName>Julia L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-0021-7627</Identifier><AffiliationInfo><Affiliation>Brookdale Department of Geriatrics and Palliative Medicine, 5925Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowman</LastName><ForeName>Brynn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center to Advance Palliative Care at the Brookdale Department of Geriatrics and Palliative Medicine, 5925Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meier</LastName><ForeName>Diane E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Center to Advance Palliative Care at the Brookdale Department of Geriatrics and Palliative Medicine, 5925Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldridge</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Brookdale Department of Geriatrics and Palliative Medicine, 5925Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>20071James J. Peters VA Medical Center, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franzosa</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7590-0316</Identifier><AffiliationInfo><Affiliation>Brookdale Department of Geriatrics and Palliative Medicine, 5925Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>20071James J. Peters VA Medical Center, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hosp Palliat Care</MedlineTA><NlmUniqueID>9008229</NlmUniqueID><ISSNLinking>1049-9091</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">burnout</Keyword><Keyword MajorTopicYN="N">palliative care</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword><Keyword MajorTopicYN="N">program design</Keyword><Keyword MajorTopicYN="N">workforce</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636994</ArticleId><ArticleId IdType="doi">10.1177/10499091231152610</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636983</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1643-3750</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><PubDate><Year>2023</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>Medical science monitor : international medical journal of experimental and clinical research</Title><ISOAbbreviation>Med Sci Monit</ISOAbbreviation></Journal><ArticleTitle>A Retrospective Population Study of 385 191 Positive Real-Time Reverse Transcription-Polymerase Chain Reaction Tests For SARS-CoV-2 from a Single Laboratory in Katowice, Poland from April 2020 to July 2022.</ArticleTitle><Pagination><StartPage>e938872</StartPage><MedlinePgn>e938872</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12659/MSM.938872</ELocationID><Abstract><AbstractText>BACKGROUND This retrospective population study identified 385 191 positive real-time reverse transcription-polymerase chain reaction (RT-PCR) tests for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a single laboratory in Katowice, Poland, from April 2020 to July 2022. MATERIAL AND METHODS The material was nasopharyngeal, nasopharyngeal swab or bronchial lavage, and bronchoalveolar lavage (BAL) to confirm or exclude SARS-CoV-2 infection with the RT-PCR technique. Personal data are use according to the Provisions on the Protection of Personal Data by the Gyn-Centrum laboratory. RESULTS In 9 months of 2020, the number of SARS-CoV-2 results was 88 986; in 2021, it was 168 439, and in the first 7 months of 2022, it was 12 786. In 2020, the highest number of positive results was recorded in the third quarter (83 094 cases); 2021, in the 1st, 2nd, and 4th quarters (58 712; 37 720; and 71 753 cases, respectively), and in 2022, in the 1st quarter (127 613 cases) of the year. A positive result was observed more often in women and people aged 30-39, followed by those 40-49 years. Patients aged 10-19 years comprised the smallest population of SARS-CoV-2-positive cases. CONCLUSIONS In the Polish population studied, from April 2020 to July 2022, the detection rates of SARS-CoV-2 positivity were significantly higher for women than for men and in the 30-49 age group for both sexes. Also, the infection detection rate of 385 191 out of 1 332 659 patient samples, or 28.9%, supports that the Polish society adhered to public health recommendations for infection control during the COVID-19 pandemic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morawiec</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Histology, Cytophysiology and Embryology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bednarska-Czerwi&#x144;ska</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Histology, Cytophysiology and Embryology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pude&#x142;ko</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Gyncentrum Fertility Clinic, Sosnowiec, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strychalska</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Gyncentrum Fertility Clinic, Sosnowiec, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broncel</LastName><ForeName>Mateusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Gyncentrum Fertility Clinic, Sosnowiec, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagan</LastName><ForeName>Dorota</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical Center Dormed Medical SP, Busko-Zdr&#xf3;j, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madej</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jasi&#x144;ska-Balwierz</LastName><ForeName>Agata</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staszkiewicz</LastName><ForeName>Rafa&#x142;</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Histology, Cytophysiology and Embryology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soba&#x144;ski</LastName><ForeName>Dawid</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Histology, Cytophysiology and Embryology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boro&#x144;</LastName><ForeName>Dariusz</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Histology, Cytophysiology and Embryology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pokusa</LastName><ForeName>Filip</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Faculty of Economics and Pedagogy, Higher School of Management and Administration in Opole, Opole, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grabarek</LastName><ForeName>Beniamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Histology, Cytophysiology and Embryology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Sci Monit</MedlineTA><NlmUniqueID>9609063</NlmUniqueID><ISSNLinking>1234-1010</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636983</ArticleId><ArticleId IdType="doi">10.12659/MSM.938872</ArticleId><ArticleId IdType="pii">938872</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636979</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0022-9040</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Kardiologiia</Title><ISOAbbreviation>Kardiologiia</ISOAbbreviation></Journal><ArticleTitle>[Case of peripartum cardiomyopathy misdiagnosed as pulmonary changes due to COVID-19].</ArticleTitle><Pagination><StartPage>80</StartPage><EndPage>84</EndPage><MedlinePgn>80-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18087/cardio.2022.12.n1668</ELocationID><Abstract><AbstractText>A 37-year-old female patient was admitted 16 days after delivery in a hospital for infectious diseases with cough, shortness of breath, and infiltrative changes in the lungs that were interpreted as viral pneumonia. Considering the failure of therapy and the history, peripartum cardiomyopathy was suspected. Examination revealed a decrease in left ventricular ejection fraction to 30&#x200a;%, ultrasonic signs of lung congestion and bilateral hydrothorax. The patient was diagnosed with peripartum cardiomyopathy accompanied by functional class 4 heart failure. A specific feature of this case was fast positive dynamics with complete regression of the clinical picture of congestion and improvement of the left ventricular myocardial function associated with the treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gavrilov</LastName><ForeName>D V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>&#x41e;&#x41e;&#x41e; "K-Skay".</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bagirova</LastName><ForeName>Z R</ForeName><Initials>ZR</Initials><AffiliationInfo><Affiliation>Emergency Care Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pleskatsevich</LastName><ForeName>D I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Emergency Care Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuznetsova</LastName><ForeName>O V</ForeName><Initials>OV</Initials><AffiliationInfo><Affiliation>Emergency Care Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivshin</LastName><ForeName>A A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Petrozavodsk State Medical University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuznetsova</LastName><ForeName>T Yu</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Petrozavodsk State Medical University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Kardiologiia</MedlineTA><NlmUniqueID>0376351</NlmUniqueID><ISSNLinking>0022-9040</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636979</ArticleId><ArticleId IdType="doi">10.18087/cardio.2022.12.n1668</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636975</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0022-9040</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Kardiologiia</Title><ISOAbbreviation>Kardiologiia</ISOAbbreviation></Journal><ArticleTitle>[Not Available].</ArticleTitle><Pagination><StartPage>38</StartPage><EndPage>49</EndPage><MedlinePgn>38-49</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18087/cardio.2022.12.n2125</ELocationID><Abstract><AbstractText>&#x426;&#x435;&#x43b;&#x44c;:&#xa0;&#xa0;&#x418;&#x437;&#x443;&#x447;&#x435;&#x43d;&#x438;&#x435; &#x43e;&#x441;&#x43e;&#x431;&#x435;&#x43d;&#x43d;&#x43e;&#x441;&#x442;&#x435;&#x439; &#x43a;&#x43b;&#x438;&#x43d;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x43e;&#x433;&#x43e; &#x442;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x44f; &#x43d;&#x43e;&#x432;&#x43e;&#x439; &#x43a;&#x43e;&#x440;&#x43e;&#x43d;&#x430;&#x432;&#x438;&#x440;&#x443;&#x441;&#x43d;&#x43e;&#x439; &#x438;&#x43d;&#x444;&#x435;&#x43a;&#x446;&#x438;&#x438; &#x438;&#xa0; &#x432;&#x43b;&#x438;&#x44f;&#x43d;&#x438;&#x44f; &#x441;&#x43e;&#x43f;&#x443;&#x442;&#x441;&#x442;&#x432;&#x443;&#x44e;&#x449;&#x438;&#x445; &#x437;&#x430;&#x431;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x43d;&#x438;&#x439; &#x43d;&#x430; &#x438;&#x441;&#x445;&#x43e;&#x434; &#x437;&#x430;&#x431;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x43d;&#x438;&#x44f; &#x443; &#x433;&#x43e;&#x441;&#x43f;&#x438;&#x442;&#x430;&#x43b;&#x438;&#x437;&#x438;&#x440;&#x43e;&#x432;&#x430;&#x43d;&#x43d;&#x44b;&#x445; &#x431;&#x43e;&#x43b;&#x44c;&#x43d;&#x44b;&#x445; &#x441; &#x438;&#x43d;&#x444;&#x435;&#x43a;&#x446;&#x438;&#x435;&#x439; SARS-CoV-2 &#x432; &#x43f;&#x435;&#x440;&#x432;&#x443;&#x44e; &#x438; &#x432;&#x442;&#x43e;&#x440;&#x443;&#x44e; &#x432;&#x43e;&#x43b;&#x43d;&#x44b; &#x43f;&#x430;&#x43d;&#x434;&#x435;&#x43c;&#x438;&#x438;.&#x41c;&#x435;&#x442;&#x43e;&#x434;&#x44b; &#x438; &#x440;&#x435;&#x437;&#x443;&#x43b;&#x44c;&#x442;&#x430;&#x442;&#x44b;.&#xa0; &#x414;&#x43b;&#x44f; &#x43e;&#x446;&#x435;&#x43d;&#x43a;&#x438; &#x43e;&#x441;&#x43e;&#x431;&#x435;&#x43d;&#x43d;&#x43e;&#x441;&#x442;&#x435;&#x439; &#x442;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x44f; COVID-19 &#x432; &#x415;&#x432;&#x440;&#x430;&#x437;&#x438;&#x439;&#x441;&#x43a;&#x43e;&#x43c; &#x440;&#x435;&#x433;&#x438;&#x43e;&#x43d;&#x435; &#x431;&#x44b;&#x43b;&#x438; &#x441;&#x43e;&#x437;&#x434;&#x430;&#x43d;&#x44b; &#x43c;&#x435;&#x436;&#x434;&#x443;&#x43d;&#x430;&#x440;&#x43e;&#x434;&#x43d;&#x44b;&#x435; &#x440;&#x435;&#x433;&#x438;&#x441;&#x442;&#x440;&#x44b; &#x410;&#x41a;&#x422;&#x418;&#x412; 1 &#x438; &#x432;&#x43e; &#x432;&#x440;&#x435;&#x43c;&#x44f; &#x432;&#x442;&#x43e;&#x440;&#x43e;&#x439; &#x432;&#x43e;&#x43b;&#x43d;&#x44b; &#x43f;&#x430;&#x43d;&#x434;&#x435;&#x43c;&#x438;&#x438; &#x410;&#x41a;&#x422;&#x418;&#x412; 2. &#x41d;&#x430;&#x431;&#x43e;&#x440; &#x431;&#x43e;&#x43b;&#x44c;&#x43d;&#x44b;&#x445; &#x432; &#x440;&#x435;&#x433;&#x438;&#x441;&#x442;&#x440; &#x410;&#x41a;&#x422;&#x418;&#x412; 1 &#x43f;&#x440;&#x43e;&#x432;&#x43e;&#x434;&#x438;&#x43b;&#x438; &#x441; 29.06.20 &#x43f;&#x43e; 29.10.20, &#x43d;&#x430;&#x431;&#x440;&#x430;&#x43d;&#x43e; 5 397 &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432;. &#x41f;&#x440;&#x438;&#x435;&#x43c; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432; &#x43d;&#x430; &#x443;&#x447;&#x435;&#x442; &#x432; &#x410;&#x41a;&#x422;&#x418;&#x412; 2 &#x43f;&#x440;&#x43e;&#x432;&#x43e;&#x434;&#x438;&#x43b;&#x438; &#x441; 01.11.20 &#x434;&#x43e; 30.03.21, &#x43d;&#x430;&#x431;&#x440;&#x430;&#x43d;&#x43e; 2 665 &#x431;&#x43e;&#x43b;&#x44c;&#x43d;&#x44b;&#x445;.&#x420;&#x435;&#x437;&#x443;&#x43b;&#x44c;&#x442;&#x430;&#x442;&#x44b;. &#x413;&#x43e;&#x441;&#x43f;&#x438;&#x442;&#x430;&#x43b;&#x44c;&#x43d;&#x430;&#x44f; &#x43b;&#x435;&#x442;&#x430;&#x43b;&#x44c;&#x43d;&#x43e;&#x441;&#x442;&#x44c; &#x441;&#x43d;&#x438;&#x437;&#x438;&#x43b;&#x430;&#x441;&#x44c; &#x432; &#xa0;&#x43f;&#x435;&#x440;&#x438;&#x43e;&#x434; &#x432;&#x442;&#x43e;&#x440;&#x43e;&#x439; &#x432;&#x43e;&#x43b;&#x43d;&#x44b; &#x43f;&#x430;&#x43d;&#x434;&#x435;&#x43c;&#x438;&#x438; &#x438; &#xa0;&#x441;&#x43e;&#x441;&#x442;&#x430;&#x432;&#x438;&#x43b;&#x430; 4,8 % &#x43f;&#x440;&#x43e;&#x442;&#x438;&#x432; 7,6 % &#x432; &#xa0;&#x43f;&#x435;&#x440;&#x438;&#x43e;&#x434; &#x43f;&#x435;&#x440;&#x432;&#x43e;&#x439; &#x432;&#x43e;&#x43b;&#x43d;&#x44b;. &#x412; &#xa0;&#x43f;&#x435;&#x440;&#x438;&#x43e;&#x434; &#x432;&#x442;&#x43e;&#x440;&#x43e;&#x439; &#x432;&#x43e;&#x43b;&#x43d;&#x44b; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x44b; &#x431;&#x44b;&#x43b;&#x438; &#x441;&#x442;&#x430;&#x440;&#x448;&#x435;, &#x438;&#x43c;&#x435;&#x43b;&#x438; &#x431;&#x43e;&#x43b;&#x44c;&#x448;&#x435; &#x441;&#x43e;&#x43f;&#x443;&#x442;&#x441;&#x442;&#x432;&#x443;&#x44e;&#x449;&#x438;&#x445; &#x437;&#x430;&#x431;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x43d;&#x438;&#x439; &#x438; &#x43f;&#x43e;&#x441;&#x442;&#x443;&#x43f;&#x430;&#x43b;&#x438; &#x432; &#x441;&#x442;&#x430;&#x446;&#x438;&#x43e;&#x43d;&#x430;&#x440; &#x432; &#x431;&#x43e;&#x43b;&#x435;&#x435; &#x442;&#x44f;&#x436;&#x435;&#x43b;&#x43e;&#x43c; &#x441;&#x43e;&#x441;&#x442;&#x43e;&#x44f;&#x43d;&#x438;&#x438;, &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x44b; &#x438;&#x43c;&#x435;&#x43b;&#x438; &#x431;&#x43e;&#x43b;&#x435;&#x435; &#x432;&#x44b;&#x441;&#x43e;&#x43a;&#x438;&#x439; &#x443;&#x440;&#x43e;&#x432;&#x435;&#x43d;&#x44c; &#x43f;&#x43e;&#x43b;&#x438;&#x43c;&#x43e;&#x440;&#x431;&#x438;&#x434;&#x43d;&#x43e;&#x441;&#x442;&#x438;. &#x412; &#x43f;&#x435;&#x440;&#x438;&#x43e;&#x434; &#x432;&#x442;&#x43e;&#x440;&#x43e;&#x439; &#x432;&#x43e;&#x43b;&#x43d;&#x44b; &#x43f;&#x430;&#x43d;&#x434;&#x435;&#x43c;&#x438;&#x438; &#x443;&#x432;&#x435;&#x43b;&#x438;&#x447;&#x438;&#x43b;&#x430;&#x441;&#x44c; &#x437;&#x430;&#x431;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x435;&#x43c;&#x43e;&#x441;&#x442;&#x44c; &#x431;&#x430;&#x43a;&#x442;&#x435;&#x440;&#x438;&#x430;&#x43b;&#x44c;&#x43d;&#x43e;&#x439; &#x43f;&#x43d;&#x435;&#x432;&#x43c;&#x43e;&#x43d;&#x438;&#x435;&#x439; &#x438; &#x441;&#x435;&#x43f;&#x441;&#x438;&#x441;&#x43e;&#x43c;, &#x43d;&#x43e; &#x440;&#x435;&#x436;&#x435; &#x432;&#x441;&#x442;&#x440;&#x435;&#x447;&#x430;&#x43b;&#x438;&#x441;&#x44c; &#x442;&#x440;&#x43e;&#x43c;&#x431;&#x43e;&#x437;&#x44b; &#x433;&#x43b;&#x443;&#x431;&#x43e;&#x43a;&#x438;&#x445; &#x432;&#x435;&#x43d; &#x438; &#xab;&#x446;&#x438;&#x442;&#x43e;&#x43a;&#x438;&#x43d;&#x43e;&#x432;&#x44b;&#x439; &#x448;&#x442;&#x43e;&#x440;&#x43c;&#xbb;. &#x41d;&#x430;&#x438;&#x431;&#x43e;&#x43b;&#x435;&#x435; &#x43d;&#x435;&#x431;&#x43b;&#x430;&#x433;&#x43e;&#x43f;&#x440;&#x438;&#x44f;&#x442;&#x43d;&#x44b;&#x43c;&#x438; &#x434;&#x43b;&#x44f; &#x43f;&#x440;&#x43e;&#x433;&#x43d;&#x43e;&#x437;&#x430; &#x441;&#x43c;&#x435;&#x440;&#x442;&#x43d;&#x43e;&#x441;&#x442;&#x438;, &#x43a;&#x430;&#x43a; &#x432; &#x43f;&#x435;&#x440;&#x432;&#x443;&#x44e;, &#x442;&#x430;&#x43a; &#x438; &#x432;&#x43e; &#x432;&#x442;&#x43e;&#x440;&#x443;&#x44e; &#x432;&#x43e;&#x43b;&#x43d;&#x44b; &#x44d;&#x43f;&#x438;&#x434;&#x435;&#x43c;&#x438;&#x438; &#x431;&#x44b;&#x43b;&#x438; &#x441;&#x43e;&#x447;&#x435;&#x442;&#x430;&#x43d;&#x438;&#x44f; &#x441;&#x43e;&#x43f;&#x443;&#x442;&#x441;&#x442;&#x432;&#x443;&#x44e;&#x449;&#x438;&#x445; &#x437;&#x430;&#x431;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x43d;&#x438;&#x439;: &#x430;&#x440;&#x442;&#x435;&#x440;&#x438;&#x430;&#x43b;&#x44c;&#x43d;&#x430;&#x44f; &#x433;&#x438;&#x43f;&#x435;&#x440;&#x442;&#x435;&#x43d;&#x437;&#x438;&#x44f; (&#x410;&#x413;) + &#x445;&#x440;&#x43e;&#x43d;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x430;&#x44f; &#x441;&#x435;&#x440;&#x434;&#x435;&#x447;&#x43d;&#x430;&#x44f; &#x43d;&#x435;&#x434;&#x43e;&#x441;&#x442;&#x430;&#x442;&#x43e;&#x447;&#x43d;&#x43e;&#x441;&#x442;&#x44c; (&#x425;&#x421;&#x41d;) + &#x441;&#x430;&#x445;&#x430;&#x440;&#x43d;&#x44b;&#x439; &#x434;&#x438;&#x430;&#x431;&#x435;&#x442; (&#x421;&#x414;) + &#x43e;&#x436;&#x438;&#x440;&#x435;&#x43d;&#x438;&#x435;, &#x410;&#x413; + &#x438;&#x448;&#x435;&#x43c;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x430;&#x44f; &#x431;&#x43e;&#x43b;&#x435;&#x437;&#x43d;&#x44c; &#x441;&#x435;&#x440;&#x434;&#x446;&#x430; (&#x418;&#x411;&#x421;) + &#x425;&#x421;&#x41d; + &#x421;&#x414;, &#x410;&#x413; + &#x418;&#x411;&#x421; + &#x425;&#x421;&#x41d; + &#x43e;&#x436;&#x438;&#x440;&#x435;&#x43d;&#x438;&#x435;.&#x417;&#x430;&#x43a;&#x43b;&#x44e;&#x447;&#x435;&#x43d;&#x438;&#x435;.&#xa0;&#x423; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432; &#x432;&#x43e; &#x432;&#x442;&#x43e;&#x440;&#x443;&#x44e; &#x432;&#x43e;&#x43b;&#x43d;&#x443; &#x43f;&#x430;&#x43d;&#x434;&#x435;&#x43c;&#x438;&#x438; &#x43d;&#x430;&#x431;&#x43b;&#x44e;&#x434;&#x430;&#x43b;&#x43e;&#x441;&#x44c; &#x431;&#x43e;&#x43b;&#x435;&#x435; &#x43e;&#x431;&#x448;&#x438;&#x440;&#x43d;&#x43e;&#x435; &#x43f;&#x43e;&#x440;&#x430;&#x436;&#x435;&#x43d;&#x438;&#x435; &#x442;&#x43a;&#x430;&#x43d;&#x438; &#x43b;&#x435;&#x433;&#x43a;&#x438;&#x445;, &#x447;&#x430;&#x449;&#x435; &#x432;&#x43e;&#x437;&#x43d;&#x438;&#x43a;&#x430;&#x43b;&#x430; &#x444;&#x435;&#x431;&#x440;&#x438;&#x43b;&#x44c;&#x43d;&#x430;&#x44f; &#x43b;&#x438;&#x445;&#x43e;&#x440;&#x430;&#x434;&#x43a;&#x430;, &#x431;&#x44b;&#x43b;&#x438; &#x432;&#x44b;&#x448;&#x435; &#x443;&#x440;&#x43e;&#x432;&#x43d;&#x438; &#x421;-&#x440;&#x435;&#x430;&#x43a;&#x442;&#x438;&#x432;&#x43d;&#x43e;&#x433;&#x43e; &#x431;&#x435;&#x43b;&#x43a;&#x430; &#x438; &#xa0;&#x442;&#x440;&#x43e;&#x43f;&#x43e;&#x43d;&#x438;&#x43d;&#x430;, &#x43d;&#x438;&#x436;&#x435; &#x443;&#x440;&#x43e;&#x432;&#x43d;&#x438; &#x433;&#x435;&#x43c;&#x43e;&#x433;&#x43b;&#x43e;&#x431;&#x438;&#x43d;&#x430; &#x438; &#x43b;&#x438;&#x43c;&#x444;&#x43e;&#x446;&#x438;&#x442;&#x43e;&#x432;. &#x42d;&#x442;&#x43e;, &#x432;&#x435;&#x440;&#x43e;&#x44f;&#x442;&#x43d;&#x43e;, &#x441;&#x432;&#x44f;&#x437;&#x430;&#x43d;&#x43e; &#x441; &#x440;&#x430;&#x437;&#x43b;&#x438;&#x447;&#x43d;&#x43e;&#x439; &#x442;&#x430;&#x43a;&#x442;&#x438;&#x43a;&#x43e;&#x439; &#x433;&#x43e;&#x441;&#x43f;&#x438;&#x442;&#x430;&#x43b;&#x438;&#x437;&#x430;&#x446;&#x438;&#x438; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432; &#x432; &#x43f;&#x435;&#x440;&#x432;&#x443;&#x44e; &#x438; &#x432;&#x442;&#x43e;&#x440;&#x443;&#x44e; &#x432;&#x43e;&#x43b;&#x43d;&#x44b; &#x43f;&#x430;&#x43d;&#x434;&#x435;&#x43c;&#x438;&#x438; &#x432; &#x441;&#x442;&#x440;&#x430;&#x43d;&#x430;&#x445;, &#x43f;&#x440;&#x438;&#x43d;&#x44f;&#x432;&#x448;&#x438;&#x445; &#x443;&#x447;&#x430;&#x441;&#x442;&#x438;&#x435; &#x432; &#x444;&#x43e;&#x440;&#x43c;&#x438;&#x440;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x438; &#x440;&#x435;&#x433;&#x438;&#x441;&#x442;&#x440;&#x43e;&#x432; &#x410;&#x41a;&#x422;&#x418;&#x412; 1 &#x438; &#x410;&#x41a;&#x422;&#x418;&#x412; 2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arutyunov</LastName><ForeName>Gregory Pavlovich</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>&#x424;&#x413;&#x410;&#x41e;&#x423; &#x412;&#x41e; &#xab;&#x420;&#x41d;&#x418;&#x41c;&#x423; &#x438;&#x43c;. &#x41d;.&#x418;. &#x41f;&#x438;&#x440;&#x43e;&#x433;&#x43e;&#x432;&#x430;&#xbb;, &#x410;&#x441;&#x441;&#x43e;&#x446;&#x438;&#x430;&#x446;&#x438;&#x44f; "&#x415;&#x432;&#x440;&#x430;&#x437;&#x438;&#x439;&#x441;&#x43a;&#x430;&#x44f; &#x410;&#x441;&#x441;&#x43e;&#x446;&#x438;&#x430;&#x446;&#x438;&#x44f; &#x422;&#x435;&#x440;&#x430;&#x43f;&#x435;&#x432;&#x442;&#x43e;&#x432;".</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarlovskaya</LastName><ForeName>Ekaterina Iosifovna</ForeName><Initials>EI</Initials><AffiliationInfo><Affiliation>&#x410;&#x441;&#x441;&#x43e;&#x446;&#x438;&#x430;&#x446;&#x438;&#x44f; "&#x415;&#x432;&#x440;&#x430;&#x437;&#x438;&#x439;&#x441;&#x43a;&#x430;&#x44f; &#x410;&#x441;&#x441;&#x43e;&#x446;&#x438;&#x430;&#x446;&#x438;&#x44f; &#x422;&#x435;&#x440;&#x430;&#x43f;&#x435;&#x432;&#x442;&#x43e;&#x432;", &#x424;&#x413;&#x411;&#x41e;&#x423; &#x412;&#x41e; &#x41f;&#x418;&#x41c;&#x423; &#x41c;&#x417; &#x420;&#x424;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arutyunov</LastName><ForeName>Alexander Grigorievich</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>&#x410;&#x441;&#x441;&#x43e;&#x446;&#x438;&#x430;&#x446;&#x438;&#x44f; "&#x415;&#x432;&#x440;&#x430;&#x437;&#x438;&#x439;&#x441;&#x43a;&#x430;&#x44f; &#x410;&#x441;&#x441;&#x43e;&#x446;&#x438;&#x430;&#x446;&#x438;&#x44f; &#x422;&#x435;&#x440;&#x430;&#x43f;&#x435;&#x432;&#x442;&#x43e;&#x432;", &#x424;&#x413;&#x410;&#x41e;&#x423; &#x412;&#x41e; &#xab;&#x420;&#x41d;&#x418;&#x41c;&#x423; &#x438;&#x43c;. &#x41d;.&#x418;. &#x41f;&#x438;&#x440;&#x43e;&#x433;&#x43e;&#x432;&#x430;&#xbb;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belenkov</LastName><ForeName>Yuri Nikitich</ForeName><Initials>YN</Initials><AffiliationInfo><Affiliation>&#x424;&#x413;&#x410;&#x41e;&#x423; &#x412;&#x41e; &#x41f;&#x435;&#x440;&#x432;&#x44b;&#x439; &#x41c;&#x413;&#x41c;&#x423; &#x438;&#x43c; &#x418;.&#x41c;. &#x421;&#x435;&#x447;&#x435;&#x43d;&#x43e;&#x432;&#x430; &#x41c;&#x438;&#x43d;&#x437;&#x434;&#x440;&#x430;&#x432;&#x430; &#x420;&#x43e;&#x441;&#x441;&#x438;&#x438;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konradi</LastName><ForeName>Alexandra Olegovna</ForeName><Initials>AO</Initials><AffiliationInfo><Affiliation>&#x424;&#x413;&#x411;&#x423; &#xab;&#x41d;&#x430;&#x446;&#x438;&#x43e;&#x43d;&#x430;&#x43b;&#x44c;&#x43d;&#x44b;&#x439; &#x43c;&#x435;&#x434;&#x438;&#x446;&#x438;&#x43d;&#x441;&#x43a;&#x438;&#x439; &#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x442;&#x435;&#x43b;&#x44c;&#x441;&#x43a;&#x438;&#x439; &#x446;&#x435;&#x43d;&#x442;&#x440; &#x438;&#x43c;. &#x412;. &#x410;. &#x410;&#x43b;&#x43c;&#x430;&#x437;&#x43e;&#x432;&#x430;&#xbb; &#x41c;&#x438;&#x43d;&#x437;&#x434;&#x440;&#x430;&#x432;&#x430; &#x420;&#x43e;&#x441;&#x441;&#x438;&#x438;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopatin</LastName><ForeName>Yury Mikhailovich</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>&#x424;&#x413;&#x411;&#x41e;&#x423; &#x412;&#x41e; &#x412;&#x43e;&#x43b;&#x433;&#x413;&#x41c;&#x423; &#x41c;&#x438;&#x43d;&#x437;&#x434;&#x440;&#x430;&#x432;&#x430; &#x420;&#x43e;&#x441;&#x441;&#x438;&#x438;.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>&#x410;&#x43d;&#x430;&#x43b;&#x438;&#x437; &#x432;&#x43b;&#x438;&#x44f;&#x43d;&#x438;&#x44f; &#x43a;&#x43e;&#x43c;&#x43e;&#x440;&#x431;&#x438;&#x434;&#x43d;&#x43e;&#x439; &#x441;&#x435;&#x440;&#x434;&#x435;&#x447;&#x43d;&#x43e;-&#x441;&#x43e;&#x441;&#x443;&#x434;&#x438;&#x441;&#x442;&#x43e;&#x439; &#x43f;&#x430;&#x442;&#x43e;&#x43b;&#x43e;&#x433;&#x438;&#x438; &#x43d;&#x430; &#x442;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x435; &#x438; &#x438;&#x441;&#x445;&#x43e;&#x434;&#x44b; COVID-19 &#x443; &#x433;&#x43e;&#x441;&#x43f;&#x438;&#x442;&#x430;&#x43b;&#x438;&#x437;&#x438;&#x440;&#x43e;&#x432;&#x430;&#x43d;&#x43d;&#x44b;&#x445; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432; &#x432; &#x43f;&#x435;&#x440;&#x432;&#x443;&#x44e; &#x438; &#x432;&#x442;&#x43e;&#x440;&#x443;&#x44e; &#x432;&#x43e;&#x43b;&#x43d;&#x443; &#x43f;&#x430;&#x43d;&#x434;&#x435;&#x43c;&#x438;&#x438; &#x432; &#x415;&#x432;&#x440;&#x430;&#x437;&#x438;&#x439;&#x441;&#x43a;&#x43e;&#x43c; &#x440;&#x435;&#x433;&#x438;&#x43e;&#x43d;&#x435;.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Kardiologiia</MedlineTA><NlmUniqueID>0376351</NlmUniqueID><ISSNLinking>0022-9040</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636975</ArticleId><ArticleId IdType="doi">10.18087/cardio.2022.12.n2125</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636974</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0022-9040</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Kardiologiia</Title><ISOAbbreviation>Kardiologiia</ISOAbbreviation></Journal><ArticleTitle>Electrocardiogram QRS Complex Duration as a Predictor of Hospital Prognosis in Patients With COVID-19.</ArticleTitle><Pagination><StartPage>30</StartPage><EndPage>37</EndPage><MedlinePgn>30-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18087/cardio.2022.12.n2260</ELocationID><Abstract><AbstractText>Aim&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; To determine the effect of major electrocardiographic (ECG) parameters on the prognosis of patients with COVID-19.Material and methods&#xa0; One of systemic manifestations of COVID-19 is heart injury. ECG is the most simple and available method for diagnosing the heart injury, which influences the therapeutic approach. This study included 174 hospitalized patients with COVID-19. Major ECG parameters recorded on admission and their changes before the discharge from the hospital or death of the patient, were analyzed, and the effect of each parameter on the in-hospital prognosis was determined. Results were compared with the left ventricular ejection fraction (LV EF), laboratory data, and results of multispiral computed tomography (MSCT) of the lungs.Results ECG data differed on admission and their changes differed for deceased and discharged patients. Of special interest was the effect of the QRS complex duration at baseline and at the end of treatment on the in-hospital survival and mortality rate. The Cox regression analysis showed that the QRS complex duration (relative risk (RR) 2.07, 95% confidence interval (CI): 1.17-3.66; &#x440;=0.01), MSCT data (RR, 1.54; 95&#x200a;% CI: 1.14-2.092; &#x440;=0.005), and glomerular filtration rate (GFR) (RR, 0.98; 95&#x200a;% CI: 0.96-0.99; &#x440;=0.001) had the highest predictive significance. In further comparison of these three indexes, the QRS duration and GFR retained their predictive significance, and a ROC analysis showed that the cut-off QRS complex duration was 125&#x2008;ms (&#x440;=0.001). Patients who developed left bundle branch block (LBBB) in the course of disease also had an unfavorable prognosis compared to other intraventricular conduction disorders (&#x440;=0.038). The presence of LBBB was associated with reduced LV EF (&#x440;=0.0078). The presence of atrial fibrillation (AF) significantly predetermines a worse outcome both at the start (&#x440;=0.011) and at the end of observation (&#x440;=0.034). A higher mortality was observed for the group of deceased patients with ST segment deviations, ST elevation (&#x440;=0.0059) and ST depression (&#x440;=0.028).Conclusion&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; Thus, the QTc interval elongation, LBBB that developed during the treatment, AF, and increased QRS complex duration are the indicators that determine the in-hospital prognosis of patients with COVID-19. The strongest electrocardiographic predictor for an unfavorable prognosis was the QRS complex duration that allowed stratification of patients to groups of risk.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kovtyukh</LastName><ForeName>I V</ForeName><Initials>IV</Initials><AffiliationInfo><Affiliation>Petrovsky Russian Scientific Center of Surgery, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baymukanov</LastName><ForeName>A M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Buyanov Municipal Clinical Hospital, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendlin</LastName><ForeName>G E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>&#x424;&#x413;&#x410;&#x41e;&#x423; &#x412;&#x41e; "&#x420;&#x43e;&#x441;&#x441;&#x438;&#x439;&#x441;&#x43a;&#x438;&#x439; &#x43d;&#x430;&#x446;&#x438;&#x43e;&#x43d;&#x430;&#x43b;&#x44c;&#x43d;&#x44b;&#x439; &#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x442;&#x435;&#x43b;&#x44c;&#x441;&#x43a;&#x438;&#x439; &#x43c;&#x435;&#x434;&#x438;&#x446;&#x438;&#x43d;&#x441;&#x43a;&#x438;&#x439; &#x443;&#x43d;&#x438;&#x432;&#x435;&#x440;&#x441;&#x438;&#x442;&#x435;&#x442; &#x438;&#x43c;&#x435;&#x43d;&#x438; &#x41d;.&#x418;. &#x41f;&#x438;&#x440;&#x43e;&#x433;&#x43e;&#x432;&#x430;" &#x41c;&#x438;&#x43d;&#x437;&#x434;&#x440;&#x430;&#x432;&#x430; &#x420;&#x43e;&#x441;&#x441;&#x438;&#x438;, &#x41c;&#x43e;&#x441;&#x43a;&#x432;&#x430;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikitin</LastName><ForeName>I G</ForeName><Initials>IG</Initials><AffiliationInfo><Affiliation>Pirogov Russian National Research Medical University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dvornikova</LastName><ForeName>S N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Petrovsky Russian Scientific Center of Surgery, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roginko</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Petrovsky Russian Scientific Center of Surgery, Moscow.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Kardiologiia</MedlineTA><NlmUniqueID>0376351</NlmUniqueID><ISSNLinking>0022-9040</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636974</ArticleId><ArticleId IdType="doi">10.18087/cardio.2022.12.n2260</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636973</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0022-9040</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Kardiologiia</Title><ISOAbbreviation>Kardiologiia</ISOAbbreviation></Journal><ArticleTitle>The Effect of COVID-19 on Long-Term Cardiac Function in Patients With Chronic Heart Failure.</ArticleTitle><Pagination><StartPage>23</StartPage><EndPage>29</EndPage><MedlinePgn>23-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18087/cardio.2022.12.n2265</ELocationID><Abstract><AbstractText>Aim&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; To evaluate functional changes in the heart in the long-term following COVID-19 in patients with chronic heart failure (CHF).Material and methods&#xa0; Case reports of 54 patients aged 69.1&#xb1;9.7 years who had COVID-19 from January 2021 through January 2022 and had been previously diagnosed with NYHA functional class II-III CHF were studied. Two comparison groups were isolated: HF with LV EF &amp;gt;50&#x200a;% (n=39) and &amp;lt;50&#x200a;% (n=15). Echocardiography was used to evaluate changes in LV EF and pulmonary artery systolic pressure (PASP) 5-6 months following COVID-19.Results In all CHF patients after COVID-19 at 5.8 months on average, LV EF decreased (median difference, 2.5&#x200a;%; 95&#x200a;% confidence interval (CI): 6.99&#xd7;10-5-&#x2009;4.99) and PASP increased (median difference, 8&#x2008;mm Hg; 95&#x200a;% CI: 4.5-12.9). In the HF group with LV EF &amp;lt;50&#x200a;%, the decrease in EF was greater than in the group with LV EF &amp;gt;50&#x200a;% (6.9 and 0.7&#x200a;%, respectively; p=0.037); furthermore, the CHF phenotype did not influence the change in PASP (p=0.4). The one-factor regression analysis showed that the dynamics of LV EF decrease was significantly influenced by the baseline decrease in LV EF, whereas the change in PASP was influenced by the dynamics of LV EF decrease, presence of dyslipidemia, and statin treatment. Furthermore, the multifactorial analysis showed that prognostically significant factors for long-term changes in LV EF following COVID-19 were male gender (odds ratio (OR), 5.92; 95&#x200a;% CI: 1.31-26.75; p=0.014), LV EF at baseline &amp;lt;50&#x200a;% (OR, 0.88; 95&#x200a;% CI: 0.8-0.96; p&amp;lt;0.001); changes in PASP depended on the presence of dyslipidemia (OR, 0.08; 95&#x200a;% CI: 0.01-0.84; p=0.018).Conclusion&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; This study showed that COVID-19 in the long term can influence the course of CHF; in this process, HF patients with EF &amp;lt;50&#x200a;% have progression of systolic dysfunction and PASP, whereas patients with EF &amp;gt;50&#x200a;% have an isolated increase in PASP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ageev</LastName><ForeName>A A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kozhevnikova</LastName><ForeName>M V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emelyanov</LastName><ForeName>A V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krivova</LastName><ForeName>A V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shumskaya</LastName><ForeName>Yu F</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>Scientific and Practical Clinical Center for Diagnostics and Telemedicine Technologies, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musaeva</LastName><ForeName>L M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popova</LastName><ForeName>L V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naymann</LastName><ForeName>Yu I</ForeName><Initials>YI</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdullaeva</LastName><ForeName>G B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Privalova</LastName><ForeName>E V</ForeName><Initials>EV</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belenkov</LastName><ForeName>Yu N</ForeName><Initials>YN</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Kardiologiia</MedlineTA><NlmUniqueID>0376351</NlmUniqueID><ISSNLinking>0022-9040</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636973</ArticleId><ArticleId IdType="doi">10.18087/cardio.2022.12.n2265</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636972</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0022-9040</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Kardiologiia</Title><ISOAbbreviation>Kardiologiia</ISOAbbreviation></Journal><ArticleTitle>Proactive anti-inflammatory therapy in the advanced stages of a new coronavirus infection. Main results of the inpatient phase of the COLORIT study (Colchicin vs. Ruxolitinib and secukinumab in an open, prospective, randomized trial in patients with novel coronavirus infection COVID-19).</ArticleTitle><Pagination><StartPage>11</StartPage><EndPage>22</EndPage><MedlinePgn>11-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18087/cardio.2022.12.n2316</ELocationID><Abstract><AbstractText>Aim&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; To evaluate clinical efficacy of the proactive anti-inflammatory therapy in patients hospitalized for COVID-19 with pneumonia and a risk of "cytokine storm".Material and methods&#xa0; The COLORIT study was a comparative study with randomization into 4 groups: colchicine (n=21) 1 mg for the first 3 days followed by 0.5&#x2008;mg/day through day 12 or discharge from the hospital; secukinumab 300&#x2008;mg/day, s.c., as a single dose (n=20); ruxolitinib 5&#x2008;mg, twice a day (n=10); and a control group with no anti-inflammatory therapy (n=22). The effect was evaluated after 12&#xb1;2 days of inpatient treatment or upon discharge, what comes first. For ethical reasons, completely randomized recruitment to the control group was not possible. Thus, for data analysis, 17 patients who did not receive any anti-inflammatory therapy for various reasons not related with inclusion into the study were added to the control group of 5 randomized patients. Inclusion criteria: presence of coronavirus pneumonia (positive PCR test for SARS-CoV-2 RNA or specific clinical presentation of pneumonia; IDC-10 codes U07.1 and U07.2); C-reactive protein (CRP) concentration &amp;gt;60&#x2008;mg/l or its threefold increase from baseline; at least 2 of 4 symptoms (fever &amp;gt;37.5&#x2009;&#xb0;C, persistent cough, shortness of breath with inspiratory rate &amp;gt;20 per min or blood saturation with oxygen &amp;lt;94&#x200a;% by the 7th-9th day of disease. The study primary endpoint was changes in COVID Clinical Condition Scale (CCS-COVID) score. The secondary endpoints were the dynamics of CRP and changes in the area of lung lesion according to data of computed tomography (CT) of the lungs from the date of randomization to 12&#xb1;2 days.Results All three drugs significantly reduced inflammation, improved the clinical course of the disease, and decreased the disease severity as evaluated by the CCS score: in the ruxolitinib group, by 5.5 (p=0.004); in the secukinumab group, by 4 (p=0.096); in the colchicine group, by 4 (p=0.017), and in the control group, by 2 (&#x440;=0.329). In all three groups, the CCS-COVID score was 2-3 by the end of observation period, which corresponded to a mild process, while in the control group, the score was 7 (&#x440;=0.005). Time-related changes in CRP were significant in all three anti-inflammatory treatment groups with no statistical difference between the groups. By the end of the study, changes in CT of the lungs were nonsignificant.Conclusion&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; In severe &#x421;OVID-19 with a risk of "cytokine storm", the proactive therapy with ruxolitinib, colchicine, and secukinumab significantly reduces the inflammation severity, prevents the disease progression, and results in clinical improvement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mareev</LastName><ForeName>V Yu</ForeName><Initials>VY</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orlova</LastName><ForeName>Y&#x430; A</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plisuk</LastName><ForeName>A G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavlikova</LastName><ForeName>E P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akopyan</LastName><ForeName>Z A</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matskeplishvili</LastName><ForeName>S T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malahov</LastName><ForeName>P S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krasnova</LastName><ForeName>T N</ForeName><Initials>TN</Initials><AffiliationInfo><Affiliation>School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seredenina</LastName><ForeName>E M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potapenko</LastName><ForeName>A V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agapov</LastName><ForeName>&#x41c; A</ForeName><Initials>&#x41c;A</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asratyan</LastName><ForeName>D A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dyachuk</LastName><ForeName>L I</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samokhodskaya</LastName><ForeName>L M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mershina</LastName><ForeName>E M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinitsyn</LastName><ForeName>V E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mareev</LastName><ForeName>Yu V</ForeName><Initials>YV</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; National Medical Research Center of Therapy and Preventive Medicine, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shatokhina</LastName><ForeName>E A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Begrambekova</LastName><ForeName>Yu L</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamalov</LastName><ForeName>A A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Kardiologiia</MedlineTA><NlmUniqueID>0376351</NlmUniqueID><ISSNLinking>0022-9040</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636972</ArticleId><ArticleId IdType="doi">10.18087/cardio.2022.12.n2316</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636959</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-0496</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Pediatric pulmonology</Title><ISOAbbreviation>Pediatr Pulmonol</ISOAbbreviation></Journal><ArticleTitle>How has the SARS-CoV-2 pandemic changed the epidemiology and management of acute bronchiolitis?</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ppul.26315</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">SARS-COV-2 pandemic profoundly impacted acute bronchiolitis epidemiology worldwide, especially RSV diffusion and burden of disease, with remarkable implications on the management of health resources. We aimed to study the epidemiology and clinical course of bronchiolitis in the past five years in our region and to assess the trends that occurred during and after the SARS-COV-2 pandemic METHODS: We conducted an observational study including all children aged 0-2 years with bronchiolitis admitted to a tertiary children's hospital during the last 5 years. Demographic, clinical, and microbiological data were collected. Comparisons between patient subgroups were carried out.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 647 patients admitted for bronchiolitis were included (median age 78 days). Molecular diagnostic tests were performed in 617 patients (95.4%) with RSV detected in 51.5% of patients in pre-pandemic years and 74.5% in pandemic years. Through the study period, we observed a progressive increase in the number of children requiring respiratory support, RSV infections, and children with a history of prematurity. Conversely, this was not true for mechanical ventilation, duration of respiratory support, ICU admission, and length of stay.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clinical course and epidemiology of bronchiolitis showed a significant change through the study years with a heavy impact during the 2021-22 season. The increase in the number of patients requiring respiratory support, although not associated with an increase in mechanical ventilation, may be explained by the higher prevalence of RSV. The change in epidemiology highlights the importance of surveillance systems to monitor RSV circulation, in order to plan prophylactic strategies, and prepare healthcare systems. This article is protected by copyright. All rights reserved.</AbstractText><CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brisca</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7992-0181</Identifier><AffiliationInfo><Affiliation>Terapia Semintensiva, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariani</LastName><ForeName>Marcello</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2989-7301</Identifier><AffiliationInfo><Affiliation>Unit&#xe0; di Malattie Infettive e COVID Hospital, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Universit&#xe0; degli Studi di Genova, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buratti</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Terapia Intensiva Neonatale e Pediatrica, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferretti</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pediatria d'Urgenza e Pronto Soccorso, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pirlo</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Terapia Semintensiva, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buffoni</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Terapia Semintensiva, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallamaci</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Terapia Semintensiva, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvati</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unit&#xe0; di Pneumologia Pediatrica e Endoscopia Respiratoria, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tagliarini</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Universit&#xe0; degli Studi di Genova, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccotti</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pediatria d'Urgenza e Pronto Soccorso, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacco</LastName><ForeName>Oliviero</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-9350-9134</Identifier><AffiliationInfo><Affiliation>Unit&#xe0; di Pneumologia Pediatrica e Endoscopia Respiratoria, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castagnola</LastName><ForeName>Elio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unit&#xe0; di Malattie Infettive e COVID Hospital, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moscatelli</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Terapia Semintensiva, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Terapia Intensiva Neonatale e Pediatrica, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Pulmonol</MedlineTA><NlmUniqueID>8510590</NlmUniqueID><ISSNLinking>1099-0496</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 pandemic</Keyword><Keyword MajorTopicYN="N">bronchiolitis</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">palivizumab</Keyword><Keyword MajorTopicYN="N">respiratory syncytial virus (RSV)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636959</ArticleId><ArticleId IdType="doi">10.1002/ppul.26315</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636955</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Relationship between immune response to SARS-CoV2 vaccines and development of breakthrough infection in solid organ transplant recipients: the CONTRAST cohort.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ciad016</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciad016</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">SARS-CoV-2 vaccination in solid organ transplant (SOT) is associated with poorer antibody response (AbR) compared to non-SOT recipients. However, its impact on the risk of breakthrough infection (BI) should yet be assessed.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Single-center prospective longitudinal cohort study enrolling adult SOT recipients who received SARS-CoV2 vaccination during 1-year period from February 2021, and followed-up to April 30th 2022. Patients were tested for AbR at multiple timepoints. Primary endpoint was BI (laboratory confirmed SARS-CoV2 infection &#x2265;14 days after 2nd dose). Immunization (positive AbR) was considered an intermediate state between vaccination and BI. Probabilities of being in vaccination, immunization and BI states were obtained for each type of graft and vaccination sequence with multistate survival analysis, then multivariable logistic regression was performed to analyse the risk of BI in AbR levels.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">614 SOT (275 kidney, 163 liver, 137 heart, 39 lung) recipients were included. Most patients (84.7%) received three vaccine doses, the first two consisted of BNT162b2 and mRNA-1273 in 73.5% and 26.5% of cases, respectively; while at the third dose mRNA-1273 was administered in 59.8% of patients. Overall, 75.4% of patients reached immunization and 18.4% developed BI. Heart transplant recipients showed lowest probability of immunization (0.418) and highest of BI (0.323), all-mRNA-1273 vaccine-sequence showed higher probability of immunization (0.732) and lowest of BI (0.098). Risk of BI was higher for non-high-level AbR, younger age and shorter time from transplant.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SOT patients with non-high-level AbR, shorter time from transplantation, and heart recipients are at highest risk of BI.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonazzetti</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tazza</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibertoni</LastName><ForeName>Dino</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Research and Innovation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquini</LastName><ForeName>Zeno</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caroccia</LastName><ForeName>Natascia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan&#xec;</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornaro</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascale</LastName><ForeName>Renato</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miani</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamberini</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morelli</LastName><ForeName>Maria Cristina</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Internal Medicine Unit for the treatment of Severe Organ Failure, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tam&#xe9;</LastName><ForeName>Mariarosa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gastroenterology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busutti</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nephrology, Dialysis and Transplantation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comai</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Nephrology, Dialysis and Transplantation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potena</LastName><ForeName>Luciano</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit of Heart Failure and Transplantation, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borgese</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit of Heart Failure and Transplantation, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvaterra</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Interventional Pulmonology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazzarotto</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scudeller</LastName><ForeName>Luigia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Research and Innovation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viale</LastName><ForeName>Pierluigi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannella</LastName><ForeName>Maddalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>CONTRAST study group
</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV2 infection</Keyword><Keyword MajorTopicYN="N">antibody-response</Keyword><Keyword MajorTopicYN="N">mRNA vaccines</Keyword><Keyword MajorTopicYN="N">multistate model</Keyword><Keyword MajorTopicYN="N">serology</Keyword><Keyword MajorTopicYN="N">solid organ transplantation</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Di Chiara</LastName><ForeName>Michela</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giacomini</LastName><ForeName>Maria Eugenia</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vatamanu</LastName><ForeName>Oana</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horna</LastName><ForeName>Clara Solera</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campoli</LastName><ForeName>Caterina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartoletti</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bussini</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trapani</LastName><ForeName>Fabio</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Attard</LastName><ForeName>Luciano</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gatti</LastName><ForeName>Milo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gramegna</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>La Manna</LastName><ForeName>Gaetano</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grandinetti</LastName><ForeName>Valeria</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Demetri</LastName><ForeName>Marcello</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbuto</LastName><ForeName>Simona</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abenavoli</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vitale</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turco</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravaioli</LastName><ForeName>Matteo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cescon</LastName><ForeName>Matteo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertuzzo</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Messina</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trombi</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masetti</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prestinenzi</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabatino</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giovannini</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alessio</LastName><ForeName>Aloisio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russo</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scuppa</LastName><ForeName>Maria Francesca</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolci</LastName><ForeName>Giampiero</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paganelli</LastName><ForeName>Gianmaria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabrielli</LastName><ForeName>Liliana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pavoni</LastName><ForeName>Matteo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leone</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lanna</LastName><ForeName>Federica</ForeName><Initials>F</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636955</ArticleId><ArticleId IdType="doi">10.1093/cid/ciad016</ArticleId><ArticleId IdType="pii">6986430</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636919</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4571</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Circulation research</Title><ISOAbbreviation>Circ Res</ISOAbbreviation></Journal><ArticleTitle>Toll-Like Receptor 4-Dependent Platelet-Related Thrombosis in SARS-CoV-2 Infection.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCRESAHA.122.321541</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">SARS-CoV-2 is associated with an increased risk of venous and arterial thrombosis, but the underlying mechanism is still unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a cross-sectional analysis of platelet function in 25 SARS-CoV-2 and 10 healthy subjects by measuring Nox2 (NADPH oxidase 2)-derived oxidative stress and thromboxane B<sub>2</sub>, and investigated if administration of monoclonal antibodies against the S protein (Spike protein) of SARS-CoV-2 affects platelet activation. Furthermore, we investigated in vitro if the S protein of SARS-CoV-2 or plasma from SARS-CoV-2 enhanced platelet activation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ex vivo studies showed enhanced platelet Nox2-derived oxidative stress and thromboxane B<sub>2</sub> biosynthesis and under laminar flow platelet-dependent thrombus growth in SARS-CoV-2 compared with controls; both effects were lowered by Nox2 and TLR4 (Toll-like receptor 4) inhibitors. Two hours after administration of monoclonal antibodies, a significant inhibition of platelet activation was observed in patients with SARS-CoV-2 compared with untreated ones. In vitro study showed that S protein per se did not elicit platelet activation but amplified the platelet response to subthreshold concentrations of agonists and functionally interacted with platelet TLR4. A docking simulation analysis suggested that TLR4 binds to S protein via three receptor-binding domains; furthermore, immunoprecipitation and immunofluorescence showed S protein-TLR4 colocalization in platelets from SARS-CoV-2. Plasma from patients with SARS-CoV-2 enhanced platelet activation and Nox2-related oxidative stress, an effect blunted by TNF (tumor necrosis factor) &#x3b1; inhibitor; this effect was recapitulated by an in vitro study documenting that TNF&#x3b1; alone promoted platelet activation and amplified the platelet response to S protein via p47phox upregulation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The study identifies 2 TLR4-dependent and independent pathways promoting platelet-dependent thrombus growth and suggests inhibition of TLR4. or p47phox as a tool to counteract thrombosis in SARS-CoV-2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Carnevale</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6216-9595</Identifier><AffiliationInfo><Affiliation>Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy (R.C., S.S., G.F., M.L.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Neuromed, Localit&#xe0; Camerelle, Pozzilli (IS), Italy (R.C., S.S., G.F.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cammisotto</LastName><ForeName>Vittoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, Italy. (V.C., S.B., C.N., L.L., P.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartimoccia</LastName><ForeName>Simona</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6266-3059</Identifier><AffiliationInfo><Affiliation>Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, Italy. (V.C., S.B., C.N., L.L., P.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nocella</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, Italy. (V.C., S.B., C.N., L.L., P.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellani</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of General Surgery and Surgical Speciality, Sapienza University of Rome, Viale del Policlinico, Italy. (V.C., F.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bufano</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6359-5978</Identifier><AffiliationInfo><Affiliation>Laboratory affiliated with the Institute Pasteur Italy - Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Italy. (M.B., A.C., R.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loffredo</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6542-6235</Identifier><AffiliationInfo><Affiliation>Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, Italy. (V.C., S.B., C.N., L.L., P.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sciarretta</LastName><ForeName>Sebastiano</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8633-6896</Identifier><AffiliationInfo><Affiliation>Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy (R.C., S.S., G.F., M.L.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Neuromed, Localit&#xe0; Camerelle, Pozzilli (IS), Italy (R.C., S.S., G.F.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frati</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2703-3761</Identifier><AffiliationInfo><Affiliation>Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy (R.C., S.S., G.F., M.L.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Neuromed, Localit&#xe0; Camerelle, Pozzilli (IS), Italy (R.C., S.S., G.F.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coluccia</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory affiliated with the Institute Pasteur Italy - Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Italy. (M.B., A.C., R.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silvestri</LastName><ForeName>Romano</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory affiliated with the Institute Pasteur Italy - Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Italy. (M.B., A.C., R.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceccarelli</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5921-3180</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico, Italy. (G.C., A.O., M.V., C.M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliva</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0832-7975</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico, Italy. (G.C., A.O., M.V., C.M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venditti</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico, Italy. (G.C., A.O., M.V., C.M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pugliese</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of General Surgery and Surgical Speciality, Sapienza University of Rome, Viale del Policlinico, Italy. (V.C., F.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maria Mastroianni</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico, Italy. (G.C., A.O., M.V., C.M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turriziani</LastName><ForeName>Ombretta</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6400-9168</Identifier><AffiliationInfo><Affiliation>Laboratory of Virology, Department of Molecular Medicine, Sapienza University of Rome, Viale del Policlinico, Italy. (O.T.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leopizzi</LastName><ForeName>Martina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9258-4191</Identifier><AffiliationInfo><Affiliation>Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy (R.C., S.S., G.F., M.L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Amati</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Italy. (G.D.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pignatelli</LastName><ForeName>Pasquale</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2265-7455</Identifier><AffiliationInfo><Affiliation>Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, Italy. (V.C., S.B., C.N., L.L., P.P.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mediterranea Cardiocentro-Napoli, Italy (P.P., F.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Violi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6610-7068</Identifier><AffiliationInfo><Affiliation>Mediterranea Cardiocentro-Napoli, Italy (P.P., F.V.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circ Res</MedlineTA><NlmUniqueID>0047103</NlmUniqueID><ISSNLinking>0009-7330</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword><Keyword MajorTopicYN="N">thromboxane B2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636919</ArticleId><ArticleId IdType="doi">10.1161/CIRCRESAHA.122.321541</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636865</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-6518</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of interpersonal violence</Title><ISOAbbreviation>J Interpers Violence</ISOAbbreviation></Journal><ArticleTitle>The Effect of the Covid-19 Pandemic on Domestic Violence in Germany: A Comparison of Three Representative Population Surveys.</ArticleTitle><Pagination><StartPage>8862605221143194</StartPage><MedlinePgn>8862605221143194</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/08862605221143194</ELocationID><Abstract><AbstractText>The COVID-19 pandemic has had profound societal and economic effects. Concerns were raised that domestic violence might increase because of the enacted infection control measures. Previous findings on this issue have been contradictory. Since existing studies mainly rely on official reports, administrative data, helpline calls, or retrospective measures, their findings are likely to prove unreliable. Few population-based surveys include pre-pandemic data, limiting their ability to test for causality regarding increasing violence. Therefore, the aim of this study was to compare findings from population-representative surveys on the prevalence of intimate partner violence (IPV) and violence against children (VAC) before and during the COVID-19 pandemic. Based on the data of <i>N</i>&#x2009;=&#x2009;3,639 individuals living with a romantic partner and <i>N</i>&#x2009;=&#x2009;1,313 parents living with at least one of their children from three German representative population surveys, we estimated average marginal effects for the temporal trends (i.e., pre vs. post infection control measures) of domestic violence separately for males and females. To minimize bias across survey waves, inverse probability weighting was used. Results show no statistically significant increase in either physical or psychological forms of IPV or VAC as a result of the implementation of COVID measures. On the contrary, the 1-year prevalence was decreasing for certain forms of violence. Our findings suggest that the assessment of the consequences of infection control measures needs an empirical basis. Further research should be conducted using high-quality data sources. Therefore, the present study should be considered a stepping stone for ongoing research efforts to examine the consequences of pandemic-related infection control measures on the general population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kliem</LastName><ForeName>S&#xf6;ren</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1788-9574</Identifier><AffiliationInfo><Affiliation>University of Applied Science, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Thadden</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6219-8495</Identifier><AffiliationInfo><Affiliation>University of Hildesheim, Hildesheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lohmann</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Applied Science, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xf6;ger</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Hildesheim, Hildesheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baier</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>ZHAW Zurich University of Applied Sciences, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Interpers Violence</MedlineTA><NlmUniqueID>8700910</NlmUniqueID><ISSNLinking>0886-2605</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">assessment</Keyword><Keyword MajorTopicYN="N">child abuse</Keyword><Keyword MajorTopicYN="N">domestic violence</Keyword><Keyword MajorTopicYN="N">mental health and violence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>4</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636865</ArticleId><ArticleId IdType="doi">10.1177/08862605221143194</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636856</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1541-3764</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Omega</Title><ISOAbbreviation>Omega (Westport)</ISOAbbreviation></Journal><ArticleTitle>Bereaved in Me: Understanding the Vicarious Grief Experiences Among Helping Professionals During the COVID-19 Pandemic.</ArticleTitle><Pagination><StartPage>302228221150870</StartPage><MedlinePgn>302228221150870</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/00302228221150870</ELocationID><Abstract><AbstractText>Literature on the experience of the bereaved during the COVID-19 pandemic suggests how complicated it has been for those who lost loved ones. However, the sense of grief experienced by those who journey with them is relatively unexplored. The present study examines vicarious experiences of grief of healthcare workers, faith-based workers and mental health workers who worked with the bereaved due to COVID-19 deaths. The study was done in two phases. In the first phase, a survey showed that compared to other helping professionals, healthcare workers reported the highest levels of vicarious grief. In the second phase, in-depth interviews revealed five themes: acknowledging contexts of grief, navigating relations with the bereaved, sharing others' grief, internalizing encounters, and negotiating challenges. Findings highlight the need for supportive interventions at the organizational level.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sera Jose</LastName><ForeName>Kaina Marie Clare</ForeName><Initials>KMC</Initials><AffiliationInfo><Affiliation>Department of Psychology, 595658Ateneo de Manila University, Quezon City, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>Agham Josiah</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Psychology, 595658Ateneo de Manila University, Quezon City, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pomida</LastName><ForeName>Angelo Nico</ForeName><Initials>AN</Initials><Identifier Source="ORCID">0000-0001-6959-1791</Identifier><AffiliationInfo><Affiliation>Department of Psychology, 595658Ateneo de Manila University, Quezon City, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hechanova-Alampay</LastName><ForeName>Maria Regina</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Psychology, 595658Ateneo de Manila University, Quezon City, Philippines.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Omega (Westport)</MedlineTA><NlmUniqueID>1272106</NlmUniqueID><ISSNLinking>0030-2228</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">coping</Keyword><Keyword MajorTopicYN="N">helping professionals</Keyword><Keyword MajorTopicYN="N">mixed methods</Keyword><Keyword MajorTopicYN="N">vicarious grief</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636856</ArticleId><ArticleId IdType="doi">10.1177/00302228221150870</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636854</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0374-9096</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Mikrobiyoloji bulteni</Title><ISOAbbreviation>Mikrobiyol Bul</ISOAbbreviation></Journal><ArticleTitle>[How to Defend Mandatory Immunization Against Vaccine Hesitancy and Vaccine Refusal? An Ethical Assessment].</ArticleTitle><Pagination><StartPage>156</StartPage><EndPage>170</EndPage><MedlinePgn>156-170</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5578/mb.20239913</ELocationID><Abstract><AbstractText>One of the basic ethical principles in medical practice is to respect personal autonomy. However, it is a widely accepted view that when it comes to health problems that concern not only the individual but also the society, especially in epidemics of infectious diseases, individual autonomy can be violated by prioritizing the benefit of the community. This view is based on the scientific fact that epidemics can only be controlled by immunizing all susceptible individuals. However, whether all susceptible individuals can be compelled to be immunized remains a matter of debate around the world. Especially in the last three years, during the worldwide Coronavirus disease-2019 (COVID-19) pandemic, a significant part of the society has been hesitant about being vaccinated, and some have argued that vaccines should be rejected altogether. In the face of the situation outlined above, the question of "should immunization be mandatory?" has become more important than ever to be able to answer the question in a way that will ensure as broad consensus as possible. In this review article; it was discussed under which conditions mandatory immunization could be justified in terms of ethics and thus, it was aimed to contribute to the solution of the vital problem created by the phenomenon of vaccine hesitancy and rejection in terms of public health. To this aim, first of all, the need to clarify some concepts was mentioned. Afterwards, the arguments "must be compulsory", "should be optional", and "should not be done to anyone" were evaluated with their justifications and it was determined that the argument that immunization should be mandatory could be justified in terms of ethics. In the article, it was argued that the conflicts of "individual freedom X community benefit" and "personal autonomy X community benefit" did not exist in today's actual conditions, but it was stated that an individual with the knowledge of reality experiences a tension in the face of not putting this knowledge into practice. It was emphasized that in order to overcome this tension, consolidation of the theoretical background and also consideration of the macro determinants of vaccine hesitancy and rejection in practice were necessary. What needs to be done to re-establish trust in the medical institution was listed, and it was argued that the question of how to implement mandatory immunization could only be answered in a healthy way through a transformation process that will be implemented through a social dialogue.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Civaner</LastName><ForeName>M Murat</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Bursa Uluda&#x11f; University Faculty of Medicine, Department of Medical History and Ethics, Bursa, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>tur</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>A&#x15f;&#x131; Karars&#x131;zl&#x131;&#x11f;&#x131; ve A&#x15f;&#x131; Reddi Olgusu Kar&#x15f;&#x131;s&#x131;nda Zorunlu Ba&#x11f;&#x131;&#x15f;&#x131;klama Nas&#x131;l Savunulmal&#x131;? Etik A&#xe7;&#x131;s&#x131;ndan Bir De&#x11f;erlendirme.</VernacularTitle></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Mikrobiyol Bul</MedlineTA><NlmUniqueID>7503830</NlmUniqueID><ISSNLinking>0374-9096</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636854</ArticleId><ArticleId IdType="doi">10.5578/mb.20239913</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636849</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0374-9096</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Mikrobiyoloji bulteni</Title><ISOAbbreviation>Mikrobiyol Bul</ISOAbbreviation></Journal><ArticleTitle>[Evaluation of the Effects of Tocilizumab Use on Oxygen Parameters, Inflammatory Markers and Survival in Patients Diagnosed with COVID-19 in Intensive Care Unit].</ArticleTitle><Pagination><StartPage>97</StartPage><EndPage>107</EndPage><MedlinePgn>97-107</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5578/mb.20239908</ELocationID><Abstract><AbstractText>Inflammation plays a key role in the progression of COVID-19 infection from acute viral disease to organ failure and death. Tocilizumab maintains its current place as a frequently preferred agent in hyperinflammatory syndrome in COVID-19 infection. This study was aimed to evaluate changes in oxygen parameters and inflammatory markers before and after treatment, to define survival rates and complications in the patients who have been followed up in the tertiary intensive care unit of our hospital with the diagnosis of COVID-19 and who have been administered tocilizumab for hyperinflammatory syndrome in the follow-up. This study was planned as a retrospective observational study. A total of 132 patients were included in the study. The patient's data; age, comorbidities, sequential organ failure assessment (SOFA) and acute physiologic assessment and chronic health evaluation II (APACHE II) scores, duration of stay on a mechanical ventilator, duration of stay in the intensive care unit, positivity of real-time polymerase chain reaction (Rt-PCR), the presence of lung tomography findings specific to SARS-CoV-2 pneumonia, survival data, laboratory parameters, lactate mmol/L, partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PCO2), oxygen saturation % (SpO2) and partial pressure of oxygen/inspired oxygen (PaO2/FiO2) values on hospitalization date, tocilizumab administration date and post-administration days one, three, five, and seven; treatments administered and drug complications were recorded. IBM SPSS Version 25.0 statistical package program was used for statistical analysis. Of the 132 patients, 36 were female and 96 were male (p= 0.972). The mean age was 61.9 &#xb1; 1.07 years, the mean APACHE 2 score &#xb1; standard deviation (SD) was 14.89 &#xb1; 5.22 and mortality was 41.7%. The mean duration on a mechanical ventilator was 9.54 &#xb1; 15.63 days and the mean length of stay in the intensive care unit was 20.50 &#xb1; 15.48 days. A statistically significant difference was found between the PaO2, SpO2, and the PaO2/FiO2 values on the day of hospitalization and days one, three, five, and seven after tocilizumab administration, and also between the day of tocilizumab administration and days following the administration (p&lt;0.001). There was a significant decrease in ferritin, D-dimer, and C-reactive protein levels, and a significant increase in the lymphocyte count (p&lt;0.05). Elevated transaminases (n= 36), acute renal injury (n= 25), atrial fibrillation (n= 10), pneumothorax (n= 10), and pneumomediastinum (n= 6) were the most common complications during the disease. In our study, a significant improvement was observed in inflammatory parameters and oxygen parameters from the first day after tocilizumab administration. In the first seven days patient mortality was zero with improvement in the P/F ratios. These data supported the opinion that tocilizumab might be an effective treatment option for COVID-19 infection. In addition to the potential benefits of tocilizumab in critical COVID-19 patients, it is essential that the side effects related to the use of the drug be closely monitored, and early identification of and intervention in thromboembolic events increases survival.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Y&#x131;lmaz</LastName><ForeName>Berna</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Manisa City Hospital, Clinic of Anesthesiology Reanimation and Intensive Care, Manisa, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do&#x11f;an</LastName><ForeName>Mustafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tekirda&#x11f; &#xc7;orlu State Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Tekirda&#x11f;, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ergut Sezer</LastName><ForeName>B&#xfc;&#x15f;ra</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Tekirda&#x11f; &#xc7;orlu State Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Tekirda&#x11f;, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>tur</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Yo&#x11f;un Bak&#x131;mda COVID-19 Tan&#x131;l&#x131; Hastalarda Tosilizumab Kullan&#x131;m&#x131;n&#x131;n Oksijen Parametreleri, Enflamatuvar Belirte&#xe7;ler ve Sa&#x11f;kal&#x131;m &#xdc;zerine Etkilerinin De&#x11f;erlendirilmesi.</VernacularTitle></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Mikrobiyol Bul</MedlineTA><NlmUniqueID>7503830</NlmUniqueID><ISSNLinking>0374-9096</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636849</ArticleId><ArticleId IdType="doi">10.5578/mb.20239908</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636846</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0374-9096</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Mikrobiyoloji bulteni</Title><ISOAbbreviation>Mikrobiyol Bul</ISOAbbreviation></Journal><ArticleTitle>[Long COVID in Children: A Pediatric Center Experience].</ArticleTitle><Pagination><StartPage>60</StartPage><EndPage>70</EndPage><MedlinePgn>60-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5578/mb.20239905</ELocationID><Abstract><AbstractText>Although COVID-19 (Coronavirus disease-2019) is observed to be milder in children, it has been observed that the symptoms continue for a long time in many people after the acute period of the disease, especially the multisystemic inflammatory syndrome (MISC) that developed after COVID-19 with the progression of the pandemic. Although it was first defined by different names such as long COVID and post COVID in adults, it has been observed in studies that similar complaints such as cough, fatigue and difficulty in concentrating continue for a long time in children, just as in adults. In our study, we aimed to evaluate the status of long COVID in childhood. Our study included patients aged from one month to 18 years with moderate and severe symptoms who were hospitalized and discharged for SARS-CoV-2 infection in &#x130;stanbul University Faculty of Medicine between November 1, 2020 and November 1, 2021. A questionnaire form was created to learn about the complaints of the patients and their ongoing complaints. The patients/parents were called by phone and their complaints were recorded in the questionnaire. The patients were classified according to the definitions in the guidelines published by NICE, RCGP and SIGN. In total, 116 patients were included; 57.8% (n= 64) male, 42.5% (n= 49) female; 53.4% (n= 62) 0-9, 46.6% (n= 54) 10-18 years old. Comorbid conditions were found in 64 (55.2%) patients. The mean follow-up period was 5.90 &#xb1; 3.61 [min-max (1-12)] months; longest symptom durations: decrease in effort loss/fatigue 19.25 &#xb1; 74.56 (0-365) days, concentration difficulties 11.12 &#xb1; 49.75 (0-365) days, fatigue 9.61 &#xb1; 34.96 (0-365) days and cough were 8.34 &#xb1; 35.37 (0-365) days. The percentage of the patients who met the definition of subacute/ongoing symptomatic COVID-19 was 37.9% (n= 44). The most common symptoms were the decrease of effort capacity/fatigue 12.1% (n= 14) and the concentration difficulties 10.3% (n= 12) in subacute symptomatic patients. The percentage of patients matching the definition of chronic/post COVID-19 was 11.2% (n= 13). In the first year of the disease, ongoing complaints such as fatigue and concentration difficulties were observed in eight patients. The rate of concentration difficulties in the 10-18 age group was statistically significantly higher than the 0-9 age group (p= 0.037). In terms of other symptoms, no significant difference was found according to age, gender and concomitant disease status. Out of these, one patient was diagnosed with Type 2 diabetes mellitus during the acute illness, and two patients were diagnosed with allergic rhinitis after COVID-19. A statistically significant difference was found in the rates of concentration disorders according to age groups with subacute/ongoing symptoms. Although only the hospitalized patients were included, fatigue and difficulty in concentration were among the most common ongoing symptoms in our study, similar to the literature, and they were seen to be more common in older children. It is important both for early diagnosis and awareness to follow up children with COVID-19 in terms of symptoms, not only in terms of prolonged symptoms but also in terms of new diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Demirbu&#x11f;a</LastName><ForeName>Asuman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, Division of Pediatric Infectious Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han&#xe7;erli T&#xf6;r&#xfc;n</LastName><ForeName>Selda</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, Division of Pediatric Infectious Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaba</LastName><ForeName>&#xd6;zge</ForeName><Initials>&#xd6;</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, Division of Pediatric Infectious Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dede</LastName><ForeName>Elif</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, Division of Pediatric Infectious Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mete Atasever</LastName><ForeName>Neslihan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, Division of Pediatric Infectious Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ery&#x131;lmaz</LastName><ForeName>Cansu Ceren</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okay</LastName><ForeName>Necla Simay</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Somer</LastName><ForeName>Ayper</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, Division of Pediatric Infectious Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>tur</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>COVID-19 Nedeniyle Hastanede Yatan &#xc7;ocuk Hastalarda Uzun D&#xf6;nem Etkilerin ve Uzam&#x131;&#x15f; COVID S&#x131;kl&#x131;&#x11f;&#x131;n&#x131;n De&#x11f;erlendirilmesi.</VernacularTitle></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Mikrobiyol Bul</MedlineTA><NlmUniqueID>7503830</NlmUniqueID><ISSNLinking>0374-9096</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636846</ArticleId><ArticleId IdType="doi">10.5578/mb.20239905</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636830</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0301-1526</ISSN><JournalIssue CitedMedium="Print"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>VASA. Zeitschrift fur Gefasskrankheiten</Title><ISOAbbreviation>Vasa</ISOAbbreviation></Journal><ArticleTitle>Spontaneous dissection of the superior mesenteric artery related to COVID-19.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1024/0301-1526/a001051</ELocationID><Abstract><AbstractText><b/><i>Background:</i> Spontaneous peripheral dissections are rare, and in a substantial number of cases, the underlying aetiology remains unclear. <i>Patients and methods:</i> We report the case of a 63-year-old male patient with a recent asymptomatic SARS-CoV-2 infection who presented with sudden-onset intermittent abdominal pain. Imaging studies revealed a dissection of the superior mesenteric artery (SMA) and large-vessel vasculitis involving the SMA as well as the carotid, subclavian, axillary and femoropopliteal arteries. In the absence of other predisposing factors, we supposed an association with prior COVID-19 and performed a systematic review of the literature to search for similar cases with arterial dissection related to acute or recent SARS-CoV-2 infection. <i>Results:</i> We identified 25 cases, including ours: 13 males and 12 females, with a median age of 48 years. In 22/25 patients, arterial dissection occurred within 4 weeks after the diagnosis of COVID-19 and involved the cerebral (11/25; 44%), coronary (10/25; 40%), splanchnic (3/25; 12%) and renal (2/25; 8%) arteries. <i>Conclusions:</i> Although initially known for its respiratory manifestations, it has become evident that SARS-CoV-2 not only infects pneumocytes but also enters the vascular endothelium, leading to endothelial dysfunction and hypercoagulability and - as shown in our case - large-vessel vasculitis, which may predispose patients to intramural haemorrhage and arterial dissection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kukulski</LastName><ForeName>Leszek</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0906-9509</Identifier><AffiliationInfo><Affiliation>Department of Vascular Surgery, University Hospital Regensburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac, Vascular and Endovascular Surgery and Tranplantology, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scharf</LastName><ForeName>Gregor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Radiology, Interventional Radiology, University Hospital Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schierling</LastName><ForeName>Wilma</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University Hospital Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfister</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University Hospital Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linnemann</LastName><ForeName>Birgit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Angiology, East Bavarian Center of Vascular Medicine, University Hospital Regensburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vasa</MedlineTA><NlmUniqueID>0317051</NlmUniqueID><ISSNLinking>0301-1526</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">arterial dissection</Keyword><Keyword MajorTopicYN="N">superior mesenteric artery</Keyword><Keyword MajorTopicYN="N">vasculitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>3</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636830</ArticleId><ArticleId IdType="doi">10.1024/0301-1526/a001051</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636828</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-0254</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of biomolecular structure &amp; dynamics</Title><ISOAbbreviation>J Biomol Struct Dyn</ISOAbbreviation></Journal><ArticleTitle>Investigation of the interactions of HSA and SARS-CoV-2 papain-like protease against eugenol for novel COVID-19 drug discovery: spectroscopic and insilico study.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>10</EndPage><MedlinePgn>1-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/07391102.2022.2164062</ELocationID><Abstract><AbstractText>Coronavirus family consist of a member known as SARS-CoV-2, spread drastically in 2019 (Covid-19), affecting millions of people worldwide. Till date there is no clear-clinical therapy or drug, targeted to cure this serious disease. Researches are going on to prevent this corona virus. Here, we tried to explore a novel SARS-CoV-2 papain-like protease as a potential inhibitor. Finally, eugenol was docked with this protease to find prime SARS-inhibitors. <i>In silico</i> studies revealed that eugenol binds to the active site of SARS-CoV-2 papain-like protease with appropriate binding. Moreover, the MD simulation for 100&#x2009;ns and MMPBSA calculation reveals that eugenol possess potential phytotherapeutic properties against COVID-19. The interaction of eugenol with human serum albumin has been examined by using fluorescence, UV-vis spectroscopy, circular dichroism as well as computational techniques such as molecular docking, molecular dynamic simulation and MMPBSA calculation. Overall investigation shows eugenol having good affinity for HSA <i>K</i><sub>a</sub> 6.80&#x2009;&#xd7;&#x2009;10<sup>6</sup> M<sup>-1</sup>.Communicated by Ramaswamy H. Sarma.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Naz</LastName><ForeName>Farheen</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biosciences, Faculty of Natural Sciences, Jamia Millia Islamia, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Imran</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Deanship of Educational Services, Qassim University, Buraidah, Al Qassim, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baammi</LastName><ForeName>Soukayna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>African Genome Centre (AGC), Mohammed VI Polytechnic University, Benguerir, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Islam</LastName><ForeName>Asimul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomol Struct Dyn</MedlineTA><NlmUniqueID>8404176</NlmUniqueID><ISSNLinking>0739-1102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">HSA</Keyword><Keyword MajorTopicYN="N">MD simulation</Keyword><Keyword MajorTopicYN="N">MMPBSA calculation</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">eugenol</Keyword><Keyword MajorTopicYN="N">fluorescence</Keyword><Keyword MajorTopicYN="N">protease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>3</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636828</ArticleId><ArticleId IdType="doi">10.1080/07391102.2022.2164062</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636825</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1346-8138</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>The Journal of dermatology</Title><ISOAbbreviation>J Dermatol</ISOAbbreviation></Journal><ArticleTitle>Cutaneous manifestations of COVID-19 and COVID-19 vaccination.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/1346-8138.16651</ELocationID><Abstract><AbstractText>In December 2019, a new infectious pathogen named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China. Transmitted through respiratory droplets, SARS-CoV-2 is the causative pathogen of coronavirus disease 2019 (COVID-19). Although this new COVID-19 infection is known to cause primarily interstitial pneumonia and respiratory failure, it is often associated with cutaneous manifestations as well. These manifestations with COVID-19 can be classified into seven categories: (i) chilblain-like skin eruption (e.g., COVID toes), (ii) urticaria-like skin eruption, (iii) maculopapular lesions, (iv) vesicular eruptions, (v) purpura, (vi) livedo reticularis and necrotic lesions, (vii) urticarial vasculitis, and others such as alopecia and herpes zoster. The pathogenesis of skin eruptions can be broadly divided into vasculitic and inflammatory skin eruptions. Various cutaneous adverse reactions have also been observed after COVID-19 mRNA vaccination. The major cutaneous adverse reactions are type I hypersensitivity (urticaria and anaphylaxis) and type IV hypersensitivity (COVID arm and erythema multiform). Autoimmune-mediated reactions including bullous pemphigus, vasculitis, vitiligo, and alopecia areata have also been reported. Several cases with chilblain-like lesions and herpes zoster after COVID-19 mRNA vaccination have been published. Various skin diseases associated with COVID-19 and COVID-19 vaccination have been reported, and the mechanism has been partly elucidated. In the process, for example, some papers have reported that it is not related to COVID-19 infection, although it was initially called COVID-toe and considered a COVID-19-associated cutaneous eruption. In fact, some COVID-19-associated skin reactions are indistinguishable from drug eruptions. In the future, the mechanisms of COVID-19- or COVID-19 vaccine-associated skin reactions need to be elucidated and verification of causal relationships is required.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. The Journal of Dermatology published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Dermatological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakashima</LastName><ForeName>Chisa</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9653-6824</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, Kindai University Hospital, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Maiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, Kindai University Hospital, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, Kindai University Hospital, Osaka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Dermatol</MedlineTA><NlmUniqueID>7600545</NlmUniqueID><ISSNLinking>0385-2407</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>3</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636825</ArticleId><ArticleId IdType="doi">10.1111/1346-8138.16651</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-42.</Citation></Reference><Reference><Citation>McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85:46-55.</Citation></Reference><Reference><Citation>Zhao Q, Fang X, Pang Z, Zhang B, Liu H, Zhang F. COVID-19 and cutaneous manifestations: a systematic review. J Eur Acad Dermatology Venereol. 2020;34:2505-10.</Citation></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kr&#xfc;ger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-80.e8.</Citation></Reference><Reference><Citation>Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, M&#xf8;ller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181:1036-45.e9.</Citation></Reference><Reference><Citation>Magro C, Nuovo G, Mulvey JJ, Laurence J, Harp J, Crowson AN. The skin as a critical window in unveiling the pathophysiologic principles of COVID-19. Clin Dermatol. 2021;39:934-65.</Citation></Reference><Reference><Citation>Klein F. Risikofaktor Komorbidit&#xe4;ten bei COVID-19- Erkrankung. Pneumologie. 2020;74:640.</Citation></Reference><Reference><Citation>Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34:e212-3.</Citation></Reference><Reference><Citation>Daneshgaran G, Dubin DP, Gould DJ. Cutaneous manifestations of COVID-19: an evidence-based review. Am J Clin Dermatol. 2020;21:627-39.</Citation></Reference><Reference><Citation>Sameni F, Hajikhani B, Yaslianifard S, Goudarzi M, Owlia P, Nasiri MJ, et al. COVID-19 and skin manifestations: an overview of case reports/case series and meta-analysis of prevalence studies. Front Med. 2020;7:1-14.</Citation></Reference><Reference><Citation>Kuriyama Y, Shimizu A, Oka H, Sato M, Makioka K, Ikota H, et al. Erythema nodosum-like eruption in coronavirus disease 2019: a case report and literature review of Asian countries. J Dermatol. 2021;48:1588-92.</Citation></Reference><Reference><Citation>Tamai M, Sakamoto R, Goto N, Morimura O, Nishida T, Iwahashi H, et al. Cutaneous manifestations of coronavirus disease 2019 patients in Japan. J Dermatol. 2022;49:872-8.</Citation></Reference><Reference><Citation>Giavedoni P, Podlipnik S, Peric&#xe0;s JM, Fuertes de Vega I, Garc&#xed;a-Herrera A, Al&#xf3;s L, et al. Clinical medicine skin manifestations in COVID-19: prevalence and relationship with disease severity. J Clin Med. 2020;9:3261.</Citation></Reference><Reference><Citation>Gehlhausen JR, Little AJ, Ko CJ, Emmenegger M, Lucas C, Wong P, et al. Lack of association between pandemic chilblains and SARS-CoV-2 infection. Proc Natl Acad Sci USA. 2022;119:e2122090119.</Citation></Reference><Reference><Citation>Mart&#xed;n Carreras-Presas C, Amaro S&#xe1;nchez J, L&#xf3;pez-S&#xe1;nchez AF, Jan&#xe9;-Salas E, Somacarrera P&#xe9;rez ML. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. Oral Dis. 2021;27(S3):710-2.</Citation></Reference><Reference><Citation>Furukawa F, Makino T, Torai R, Mori S, Terada Y, Seki T, et al. Effectiveness of combined bexarotene and excimer laser treatment for folliculotropic mycosis fungoides. Eur J Dermatol. 2021;31:567-8.</Citation></Reference><Reference><Citation>Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases AT A GLANCE COMMENTARY Background. Transl Res. 2020;220:1-13.</Citation></Reference><Reference><Citation>de Perosanz-Lobo D, Fernandez-Nieto D, Burgos-Blasco P, Selda-Enriquez G, Carretero I, Moreno C, et al. Urticarial vasculitis in COVID-19 infection: a vasculopathy-related symptom? J Eur Acad Dermatol Venereol. 2020;34:e244-5.</Citation></Reference><Reference><Citation>Criado PR, Criado RFJ, Gianotti R, Abdalla BAZ, Pincelli TPH, Michalany AO, et al. Urticarial vasculitis revealing immunolabelled nucleocapsid protein of SARS-CoV-2 in two Brazilian asymptomatic patients: the tip of the COVID-19 hidden iceberg? J Eur Acad Dermatol Venereol. 2021;35:e563-6.</Citation></Reference><Reference><Citation>Bhavsar A, Lonnet G, Wang C, Chatzikonstantinidou K, Parikh R, Brabant Y, et al. Increased risk of herpes zoster in adults &#x2265;50&#x2009;years old diagnosed with COVID-19 in the United States. Open Forum Infect Dis. 2022;9:ofac118.</Citation></Reference><Reference><Citation>Miyazato Y, Morioka S, Tsuzuki S, Akashi M, Osanai Y, Tanaka K, et al. Prolonged and late-onset symptoms of coronavirus disease 2019. Open Forum Infect Dis. 2020;7:ofaa507.</Citation></Reference><Reference><Citation>Xue X, Mi Z, Wang Z, Pang Z, Liu H, Zhang F. High expression of ACE2 on keratinocytes reveals skin as a potential target for SARS-CoV-2. J Invest Dermatol. 2021;141:206-9.e1.</Citation></Reference><Reference><Citation>Magro C, Nuovo G, Mulvey JJ, Laurence J, Harp J, Crowson AN. The skin as a critical window in unveiling the pathophysiologic principles of COVID-19. Clin Dermatol. 2021;39:934-65.</Citation></Reference><Reference><Citation>Hubiche T, Cardot-Leccia N, Florence LD, Seitz-Polski B, Giordana P, le Duff F, et al. Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic supplemental content. JAMA Dermatol. 2021;157:202-6.</Citation></Reference><Reference><Citation>Damsky W, Peterson D, King B. When interferon tiptoes through COVID-19: Pernio-like lesions and their prognostic implications during SARS-CoV-2 infection. J Am Acad Dermatol. 2020;83:e269-70.</Citation></Reference><Reference><Citation>Catal&#xe0; A, Mu&#xf1;oz-Santos C, Galv&#xe1;n-Casas C, Roncero Riesco M, Revilla Nebreda D, Sol&#xe1;-Truyols A, et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases*. Br J Dermatol. 2022;186:142-52.</Citation></Reference><Reference><Citation>Gambichler T, Boms S, Susok L, Dickel H, Finis C, Abu Rached N, et al. Cutaneous findings following COVID-19 vaccination: review of world literature and own experience. J Eur Acad Dermatology Venereol. 2022;36:172-80.</Citation></Reference><Reference><Citation>Cabanillas B, Novak N. Allergy to COVID-19 vaccines: a current update. Allergol Int. 2021;70:313-8.</Citation></Reference><Reference><Citation>Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021;325:1101-2.</Citation></Reference><Reference><Citation>Nelson EJ, McKune SL, Ryan KA, Lednicky JA, Crowe SR, Myers PD, et al. SARS-CoV-2 positivity on or after 9&#x2009;days among quarantined student contacts of confirmed cases. JAMA. 2021;325:1561-2.</Citation></Reference><Reference><Citation>Stone CA Jr, Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 2019;7:1533-40.e8.</Citation></Reference><Reference><Citation>Erdeljic Turk V. Anaphylaxis associated with the mRNA COVID-19 vaccines: approach to allergy investigation. Clin Immunol. 2021;227:108748.</Citation></Reference><Reference><Citation>Jedlowski PM, Jedlowski MF. Morbilliform rash after administration of pfizer-biontech covid-19 mrna vaccine. Dermatol Online J. 2021;27:13030/qt4xs486zg.</Citation></Reference><Reference><Citation>Niebel D, Ralser-Isselstein V, Jaschke K, Braegelmann C, Bieber T, Wenzel J. Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine. Dermatol Ther. 2021;34:3-5.</Citation></Reference><Reference><Citation>Tomayko MM, Damsky W, Fathy R, McMahon DE, Turner N, Valentin MN, et al. Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination. J Allergy Clin Immunol. 2021;148:750-1.</Citation></Reference><Reference><Citation>Since January 2020 Elsevier has created a COVID-19 resource Centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information. 2020.</Citation></Reference><Reference><Citation>Cebeci F, Kartal I. Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results. Eur J Hosp Pharm. 2021. https://doi.org/10.1136/ejhpharm-2021-002794</Citation></Reference><Reference><Citation>Lam M, Egail M, Bedlow AJ, Tso S. Ribonucleic acid COVID-19 vaccine-associated cutaneous adverse drug events: a case series of two patients. Clin Exp Dermatol. 2021;46:1131-4.</Citation></Reference><Reference><Citation>Pamuk&#xe7;u B. Inflammation and thrombosis in patients with COVID-19: a prothrombotic and inflammatory disease caused by SARS coronavirus-2. Anatol J Cardiol. 2020;24:224-34.</Citation></Reference><Reference><Citation>McGonagle D, De Marco G, Bridgewood C. Mechanisms of Immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. J Autoimmun. 2021;121:102662.</Citation></Reference><Reference><Citation>Welsh KJ, Baumblatt J, Chege W, Goud R, Nair N. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the vaccine adverse event reporting system (VAERS). Vaccine. 2021;39:3329-32.</Citation></Reference><Reference><Citation>Abdelmaksoud A, Wollina U, Temiz SA, Hasan A. SARS-CoV-2 vaccination-induced cutaneous vasculitis: report of two new cases and literature review. Dermatol Ther. 2022;35:1-8.</Citation></Reference><Reference><Citation>Gambichler T, Reuther J, St&#xfc;cker M, Stranzenbach R, Torres-Reyes C, Schlottmann R, et al. SARS-CoV-2 spike protein is present in both endothelial and eccrine cells of a chilblain-like skin lesion. J Eur Acad Dermatology Venereol. 2021;35:e187-9.</Citation></Reference><Reference><Citation>Drago F, Ciccarese G, Rebora A, Parodi A. Human herpesvirus-6, &#x2212;7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19. J Med Virol. 2021;93:1850-1.</Citation></Reference><Reference><Citation>Arora P, Sardana K, Mathachan SR, Malhotra P. Herpes zoster after inactivated COVID-19 vaccine: a cutaneous adverse effect of the vaccine. J Cosmet Dermatol. 2021;20:3389.</Citation></Reference><Reference><Citation>Eid E, Abdullah L, Kurban M, Abbas O. Herpes zoster emergence following mRNA COVID-19 vaccine. J Med Virol. 2021;93:5231-2.</Citation></Reference><Reference><Citation>Bostan E, Yalici-Armagan B. Herpes zoster following inactivated COVID-19 vaccine: a coexistence or coincidence? J Cosmet Dermatol. 2021;20:1566-7.</Citation></Reference><Reference><Citation>Walter R, Hartmann K, Fleisch F, Reinhart WH, Kuhn M. Reactivation of herpesvirus infections after vaccinations? Lancet. 1999;353:810.</Citation></Reference><Reference><Citation>Shors AR. Herpes zoster and severe acute herpetic neuralgia as a complication of COVID-19 infection. JAAD Case Reports. 2020;6:656-7.</Citation></Reference><Reference><Citation>Elsaie ML, Youssef EA, Nada HA. Herpes zoster might be an indicator for latent COVID 19 infection. Dermatol Ther. 2020;33:e13666.</Citation></Reference><Reference><Citation>Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17:541-3.</Citation></Reference><Reference><Citation>Rodr&#xed;guez-Jim&#xe9;nez P, Chicharro P, Cabrera LM, Segu&#xed; M, Morales-Caballero &#xc1;, Llamas-Velasco M, et al. Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases. JAAD Case Rep. 2021;12:58-9.</Citation></Reference><Reference><Citation>Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a Nationwide setting. N Engl J Med. 2021;385:1078-90.</Citation></Reference><Reference><Citation>Scollan ME, Breneman A, Kinariwalla N, Soliman Y, Youssef S, Bordone LA, et al. Alopecia areata after SARS-CoV-2 vaccination. JAAD Case Rep. 2022;20:1-5.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636820</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2796</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of internal medicine</Title><ISOAbbreviation>J Intern Med</ISOAbbreviation></Journal><ArticleTitle>Regarding: The long and winding road of COVID-19 in survivors of hospitalization.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/joim.13604</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jolobe</LastName><ForeName>Oscar M P</ForeName><Initials>OMP</Initials><Identifier Source="ORCID">0000-0002-6776-2734</Identifier><AffiliationInfo><Affiliation>British Medical Association, BMA House, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Intern Med</MedlineTA><NlmUniqueID>8904841</NlmUniqueID><ISSNLinking>0954-6820</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>3</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636820</ArticleId><ArticleId IdType="doi">10.1111/joim.13604</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Dias MB, Medeiros AP, de Melo SS, Fonseca CS, Jacob-Filho W, Avelino-Silva TJ, et&#xa0;al. The long and winding road of COVID-19 in survivors of hospitalisation: symptoms trajectory and predictors of long COVID. J Intern Med. 2022;293:264-8. https://doi.org/10.1111/joim.13583.</Citation></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Nirmatrelvir and risk of post-acute sequelae of COVID-19. medRxiv preprint posted November 5, 2022. https://doi.org/10.1101/2022.11.03.22281783</Citation></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Ardner A, Abreu P, Bao W, Wisemandle W, et&#xa0;al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386:1397-408.</Citation></Reference><Reference><Citation>Swank Z, Senussi Y, Alter G, Walt DR. Persistent circulating SARS-2-CoV-2 spike is associated with post-acute COVID-19. sequelae medRxiv preprint posted June 16, 2022. https://doi.org/10.1101/2022.06.12.22276401.</Citation></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JC, Muecksch F, Finkin S, Tokuyama M, et&#xa0;al. Evolution of antibody immunity to SARS-CoV-2. Nature 2021;591:639-44.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636817</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1472-1465</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Association between SARS-CoV-2 infection and self-harm: Danish nationwide register-based cohort study.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>8</EndPage><MedlinePgn>1-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1192/bjp.2022.194</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Case studies have linked SARS-CoV-2 infection to suicidal behaviour. However, conclusive evidence is lacking.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To examine whether a history of SARS-CoV-2 infection or SARS-CoV-2-related hospital admission was associated with self-harm in the general population and in high-risk groups.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A cohort design was applied to nationwide data on all people aged &#x2265;15 years and living in Denmark between 27 February 2020 and 15 October 2021. Exposure was identified as having had a positive SARS-CoV-2 PCR test, and further assessed as SARS-CoV-2-related hospital admission. Rates of probable self-harm were examined using adjusted incidence rate ratios (aIRRs). The following subgroups were identified: (a) lower educational level, (b) chronic medical conditions, (c) disability pension, (d) mental disorders, (e) substance use disorders, and history of (f) homelessness and (g) imprisonment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 4 412 248 included individuals, 260 663 (5.9%) had tested positive for SARS-CoV-2. Out of 5453 individuals presenting with self-harm, 131 (2.4%) had been infected. Individuals with a history of a positive SARS-CoV-2 test result had an aIRR for self-harm of 0.86 (95% CI 0.72-1.03) compared with those without. High rates were found after a SARS-CoV-2-related hospital admission (aIRR = 7.68; 95% CI 5.61-10.51) or a non-SARS-CoV-2-related admission (aIRR = 10.27; 95% CI 9.65-10.93) versus non-infected and not admitted. In sensitivity analyses with a more restrictive definition of self-harm, a positive PCR test was associated with lower rates of self-harm.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Individuals with a PCR-confirmed SARS-CoV-2 infection did not have higher rates of self-harm than those without. Hospital admission in general, rather than being SARS-CoV-2 positive. seemed to be linked to elevated rates of self-harm.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erlangsen</LastName><ForeName>Annette</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3475-0558</Identifier><AffiliationInfo><Affiliation>Danish Research Institute for Suicide Prevention, Mental Health Centre Copenhagen, Copenhagen, Denmark; Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen, Denmark; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; and Center of Mental Health Research, Australian National University, Canberra, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Ping</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6741-6228</Identifier><AffiliationInfo><Affiliation>National Center for Suicide Research and Prevention, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madsen</LastName><ForeName>Trine</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4918-5862</Identifier><AffiliationInfo><Affiliation>Danish Research Institute for Suicide Prevention, Mental Health Centre Copenhagen, Copenhagen, Denmark; Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen, Denmark; and Section of Epidemiology, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawton</LastName><ForeName>Keith</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4985-5715</Identifier><AffiliationInfo><Affiliation>Centre for Suicide Research, University of Oxford, Oxford, UK; and Oxford Health NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osler</LastName><ForeName>Merete</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6921-220X</Identifier><AffiliationInfo><Affiliation>Center for Clinical Research and Prevention, Bispebjerg &amp; Frederiksberg Hospitals, Copenhagen, Denmark; and Section of Epidemiology, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hjorth&#xf8;j</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6943-4785</Identifier><AffiliationInfo><Affiliation>Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen University Hospital, Hellerup, Denmark; and Section of Epidemiology, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benros</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0003-4939-9465</Identifier><AffiliationInfo><Affiliation>Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen, Denmark; and Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ethelberg</LastName><ForeName>Steen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9709-356X</Identifier><AffiliationInfo><Affiliation>Infectious Disease Epidemiology &amp; Prevention, Statens Serum Institut, Copenhagen, Denmark; and Department of Global Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;lbak</LastName><ForeName>K&#xe5;re</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Epidemiological Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark; and Department of Veterinary and Animal Science, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laursen</LastName><ForeName>Thomas Munk</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0001-6934-1784</Identifier><AffiliationInfo><Affiliation>National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordentoft</LastName><ForeName>Merete</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Danish Research Institute for Suicide Prevention, Mental Health Centre Copenhagen, Copenhagen, Denmark; Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen, Denmark; and Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Sandra Feodor</ForeName><Initials>SF</Initials><Identifier Source="ORCID">0000-0002-7598-5014</Identifier><AffiliationInfo><Affiliation>Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen University Hospital, Hellerup, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Suicide attempt</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">self-harm</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636817</ArticleId><ArticleId IdType="doi">10.1192/bjp.2022.194</ArticleId><ArticleId IdType="pii">S0007125022001945</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636816</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2056-4724</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>BJPsych open</Title><ISOAbbreviation>BJPsych Open</ISOAbbreviation></Journal><ArticleTitle>The impact of the COVID-19 pandemic on perinatal services and maternal mental health in the UK.</ArticleTitle><Pagination><StartPage>e13</StartPage><MedlinePgn>e13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1192/bjo.2022.632</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19 has created many challenges for women in the perinatal phase. This stems from prolonged periods of lockdowns, restricted support networks and media panic, alongside altered healthcare provision.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">We aimed to review the evidence regarding the psychological impact on new and expecting mothers following changes to antenatal and postnatal service provision within the UK throughout the pandemic.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We conducted a narrative literature search of major databases (PubMed, Medline, Google Scholar). The literature was critically reviewed by experts within the field of antenatal and perinatal mental health.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Changes to service provision, including the introduction of telemedicine services, attendance of antenatal appointments without partners or loved ones, and lack of support during the intrapartum period, are associated with increased stress, depression and anxiety. Encouraging women and their partners to engage with aspects of positive psychology through newly introduced digital platforms and virtual service provision has the potential to improve access to holistic care and increase mental well-being. An online course, designed by Imperial College Healthcare NHS Trust in response to changes to service provision, focuses on postnatal recovery inspiration and support for motherhood (PRISM) through a 5-week programme. So far, the course has received positive feedback.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The pandemic has contributed to increased rates of mental illness among pregnant and new mothers in the UK. Although the long-term implications are largely unpredictable, it is important to anticipate increased prevalence and complexity of symptoms, which could be hugely detrimental to an already overburdened National Health Service.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kasaven</LastName><ForeName>Lorraine S</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0000-0002-1752-5220</Identifier><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Imperial College London, UK; Cutrale Perioperative and Ageing Group, Imperial College London, UK; and Department of Obstetrics and Gynaecology, Queen Charlottes and Chelsea Hospital, Imperial College NHS Trust, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raynaud</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>West Middlesex University Hospital, Chelsea and Westminster Hospitals NHS Trust, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jalmbrant</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sloane Court Clinic, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joash</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynaecology, Queen Charlottes and Chelsea Hospital, Imperial College NHS Trust, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Benjamin P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Imperial College London, UK; and Department of Obstetrics and Gynaecology, Queen Charlottes and Chelsea Hospital, Imperial College NHS Trust, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BJPsych Open</MedlineTA><NlmUniqueID>101667931</NlmUniqueID><ISSNLinking>2056-4724</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Perinatal psychiatry</Keyword><Keyword MajorTopicYN="N">anxiety disorders</Keyword><Keyword MajorTopicYN="N">community mental health teams</Keyword><Keyword MajorTopicYN="N">patients</Keyword><Keyword MajorTopicYN="N">psychosocial interventions</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636816</ArticleId><ArticleId IdType="doi">10.1192/bjo.2022.632</ArticleId><ArticleId IdType="pii">S2056472422006329</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636728</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2055-2076</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2023</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Digital health</Title><ISOAbbreviation>Digit Health</ISOAbbreviation></Journal><ArticleTitle>Telemedicine ready or not? A cross-sectional assessment of telemedicine maturity of federally funded tertiary health institutions in Nigeria.</ArticleTitle><Pagination><StartPage>20552076221150072</StartPage><MedlinePgn>20552076221150072</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/20552076221150072</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND OBJECTIVE" NlmCategory="UNASSIGNED">Telemedicine has reinforced its position as a means for the continuity of healthcare services and a cost-effective approach to improving health equity as demonstrated during the COVID-19 pandemic. The preparedness of health systems for telemedicine is an indicator of the scalability of their services, especially during catastrophes. We aimed to assess the maturity and preparedness of federally funded tertiary health institutions in Nigeria, to deploy telemedicine as such data are currently lacking and are required to drive improvements in health services delivery.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a cross-sectional survey of thirty randomly selected federally funded tertiary health institutions in Nigeria using the Pan American Health Organization's tool for assessing the maturity level of health institutions to implement telemedicine between 17 September 2020 and 1 September 2021. Descriptive statistics were used for overall maturity levels and non-parametric tests to compare scores for overall maturity and specific Pan American Health Organization domains per region. The level of significance was set at <i>p</i>-value &lt;0.05.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The response rate was 77.4% (24 of 30 randomly polled federally funded tertiary health institutions responded). Overall, the median telemedicine maturity level was 2.0 (1.75) indicating a beginner level. No significant inter-zonal difference in the median overall maturity level (<i>p&#x2009;</i>=&#x2009;0.87). The median maturity levels for telemedicine readiness in specific domains were organizational readiness - 2.0 (2.0), processes 1.0 (1.0), digital environment 2.0 (3.0), human resources 2.0 (1.0), regulatory issues - 1.5 (1.0) and expertise 2.0 (2.0); mostly at beginner level, with no inter-zonal differences. Most participating institutions had no initiatives in place for domains of processes and regulatory issues.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The current telemedicine maturity level of federally funded tertiary health institutions in Nigeria is at the beginner level. This behoves policy-makers to advance the implementation and deployment of telemedicine nationwide as part of digital quality healthcare, to improve health equity and to ensure continuity of healthcare services in the event of another pandemic.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olufunlayo</LastName><ForeName>Tolulope F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Department of Community Health and Primary Care, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Health, Lagos University Teaching Hospital, Idi-Araba, Lagos, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ojo</LastName><ForeName>Oluwadamilola O</ForeName><Initials>OO</Initials><Identifier Source="ORCID">0000-0001-6461-2653</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Lagos University Teaching Hospital, Idi-Araba, Lagos, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozoh</LastName><ForeName>Obianuju B</ForeName><Initials>OB</Initials><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Lagos University Teaching Hospital, Idi-Araba, Lagos, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agabi</LastName><ForeName>Osigwe P</ForeName><Initials>OP</Initials><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Lagos University Teaching Hospital, Idi-Araba, Lagos, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Opara</LastName><ForeName>Chuks R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Medicine, Lagos University Teaching Hospital, Idi-Araba, Lagos, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taiwo</LastName><ForeName>Funmilola T</ForeName><Initials>FT</Initials><AffiliationInfo><Affiliation>Department of Medicine, University College Hospital, Ibadan, Oyo, Nigeria.</Affiliation><Identifier Source="RINGGOLD">107962</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fasanmade</LastName><ForeName>Olufemi A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Lagos University Teaching Hospital, Idi-Araba, Lagos, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okubadejo</LastName><ForeName>Njideka U</ForeName><Initials>NU</Initials><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Lagos University Teaching Hospital, Idi-Araba, Lagos, Nigeria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Digit Health</MedlineTA><NlmUniqueID>101690863</NlmUniqueID><ISSNLinking>2055-2076</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Nigeria</Keyword><Keyword MajorTopicYN="N">Telemedicine</Keyword><Keyword MajorTopicYN="N">eHealth</Keyword><Keyword MajorTopicYN="N">hospitals teaching</Keyword><Keyword MajorTopicYN="N">telehealth</Keyword><Keyword MajorTopicYN="N">tertiary care centers</Keyword><Keyword MajorTopicYN="N">virtual medicine</Keyword></KeywordList><CoiStatement>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636728</ArticleId><ArticleId IdType="pmc">PMC9829877</ArticleId><ArticleId IdType="doi">10.1177/20552076221150072</ArticleId><ArticleId IdType="pii">10.1177_20552076221150072</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636688</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2330-1910</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>American journal of clinical and experimental urology</Title><ISOAbbreviation>Am J Clin Exp Urol</ISOAbbreviation></Journal><ArticleTitle>The state of telehealth: 2 years into the COVID-19 pandemic - back to business as usual?</ArticleTitle><Pagination><StartPage>390</StartPage><EndPage>396</EndPage><MedlinePgn>390-396</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Telemedicine (TM) was underutilized prior to the COVID-19 pandemic presumably due to non-standardized reimbursement routes and a perceived lack of need. Early experience with the pandemic necessitated this form of medical care, although durability of consistent delivery remains in question. We quantify the utilization patterns of TM over the past 2 years over multiple waves of the pandemic across various service lines in a large rural health system.</AbstractText><AbstractText Label="MATERIALS" NlmCategory="METHODS">Data of TM utilization were prospectively collected between March 2020-January 2022. Rates of adoption among the various surgical and non-surgical services disciplines were compared. Subgroup analyses between different surgical subspecialties and within the urologic subspecialties was performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">3.5 million visits were recorded; 3.14 million (90%) on-site and 349,989 (10%) TM; 254,919 (73%) video-assisted and 95,070 (27%) were telephonic. Throughout the pandemic, non-surgical services utilized TM to a greater extent than surgical services (mean% 12 vs 6). Significant variation in the utilization among surgical services was reported, with Urology representing a high utilizer (15%); Among Urologic subspecialties utilization, Endourology (28%) was highest and Pediatric Urology (5%) was lowest. Following an initial spike in TM utilization during the pandemic, rates have declined and plateaued at 5-7% of all visits over the past 6-months.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">TM utilization in this large health system has remained under 10% following the initial surge in 2020. Non-surgical services preferentially use TM more than surgical domains. Certain subspecialties utilize TM more than others, possible due to patient population, practice patterns and medical conditions. Barriers to adoption are essential to determine the relatively low volume of use across this health system.</AbstractText><CopyrightInformation>AJCEU Copyright &#xa9; 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alzubaidi</LastName><ForeName>Ahmad N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Urology, Penn State Health Milton S. Hershey Medical Center Hershey, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Xuanjia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Penn State College of Medicine, Penn State Health Milton S. Hershey Medical Center Hershey, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eidelman</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Urology, Penn State Health Milton S. Hershey Medical Center Hershey, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Vonn</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Penn State University College of Medicine Hershey, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Littlejohn</LastName><ForeName>Joe O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Department of Urology, Penn State Health Milton S. Hershey Medical Center Hershey, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>Jay D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Urology, Penn State Health Milton S. Hershey Medical Center Hershey, PA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Clin Exp Urol</MedlineTA><NlmUniqueID>101634566</NlmUniqueID><ISSNLinking>2330-1910</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Telemedicine</Keyword><Keyword MajorTopicYN="N">delivery</Keyword><Keyword MajorTopicYN="N">healthcare</Keyword><Keyword MajorTopicYN="N">trends</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636688</ArticleId><ArticleId IdType="pmc">PMC9831913</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636667</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-1078</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in psychology</Title><ISOAbbreviation>Front Psychol</ISOAbbreviation></Journal><ArticleTitle>Necessity and challenges for the post-pandemic Hangzhou Asian Games: An interdisciplinary data science assessment.</ArticleTitle><Pagination><StartPage>1047990</StartPage><MedlinePgn>1047990</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpsyg.2022.1047990</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The postponement of the Hangzhou Asian Games has reignited controversy over whether it is necessary and safe to hold. This study aimed to assess its necessity for Asian elite sport and the challenges brought by the COVID-19 pandemic through joint data science research on elite sports and public health Internet big data.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">For necessity, we used seven pre-pandemic Asian Games to investigate its long-term internal balance and six pre-pandemic Olympic Games to examine its contribution to the external competitiveness of Asian sport powers through bivariate Pearson correlation analyses between sport variables and holding year. For challenges, we used Johns Hopkins COVID-19 data and Tokyo 2020 Olympic data to quantify the past impact of the pandemic on elite sport by another correlation analysis between pandemic variables and the change in the weighted score of medal share (CWSMS), built a transferable linear regression model, transferred the model to Jakarta 2018 Asian Games data, and eventually forecasted the possible impact of the pandemic on the results of the Hangzhou Asian Games.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The proportion of gold medal countries in the Asian Games showed a long-term upward trend (Pearson <i>r</i> <sub>(7)</sub> = 0.849, <i>p</i> &lt; 0.05), and the share of medals won by Asian countries showed a significant increasing process (Pearson <i>r</i> <sub>(6)</sub> = 0.901, <i>p</i> &lt; 0.05). The cumulative number of COVID-19 deaths (CND) was most significantly correlated to CWSMS (Pearson <i>r</i> <sub>(100)</sub> = -0.455, <i>p</i> &lt; 0.001). The total Olympic model output of Asian countries was 0.0115 in Tokyo 2020 and is predicted to be 0.0093 now. The prediction of CWSMS in Hangzhou was 0.0013 for China, 0.0006 for Japan, and 0.0008 for South Korea.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">We documented that Asian Games played a significant role in the long-term balanced internal structure and the increasing global competitiveness of Asian elite sport. We proved that the COVID-19 pandemic has significantly affected the Olympic performance of countries worldwide, while the competitive performance at the Hangzhou Games would be less affected than the world average level. This study also highlights the importance of interdisciplinary data science research on large-scale sports events and public health.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Guo, Zhang and Cui.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jianwei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Artificial Intelligence in Sports, Capital University of Physical Education and Sports, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Institute for International Olympic Studies, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiangning</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Artificial Intelligence in Sports, Capital University of Physical Education and Sports, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Institute for International Olympic Studies, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Dandan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Artificial Intelligence in Sports, Capital University of Physical Education and Sports, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Institute for International Olympic Studies, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Psychol</MedlineTA><NlmUniqueID>101550902</NlmUniqueID><ISSNLinking>1664-1078</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Asian Games</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Olympic Games</Keyword><Keyword MajorTopicYN="N">elite sport</Keyword><Keyword MajorTopicYN="N">public health</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636667</ArticleId><ArticleId IdType="pmc">PMC9831677</ArticleId><ArticleId IdType="doi">10.3389/fpsyg.2022.1047990</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636645</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1828-695X</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><PubDate><Year>2022</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>Multidisciplinary respiratory medicine</Title><ISOAbbreviation>Multidiscip Respir Med</ISOAbbreviation></Journal><ArticleTitle>Nebivolol: an effective option against long-lasting dyspnoea following COVID-19 pneumonia - a pivotal double-blind, cross-over controlled study.</ArticleTitle><Pagination><StartPage>886</StartPage><MedlinePgn>886</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4081/mrm.2022.886</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Pulmonary microvascular occlusions can aggravate SARS-CoV-2 pneumonia and result in a variable decrease in capillary blood volume (Vc). Dyspnoea may persist for several weeks after hospital discharge in many patients who have "radiologically recovered" from COVID-19 pneumonia. Dyspnoea is frequently "unexplained" in these cases because abnormalities in lung vasculature are understudied. Furthermore, even when they are identified, therapeutic options are still lacking in clinical practice, with nitric oxide (NO) supplementation being used only for severe respiratory failure in the hospital setting. Nebivolol is the only selective &#x3b2;<sup>1</sup> adrenoceptor antagonist capable of inducing nitric oxide-mediated vasodilation by stimulating endothelial NO synthase <i>via</i> &#x3b2;<sub>3</sub> agonism. The purpose of this study was to compare the effect of nebivolol <i>versus</i> placebo in patients who had low Vc and complained of dyspnoea for several weeks after COVID-19 pneumonia.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Patients of both genders, aged &#x2265;18 years, non-smokers, who had a CT scan that revealed no COVID-related parenchymal lesions but still complaining of dyspnoea 12-16 weeks after hospital discharge, were recruited. Spirometrical volumes, blood haemoglobin, SpO<sub>2</sub>, simultaneous diffusing capacity for carbon monoxide (CO) and NO (DL<sub>CO</sub> and DL<sub>NO</sub>, respectively), DL<sub>NO</sub>/DL<sub>CO</sub> ratio, Vc and exhaled NO (eNO) were measured together with their dyspnoea score (DS), heart frequency (HF), and blood arterial pressure (BAP). Data were collected before and one week after both placebo (P) and nebivolol (N) (2.5 mg od) double-blind cross-over administered at a two-week interval. Data were statistically compared, and p&lt;0.05 assumed as statistically significant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Eight patients (3 males) were investigated. In baseline, their mean DS was 2.5&#xb1;0.6 SD, despite the normality of lung volumes. DL<sub>CO</sub> and DL<sub>NO</sub> mean values were lower than predicted, while mean DL<sub>NO</sub>/DL<sub>CO</sub> ratio was higher. Mean Vc proved substantially reduced. Placebo did not modify any variable (all p=ns) while N improved DLco and Vc significantly (+8.5%, p&lt;0.04 and +17.7%, p&lt;0.003, respectively). eNO also was significantly increased (+17.6%, p&lt;0.002). Only N lowered the dyspnoea score (-76%, p&lt;0.001). Systolic and diastolic BAP were slightly lowered (-7.5%, p&lt;0.02 and -5.1%, p&lt;0.04, respectively), together with HF (-16.8%, p&lt;0.03).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The simultaneous assessment of DL<sub>NO</sub>, DL<sub>CO</sub>, DL<sub>NO</sub>/DL<sub>CO</sub> ratio, and Vc confirmed that long-lasting dyspnoea is related to hidden abnormalities in the lung capillary vasculature. These abnormalities can persist even after the complete resolution of parenchymal lesions regardless of the normality of lung volumes. Nebivolol, but not placebo, improves DS and Vc significantly. The mechanism suggested is the NO-mediated vasodilation <i>via</i> the &#x3b2;3 adrenoceptor stimulation of endothelial NO synthase. This hypothesis is supported by the substantial increase of eNO only assessed after nebivolol. As the nebivolol tolerability in these post-COVID normotensive patients was very good, the therapeutic use of nebivolol against residual and symptomatic signs of long-COVID can be suggested in out-patients.</AbstractText><CopyrightInformation>&#xa9;Copyright: the Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dal Negro</LastName><ForeName>Roberto W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>National Centre for Respiratory Pharmacoeconomics and Pharmacoepidemiology - CESFAR, Verona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turco</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Research &amp; Clinical Governance, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Povero</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research &amp; Clinical Governance, Verona, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Multidiscip Respir Med</MedlineTA><NlmUniqueID>101477642</NlmUniqueID><ISSNLinking>1828-695X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Nebivolol</Keyword><Keyword MajorTopicYN="N">capillary blood volume (Vc)</Keyword><Keyword MajorTopicYN="N">lung perfusion</Keyword><Keyword MajorTopicYN="N">simultaneous DLCO and DLNO assessment</Keyword><Keyword MajorTopicYN="N">vascular effects</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636645</ArticleId><ArticleId IdType="pmc">PMC9830396</ArticleId><ArticleId IdType="doi">10.4081/mrm.2022.886</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636616</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2398-8835</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Health science reports</Title><ISOAbbreviation>Health Sci Rep</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 booster effect and waning immunity in hemodialysis patients: A cohort study.</ArticleTitle><Pagination><StartPage>e1040</StartPage><MedlinePgn>e1040</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hsr2.1040</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goggins</LastName><ForeName>Eibhlin</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7952-7726</Identifier><AffiliationInfo><Affiliation>Division of Nephrology University of Virginia School of Medicine Charlottesville Virginia USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Binu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Nephrology University of Virginia School of Medicine Charlottesville Virginia USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jennie Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Division of Nephrology University of Virginia School of Medicine Charlottesville Virginia USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health Sciences University of Virginia School of Medicine Charlottesville Virginia USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gautam</LastName><ForeName>Jitendra</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Nephrology University of Virginia School of Medicine Charlottesville Virginia USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowman</LastName><ForeName>Brendan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Nephrology University of Virginia School of Medicine Charlottesville Virginia USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Health Sci Rep</MedlineTA><NlmUniqueID>101728855</NlmUniqueID><ISSNLinking>2398-8835</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19 vaccination</Keyword><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2</Keyword><Keyword MajorTopicYN="N">booster</Keyword><Keyword MajorTopicYN="N">end&#x2010;stage kidney disease</Keyword><Keyword MajorTopicYN="N">hemodialysis</Keyword><Keyword MajorTopicYN="N">humoral immunity</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636616</ArticleId><ArticleId IdType="pmc">PMC9830886</ArticleId><ArticleId IdType="doi">10.1002/hsr2.1040</ArticleId><ArticleId IdType="pii">HSR21040</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636611</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2772-6533</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Dialogues in health</Title><ISOAbbreviation>Dialogues Health</ISOAbbreviation></Journal><ArticleTitle>COVID-19 and food insecurity in a vulnerable rural state.</ArticleTitle><Pagination><StartPage>100013</StartPage><MedlinePgn>100013</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dialog.2022.100013</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This study explored variations in food insecurity across sociodemographic groups and changes specific to the COVID-19 pandemic, including income loss, stimulus check receipt, and changes in household size.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">A cross-sectional online survey was conducted using a 2-item food insecurity screener. COVID-19 related factors and sociodemographic data were collected.</AbstractText><AbstractText Label="SETTING" NlmCategory="UNASSIGNED">Data were collected in Arkansas, United States, during July and August 2020.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="UNASSIGNED">A sample of 1205 adults was recruited using ARresearch, a volunteer research registry. Participants were over the age of 18 and living, working, or receiving health care in Arkansas.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The prevalence of food insecurity was 24.9% during the COVID-19 pandemic. Food insecurity was elevated even after the majority of respondents received a stimulus check. Chi-square and <i>t</i>-tests revealed that food insecurity was more prevalent among those who are younger, Black, Hispanic/Latinx, lower-income, less educated, and living in households with children. Multivariate logistic regression revealed that odds of food insecurity were greater for individuals who reported income loss due to the pandemic (OR&#x202f;=&#x202f;3.29; <i>p</i>&#x202f;&lt;&#x202f;.001), Black respondents (OR&#x202f;=&#x202f;2.06, <i>p</i> =&#x202f;.014), Hispanic respondents (OR&#x202f;=&#x202f;3.34, <i>p</i>&#x202f;=&#x202f;.001), those earning less than $25,000 annually (OR&#x202f;=&#x202f;4.92; <i>p</i> &lt; .001) or between $25,000 to $49,999 (OR&#x202f;=&#x202f;2.04; <i>p</i>&#x202f;=&#x202f;.023), respondents with a high school degree or less (OR&#x202f;=&#x202f;4.21; <i>p</i>&#x202f;&lt;&#x202f;.001) or some college (OR&#x202f;=&#x202f;2.55; <i>p</i>&#x202f;&lt;&#x202f;.001), and those living in households with children (OR&#x202f;=&#x202f;1.62; <i>p</i> =&#x202f;.021). Odds of food insecurity were lower for those who had received a stimulus check (OR&#x202f;=&#x202f;0.60; <i>p</i> = .026).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Food insecurity prevalence was high in Arkansas in July and August 2020. The risk of food insecurity was uneven across sociodemographic groups. Several factors related to the COVID-19 pandemic were indicators for increased risk of food insecurity. Interventions to address food insecurity that recognize social factors unique to the pandemic are needed to reduce levels of food insecurity.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Willis</LastName><ForeName>Don E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>University of Arkansas for Medical Sciences Northwest, College of Medicine, 1125 N. College Avenue, Fayetteville, AR 72703, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Christopher R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>University of Arkansas for Medical Sciences Northwest, College of Medicine, 1125 N. College Avenue, Fayetteville, AR 72703, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowland</LastName><ForeName>Brett</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University of Arkansas for Medical Sciences Northwest, Office of Community Health and Research, 1125 N. College Avenue, Fayetteville, AR 72703, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tidwell</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Arkansas for Medical Sciences Northwest, Office of Community Health and Research, 1125 N. College Avenue, Fayetteville, AR 72703, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>University of Arkansas for Medical Sciences Northwest, College of Medicine, 1125 N. College Avenue, Fayetteville, AR 72703, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McElfish</LastName><ForeName>Pearl A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>University of Arkansas for Medical Sciences Northwest, College of Medicine, 1125 N. College Avenue, Fayetteville, AR 72703, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dialogues Health</MedlineTA><NlmUniqueID>9918506184906676</NlmUniqueID><ISSNLinking>2772-6533</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Food insecurity</Keyword><Keyword MajorTopicYN="N">Housing</Keyword><Keyword MajorTopicYN="N">Income</Keyword><Keyword MajorTopicYN="N">Pandemic</Keyword><Keyword MajorTopicYN="N">Public health nutrition</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636611</ArticleId><ArticleId IdType="pmc">PMC9098512</ArticleId><ArticleId IdType="doi">10.1016/j.dialog.2022.100013</ArticleId><ArticleId IdType="pii">S2772-6533(22)00013-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636610</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2772-6533</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Dialogues in health</Title><ISOAbbreviation>Dialogues Health</ISOAbbreviation></Journal><ArticleTitle>Contextualization of the trends in number of beneficiaries vaccinated at a COVID-19 vaccination centre in Delhi, India.</ArticleTitle><Pagination><StartPage>100012</StartPage><MedlinePgn>100012</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dialog.2022.100012</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="UNASSIGNED">India started vaccination against COVID-19 on 16<sup>th</sup> January 2021. Present study was conducted to describe the trends in the number of beneficiaries vaccinated at a tertiary care hospital in India against the dynamic background of changing contextual factors.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This was a descriptive records-based study conducted at one of the COVID vaccination centre from January 2021 to June 2021. Data on dose-wise daily number of beneficiaries in various categories were collected and analyzed using Excel. The website of the Ministry of Health and Family Welfare (MoHFW), India, press releases and news reports of major media houses were reviewed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The peaks observed in number of beneficiaries vaccinated were mainly due to opening up of program for new categories of beneficiaries in a phased manner, announcements made to complete the vaccination coverage within a stipulated time for some categories and publication of trial results by vaccine manufacturers. The dips could be attributed to essential requirement of certain documents, major festivals, disastrous second wave and resulting lockdown in state.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The time-trend may not remain uniform across the course, but can be predicted in advance to some extent by analyzing past trends. Minimizing the avoidable dips and peaks and managing the unavoidable ones will help in improving the service delivery and beneficiary satisfaction.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, North DMC Medical College and Hindu Rao Hospital, Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pardeshi</LastName><ForeName>Geeta</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dialogues Health</MedlineTA><NlmUniqueID>9918506184906676</NlmUniqueID><ISSNLinking>2772-6533</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccination</Keyword><Keyword MajorTopicYN="N">healthcare workers</Keyword><Keyword MajorTopicYN="N">trends</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636610</ArticleId><ArticleId IdType="pmc">PMC9087152</ArticleId><ArticleId IdType="doi">10.1016/j.dialog.2022.100012</ArticleId><ArticleId IdType="pii">S2772-6533(22)00012-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636594</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2192-8304</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>JIMD reports</Title><ISOAbbreviation>JIMD Rep</ISOAbbreviation></Journal><ArticleTitle>Recommendations on the follow-up of patients with Gaucher disease in Spain: Results from a Delphi survey.</ArticleTitle><Pagination><StartPage>90</StartPage><EndPage>103</EndPage><MedlinePgn>90-103</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmd2.12342</ELocationID><Abstract><AbstractText>Management of Gaucher disease (GD) is challenging due to its wide genotypic and phenotypic variability and changing clinical manifestations due to effective treatment. Sixteen face-to-face meetings with experts were held in order to discuss daily clinical practice and identify controversies regarding the management of GD. With this information, a questionnaire with 93 recommendations for different clinical scenarios was designed, and a Delphi survey among 86 physicians with experience in GD was conducted. Consensus was reached on 73 out of the 93 items. Recommendations on follow-up of adult and pediatric patients were in line with current guidelines, and underscored the importance of a patient-tailored approach. For the follow-up of stable patients receiving long-term treatment, consensus was reached on the importance of multidisciplinary care that involves pediatricians, internal medicine, and primary care, specialized radiologists, orthopedic surgeons, and hematologists when required. Degree of pain, use of painkillers and antidepressants, and quality of life should be evaluated at every follow-up visit or at least once per year. In general, a closer follow-up was recommended for untreated patients or patients who underwent a treatment change (every 3&#xa0;months during the first year) and during pregnancy. For pregnant patients, hemostasis and risk of hemorrhage should be assessed, but no consensus was reached for initiation of treatment in asymptomatic pregnant patients. Lastly, recommendations on how to adapt GD management during a COVID-19 pandemic were collected. This expert consensus may help decision-making during the management of GD in specific clinical scenarios.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. JIMD Reports published by John Wiley &amp; Sons Ltd on behalf of SSIEM.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giraldo</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-8791-1901</Identifier><AffiliationInfo><Affiliation>Hematology Hospital Quironsalud Zaragoza Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3;n Espa&#xf1;ola para el Estudio y Tratamiento de la Enfermedad de Gaucher (FEETEG) Zaragoza Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrade-Campos</LastName><ForeName>Marcio</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1637-7112</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3;n Espa&#xf1;ola para el Estudio y Tratamiento de la Enfermedad de Gaucher (FEETEG) Zaragoza Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematology Institut Hospital del Mar d'Investigacions M&#xe8;diques, IMIM-Parc de Salut Mar Barcelona Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Montserrat</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0064-9718</Identifier><AffiliationInfo><Affiliation>Reference Unit for Inherited Metabolic Disease, Hospital Universitario "12 de Octubre" Madrid Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>SEGA (SEguimiento del paciente de GAucher, Gaucher patient follow&#x2010;up) Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JIMD Rep</MedlineTA><NlmUniqueID>101568557</NlmUniqueID><ISSNLinking>2192-8304</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Delphi consensus</Keyword><Keyword MajorTopicYN="N">Gaucher disease</Keyword><Keyword MajorTopicYN="N">adult patients</Keyword><Keyword MajorTopicYN="N">follow&#x2010;up recommendations</Keyword><Keyword MajorTopicYN="N">pediatric patients</Keyword><Keyword MajorTopicYN="N">pregnancy</Keyword></KeywordList><CoiStatement>Pilar Giraldo reports personal fees for lectures, advisory boards, and research project from the following pharmaceuticals: Alexion, Amicus, Chiesi, Pfizer, Sanofi, and Takeda. The financial contributions are dedicated to research on Gaucher and other lysosomal diseases through the Spanish Foundation for the Study and Therapeutics of Gaucher and other Lysosomal Diseases (FEETEG). Marcio Andrade&#x2010;Campos reports he is an employee of AstraZeneca. Montserrat Morales reports personal fees for consultancy, support for research projects, and transport for conference attendance from the following companies: Genzyme Corporation, Alnylam, and Takeda.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636594</ArticleId><ArticleId IdType="pmc">PMC9830018</ArticleId><ArticleId IdType="doi">10.1002/jmd2.12342</ArticleId><ArticleId IdType="pii">JMD212342</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636572</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1920-8642</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>World journal of emergency medicine</Title><ISOAbbreviation>World J Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Exploratory COVID-19 death risk score based on basic laboratory tests and physiological clinical measurements.</ArticleTitle><Pagination><StartPage>453</StartPage><EndPage>458</EndPage><MedlinePgn>453-458</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5847/wjem.j.1920-8642.2022.103</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In the event of a sudden shortage of medical resources, a rapid, simple, and accurate prediction model is essential for the 30-day mortality rate of patients with COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective study compared the characteristics of the survivals and non-survivals of 278 patients with COVID-19. Logistic regression analysis was performed to obtain the "COVID-19 death risk score" (CDRS) model. Using the area under the receiver operating characteristic (AUROC) curve and Hosmer-Lemeshow goodness-of-fit test, discrimination and calibration were assessed. Internal validation was conducted using a regular bootstrap method.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 63 (22.66%) of 278 included patients died. The logistic regression analysis revealed that high-sensitivity C-reactive protein (hsCRP; odds ratio [OR]=1.018), D-dimer (OR=1.101), and respiratory rate (RR; OR=1.185) were independently associated with 30-day mortality. CDRS was calculated as follows: CDRS=-10.245+(0.022&#xd7;hsCRP)+(0.172&#xd7;D-dimer)+(0.203&#xd7;RR). CDRS had the same predictive effect as the sequential organ failure assessment (SOFA) and "confusion, uremia, respiratory rate, blood pressure, and age over 65 years" (CURB-65) scores, with AUROCs of 0.984 for CDRS, 0.975 for SOFA, and 0.971 for CURB-65, respectively. And CDRS showed good calibration. The AUROC through internal validations was 0.980 (95% confidence interval [CI]: 0.965-0.995). Regarding the clinical value, the decision curve analysis of CDRS showed a net value similar to that of CURB-65 in this cohort.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CDRS is a novel, efficient and accurate prediction model for the early identification of COVID-19 patients with poor outcomes. Although it is not as advanced as the other models, CDRS had a similar performance to that of SOFA and CURB-65.</AbstractText><CopyrightInformation>Copyright: &#xa9; World Journal of Emergency Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Gui-Ying</ForeName><Initials>GY</Initials><AffiliationInfo><Affiliation>Emergency Department, Peking University People's Hospital, Beijing 100044, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Fei-Fei</ForeName><Initials>FF</Initials><AffiliationInfo><Affiliation>Trauma Center, Peking University People's Hospital, Key Laboratory of Trauma and Neural Regeneration (Peking University), Ministry of Education, Beijing100044, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing100044, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chun-Bo</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Emergency Department, Peking University People's Hospital, Beijing 100044, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Ji-Hong</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Emergency Department, Peking University People's Hospital, Beijing 100044, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tian-Bing</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Trauma Center, Peking University People's Hospital, Key Laboratory of Trauma and Neural Regeneration (Peking University), Ministry of Education, Beijing100044, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>World J Emerg Med</MedlineTA><NlmUniqueID>101549691</NlmUniqueID><ISSNLinking>1920-8642</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">30-day mortality</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Prediction model</Keyword></KeywordList><CoiStatement>Conflicts of interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636572</ArticleId><ArticleId IdType="pmc">PMC9807385</ArticleId><ArticleId IdType="doi">10.5847/wjem.j.1920-8642.2022.103</ArticleId><ArticleId IdType="pii">WJEM-13-453</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636567</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1920-8642</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>World journal of emergency medicine</Title><ISOAbbreviation>World J Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Medical services for sports injuries and illnesses in the Beijing 2022 Olympic Winter Games.</ArticleTitle><Pagination><StartPage>459</StartPage><EndPage>466</EndPage><MedlinePgn>459-466</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5847/wjem.j.1920-8642.2022.106</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Beijing 2022 Olympic Winter Games was the second Games held amid the COVID-19 pandemic. To a certain extent, it has altered the way sporting activities operate. There is a lack of knowledge on injury risk and illness occurrence in elite winter sport athletes amid the COVID-19 pandemic. This study aimed to describe the incidence of injuries and illnesses sustained during the XXIV Olympic Winter Games in Beijing from February 4 to 20, 2022.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We recorded the daily number of injuries and illnesses among athletes reported by Beijing 2022 medical staff in the polyclinic, medical venues, and ambulance. We calculated injury and illness incidence as the number of injuries or illnesses occurring during competition or training, respectively, with incidence presented as injuries/illnesses per 100 athlete-days.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 2,897 athletes from 91 nations experienced injury or illness. Beijing 2022 medical staff reported 326 injuries and 80 illnesses, equaling 11.3 injuries and 2.8 illnesses per 100 athletes over the 17-day period. Altogether, 11% of the athletes incurred at least one injury and nearly 3% incurred at least one illness. The number of injured athletes was highest in the skating sports (n=104), followed by alpine skiing (n=53), ice track (n=37), freestyle skiing (n=36), and ice hockey (n=35), and was the lowest in the Nordic skiing disciplines (n=20). Of the 326 injuries, 14 (4.3%) led to an estimated absence from training or competition of more than 1 week. A total of 52 injured athletes were transferred to hospitals for further care. The number of athletes with illness (n=80) was the highest for skating (n=33) and Nordic skiing (n=22). A total of 50 illnesses (62.5%) were admitted to the department of dentistry/ophthalmology/otolaryngology, and the most common cause of illness was other causes, including preexisting illness and medicine (n=52, 65%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Overall, 11% of athletes incurred at least one injury during the Games, which is similar to the findings during the Olympic Winter Games in 2014 and 2018. Regarding illness, 2% of athletes were affected, which is approximately one-third of the number affected in the 2018 Olympic Winter Games.</AbstractText><CopyrightInformation>Copyright: &#xa9; World Journal of Emergency Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Peng-da</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Emergence Medical Service Group for Beijing 2022 Olympic Winter Games, Beijing Emergency Medical Center, Beijing 100031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Ding</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Emergence Medical Service Group for Beijing 2022 Olympic Winter Games, Beijing Emergency Medical Center, Beijing 100031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Emergence Medical Service Group for Beijing 2022 Olympic Winter Games, Beijing Emergency Medical Center, Beijing 100031, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lou</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Emergence Medical Service Group for Beijing 2022 Olympic Winter Games, Beijing Emergency Medical Center, Beijing 100031, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Games Services Department, Beijing Organizing Committee for the 2022 Olympic and Paralympic Winter Games, Beijing 100041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Si-Jia</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Emergence Medical Service Group for Beijing 2022 Olympic Winter Games, Beijing Emergency Medical Center, Beijing 100031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lian</LastName><ForeName>Hui-Xin</ForeName><Initials>HX</Initials><AffiliationInfo><Affiliation>Emergence Medical Service Group for Beijing 2022 Olympic Winter Games, Beijing Emergency Medical Center, Beijing 100031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Sheng-Mei</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Emergence Medical Service Group for Beijing 2022 Olympic Winter Games, Beijing Emergency Medical Center, Beijing 100031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lu-Xi</ForeName><Initials>LX</Initials><AffiliationInfo><Affiliation>Emergence Medical Service Group for Beijing 2022 Olympic Winter Games, Beijing Emergency Medical Center, Beijing 100031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Emergence Medical Service Group for Beijing 2022 Olympic Winter Games, Beijing Emergency Medical Center, Beijing 100031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jin-Jun</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Emergence Medical Service Group for Beijing 2022 Olympic Winter Games, Beijing Emergency Medical Center, Beijing 100031, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>World J Emerg Med</MedlineTA><NlmUniqueID>101549691</NlmUniqueID><ISSNLinking>1920-8642</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Emergency medical service</Keyword><Keyword MajorTopicYN="N">Illnesses</Keyword><Keyword MajorTopicYN="N">Injuries</Keyword><Keyword MajorTopicYN="N">Olympic Winter Games</Keyword></KeywordList><CoiStatement>Conflicts of interest: The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636567</ArticleId><ArticleId IdType="pmc">PMC9807383</ArticleId><ArticleId IdType="doi">10.5847/wjem.j.1920-8642.2022.106</ArticleId><ArticleId IdType="pii">WJEM-13-459</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636554</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2052-8817</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Acute medicine &amp; surgery</Title><ISOAbbreviation>Acute Med Surg</ISOAbbreviation></Journal><ArticleTitle>Impact of coronavirus disease 2019 on the mortality of patients who received emergency transportation: a population-based cross-sectional study.</ArticleTitle><Pagination><StartPage>e813</StartPage><MedlinePgn>e813</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ams2.813</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="UNASSIGNED">The spread of coronavirus disease 2019 (COVID-19) has a widespread impact on emergency medical care systems. However, its effects on the mortality of emergency transportation patients are unclear. This population-based, cross-sectional study investigated how COVID-19 impacted the mortality and outcomes of emergency transportation patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We compared mortality in the emergency department and at day 21 after an emergency visit for patients transported by ambulance to medical facilities in the Osaka Prefecture, Japan, between January 29 and December 31, 2020 (first pandemic year) and between January 29 and December 31, 2019 (immediate pre-pandemic year; 804,718 patients in total), using multivariable analysis to adjust for potential confounders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">During the first pandemic year, 50,446 fewer patients received emergency transportation compared with the immediate prepandemic year. Emergency department deaths increased by 603 during the first pandemic year (4,922 versus 4,319 deaths) and 640 within 21&#x2009;days (14,569 versus 13,929 deaths). Multivariable analysis revealed an association between the first pandemic year and increased mortality rates among patients given emergency transportation compared with the immediate prepandemic year (odds ratio for emergency department deaths 1.31; 95% confidence interval 1.26-1.38; odds ratio for deaths within 21&#x2009;days 1.17; 95% confidence interval 1.14-1.20).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The study results indicate that the spread of COVID-19 impacted the mortality of patients who received emergency transportation. Further studies are expected to clarify the impact of COVID-19 on emergency medical care systems.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Acute Medicine &amp; Surgery published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakao</LastName><ForeName>Shota</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8560-4086</Identifier><AffiliationInfo><Affiliation>Rinku General Medical Center Senshu Trauma and Critical Care Center Izumisano Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Working Group to Utilize ORION in Osaka Prefecture Osaka Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masui</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Working Group to Utilize ORION in Osaka Prefecture Osaka Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Administration Division, Department of Public Health and Medical Affairs Osaka Prefectural Government Osaka Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katayama</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2585-4259</Identifier><AffiliationInfo><Affiliation>Working Group to Utilize ORION in Osaka Prefecture Osaka Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Traumatology and Acute Critical Medicine Osaka University Graduate School of Medicine Suita Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitamura</LastName><ForeName>Tetsuhisa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0107-0580</Identifier><AffiliationInfo><Affiliation>Working Group to Utilize ORION in Osaka Prefecture Osaka Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Environmental Medicine and Population Sciences, Department of Social and Environmental Medicine Osaka University Graduate School of Medicine Suita Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9913-8186</Identifier><AffiliationInfo><Affiliation>Rinku General Medical Center Senshu Trauma and Critical Care Center Izumisano Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Working Group to Utilize ORION in Osaka Prefecture Osaka Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acute Med Surg</MedlineTA><NlmUniqueID>101635464</NlmUniqueID><ISSNLinking>2052-8817</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">emergency medical care system</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636554</ArticleId><ArticleId IdType="pmc">PMC9830966</ArticleId><ArticleId IdType="doi">10.1002/ams2.813</ArticleId><ArticleId IdType="pii">AMS2813</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636543</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Community-Based Seroprevelance of SARS-CoV-2 in Saudi Arabia.</ArticleTitle><Pagination><StartPage>e32419</StartPage><MedlinePgn>e32419</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.32419</ELocationID><Abstract><AbstractText>Introduction&#xa0; The new coronavirus disease 2019 (COVID-19) is a major global concern. Due to the number of asymptomatic cases that go untested, the actual proportion of those who have been infected is likely to be higher than the reported prevalence. Thus, investigating the exact proportion of those who developed antibodies against the virus through serological surveys is crucial to identify the immune status of the population and direct public health decisions accordingly. Objectives The aim of this study is to estimate the seroprevalence of SARS-CoV-2 in the community and to describe the epidemiological characteristics of the discovered cases. Methods Between July and October 2020, a cross-sectional sero-survey was conducted including a total of 15,873 serum samples collected from seven regions within the kingdom. Using a multistage convenient sampling, people were invited to participate in an interviewer-administrated questionnaire. Afterward, blood samples were collected and seroprevalence was determined using the SARS-CoV-2 virus IgG/IgM antibody detection kits (ELISA). A p-value of &lt;0.05 and 95% CI were used to report the significance. Results The overall seroprevalence of SARS-CoV-2 in the sample was 17.0%, and Makkah region constituted the highest number of reactive cases (33.3%). There was a significant association between all comorbidities and having symptoms except for diabetes. In addition, age, education, nationality, and region were all significant predeterminants of sero-result. Also, contact with a confirmed or suspected case increased the risk of being seropositive by nearly 1.5 times. Conclusion This study estimated the national seroprevalence of SARS-CoV-2 in Saudi Arabia to be 17%. At the time of this study, most of the population did not have the SARS-CoV-2 specific antibodies. This suggests that the population is still below the threshold of herd immunity and emphasizes the importance of mass vaccination programs and abiding by recommended prevention precautions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022, Alassaf et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alassaf</LastName><ForeName>Lujain</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Population Health Management, Center for National Health Insurance, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almudarra</LastName><ForeName>Sami</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Gulf Center for Disease Prevention and Control, Gulf Health Council, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almudaiheem</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Public Health Intelligence, Public Health Authority, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almutlaq</LastName><ForeName>Hind</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Public Health intelligence, Public Health Authority, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alqunaibet</LastName><ForeName>Ada</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Public Health Intelligence, Public Health Authority, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alseraihi</LastName><ForeName>Haleemah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Infectious Disease Consultant, Ministry of Health, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alaswad</LastName><ForeName>Rehab</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Public Health Intelligence, Public Health Authority, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoja</LastName><ForeName>Abdullah T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Public Health and Preventive Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>AlAbdulkareem</LastName><ForeName>Khaled</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Primary Health Care, Ministry of Health, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>AlSaif</LastName><ForeName>Faisal</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Surgery. College of Medicine, King Saud University, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abu Saris</LastName><ForeName>Raghib</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, College of Public Health and Health Informatics, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">sars-cov-2</Keyword><Keyword MajorTopicYN="N">saudi arabia</Keyword><Keyword MajorTopicYN="N">serological survey</Keyword><Keyword MajorTopicYN="N">seroprevalence</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636543</ArticleId><ArticleId IdType="pmc">PMC9832282</ArticleId><ArticleId IdType="doi">10.7759/cureus.32419</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636529</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Two Cases of Rare Intratumoral Hemorrhage Following COVID-19 Vaccination.</ArticleTitle><Pagination><StartPage>e32400</StartPage><MedlinePgn>e32400</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.32400</ELocationID><Abstract><AbstractText>The increase in the rate of mRNA vaccination against&#xa0;coronavirus disease 2019 (COVID-19) worldwide has been accompanied by reports of an increase in the side effects of the vaccine. In the field of neurosurgery, several cases of venous thrombosis have been reported as possible complications after COVID-19 vaccination. However, no such side effects have been reported in patients with brain tumors, and COVID-19 vaccination is considered safe for this patient population. In this report, we present the cases of two patients with brain tumors who experienced intratumoral hemorrhage as a possible side effect of the COVID-19 vaccine. In the first case, a 54-year-old man who had received CyberKnife treatment for a vestibular schwannoma eight years prior presented with tongue discomfort, right-side facial numbness, and dizziness since the day after his COVID-19 vaccination. MRI revealed intratumoral hemorrhage of the vestibular schwannoma. The second patient was a 60-year-old woman who presented with a sudden-onset headache and vomiting that had started three days after her COVID-19 vaccination. CT revealed a meningioma with intratumoral hemorrhage. Both patients had undergone surgery prior to this presentation, and their symptoms had improved. They had no risk factors for intratumoral hemorrhage, suggesting that it may be a side effect of the mRNA vaccine against COVID-19. Although the causal relationship is unclear, acute inflammation with predominantly lymphocytic infiltration and thrombogenicity after COVID-19 vaccination may damage the fragile microcirculation of the tumor.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022, Sugasawa et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sugasawa</LastName><ForeName>Shin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Stroke and Cerebrovascular Surgery, Sagamihara Kyodo Hospital, Sagamihara, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Toshikazu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neurological Surgery, Japanese Red Cross Medical Center, Tokyo, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bae</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Pathology, Japanese Red Cross Medical Center, Tokyo, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumasaka</LastName><ForeName>Toshio</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Pathology, Japanese Red Cross Medical Center, Tokyo, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichi</LastName><ForeName>Shunsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurological Surgery, Japanese Red Cross Medical Center, Tokyo, JPN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">covid-19 vaccine</Keyword><Keyword MajorTopicYN="N">intratumoral hemorrhage</Keyword><Keyword MajorTopicYN="N">meningioma</Keyword><Keyword MajorTopicYN="N">neurosurgery cyberknife</Keyword><Keyword MajorTopicYN="N">vestibular schwannoma</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636529</ArticleId><ArticleId IdType="pmc">PMC9831113</ArticleId><ArticleId IdType="doi">10.7759/cureus.32400</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636528</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Bullous Pilomatrixoma After COVID-19 Vaccination.</ArticleTitle><Pagination><StartPage>e32370</StartPage><MedlinePgn>e32370</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.32370</ELocationID><Abstract><AbstractText>Pilomatrixoma, or calcifying epithelioma of Malherbe, is a benign tumor with differentiation toward the hair matrix cells and is one of childhood's most common epithelial tumors. Bullous pilomatrixoma has an extremely low incidence of occurrence, usually appears in the upper extremities, and is frequently associated with trauma. We report the case of a bullous pilomatrixoma in a patient with a rapid-growing neoformation one month after receiving a coronavirus disease 2019 (COVID-19) vaccine in his left upper arm, and we discuss whether the bullous appearance is part of the biology of the tumor or a secondary anetoderma.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022, Alvarez-Rubio et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alvarez-Rubio</LastName><ForeName>Francisco Javier</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Instituto Dermatol&#xf3;gico de Jalisco "Dr. Jos&#xe9; Barba Rubio", Guadalajara, MEX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Ortega</LastName><ForeName>Jes&#xfa;s Iv&#xe1;n</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Instituto Dermatol&#xf3;gico de Jalisco "Dr. Jos&#xe9; Barba Rubio", Guadalajara, MEX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Reyna</LastName><ForeName>Ilse</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital General "Dr. Agust&#xed;n O'Hor&#xe1;n", M&#xe9;rida, MEX.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bullous pilomatrixoma</Keyword><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">cutaneous neoplasm</Keyword><Keyword MajorTopicYN="N">pilomatrixoma</Keyword><Keyword MajorTopicYN="N">secundary anetoderma</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636528</ArticleId><ArticleId IdType="pmc">PMC9831617</ArticleId><ArticleId IdType="doi">10.7759/cureus.32370</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636518</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>The Effect of the COVID-19 Lockdown on the Frequency of Acute Poisoning Presentation to Adult and Pediatric Emergency Departments.</ArticleTitle><Pagination><StartPage>e33581</StartPage><MedlinePgn>e33581</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.33581</ELocationID><Abstract><AbstractText>Background The coronavirus type 2 that causes severe acute respiratory syndrome (SARS-CoV-2) was detected in December 2019 in Wuhan, China. A worldwide emergency response has been initiated because of the fast rise in the number of cases and fatalities during the early stages of the pandemic when vaccinations and efficient medical care were unavailable.&#xa0;Misinformation spread quickly in the early phases of the pandemic, leading to the inappropriate use of medications, chemicals, and traditional remedies for their claimed preventive or therapeutic purposes. Thus, our aim is to identify the impact of the coronavirus disease 2019 (COVID-19) lockdown on the patterns of intoxicated patients presenting to King Abdulaziz Medical City's adult and pediatric emergency departments. Methods A retrospective cohort study was conducted&#xa0;in the adult emergency department at King Abdulaziz Medical City and the pediatric emergency department at King Abdullah Specialized Children's Hospital in Riyadh, Saudi Arabia.&#xa0;All patients presented with poisoning as a chief complaint between March 23 to June 21 in 2019 (pre-lockdown), 2020 (the lockdown), and 2021 (post-lockdown) were included. Cases of registered poisoning complaints were reviewed and assessed with respect to patient demographics, the causative agent/substance responsible for the poisoning, management of poisoning, and particular outcomes on the approved data collection form by the research team.&#xa0;The data were entered and analyzed by using SPSS v26 (IBM Corp, Armonk, NY). The descriptive statistics are presented as frequency and percentage for the categorical data variables and mean and standard deviation for the numerical data. The data were further analyzed by using cross-tabulation (chi-square test), for the data that are both the predictor and the outcome was categorical. A p-value of &lt; 0.05 was considered significant for all&#xa0;statistical tests. Results Out of 318 patients identified, 164 were adults and 154 were pediatric patients. The mean age of adult and pediatric patients was 33.3&#xb1;15.5 years and 4&#xb1;3.6 years, respectively. The majority of patients (115; 70.1%) were males in the adult group and females (90; 58.4%) in the pediatric.&#xa0;The majority of self-harm cases were accidental among both adults and pediatrics, 109 (66.5%) and 144 (93.5%), respectively. The disposition&#xa0;from the emergency department was discharged for 113 (68.7%) adult patients and&#xa0;134 (87.0%) pediatric patients.&#xa0;The number of cases presented to ER with poisoning cases during the lockdown decreased. This was further tested inferentially, but no significant association was seen among study variables, i.e., p &gt; 0.05. Conclusion The lockdown and pandemic had a significant impact on the rate and patterns of ED visits. The establishment and operation of Drug and Poison Information Centers (DPIC) across the Kingdom, in addition to increasing awareness through campaigns addressing drug and substance safety, is recommended.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023, Alhussein et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alhussein</LastName><ForeName>Naif</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medicine, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alosaimi</LastName><ForeName>Meshari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medicine, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alageel</LastName><ForeName>Mohammed K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Medicine, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alwatban</LastName><ForeName>Saud M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Medicine, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldusari</LastName><ForeName>Rakan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medicine, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldeeb</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Emergency Medicine, King Abdulaziz Medical City, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsomali</LastName><ForeName>Sameerah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Emergency Medicine, King Abdulaziz Medical City, Riyadh, SAU.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult emergency department</Keyword><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">lockdown</Keyword><Keyword MajorTopicYN="N">pediatric emergency department (ped)</Keyword><Keyword MajorTopicYN="N">poisoning</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636518</ArticleId><ArticleId IdType="pmc">PMC9830523</ArticleId><ArticleId IdType="doi">10.7759/cureus.33581</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636500</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1225-729X</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Soa--ch'ongsonyon chongsin uihak = Journal of child &amp; adolescent psychiatry</Title><ISOAbbreviation>Soa Chongsonyon Chongsin Uihak</ISOAbbreviation></Journal><ArticleTitle>Promoting Mental Health Literacy at Schools in South Korea.</ArticleTitle><Pagination><StartPage>15</StartPage><EndPage>20</EndPage><MedlinePgn>15-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5765/jkacap.220037</ELocationID><Abstract><AbstractText>The onset of many lifelong mental illnesses is during childhood and adolescence. There has been an increase in these conditions among children and adolescents especially, during the COVID-19 pandemic. It is essential to promote mental health literacy (MHL) as a preventive and universal intervention for children and adolescents. Positive mental health status in adolescence is related to an increased level of MHL, and various MHL programs at schools have been reported to be effective for adolescent students worldwide. Recently, MHL programs have been developed in South Korea to be used by schoolteachers. There is a need for active dissemination and development of future programs. For continuous and effective education, it is desirable to include MHL education in regular school curricula.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Korean Academy of Child and Adolescent Psychiatry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jeewook</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9335-7951</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Soa Chongsonyon Chongsin Uihak</MedlineTA><NlmUniqueID>9440189</NlmUniqueID><ISSNLinking>1225-729X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Child and adolescent</Keyword><Keyword MajorTopicYN="N">Mental health</Keyword><Keyword MajorTopicYN="N">Mental health literacy</Keyword><Keyword MajorTopicYN="N">School mental health</Keyword></KeywordList><CoiStatement>Conflicts of Interest The author has no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636500</ArticleId><ArticleId IdType="pmc">PMC9816008</ArticleId><ArticleId IdType="doi">10.5765/jkacap.220037</ArticleId><ArticleId IdType="pii">jkacap-34-1-15</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636498</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1225-729X</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Soa--ch'ongsonyon chongsin uihak = Journal of child &amp; adolescent psychiatry</Title><ISOAbbreviation>Soa Chongsonyon Chongsin Uihak</ISOAbbreviation></Journal><ArticleTitle>Deterioration of Mental Health in Children and Adolescents During the COVID-19 Pandemic.</ArticleTitle><Pagination><StartPage>21</StartPage><EndPage>29</EndPage><MedlinePgn>21-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5765/jkacap.220041</ELocationID><Abstract><AbstractText>This paper reviews the global effect of the coronavirus disease 2019 (COVID-19) pandemic on the mental health of children and adolescents in South Korea, the U.S., Japan, and China. We reviewed research on deteriorated mental health, including increased suicide, suicidal thoughts, and self-harm. Various studies have shown that students' mental health issues, such as depression and anxiety, have worsened during the COVID-19 pandemic. Furthermore, the number of students who committed suicide has significantly increased in the U.S. and Japan. Factors such as prior mental health status, change in daily routine, reduced physical activity, excessive screen time, overuse of electronic devices, and reduced social support have been reported to have a significant effect. The chain of deteriorating mental health among the youth began at the onset of COVID-19, social distancing, and school closure. As youths began to stay at home instead of going to school, they lost opportunities to connect with their friends or teachers, who could provide support outside of their homes. Young people spent less time on physical activity and more time online, which damaged their sleeping schedule and daily routine. In preparing for the post-pandemic phase, we should thoroughly analyze the long-term effects of the pandemic on youth mental health, while simultaneously tackling current imminent issues.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Korean Academy of Child and Adolescent Psychiatry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Eunkyung</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-5616-9206</Identifier><AffiliationInfo><Affiliation>Creative Mindful Leadership, Dongguk University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Kyoil</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8326-9296</Identifier><AffiliationInfo><Affiliation>Creative Mindful Leadership, Dongguk University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Boram</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-2902-9950</Identifier><AffiliationInfo><Affiliation>Creative Mindful Leadership, Dongguk University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Deokyong</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-1153-2937</Identifier><AffiliationInfo><Affiliation>Creative Mindful Leadership, Dongguk University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seohyun</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0358-3788</Identifier><AffiliationInfo><Affiliation>Creative Mindful Leadership, Dongguk University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Youngil</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9639-0813</Identifier><AffiliationInfo><Affiliation>Creative Mindful Leadership, Dongguk University, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dharma College, Dongguk University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Aeju</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8701-9091</Identifier><AffiliationInfo><Affiliation>Creative Mindful Leadership, Dongguk University, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of English Language and Literature, Dongguk University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yeni</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-2624-8026</Identifier><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Dongguk University International Hospital, Goyang, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Psychopharmacology, Dongguk University School of Medicine, Goyang, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Soa Chongsonyon Chongsin Uihak</MedlineTA><NlmUniqueID>9440189</NlmUniqueID><ISSNLinking>1225-729X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adolescent</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Children</Keyword><Keyword MajorTopicYN="N">Mental health</Keyword><Keyword MajorTopicYN="N">Suicide</Keyword></KeywordList><CoiStatement>Conflicts of Interest The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636498</ArticleId><ArticleId IdType="pmc">PMC9816000</ArticleId><ArticleId IdType="doi">10.5765/jkacap.220041</ArticleId><ArticleId IdType="pii">jkacap-34-1-21</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636497</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1225-729X</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Soa--ch'ongsonyon chongsin uihak = Journal of child &amp; adolescent psychiatry</Title><ISOAbbreviation>Soa Chongsonyon Chongsin Uihak</ISOAbbreviation></Journal><ArticleTitle>Enhancing the School Mental Health Initiative Amid COVID-19.</ArticleTitle><Pagination><StartPage>2</StartPage><EndPage>3</EndPage><MedlinePgn>2-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5765/jkacap.220045</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kweon</LastName><ForeName>Yong-Sil</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Soa Chongsonyon Chongsin Uihak</MedlineTA><NlmUniqueID>9440189</NlmUniqueID><ISSNLinking>1225-729X</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636497</ArticleId><ArticleId IdType="pmc">PMC9816001</ArticleId><ArticleId IdType="doi">10.5765/jkacap.220045</ArticleId><ArticleId IdType="pii">jkacap-34-1-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636492</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1225-729X</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Soa--ch'ongsonyon chongsin uihak = Journal of child &amp; adolescent psychiatry</Title><ISOAbbreviation>Soa Chongsonyon Chongsin Uihak</ISOAbbreviation></Journal><ArticleTitle>Introduction of Child and Adolescent Mental Health Services in Korea and Their Role During the COVID-19 Pandemic: Focusing on the Ministry of Education Policy.</ArticleTitle><Pagination><StartPage>4</StartPage><EndPage>14</EndPage><MedlinePgn>4-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5765/jkacap.220034</ELocationID><Abstract><AbstractText>This study aimed to discuss mental health services for children and adolescents that are being implemented as initiatives of the Korean government and to review the functions and roles of these projects during the COVID-19 pandemic. Three government departments are in charge of providing mental health services for children and adolescents: Ministry of Education, Ministry of Gender Equality and Family, and Ministry of Health and Welfare. The Ministry of Education has implemented several policies to facilitate the early detection of mental health issues among school students (from preventive interventions to selective interventions for high-risk students). The Ministry of Gender Equality and Family additionally serves out-of-school children and adolescents by facilitating early identification of adolescents in crises and providing temporary protection or emergency assistance (as required) through the Community Youth Safety-Net Project. Furthermore, the Ministry of Health and Welfare operates relevant mental health agencies for individuals of all ages including children and adolescents. Any high-risk students who have been screened through the projects of the Ministry of Education are supported through referrals to the following institutions for appropriate treatment of their symptoms: specialized hospitals, the Youth Counseling and Welfare Center operated by the Ministry of Gender Equality and Family, the National Youth Healing Center, the Mental Health Welfare Center operated by the Ministry of Health and Welfare, the Suicide Prevention Center, and the Child Welfare Center. To assist students who are facing any psychological difficulties because of the COVID-19 pandemic, the Ministry of Education has established a psychiatric support group for providing emergency mental health care; furthermore, schools are promoting psychological surveillance (e.g., provision of non-face-to-face counseling services that are centered around the Wee Center). The Ministry of Education, Ministry of Gender Equality and Family, and Ministry of Health and Welfare have provided varied mental health support services in order to address the challenges faced by children and adolescents during the pandemic. Nevertheless, the mental health services operated by each ministry do show some limitations because their service provision system is insufficiently collaborative. The present study discussed the positive effects of each initiative as well as its limitations; furthermore, it suggested improvements for facilitating the healthy development of children and adolescents' mental health.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Korean Academy of Child and Adolescent Psychiatry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seo Jung</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-4986-7217</Identifier><AffiliationInfo><Affiliation>Department of Education, Ewha Womans University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jongha</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0824-8564</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Korea University Ansan Hospital, Ansan, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Soa Chongsonyon Chongsin Uihak</MedlineTA><NlmUniqueID>9440189</NlmUniqueID><ISSNLinking>1225-729X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adolescent</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Child</Keyword><Keyword MajorTopicYN="N">Mental health services</Keyword><Keyword MajorTopicYN="N">Schools</Keyword></KeywordList><CoiStatement>Conflicts of Interest The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636492</ArticleId><ArticleId IdType="pmc">PMC9815998</ArticleId><ArticleId IdType="doi">10.5765/jkacap.220034</ArticleId><ArticleId IdType="pii">jkacap-34-1-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636472</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-1402</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>F1000Research</Title><ISOAbbreviation>F1000Res</ISOAbbreviation></Journal><ArticleTitle>Health literacy on COVID-19 and COVID-19 vaccinations in Indonesia.</ArticleTitle><Pagination><StartPage>1296</StartPage><MedlinePgn>1296</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12688/f1000research.125551.1</ELocationID><Abstract><AbstractText><b>Introduction:</b> Health literacy on the coronavirus disease 2019 (COVID-19) affects people's capability to ascertain their health and health care quality during the pandemic. The objective of this study was to determine the levels of health literacy about COVID-19 vaccines and vaccinations (Vaccines and Vaccinations literacy-VL) in the Indonesian adult general population, assessing the perceptions of the respondents about current adult immunization and beliefs about vaccinations in general, and analyzing correlations of these variables with the VL levels. <b>Methods:</b> A cross-sectional study using a rapid survey was administered via the Internet. Data were analyzed using descriptive and inferential statistics; the internal consistency of the VL scales was evaluated using Cronbach's alpha coefficient; the inter-correlation between the functional and interactive-critical VL questions, the underlying components (factors) and each question's load on the components were identified using a Principal Component Analysis (PCA). An alpha level lesser than 0.05 was considered significant. <b>Results:</b> Responses to functional- and interactive/ critical- VL questions were acceptable and showed internal consistency (Cronbach's alpha = 0.817 and 0.699, respectively), lowest values observed were 0.806 for functional scale and 0.640 for the interactive-critical scale. The PCA demonstrated that there were two components accounting for 52.45% of the total variability. Approximately 60% of respondents were females (n=686). Almost all respondents used the internet to seek information regarding COVID-19 and COVID-19 vaccinations. Many used at least one social media actively with 74.4% of respondents sometimes believing the validity of this information. <b>Conclusions:</b> High scores were observed in both functional- and interactive/ critical-VL, and were quite in a balance between sexes in the prior VL and higher in females for the latter; these were also closely related to the educational level and age group. It is crucial to increase public health literacy in managing the pandemic.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2022 Kalanjati VP et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Kalanjati</LastName><ForeName>Viskasari P</ForeName><Initials>VP</Initials><Identifier Source="ORCID">0000-0002-7005-0025</Identifier><AffiliationInfo><Affiliation>Department of Anatomy, Histology and Pharmacology, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hasanatuludhhiyah</LastName><ForeName>Nurina</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-3535-2271</Identifier><AffiliationInfo><Affiliation>Department of Anatomy, Histology and Pharmacology, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>d'Arqom</LastName><ForeName>Annette</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5412-9913</Identifier><AffiliationInfo><Affiliation>Department of Anatomy, Histology and Pharmacology, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muhammad</LastName><ForeName>Azlin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9308-4175</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, 56000, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marchianti</LastName><ForeName>Ancah Caesarina Novi</ForeName><Initials>ACN</Initials><Identifier Source="ORCID">0000-0002-4813-5356</Identifier><AffiliationInfo><Affiliation>Public Health Division, Faculty of Medicine Universitas Jember, Kalimantan Street No. 37, Kampus Tegalboto, Jember, East Java, 68121, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arsyi</LastName><ForeName>Danial Habri</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Universitas Airlangga, Street no. 47, Surabaya, East Java, 60132, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Permana</LastName><ForeName>Putu Bagus Dharma</ForeName><Initials>PBD</Initials><Identifier Source="ORCID">0000-0001-6458-0866</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Universitas Airlangga, Street no. 47, Surabaya, East Java, 60132, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Susila</LastName><ForeName>I Made Dwi Yudiartana Putra</ForeName><Initials>IMDYP</Initials><Identifier Source="ORCID">0000-0002-5182-6510</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Universitas Airlangga, Street no. 47, Surabaya, East Java, 60132, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratiwi</LastName><ForeName>Octaviana Galuh</ForeName><Initials>OG</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Universitas Airlangga, Street no. 47, Surabaya, East Java, 60132, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purwitasari</LastName><ForeName>Diana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7000-7628</Identifier><AffiliationInfo><Affiliation>Department of Informatics, Institut Teknologi Sepuluh Nopember, Teknik Informatika Department Building, Sukolilo, Surabaya, 60111, Indonesia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>Dryad</DataBankName><AccessionNumberList><AccessionNumber>10.5061/dryad.2fqz612sg</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>F1000Res</MedlineTA><NlmUniqueID>101594320</NlmUniqueID><ISSNLinking>2046-1402</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Indonesia</Keyword><Keyword MajorTopicYN="N">adult vaccinations</Keyword><Keyword MajorTopicYN="N">health risk</Keyword><Keyword MajorTopicYN="N">vaccines literacy</Keyword></KeywordList><CoiStatement>No competing interests were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636472</ArticleId><ArticleId IdType="pmc">PMC9811029</ArticleId><ArticleId IdType="doi">10.12688/f1000research.125551.1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636471</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-1402</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>F1000Research</Title><ISOAbbreviation>F1000Res</ISOAbbreviation></Journal><ArticleTitle>Adverse drug reactions to the three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) mRNA-1273 vaccine in a cohort of cancer patients under active treatment of a tertiary hospital in Madrid, Spain.</ArticleTitle><Pagination><StartPage>434</StartPage><MedlinePgn>434</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12688/f1000research.110268.1</ELocationID><Abstract><AbstractText><b>Background:</b> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines efficacy and safety have been tested in phase 3 studies in which cancer patients were not included or were underrepresented. <b>Methods:</b> The objective of this study is to evaluate the safety profile of the mRNA-1273 vaccine across cancer patients and its relationship to patients' demographics. This retrospective cohort study included patients 18-years or older with solid malignancies receiving active treatment in our hospital who had received the three-dose schedule of the mRNA9 1273 vaccine and whose side effects after each dose were recorded. Patient electronic medical records were reviewed retrospectively to collect data between April 19, 2021, and December 31, 2021. Patients with documented previous infection by SARS-Cov-2 were excluded from the study. <b>Results:</b> A total of 93 patients met the inclusion criteria. Local adverse drug reactions (ADRs) were reported more frequently after the first and second dose than after the third (41.9%, 43% and 31.1% of the patients respectively), while systemic ADRs followed the opposite pattern (16.1%, 34.4% and 52.6% of the patients respectively). We found a statistically significant association between sex and systemic ADRs after the third dose. Cochran-Armitage test showed a statistically significant linear trend, <i>p</i> = 0.012, with a higher Eastern Cooperative Oncology Group (ECOG) score associated with a lower proportion of patients suffering from systemic side effects. A logistic regression showed that women had 5.79 times higher odds to exhibit systemic ADRs after the third dose (p=0.01) compared to males. Increasing age was associated with a decreased likelihood of exhibiting ADRs (p=0.016). <b>Conclusion:</b>&#xa0;The mRNA-1273 vaccine shows a tolerable safety profile. The likelihood of ADRs appears to be associated with gender and age. Its association with ECOG scores is less evident. Further studies are needed to elucidate this data in cancer patients.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2022 Benitez Fuentes JD et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benitez Fuentes</LastName><ForeName>Javier David</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0001-8827-2497</Identifier><AffiliationInfo><Affiliation>Medical Oncology Department, IdISSC, Hospital Clinico San Carlos, Madrid, Madrid, 28040, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bloomberg School of Public Health MD, 21205, USA, Johns Hopkins University, Baltimore, Maryland, 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Luna Aguilar</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, IdISSC, Hospital Clinico San Carlos, Madrid, Madrid, 28040, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimenez Ortega</LastName><ForeName>Alejandro Francisco</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology Department, IdISSC, Hospital Clinico San Carlos, Madrid, Madrid, 28040, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores Navarro</LastName><ForeName>Paloma</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, IdISSC, Hospital Clinico San Carlos, Madrid, Madrid, 28040, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartolom&#xe9; Arcilla</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2715-6529</Identifier><AffiliationInfo><Affiliation>Medical Oncology Department, IdISSC, Hospital Clinico San Carlos, Madrid, Madrid, 28040, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baos Mu&#xf1;oz</LastName><ForeName>Elvira</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Microbiology Department, IdISSC, Hospital Cl&#xed;nico San Carlos, Madrid, Madrid, 28040, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delgado-Iribarren Garc&#xed;a-Campero</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7539-5404</Identifier><AffiliationInfo><Affiliation>Clinical Microbiology Department, IdISSC, Hospital Cl&#xed;nico San Carlos, Madrid, Madrid, 28040, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil Useros</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, IdISSC, Hospital Clinico San Carlos, Madrid, Madrid, 28040, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez Capella</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Innovation Unit, IdISSC, Hospital Cl&#xed;nico San Carlos, Madrid, Madrid, 28040, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llorente Sanz</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-6496-1300</Identifier><AffiliationInfo><Affiliation>Innovation Unit, IdISSC, Hospital Cl&#xed;nico San Carlos, Madrid, Madrid, 28040, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torrego Ellacur&#xed;a</LastName><ForeName>Macarena</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8071-8976</Identifier><AffiliationInfo><Affiliation>Innovation Unit, IdISSC, Hospital Cl&#xed;nico San Carlos, Madrid, Madrid, 28040, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez Segura</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, IdISSC, Hospital Clinico San Carlos, Madrid, Madrid, 28040, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>Dryad</DataBankName><AccessionNumberList><AccessionNumber>10.5061/dryad.cnp5hqc6d</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>F1000Res</MedlineTA><NlmUniqueID>101594320</NlmUniqueID><ISSNLinking>2046-1402</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Oncology</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Safety</Keyword><Keyword MajorTopicYN="N">mRNA-1273 Vaccine</Keyword></KeywordList><CoiStatement>No competing interests were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636471</ArticleId><ArticleId IdType="pmc">PMC9816496</ArticleId><ArticleId IdType="doi">10.12688/f1000research.110268.1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636469</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-1402</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>F1000Research</Title><ISOAbbreviation>F1000Res</ISOAbbreviation></Journal><ArticleTitle>The family situation of wards under the supervision of court - appointed custodians during COVID-19 pandemic in Poland: a self-report study to examine the perception of probation officers.</ArticleTitle><Pagination><StartPage>1528</StartPage><MedlinePgn>1528</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12688/f1000research.110435.1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Polish Probation Service is strongly linked to social work. This text presents how the work and the problems of clients have changed in the Polish Probation Service during the COVID-19 pandemic. The article presents empirical data.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A questionnaire was used among 216 Polish probation officers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The obtained results describe the changes in the problems experienced by clients of the Probation Service during the COVID-19 pandemic.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Since we can expect further increase in the frequency of occurring personal and social problems experienced by court-appointed custodians' wards, financial resources and energy of social institutions, cooperation with court guardianship should be focused on psycho-educational campaigns concentrating on providing information on symptoms of problems in the mental and emotional sphere. Preventing exclusion of groups at risk in the labour market and supporting families to prevent the escalation of psychopathology, development of addictions and domestic violence should be priority areas.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2022 Opora R.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Opora</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1560-4136</Identifier><AffiliationInfo><Affiliation>Department of of Social Sciences, University of Gdansk, Ba&#x17c;y&#x144;skiego 4, Gda&#x144;sk, 80-309, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>figshare</DataBankName><AccessionNumberList><AccessionNumber>10.6084/m9.figshare.19447193.v3</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>F1000Res</MedlineTA><NlmUniqueID>101594320</NlmUniqueID><ISSNLinking>2046-1402</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pandemic COVID &#x2013; 19</Keyword><Keyword MajorTopicYN="N">Probation supervision</Keyword><Keyword MajorTopicYN="N">Social problems</Keyword><Keyword MajorTopicYN="N">family</Keyword><Keyword MajorTopicYN="N">social rehabilitation</Keyword></KeywordList><CoiStatement>No competing interests were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636469</ArticleId><ArticleId IdType="pmc">PMC9813447</ArticleId><ArticleId IdType="doi">10.12688/f1000research.110435.1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636391</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1559-8284</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>American journal of lifestyle medicine</Title><ISOAbbreviation>Am J Lifestyle Med</ISOAbbreviation></Journal><ArticleTitle>Long COVID: A New Challenge for Prevention of Obesity in Women.</ArticleTitle><Pagination><StartPage>164</StartPage><EndPage>168</EndPage><MedlinePgn>164-168</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/15598276221111054</ELocationID><Abstract><AbstractText>The long COVID affects individuals that do not recover for several weeks or months following the onset of symptoms of COVID-19. Obesity could play a role in the long COVID syndrome. During the pandemic, various factors contributed greatly to aggravating obesity in women leading to a pro-inflammatory and prothrombotic status. The present commentary explores the relationship between long COVID and obesity in women.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mattioli</LastName><ForeName>Anna Vittoria</ForeName><Initials>AV</Initials><Identifier Source="ORCID">0000-0003-1487-9530</Identifier><AffiliationInfo><Affiliation>Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena Italy (AVM, MN); Cardiology Division, Policlinico di Modena, Modena, Italy (FC); Department of Life science, University of Modena and Reggio Emilia, Modena, Italy (MP); and Department of Neuroscience, Imaging and Clinical Sciences, "G. D'Annunzio" University, Chieti, Italy (SG).</Affiliation><Identifier Source="RINGGOLD">60236</Identifier><Identifier Source="RINGGOLD">60236</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coppi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena Italy (AVM, MN); Cardiology Division, Policlinico di Modena, Modena, Italy (FC); Department of Life science, University of Modena and Reggio Emilia, Modena, Italy (MP); and Department of Neuroscience, Imaging and Clinical Sciences, "G. D'Annunzio" University, Chieti, Italy (SG).</Affiliation><Identifier Source="RINGGOLD">60236</Identifier><Identifier Source="RINGGOLD">60236</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasi</LastName><ForeName>Milena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena Italy (AVM, MN); Cardiology Division, Policlinico di Modena, Modena, Italy (FC); Department of Life science, University of Modena and Reggio Emilia, Modena, Italy (MP); and Department of Neuroscience, Imaging and Clinical Sciences, "G. D'Annunzio" University, Chieti, Italy (SG).</Affiliation><Identifier Source="RINGGOLD">60236</Identifier><Identifier Source="RINGGOLD">60236</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinti</LastName><ForeName>Marcello</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena Italy (AVM, MN); Cardiology Division, Policlinico di Modena, Modena, Italy (FC); Department of Life science, University of Modena and Reggio Emilia, Modena, Italy (MP); and Department of Neuroscience, Imaging and Clinical Sciences, "G. D'Annunzio" University, Chieti, Italy (SG).</Affiliation><Identifier Source="RINGGOLD">60236</Identifier><Identifier Source="RINGGOLD">60236</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallina</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena Italy (AVM, MN); Cardiology Division, Policlinico di Modena, Modena, Italy (FC); Department of Life science, University of Modena and Reggio Emilia, Modena, Italy (MP); and Department of Neuroscience, Imaging and Clinical Sciences, "G. D'Annunzio" University, Chieti, Italy (SG).</Affiliation><Identifier Source="RINGGOLD">60236</Identifier><Identifier Source="RINGGOLD">60236</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Lifestyle Med</MedlineTA><NlmUniqueID>101300023</NlmUniqueID><ISSNLinking>1559-8276</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">obesity</Keyword><Keyword MajorTopicYN="N">women</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>2</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636391</ArticleId><ArticleId IdType="pmc">PMC9830233</ArticleId><ArticleId IdType="doi">10.1177/15598276221111054</ArticleId><ArticleId IdType="pii">10.1177_15598276221111054</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636302</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">0974-777X</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Season>Oct-Dec</Season></PubDate></JournalIssue><Title>Journal of global infectious diseases</Title><ISOAbbreviation>J Glob Infect Dis</ISOAbbreviation></Journal><ArticleTitle>High Prevalence of Fungal and NDM-OXA Producing Gram-Negative Bacterial Superinfections in the Second Wave of Coronavirus Disease 2019 in India: Experience from a Dedicated Coronavirus Disease 2019 Hospital in North India.</ArticleTitle><Pagination><StartPage>154</StartPage><EndPage>161</EndPage><MedlinePgn>154-161</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/jgid.jgid_238_21</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">During the second wave of coronavirus disease 2019 (COVID-19), superinfection caused by fungus and multidrug-resistant bacteria worsened the severity of illness in COVID-19 patients. Limited studies from India reported the antimicrobial resistance pattern of secondary infections. In this study, we aim to study the epidemiology of pathogens causing superinfections and genotyping of Gram-negative isolates in COVID-19 patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This retrospective study was conducted at a dedicated COVID-19 center, India. The identification of bacteria/fungi was done by Vitek2<sup>&#xae;</sup> and matrix-assisted laser desorption/ionization-time of flight mass spectrometry system. Identification of beta-lactamase genes was done using thermal cycler. The diagnosis of mucormycosis was based on 10% potassium hydroxide direct microscopy. Statistical analyses were performed using STATA version 15.1 (StataCorp., College Station, TX, USA). For continuous variables, mean and standard deviation were computed. For comparing proportions of secondary infections across admission location and outcomes, the Chi-squared test of independence was used. To compare the mean and median between intensive care units and outcomes, an independent <i>t</i>-test and a Mann-Whitney test were used.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of all the clinical samples, 45.4% of samples were cultured positive for secondary infections. <i>Acinetobacter baumannii</i> (35%) was the most common Gram-negative pathogen, while among Gram positive, it was <i>Enterococcus faecium</i> (40%). Among fungus, Candida spp. (61%) predominates followed by molds. Colistin and tigecycline proved effective against these pathogens. <i>bla<sub>NDM</sub></i> was the most prevalent gene followed by the <i>bla<sub>OX</sub></i> among the carbapenemase genes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The mortality rate among COVID-19 patients with secondary infection was significantly higher compared to the overall mortality rate in COVID-19 patients.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2022 Journal of Global Infectious Diseases.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katoch</LastName><ForeName>Omika</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, AIIMS, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharad</LastName><ForeName>Neha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Microbiology, AIIMS, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Parul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Microbiology, AIIMS, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastav</LastName><ForeName>Sharad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, AIIMS, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggrawal</LastName><ForeName>Richa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, AIIMS, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malhotra</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, JPNATC, AIIMS, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathur</LastName><ForeName>Purva</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, AIIMS, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>J Glob Infect Dis</MedlineTA><NlmUniqueID>101521436</NlmUniqueID><ISSNLinking>0974-777X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antimicrobial resistance</Keyword><Keyword MajorTopicYN="N">Mucor</Keyword><Keyword MajorTopicYN="N">NDM</Keyword><Keyword MajorTopicYN="N">coronavirus disease 2019</Keyword></KeywordList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636302</ArticleId><ArticleId IdType="pmc">PMC9831212</ArticleId><ArticleId IdType="doi">10.4103/jgid.jgid_238_21</ArticleId><ArticleId IdType="pii">JGID-14-154</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636300</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">0974-777X</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Season>Oct-Dec</Season></PubDate></JournalIssue><Title>Journal of global infectious diseases</Title><ISOAbbreviation>J Glob Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Post-COVID-19 Cerebral Pheohyphomycosis due to <i>Rhinocladiella mackenziei</i>: A Middle Eastern Replica of Post-COVID-19 Mucormycosis?</ArticleTitle><Pagination><StartPage>173</StartPage><EndPage>174</EndPage><MedlinePgn>173-174</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/jgid.jgid_105_22</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wankhade</LastName><ForeName>Bhushan Sudhakar</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Department of Surgical Intensive Care, Rashid Hospital, Oud Metha, Dubai, UAE.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdel Hadi</LastName><ForeName>Ammar Mohamed</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Surgical Intensive Care, Rashid Hospital, Oud Metha, Dubai, UAE.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alrais</LastName><ForeName>Ghaya Zeyad</ForeName><Initials>GZ</Initials><AffiliationInfo><Affiliation>Dubai Medical College, Dubai, UAE.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alrais</LastName><ForeName>Zeyad Faoor</ForeName><Initials>ZF</Initials><AffiliationInfo><Affiliation>Department of Surgical Intensive Care, Rashid Hospital, Oud Metha, Dubai, UAE.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elzayyat</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgical Intensive Care, Rashid Hospital, Oud Metha, Dubai, UAE.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>J Glob Infect Dis</MedlineTA><NlmUniqueID>101521436</NlmUniqueID><ISSNLinking>0974-777X</ISSNLinking></MedlineJournalInfo><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636300</ArticleId><ArticleId IdType="pmc">PMC9831205</ArticleId><ArticleId IdType="doi">10.4103/jgid.jgid_105_22</ArticleId><ArticleId IdType="pii">JGID-14-173</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636294</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-5370</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>EClinicalMedicine</Title><ISOAbbreviation>EClinicalMedicine</ISOAbbreviation></Journal><ArticleTitle>The role of the electroencephalogram (EEG) in determining the aetiology of catatonia: a systematic review and meta-analysis of diagnostic test accuracy.</ArticleTitle><Pagination><StartPage>101808</StartPage><MedlinePgn>101808</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eclinm.2022.101808</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Catatonia is a psychomotor syndrome that has a wide range of aetiologies. Determining whether catatonia is due to a medical or psychiatric cause is important for directing treatment but is clinically challenging. We aimed to ascertain the performance of the electroencephalogram (EEG) in determining whether catatonia has a medical or psychiatric cause, conventionally defined.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this systematic review and meta-analysis of diagnostic test accuracy (PROSPERO CRD42021239027), Medline, EMBASE, PsycInfo, and AMED were searched from inception to May 11, 2022 for articles published in peer-reviewed journals that reported EEG findings in catatonia of a medical or psychiatric origin and were reported in English, French, or Italian. Eligible study types were clinical trials, cohort studies, case-control studies, cross-sectional studies, case series, and case reports. The reference standard was the final clinical diagnosis. Data extraction was conducted using individual patient-level data, where available, by two authors. We prespecified two types of studies to overcome the limitations anticipated in the data: larger studies (<i>n</i>&#xa0;&#x2265;&#xa0;5), which were suitable for formal meta-analytic methods but generally lacked detailed information about participants, and smaller studies (<i>n</i>&#xa0;&lt;&#xa0;5), which were unsuitable for formal meta-analytic methods but had detailed individual patient level data, enabling additional sensitivity analyses. Risk of bias and applicability were assessed with the QUADAS-2 tool for larger studies, and with a published tool designed for case reports and series for smaller studies. The primary outcomes were sensitivity and specificity, which were derived using a bivariate mixed-effects regression model.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">355 studies were included, spanning 707 patients. Of the 12 larger studies (5 cohort studies and 7 case series), 308 patients were included with a mean age of 48.2 (SD&#xa0;=&#xa0;8.9) years. 85 (52.8%) were reported as male and 99 had catatonia due to a general medical condition. In the larger studies, we found that an abnormal EEG predicted a medical cause of catatonia with a sensitivity of 0.82 (95% CI 0.67-0.91) and a specificity of 0.66 (95% CI 0.45-0.82) with an <i>I</i> <sup>2</sup> of 74% (95% CI 42-100%). The area under the summary ROC curve offered excellent discrimination (AUC&#xa0;=&#xa0;0.83). The positive likelihood ratio was 2.4 (95% CI 1.4-4.1) and the negative likelihood ratio was 0.28 (95% CI 0.15-0.51). Only 5 studies had low concerns in terms of risk of bias and applicability, but a sensitivity analysis limited to these studies was similar to the main analysis. Among the 343 smaller studies, 399 patients were included, resulting in a sensitivity of 0.76 (95% CI 0.71-0.81), specificity of 0.67 (0.57-0.76) and AUC&#xa0;=&#xa0;0.71 (95% CI 0.67-0.76). In multiple sensitivity analyses, the results were robust to the exclusion of reports of studies and individuals considered at high risk of bias. Features of limbic encephalitis, epileptiform discharges, focal abnormality, or status epilepticus were highly specific to medical catatonia, but features of encephalopathy had only moderate specificity and occurred in 23% of the cases of psychiatric catatonia in smaller studies.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">In cases of diagnostic uncertainty, the EEG should be used alongside other investigations to ascertain whether the underlying cause of catatonia is medical. The main limitation of this review is the differing thresholds for considering an EEG abnormal between studies.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">Wellcome Trust, NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust.</AbstractText><CopyrightInformation>&#xa9; 2022 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hosseini</LastName><ForeName>Paris</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, University College London Hospitals NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whincup</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Leicestershire Partnership NHS Trust, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devan</LastName><ForeName>Karrish</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>South London and Maudsley NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghanem</LastName><ForeName>Dory Anthony</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Medical School, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fanshawe</LastName><ForeName>Jack B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saini</LastName><ForeName>Aman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical School, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cross</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Mersey Care NHS Foundation Trust, Prescot, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vijay</LastName><ForeName>Apoorva</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>GKT School of Medical Education, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastellari</LastName><ForeName>Tomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm U1172, CHU de Lille, Lille Neuroscience &amp; Cognition (LilNCog), Universit&#xe9; de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vivekananda</LastName><ForeName>Umesh</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Epilepsy, Institute of Neurology UCL, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Hospital for Neurology and Neurosurgery, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunnhuber</LastName><ForeName>Franz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurophysiology, King's College Hospital NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zandi</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>National Hospital for Neurology and Neurosurgery, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>Anthony S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Institute of Mental Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Health Informatics, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliver</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychosis Studies, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Glyn</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fry</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurophysiology, King's College Hospital NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Puja R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanton</LastName><ForeName>Biba</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, King's College Hospital NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuropsychiatry Service, South London and Maudsley NHS Trust, St. Thomas' Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Jonathan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>South London and Maudsley NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EClinicalMedicine</MedlineTA><NlmUniqueID>101733727</NlmUniqueID><ISSNLinking>2589-5370</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Catatonia</Keyword><Keyword MajorTopicYN="N">Diagnostic test accuracy</Keyword><Keyword MajorTopicYN="N">EEG</Keyword><Keyword MajorTopicYN="N">Electroencephalogram</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword></KeywordList><CoiStatement>G.L. declares payments made to his institution by the Wellcome Trust and the NIHR UCLH BRC. J.P.R. declare payments to his institution for his salary by the Wellcome Trust. M.S.Z. declares salary support to support research time from the NIHR UCLH BRC. M.S.Z. declares honoraria for one lecture each for each of the four mentioned in the last three years: Norwegian Neurological Society; Copenhagen Neuropsychological Society, Rigshospitalet; Cygnet Healthcare; and UCB Pharma. M.S.Z. declares travel and hotel support for a stay in Florence from the European Association of Neurology (EAN) for an EAN meeting on autoimmune encephalitis in April 2022. M.S.Z. represents neurology in the UK for the Association of British Neurologists for matters related to Covid in meetings with NHS England and Royal College of Physicians. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636294</ArticleId><ArticleId IdType="pmc">PMC9829703</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2022.101808</ArticleId><ArticleId IdType="pii">S2589-5370(22)00537-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636288</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1177-889X</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Patient preference and adherence</Title><ISOAbbreviation>Patient Prefer Adherence</ISOAbbreviation></Journal><ArticleTitle>Patient Preferences for Cardiac Rehabilitation - A Systematic Review.</ArticleTitle><Pagination><StartPage>75</StartPage><EndPage>88</EndPage><MedlinePgn>75-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/PPA.S392417</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Although a large number of studies have demonstrated the effectiveness of cardiac rehabilitation(CR), patient preferences for CR remain unclear. Knowing patient preferences may contribute to increasing patient participation and adherence, thus improving patient prognosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A systematic search was carried out using electronic databases and manual reference checks from inception until 15th June 2022. Quantitative studies, qualitative studies and mixed methods studies assessing patient preferences for CR were included. Two researchers independently conducted study selectionand data extraction. CR preferences were divided into three categories: CR settings, CR components, and CR contents. A narrative synthesis was applied to integrate the results of the included studies. The Mixed Methods Appraisal Tool (MMAT) was used to assess the quality of included studies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Ultimately, 17 publications were included in this study. Regarding CR settings, most patients preferred the hospital to home, some considered both, and a few were willing to accept the local CR club as an alternative setting to the hospital. For CR components, regardless of age and gender, patients considered exercise training and nutrition counseling to be the most important and smoking cessation to be the least important. In exercise intervention of CR contents, progress discussion and encouragement were rated as most critical, and non-conflicting with other activities was rated as least critical. In psychological intervention of CR contents, most patients were willing to accept psychological intervention, and a few patients wanted to heal the trauma with the passage of time.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This systematic review provides important insights into patient preferences for CR, clarifying patient preferences for CR settings, components, and contents, along with possible influencing factors. Patient preferences may change due to the COVID-19 epidemic, and there is still a need to focus on patient preferences for CR and conduct more relevant primary research to validate the findings of this paper in the future.</AbstractText><CopyrightInformation>&#xa9; 2023 Liu et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Yunyue</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0506-5738</Identifier><AffiliationInfo><Affiliation>School of Nursing, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Su</LastName><ForeName>Mengyu</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5760-5356</Identifier><AffiliationInfo><Affiliation>School of Nursing, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-6905-9698</Identifier><AffiliationInfo><Affiliation>School of Nursing, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Jinping</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5225-1851</Identifier><AffiliationInfo><Affiliation>School of Nursing, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, the First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Leng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Nursing, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-2816-6489</Identifier><AffiliationInfo><Affiliation>School of Nursing, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Patient Prefer Adherence</MedlineTA><NlmUniqueID>101475748</NlmUniqueID><ISSNLinking>1177-889X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cardiac rehabilitation</Keyword><Keyword MajorTopicYN="N">patient preference</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636288</ArticleId><ArticleId IdType="pmc">PMC9831083</ArticleId><ArticleId IdType="doi">10.2147/PPA.S392417</ArticleId><ArticleId IdType="pii">392417</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636276</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1662-680X</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Season>Sep-Dec</Season></PubDate></JournalIssue><Title>Case reports in neurology</Title><ISOAbbreviation>Case Rep Neurol</ISOAbbreviation></Journal><ArticleTitle>Rhabdomyolysis after COVID-19 Comirnaty Vaccination: A Case Report.</ArticleTitle><Pagination><StartPage>429</StartPage><EndPage>432</EndPage><MedlinePgn>429-432</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000527599</ELocationID><Abstract><AbstractText>Rhabdomyolysis is an acute disruption in skeletal muscle integrity, leading to the rapid release of 4 muscle contents into the bloodstream, such as creatine kinase (CK). It can have various causes, including infections. Throughout the pandemic, multiple cases of rhabdomyolysis following COVID-19 infections have been reported. However, rhabdomyolysis subsequent to COVID-19 vaccinations appears to be relatively rare. Here, we report such a case after a second COVID-19 Comirnaty (BioNTech/Pfizer) vaccination. Our patient developed rhabdomyolysis 1 day after the second Comirnaty vaccination with high creatine kinase (CK) levels, generalized weakness, and kidney failure. CK levels and muscle weakness resolved after treatment with intravenous fluids, but unfortunately, he remained hemodialysis dependent after discharge. To our knowledge, this is one of the first case reports describing a patient with rhabdomyolysis after a Comirnaty vaccination. However, as millions of people have received the Comirnaty vaccine, it is unclear whether the rhabdomyolysis in our patient is a rare side effect or an unrelated, coincidental event. Large observational studies are needed to elucidate the causality between the Comirnaty vaccination and rhabdomyolysis. Awareness is warranted in patients with myalgia and muscle weakness shortly after COVID-19 vaccination, in order to initiate treatment early and prevent life-threatening complications.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 by The Author(s). Published by S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruijters</LastName><ForeName>Veerle J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Disorders, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Meulen</LastName><ForeName>Marjon F G</ForeName><Initials>MFG</Initials><AffiliationInfo><Affiliation>Department of Neurology, St. Antonius Hospital, Nieuwegein, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Disorders, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smit</LastName><ForeName>Tessa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoogendijk</LastName><ForeName>Jessica E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Disorders, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Case Rep Neurol</MedlineTA><NlmUniqueID>101517693</NlmUniqueID><ISSNLinking>1662-680X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccine Pfizer-BioNTech</Keyword><Keyword MajorTopicYN="N">Rhabdomyolysis</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636276</ArticleId><ArticleId IdType="pmc">PMC9830288</ArticleId><ArticleId IdType="doi">10.1159/000527599</ArticleId><ArticleId IdType="pii">crn-0014-0429</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636258</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1016-1430</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Medical journal of the Islamic Republic of Iran</Title><ISOAbbreviation>Med J Islam Repub Iran</ISOAbbreviation></Journal><ArticleTitle>Psychosomatic Aspects of The Development of Comorbid Pathology: A Review.</ArticleTitle><Pagination><StartPage>152</StartPage><MedlinePgn>152</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.47176/mjiri.36.152</ELocationID><Abstract><AbstractText><b>Background:</b> The article reviews the literature data on various somatic and mental pathologies, which are comorbid processes with similar pathophysiological, genetic and neurochemical mechanisms. The psychosomatic manifestations of cardiovascular diseases and coronavirus disease (COVID-19) are considered. Particular attention is paid to post-traumatic stress disorder of participants in local wars. Comorbid pathology, in combination with depression and anxiety, aggravates the course of the disease, leading to disability in the adult population and premature death. <b>Methods:</b> The literature was searched in PubMed, Mendeley, Google Scholar, and ScienceDirect databases to identify relevant studies published from 2012 to 2022. <b>Results:</b>Our literature search revealed a bidirectional association between comorbid psychiatric and somatic disorders. The prevalence of somatic diseases increases in people with a predominance of mental disorders. <b>Conclusion:</b>There is growing evidence that the combination of anxiety-depressive disorders and physical illness worsens the severity of the disease, complicating the diagnosis of the presence of one and/or several physical symptoms. However, more clinical trials are still needed to determine their full mechanisms of action.</AbstractText><CopyrightInformation>&#xa9; 2022 Iran University of Medical Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tatayeva</LastName><ForeName>Roza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of General Biology and Genomics, L.N. Gumilyov Eurasian National University, Nur-Sultan, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossadchaya</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of General Biology and Genomics, L.N. Gumilyov Eurasian National University, Nur-Sultan, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarculova</LastName><ForeName>Saule</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Diseases with Course of Nephrology, Hematology, Allergy and Immunology, NJSC "Astana Medical University", Nur-Sultan, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sembayeva</LastName><ForeName>Zhibek</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Biology and Genomics, L.N. Gumilyov Eurasian National University, Nur-Sultan, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koigeldinova</LastName><ForeName>Sholpan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Karaganda Medical University, Karaganda, Kazakhstan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Iran</Country><MedlineTA>Med J Islam Repub Iran</MedlineTA><NlmUniqueID>8910777</NlmUniqueID><ISSNLinking>1016-1430</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anxiety</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Comorbid Pathology</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Post-traumatic Stress Disorder (PTSD)Cardiovascular Disease (CVD)</Keyword><Keyword MajorTopicYN="N">Stress</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636258</ArticleId><ArticleId IdType="pmc">PMC9826781</ArticleId><ArticleId IdType="doi">10.47176/mjiri.36.152</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636172</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1757-1774</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of infection prevention</Title><ISOAbbreviation>J Infect Prev</ISOAbbreviation></Journal><ArticleTitle>Reduction in cycle time for a rapid polymerase chain reaction diagnostic test at the point of care.</ArticleTitle><Pagination><StartPage>23</StartPage><EndPage>29</EndPage><MedlinePgn>23-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/17571774221148072</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Rapid testing facilitates safe and effective diagnosis, but the true speed of the process is the time from collection of a sample to delivery of an accurate and reliable test result - 'end-to-end' time. Transport, unpacking and relaying of information can extend this time considerably beyond the minimum laboratory turnaround times as stipulated by PCR testing protocols.</AbstractText><AbstractText Label="AIM/OBJECTIVE" NlmCategory="UNASSIGNED">This study aimed to minimise time needed to ascertain SARS-CoV-2 status prior to treatment in a UK Dental Hospital using a novel, mobile, direct to polymerase chain reaction (PCR) workflow.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Process flow analysis and PDSA (Plan, Do, Study, Act) cycles for rapid continuous improvement were employed in a service improvement programme. Primerdesign&#x2122; q16 rapid PCR instruments and PROmate&#xae; COVID-19 direct assays were used for molecular testing.</AbstractText><AbstractText Label="FINDINGS/RESULTS" NlmCategory="UNASSIGNED">We showed a reduction in real-world end-to-end time for a diagnostic test from 240&#xa0;min to 85&#xa0;min (65% reduction) over a 4-week period.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">New rapid technologies have become available that reduce analytical time to under 90&#xa0;min, but the real-world clinical implementation of the test requires a fully integrated workflow from clinic to reporting.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nanayakkara</LastName><ForeName>Lochana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Restorative Dentistry, Barts Health NHS Trust, UK.</Affiliation><Identifier Source="RINGGOLD">9744</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pettigrew</LastName><ForeName>Talia R</ForeName><Initials>TR</Initials><Identifier Source="ORCID">0000-0003-2841-9914</Identifier><AffiliationInfo><Affiliation>Chartwell Consulting, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Overton</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Chartwell Consulting, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Paul L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0002-7091-9974</Identifier><AffiliationInfo><Affiliation>Department of Restorative Dentistry, Barts Health NHS Trust, UK.</Affiliation><Identifier Source="RINGGOLD">9744</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawar</LastName><ForeName>Avaneet K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Midson</LastName><ForeName>Hebe M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coldwell</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-6243-3886</Identifier><AffiliationInfo><Affiliation>Dept. Research and Development, Novacyt Group, UK.</Affiliation><Identifier Source="RINGGOLD">486012</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Joanne E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Restorative Dentistry, Barts Health NHS Trust, UK.</Affiliation><Identifier Source="RINGGOLD">9744</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect Prev</MedlineTA><NlmUniqueID>101469725</NlmUniqueID><ISSNLinking>1757-1782</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">aerosol generating procedures</Keyword><Keyword MajorTopicYN="N">near patient testing</Keyword><Keyword MajorTopicYN="N">point of care</Keyword><Keyword MajorTopicYN="N">rapid polymerase chain reaction</Keyword></KeywordList><CoiStatement>The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Lochana Nanayakkara, Paul Ryan, Hebe Midson and Avaneet Pawar &#x2013; no conflicts of interest. Talia Pettigrew and Jenny Overton are project co-ordination experts employed by Chartwell and commissioned by Novacyt. Mark Coldwell is the Head of Scientific Communication at Novacyt. This research was supported by Novacyt Group, who provided consumables, staff, training and testing kits. Joanne Martin has no direct conflicts of interest. She is a principal investigator of a care home trial using Novacyt rapid testing and National Specialty Advisor for Pathology for NHS England and Improvement; a director and shareholder of Biomoti, a drug delivery company; and has a shareholding in Glyconics, a diagnostics company.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636172</ArticleId><ArticleId IdType="pmc">PMC9813656</ArticleId><ArticleId IdType="doi">10.1177/17571774221148072</ArticleId><ArticleId IdType="pii">10.1177_17571774221148072</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636154</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2327-8994</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>AIMS public health</Title><ISOAbbreviation>AIMS Public Health</ISOAbbreviation></Journal><ArticleTitle>Temporal dynamics for areal unit-based co-occurrence COVID-19 trajectories.</ArticleTitle><Pagination><StartPage>703</StartPage><EndPage>717</EndPage><MedlinePgn>703-717</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3934/publichealth.2022049</ELocationID><Abstract><AbstractText>The dynamic mechanism of the COVID-19 pandemic has been studied for disease prevention and health protection through areal unit-based log-linear Poisson processes to understand the outbreak of the virus with confirmed daily empirical cases. The predictor of the evolution is structured as a function of a short-term dependence and a long-term trend to identify the pattern of exponential growth in the main epicenters of the virus. The study provides insight into the possible pandemic path of each areal unit and a guide to drive policymaking on preventive measures that can be applied or relaxed to mitigate the spread of the virus. It is significant that knowing the trend of the virus is very helpful for institutions and organizations in terms of instituting resources and measures to help provide a safe working environment and support for all workers/staff/students.</AbstractText><CopyrightInformation>&#xa9; 2022 the Author(s), licensee AIMS Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Owusu</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Applied Statistics and Research Methods, University of Northern Colorado, Greeley, CO 80639, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Applied Statistics and Research Methods, University of Northern Colorado, Greeley, CO 80639, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Information, University of South Florida, Tampa, FL, 33620, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AIMS Public Health</MedlineTA><NlmUniqueID>101635098</NlmUniqueID><ISSNLinking>2327-8994</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">co-occurrence</Keyword><Keyword MajorTopicYN="N">hierarchical models</Keyword><Keyword MajorTopicYN="N">latent log-linear Poisson process</Keyword><Keyword MajorTopicYN="N">temporal dynamics</Keyword></KeywordList><CoiStatement>Conflict of interests: The authors declare that there are no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636154</ArticleId><ArticleId IdType="pmc">PMC9807409</ArticleId><ArticleId IdType="doi">10.3934/publichealth.2022049</ArticleId><ArticleId IdType="pii">publichealth-09-04-049</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636149</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2327-8994</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>AIMS public health</Title><ISOAbbreviation>AIMS Public Health</ISOAbbreviation></Journal><ArticleTitle>Promoting fruit and vegetable consumption during the COVID-19 pandemic - SportStudisMoveYou (SSMY): A randomized controlled trial.</ArticleTitle><Pagination><StartPage>690</StartPage><EndPage>702</EndPage><MedlinePgn>690-702</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3934/publichealth.2022048</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The stay-at-home circumstances due to the global coronavirus pandemic have had some negative impacts on people's eating behavior.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">Therefore, this study attempted to improve fruit and vegetable (FV) consumption intention and behavior through an online video intervention based on the social cognitive theory.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Participants were recruited with a promotion video posted on social media channels. After consenting and completing a pre-survey, participants were randomly assigned to either a) the intervention group addressing FV consumption or the b) attention control group addressing physical activity. After two weeks, the participants completed an online post-survey.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The participants (N = 82) were 77% female and 50% students; 95% chose German for the survey language, and 84% were from Switzerland. The mean baseline FV consumption intention was 3.05 (standard deviation: 1.03), and FV consumption was 4.64 (standard deviation: 2.06) portions a day. The analysis showed no significant change in FV consumption intention (F = (1, 78) = 0.02, p = 0.88, &#x3b7;p<sup>2</sup> = 0.00) or behavior (F = (1, 78) = 0.019, p = 0.89, &#x3b7;p<sup>2</sup> = 0.03) due to the intervention.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Plausible reasons why no significant effect was found were the brief intervention duration, the setting and insufficient tailoring. The lessons learned from this study are to plan better, tailor more to the needs of participants and carefully consider the goals before promoting an intervention.</AbstractText><CopyrightInformation>&#xa9; 2022 the Author(s), licensee AIMS Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Joram</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Health Science, Institute of Sport Science, University of Bern, Bremgartenstrasse 145, 3012 Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nigg</LastName><ForeName>Claudio R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Health Science, Institute of Sport Science, University of Bern, Bremgartenstrasse 145, 3012 Bern, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AIMS Public Health</MedlineTA><NlmUniqueID>101635098</NlmUniqueID><ISSNLinking>2327-8994</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">behavior</Keyword><Keyword MajorTopicYN="N">fruit</Keyword><Keyword MajorTopicYN="N">health</Keyword><Keyword MajorTopicYN="N">intervention</Keyword><Keyword MajorTopicYN="N">vegetable</Keyword></KeywordList><CoiStatement>Conflict of interest: All authors declare no conflict of interest regarding this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636149</ArticleId><ArticleId IdType="pmc">PMC9807408</ArticleId><ArticleId IdType="doi">10.3934/publichealth.2022048</ArticleId><ArticleId IdType="pii">publichealth-09-04-048</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636145</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2327-8994</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>AIMS public health</Title><ISOAbbreviation>AIMS Public Health</ISOAbbreviation></Journal><ArticleTitle>Mental health and psychosocial impact of the COVID-19 pandemic and social distancing measures among young adults in Bogot&#xe1;, Colombia.</ArticleTitle><Pagination><StartPage>630</StartPage><EndPage>643</EndPage><MedlinePgn>630-643</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3934/publichealth.2022044</ELocationID><Abstract><AbstractText Label="UNLABELLED">We sought to explore mental health and psychosocial impact among young people (18 to 24 years old) in Bogot&#xe1; during the first months of the COVID-19 pandemic.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We carried a cross sectional study using a web-based survey to assess mental health and personal impact among 18 to 24 years old living in Bogot&#xe1; during the first 4 months of the 2020 COVID-19 pandemic lockdown. The depressive symptoms were measured with PHQ-8 and anxiety symptoms with (GAD-7). We also designed a questionnaire exploring changes in personal, family and social life.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Overall, 23% of the sample (n = 834) reported mild depressive symptoms (males 24% and females 23%); 29% reported moderate depressive symptoms (males 28%, females 30%); 22% moderate-severe symptoms (males 20%, females 23%) and 17% severe symptoms (males 15%, females 17%). Mild anxiety symptoms were reported by 29% of the sample (males 30%, females 29%); moderate anxiety symptoms by 29% (males 26%, females 30%); moderate-severe 18% (males 15%, females 20%) and severe anxiety by 6.0% (males 6.0% and females 6.0%). High symptoms of depression (PHQ-8 &#x2265; 10) were associated with being female, considering that the quarantine was stressful, having one member of the family losing their job, worsening of family relationships, decrease of physical activity and having a less nutritious diet. Having high anxiety symptoms (GAD-7 &#x2265; 10) were associated with sometimes not having enough money to buy food.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The first months of the pandemic lockdown were associated with high depressive and anxiety symptoms among young persons living in Bogot&#xe1;, Colombia. Increasing public health measures to provide support for young people is needed during lockdowns and it is necessary to further explore the long-term mental health impact due to personal, family and social changes brought by the COVID-19 pandemic.</AbstractText><CopyrightInformation>&#xa9; 2022 the Author(s), licensee AIMS Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uribe-Restrepo</LastName><ForeName>Jos&#xe9; Miguel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Mental health, Pontificia Universidad Javeriana School of Medicine, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waich-Cohen</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Mental health, Pontificia Universidad Javeriana School of Medicine, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ospina-Pinillos</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Mental health, Pontificia Universidad Javeriana School of Medicine, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera</LastName><ForeName>Arturo Marroqu&#xed;n</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana School of Medicine, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro-D&#xed;az</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana School of Medicine, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pati&#xf1;o-Trejos</LastName><ForeName>Juan Agust&#xed;n</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Mental health, Pontificia Universidad Javeriana School of Medicine, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sep&#xfa;lveda</LastName><ForeName>Mart&#xed;n Alonso Rond&#xf3;n</ForeName><Initials>MAR</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana School of Medicine, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ariza-Salazar</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana School of Medicine, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardona-Porras</LastName><ForeName>Luisa Fernanda</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Mental health, Pontificia Universidad Javeriana School of Medicine, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Restrepo</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Mental health, Pontificia Universidad Javeriana School of Medicine, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana School of Medicine, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Universitario San Ignacio, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diez-Canseco</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AIMS Public Health</MedlineTA><NlmUniqueID>101635098</NlmUniqueID><ISSNLinking>2327-8994</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">anxiety</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">mental health</Keyword><Keyword MajorTopicYN="N">psychiatry</Keyword><Keyword MajorTopicYN="N">survey</Keyword><Keyword MajorTopicYN="N">young people</Keyword></KeywordList><CoiStatement>Conflict of interest: The authors do not declare any conflict of interest related to this research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636145</ArticleId><ArticleId IdType="pmc">PMC9807414</ArticleId><ArticleId IdType="doi">10.3934/publichealth.2022044</ArticleId><ArticleId IdType="pii">publichealth-09-04-044</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636119</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2473-1242</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Health equity</Title><ISOAbbreviation>Health Equity</ISOAbbreviation></Journal><ArticleTitle>COVID-19 Testing and Vaccine Willingness: Cross-Sectional Survey in a Culturally Diverse Community in Sydney, Australia.</ArticleTitle><Pagination><StartPage>965</StartPage><EndPage>974</EndPage><MedlinePgn>965-974</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/heq.2021.0171</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">The current study examined patterns in COVID-19 testing and vaccination intentions across multiple language groups in Greater Western Sydney, Australia.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Participants completed a cross-sectional survey available from March 21 to July 9, 2021 in Sydney, Australia. Surveys were available in English or translated (11 languages). Participants could complete surveys independently or with support from bilingual staff. Logistic regression models using poststratification weighted frequencies identified factors associated with testing and vaccination intentions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Most of the 708 participants (88%, <i>n</i>=622) were not born in Australia; 31% reported that they did not speak English well or at all (<i>n</i>=220); 70% had no tertiary qualifications (<i>n</i>=497); and 41% had inadequate health literacy (<i>n</i>=290). Half (53.0%) reported willingness to get a COVID-19 vaccine if recommended to them (<i>n</i>=375); 18% were unwilling (<i>n</i>=127), and the remainder unsure (29%, <i>n</i>=205). These proportions varied significantly by language group (<i>p</i>&lt;0.001). Participants were more likely to be unwilling/hesitant if they were female (<i>p</i>=0.02) or did not use Australian commercial information sources (<i>p</i>=0.01). Concerns about side effects (30.4%, <i>n</i>=102) and safety (23.9%, <i>n</i>=80), were key reported barriers to vaccination. Most participants reported high testing intention (77.2%, <i>n</i>=546), with differences observed across language groups (<i>p</i>&lt;0.001). The most frequently reported barrier to testing was concerns about infection at the clinic (26.1%) followed by concerns that testing was painful (25.3%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Different language groups have unique and specific needs to support uptake of COVID-19 testing and vaccination. Health services must work collaboratively with culturally and linguistically diverse communities to provide tailored support to encourage COVID-19 testing and vaccination.</AbstractText><CopyrightInformation>&#xa9; Julie Ayre et al., 2022; Published by Mary Ann Liebert, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ayre</LastName><ForeName>Julie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5279-5189</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Sydney Health Literacy Lab, School of Public Health, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muscat</LastName><ForeName>Danielle M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Sydney Health Literacy Lab, School of Public Health, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mac</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Sydney Health Literacy Lab, School of Public Health, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batcup</LastName><ForeName>Carys</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Sydney Health Literacy Lab, School of Public Health, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cvejic</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Sydney Health Literacy Lab, School of Public Health, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickles</LastName><ForeName>Kristen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Sydney Health Literacy Lab, School of Public Health, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolan</LastName><ForeName>Hankiz</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Sydney Health Literacy Lab, School of Public Health, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonner</LastName><ForeName>Carissa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Sydney Health Literacy Lab, School of Public Health, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouwad</LastName><ForeName>Dana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Western Sydney Local Health District, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zachariah</LastName><ForeName>Dipti</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Western Sydney Local Health District, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turalic</LastName><ForeName>Una</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Nepean Blue Mountains Local Health District, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santalucia</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>South Western Sydney Local Health District, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Western Sydney Local Health District, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasic</LastName><ForeName>Gordana</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Western Sydney Local Health District, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCaffery</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Sydney Health Literacy Lab, School of Public Health, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Health Equity</MedlineTA><NlmUniqueID>101708316</NlmUniqueID><ISSNLinking>2473-1242</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">community health promotion</Keyword><Keyword MajorTopicYN="N">culture</Keyword><Keyword MajorTopicYN="N">health knowledge promotion</Keyword><Keyword MajorTopicYN="N">health literacy</Keyword></KeywordList><CoiStatement>No competing financial interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636119</ArticleId><ArticleId IdType="pmc">PMC9811837</ArticleId><ArticleId IdType="doi">10.1089/heq.2021.0171</ArticleId><ArticleId IdType="pii">10.1089/heq.2021.0171</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636104</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-3287</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>JAAD international</Title><ISOAbbreviation>JAAD Int</ISOAbbreviation></Journal><ArticleTitle>A retrospective analysis of rates of dermatology follow-up and new skin cancer diagnosis among solid organ transplant recipients during the COVID-19 pandemic.</ArticleTitle><Pagination><StartPage>53</StartPage><EndPage>54</EndPage><MedlinePgn>53-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jdin.2022.10.009</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saranath</LastName><ForeName>Ritika</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Braulio</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novack</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, New York City, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parvathala</LastName><ForeName>Neha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Ema</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong-Michalak</LastName><ForeName>Shannon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodman</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Southern California Clinical and Translational Science Institute, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganesh</LastName><ForeName>Sivagini</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Critical Care, and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Hyosun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>In</LastName><ForeName>Gino K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liebler</LastName><ForeName>Janice</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Critical Care, and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maw</LastName><ForeName>Thin Thin</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Preventative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smogorzewski</LastName><ForeName>Miroslaw</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngo</LastName><ForeName>Binh</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahronowitz</LastName><ForeName>Iris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAAD Int</MedlineTA><NlmUniqueID>101774762</NlmUniqueID><ISSNLinking>2666-3287</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 pandemic</Keyword><Keyword MajorTopicYN="N">Mohs</Keyword><Keyword MajorTopicYN="N">basal cell carcinoma</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">immunosuppression</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword><Keyword MajorTopicYN="N">prevention</Keyword><Keyword MajorTopicYN="N">solid organ transplantation</Keyword><Keyword MajorTopicYN="N">squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">teledermatology/telemedicine</Keyword></KeywordList><CoiStatement>None disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636104</ArticleId><ArticleId IdType="pmc">PMC9829740</ArticleId><ArticleId IdType="doi">10.1016/j.jdin.2022.10.009</ArticleId><ArticleId IdType="pii">S2666-3287(22)00151-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636063</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2078-6891</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of gastrointestinal oncology</Title><ISOAbbreviation>J Gastrointest Oncol</ISOAbbreviation></Journal><ArticleTitle>Congenital cardiac liver cirrhosis with combined hepatocellular-cholangiocarcinoma-a case report.</ArticleTitle><Pagination><StartPage>3321</StartPage><EndPage>3328</EndPage><MedlinePgn>3321-3328</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/jgo-21-878</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Cardiac liver cirrhosis secondary to Fontan procedure has been associated with hepatocellular carcinoma at a younger age. However, Fontan associated liver disease and combined hepatocellular-cholangiocarcinoma has not been previously reported. Combined hepatocellular-cholangiocarcinoma is a rare cancer that accounts for 2-5% of primary liver tumors and poses significant diagnostic and treatment challenges. This case highlights these needs and potential screening and treatment considerations. Herein we describe a case of combined hepatocellular-cholangiocarcinoma in a patient with autism, congenital heart disease, and Fontan procedure.</AbstractText><AbstractText Label="CASE DESCRIPTION" NlmCategory="UNASSIGNED">The patient is a 27-year-old male who presented with a liver mass detected on MRI performed in the context of a rising alpha-fetoprotein during a screening visit. Biopsy of the mass revealed a combined hepatocellular-cholangiocarcinoma which was staged as localized. Due to the COVID-19 pandemic and subsequent halt of all elective surgeries, the patient received local therapy with chemoembolization followed by pembrolizumab. The disease progressed though, and therapy was changed to gemcitabine plus cisplatin. Patient received 2 cycles of therapy, after which he and his family decided to transfer medical care to Memorial Sloan Kettering. Next generation sequencing of the tumor revealed <i>TP53</i> and <i>FGFR2</i> mutations. By then patient was also found to have lung metastasis. To help address the hepatocellular carcinoma, lenvatinib was added. Patient had sustainable disease control for about a year, yet eventually developed thrombocytopenia complicated by an episode of gastrointestinal bleeding. With a worsening performance status, adverse events of the treatment, and recurrent hospitalizations, a goals of care discussion with his family led to the discontinuation of active cancer therapy and patient was started on best supportive care. Patient remained in active follow-up until the time of this report and passed away less than a year from initiating best supportive care alone.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This challenging case raises awareness towards screening and monitoring all patients with Fontan procedure for Fontan associated liver disease and liver cancers, including combined hepatocellular-cholangiocarcinoma. To the best of our knowledge, this is the first description of combined hepatocellular-cholangiocarcinoma occurring in the context of cardiac cirrhosis. The management difficulties that led to altering the goals of care, is another reminder of the dynamic nature of the care oncologists would provide.</AbstractText><CopyrightInformation>2022 Journal of Gastrointestinal Oncology. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>El Dika</LastName><ForeName>Imane</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell College of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shia</LastName><ForeName>Jinru</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell College of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Carol L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell College of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paroder</LastName><ForeName>Viktoriya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell College of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carver</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell College of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shamseddine</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>American University of Beirut, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukherji</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>American University of Beirut, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sirohi</LastName><ForeName>Bhawna</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>BALCO Medical Center, Raipur, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makondi</LastName><ForeName>Precious Takondwa</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Kamuzu Central Hospital - National Cancer Center, Lilongwe, Malawi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asseily</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matar</LastName><ForeName>Charbel F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>American University of Beirut, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elias</LastName><ForeName>Rawad</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hartford Healthcare Cancer Institute, Hartford, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slater</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenbaum</LastName><ForeName>Marlon Steven</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paramesawaran</LastName><ForeName>Rekha</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell College of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breitbart</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell College of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abou-Alfa</LastName><ForeName>Ghassan K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell College of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Gastrointest Oncol</MedlineTA><NlmUniqueID>101557751</NlmUniqueID><ISSNLinking>2078-6891</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Fontan</Keyword><Keyword MajorTopicYN="N">cardiac cirrhosis</Keyword><Keyword MajorTopicYN="N">case report</Keyword><Keyword MajorTopicYN="N">combined hepatocellular-cholangiocarcinoma</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available a https://jgo.amegroups.com/article/view/10.21037/jgo-21-878/coif). DM reports that she received honoraria from Astra Zeneca for lectures, presentations, and educational events. WB reports that he received royalties from Oxford University Press Royalty textbooks and Kluwer Publishing, consulting fees from Blue Note Therapeutics, and honoraria from Kubler Ross Foundation of Argentina for lecture, GKA reports that he received support from Adicet, Alnylam, AstraZeneca, Autem, Beigene, Berry Genomics, Boehringer Ingelheim, Celgene, Cend, CytomX, Eisai, Eli Lilly, Exelixis,Flatiron, Genentech/Roche, Genoscience, Helio, Helsinn, Incyte, Ipsen, Merck, Nerviano, Newbridge, Novartis, QED, Redhill, Rafael, Servier, Silenseed, Sobi, Vector, Yiviva for consultancy and from Arcus, Astra Zeneca, BioNtech, BMS, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Silenseed, Yiviva for institutional grants. The other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636063</ArticleId><ArticleId IdType="pmc">PMC9830364</ArticleId><ArticleId IdType="doi">10.21037/jgo-21-878</ArticleId><ArticleId IdType="pii">jgo-13-06-3321</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36636036</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1179-1594</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Risk management and healthcare policy</Title><ISOAbbreviation>Risk Manag Healthc Policy</ISOAbbreviation></Journal><ArticleTitle>Risk Characteristics of Catastrophic Health Expenditure in Multidimensional Borderline Poor Households in China.</ArticleTitle><Pagination><StartPage>15</StartPage><EndPage>29</EndPage><MedlinePgn>15-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/RMHP.S382812</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Ending poverty and realizing common prosperity are the essential requirements for the localization of Marxism in China. The ongoing COVID-19 pandemic in the post-poverty era further aggravates the risk of catastrophic health expenditure for borderline poor households and increases the uncertainty of returning to poverty due to illness, potentially undermining decades of hard-won efforts to eradicate poverty in China.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Based on the latest data released by China Health and Retirement Longitudinal Survey (CHARLS) database, this paper uses the Logit model to empirically explore the risk characteristics of catastrophic health expenditure of multidimensional borderline poor households based on identifying multidimensional borderline poor households.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The results show that factors such as family income level, child support, and medical insurance have different impacts on catastrophic health expenditure, and the risk of catastrophic health expenditure of multidimensional borderline poor households is much higher than that of non- multidimensional borderline poor households, and there is a certain difference between urban and rural areas.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">The government should strengthen and improve the social security system and health service system, such as medical insurance, and more resources should be allocated to multidimensional borderline poor households, especially in rural areas.</AbstractText><CopyrightInformation>&#xa9; 2023 Xu and Huang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiaocang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Economics and Management, Huzhou University, Huzhou, 313000, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xiuquan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Faculty of Humanities and Social Sciences, Macao Polytechnic University, Macao, 999078, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Risk Manag Healthc Policy</MedlineTA><NlmUniqueID>101566264</NlmUniqueID><ISSNLinking>1179-1594</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">catastrophic health expenditure</Keyword><Keyword MajorTopicYN="N">common prosperity</Keyword><Keyword MajorTopicYN="N">insurance system</Keyword><Keyword MajorTopicYN="N">multidimensional borderline poor households</Keyword><Keyword MajorTopicYN="N">urban-rural differences</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636036</ArticleId><ArticleId IdType="pmc">PMC9830416</ArticleId><ArticleId IdType="doi">10.2147/RMHP.S382812</ArticleId><ArticleId IdType="pii">382812</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636017</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-7027</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>Health communication</Title><ISOAbbreviation>Health Commun</ISOAbbreviation></Journal><ArticleTitle>Exploring First Responder Beliefs and Decisions to Vaccinate Against SARS-COV-2.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>10</EndPage><MedlinePgn>1-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/10410236.2022.2149065</ELocationID><Abstract><AbstractText>As frontline providers, first responders are not always thought of as patients with unique health beliefs. During early and continued distribution, many first responders in the United States chose to refuse vaccination. Guided by the health belief model and emerging research related to SARS-COV-2, the aim of this study was to further explore the complex message conditions that contributed to first responders' early vaccination decisions. An online survey was conducted between March 1 and March 31 2021, among first responders in the state of Kentucky, which has lagged behind most states in the percentage of the population who are fully vaccinated. The first responder sample included Firefighters, Emergency Medical Technicians (EMTs), and paramedics who completed a Qualtrics survey that included measures aimed at assessing health beliefs about SARS-COV-2, beliefs about SARS-COV-2 vaccines, source trustworthiness, and vaccine motivation. First responders were also asked to rank the importance of various information sources about SARS-COV-2 and its vaccines. Findings suggest significant differences exist among first responders who have chosen to receive SARS-COV-2 vaccines and those who have refused, including source preference, conspiracy beliefs, and perceived risk. Future directions, including the exploration of institutional mistrust as a health belief are discussed. These findings offer practical insights that may improve continuing approaches to discover and use preferred communication sources to reach the vaccine-hesitant.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Darnell</LastName><ForeName>Whittney H</ForeName><Initials>WH</Initials><Identifier Source="ORCID">0000-0003-3302-0457</Identifier><AffiliationInfo><Affiliation>Department of Communication, Northern Kentucky University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daugherty</LastName><ForeName>Crystal D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Communication, Northern Kentucky University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>Zachary P</ForeName><Initials>ZP</Initials><AffiliationInfo><Affiliation>Department of Communication, Northern Kentucky University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert South</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Communication, Northern Kentucky University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Health Commun</MedlineTA><NlmUniqueID>8908762</NlmUniqueID><ISSNLinking>1041-0236</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636017</ArticleId><ArticleId IdType="doi">10.1080/10410236.2022.2149065</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636003</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2224-5839</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of palliative medicine</Title><ISOAbbreviation>Ann Palliat Med</ISOAbbreviation></Journal><ArticleTitle>Lung ultrasound-guided treatment for acute respiratory distress syndrome in a critically ill patient with severe COVID-19: a case report.</ArticleTitle><Pagination><StartPage>3794</StartPage><EndPage>3803</EndPage><MedlinePgn>3794-3803</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/apm-22-1319</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute respiratory distress syndrome (ARDS) is a very common disease in the intensive care unit (ICU), with rapid progression and high mortality. Infections caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can easily progress to ARDS in severely ill patients. Early and rapid diagnosis as well as screening for ARDS during treatment is very important. Owing to the particularity of patients with coronavirus disease 2019 (COVID-19), computed tomography (CT) examination is not always possible, and chest radiographs have a low sensitivity and specificity for the diagnosis of lung diseases. Therefore, bedside lung ultrasound (LUS) can be used as a new tool for the diagnosis of ARDS in patients with COVID-19. In the non-gravity-dependent pulmonary field, there are bilateral non-uniform B lines. In the dorsal pulmonary field, the B lines are denser and even appears as "white lung". Areas of consolidation are usually found in the dorsal pulmonary field, especially at the basilar part, with static or dynamic air bronchogram sign. In the fused B-line area, the "lung slip" usually decreases or disappears. The pleural line is irregular, thickened, and rough, with multiple small consolidations. The pulmonary ultrasound findings of primary and secondary ARDS were similar.</AbstractText><AbstractText Label="CASE DESCRIPTION" NlmCategory="METHODS">In the abovementioned context, we share our experience with the treatment of one critical COVID-19 case and review the literature. An 81-year-old male patient with ARDS which is caused by COVID-19. The implementation of prone ventilation was guided by LUS, and we found that the pulmonary edema in the gravity-dependent area did improve over time. After 9 h of prone ventilation, the consolidation of the posterior area began to open. LUS shows the change from fragment sign to B line. After 16 h, the B-line was educed, indicating that pulmonary edema was improving. The oxygenation could be improved. Pulmonary ultrasound makes the monitoring of prone ventilation visualized. As the same time, the patient was accepted high-flow nasal oxygen, mechanical ventilation and treated with oseltamivir, lopinavir/ritonavir, abidol and cefoperazone-sulbactam.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">LUS-guided treatment was the key factor in the successful treatment of this case.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Haozhe</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Hongjie</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Ann Palliat Med</MedlineTA><NlmUniqueID>101585484</NlmUniqueID><ISSNLinking>2224-5820</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">acute respiratory distress syndrome (ARDS)</Keyword><Keyword MajorTopicYN="N">coronavirus disease 2019 (COVID-19)</Keyword><Keyword MajorTopicYN="N">lung ultrasound (LUS)</Keyword><Keyword MajorTopicYN="N">prone position ventilation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636003</ArticleId><ArticleId IdType="doi">10.21037/apm-22-1319</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36635993</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2224-5839</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of palliative medicine</Title><ISOAbbreviation>Ann Palliat Med</ISOAbbreviation></Journal><ArticleTitle>The current scope of the COVID-19 pandemic and its influence on palliative medicine.</ArticleTitle><Pagination><StartPage>3581</StartPage><EndPage>3583</EndPage><MedlinePgn>3581-3583</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/apm-22-1440</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simone</LastName><ForeName>Charles B</ForeName><Initials>CB</Initials><Suffix>2nd</Suffix><AffiliationInfo><Affiliation>New York Proton Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Ann Palliat Med</MedlineTA><NlmUniqueID>101585484</NlmUniqueID><ISSNLinking>2224-5820</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">hospitalizations</Keyword><Keyword MajorTopicYN="N">palliative</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36635993</ArticleId><ArticleId IdType="doi">10.21037/apm-22-1440</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36635974</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1945-8932</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>American journal of rhinology &amp; allergy</Title><ISOAbbreviation>Am J Rhinol Allergy</ISOAbbreviation></Journal><ArticleTitle>The Efficacy of Olfactory Training as a Treatment for Olfactory Disorders Caused by Coronavirus Disease-2019: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>19458924221150977</StartPage><MedlinePgn>19458924221150977</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/19458924221150977</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There have been reports investigating the use of olfactory training in olfactory dysfunction after COVID-19.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We evaluated the effect of olfactory training on the olfactory dysfunction of patients infected with COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched PubMed, EMBASE, the Web of Science, the Cochrane database, SCOPUS, and Google Scholar up to May 2022. We retrieved studies that compared the extents of olfactory dysfunction before and after olfactory training. We performed a subgroup analysis by the duration of olfactory dysfunction.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The olfactory score after olfactory training (standard mean difference [SMD] = 1.0830, 95% confidence interval [CI] [0.6416; 1.5245], <i>P</i> &lt; .0001, I<sup>2</sup> = 90.4%) was higher than that before training. The olfactory dysfunction rate differed significantly (OR = 0.0232, 95% CI [0.0052; 0.1044], <i>P</i> &lt; .0001, I<sup>2</sup> = 63.1%) before and after olfactory training. On subgroup analysis, although patients with both acute (onset &lt; 30 days prior) and chronic (onset &gt; 30 days prior) olfactory dysfunction evidenced clinically significant improvements, training during acute dysfunction (compared to acute dysfunction) increased the olfactory score to a greater extent (SMD = 1.7779, 95% CI [1.0077; 2.5481] vs 0.6928 [0.2143; 1.1712], <i>P</i> = 0.0190). Moreover, as a result of subgroup analysis by dividing the included studies into2 using 2-month training period as standard, there was no statistically significant difference in the effect of the training period in the included study.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Olfactory training improved olfactory disorders caused by COVID-19. Such training was effective in both the acute and chronic phases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Se Hwan</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, 46667Bucheon Saint Mary's Hospital, College of Medicine, 37128The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sung Won</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0002-8981-2536</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, 65570Seoul Saint Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basurrah</LastName><ForeName>Mohammed Abdullah</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Surgery, College of Medicine, 125895Taif University, Taif, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Do Hyun</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0002-9248-5572</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, 65570Seoul Saint Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Rhinol Allergy</MedlineTA><NlmUniqueID>101490775</NlmUniqueID><ISSNLinking>1945-8932</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N"> comparison</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">acute</Keyword><Keyword MajorTopicYN="N">analysis</Keyword><Keyword MajorTopicYN="N">chronic</Keyword><Keyword MajorTopicYN="N">database</Keyword><Keyword MajorTopicYN="N">improvement</Keyword><Keyword MajorTopicYN="N">olfactory dysfunction</Keyword><Keyword MajorTopicYN="N">olfactory score</Keyword><Keyword MajorTopicYN="N">olfactory training</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36635974</ArticleId><ArticleId IdType="doi">10.1177/19458924221150977</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36635934</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2042-8189</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>The journal of the Royal College of Physicians of Edinburgh</Title><ISOAbbreviation>J R Coll Physicians Edinb</ISOAbbreviation></Journal><ArticleTitle>Tackling the NHS mental health crisis of working through the COVID-19 pandemic; pilot creative writing programme has potential to support wellbeing of recovering healthcare workers.</ArticleTitle><Pagination><StartPage>14782715221149625</StartPage><MedlinePgn>14782715221149625</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/14782715221149625</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wakefield</LastName><ForeName>Donna</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Specialist Palliative Care Team, North Tees and Hartlepool NHS Foundation Trust, Stockton-On-Tees, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEvoy</LastName><ForeName>Mel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Specialist Palliative Care Team, North Tees and Hartlepool NHS Foundation Trust, Stockton-On-Tees, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blackburn-Daniels</LastName><ForeName>Sally</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Arts and Social Sciences, The Open University, Milton Keynes, Buckinghamshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Siobhan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Arts and Social Sciences, The Open University, Milton Keynes, Buckinghamshire, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J R Coll Physicians Edinb</MedlineTA><NlmUniqueID>101144324</NlmUniqueID><ISSNLinking>1478-2715</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36635934</ArticleId><ArticleId IdType="doi">10.1177/14782715221149625</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36635919</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1541-0331</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>Women &amp; health</Title><ISOAbbreviation>Women Health</ISOAbbreviation></Journal><ArticleTitle>An investigation of women's hygiene habits and the affecting factors during the Covid-19 pandemic.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>7</EndPage><MedlinePgn>1-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/03630242.2023.2165600</ELocationID><Abstract><AbstractText>This study aims to investigate women's hygiene habits and the affecting factors during the COVID-19 pandemic. It was conducted with women aged 21 to 64 between July and September 2021. The sample size was calculated as 384 individuals using the method for an unknown population, and the study included 405 women who agreed to participate. Data were collected through the Descriptive Characteristics Form and the COVID-19 Hygiene Scale. According to the women's descriptive characteristics Hygiene Scale mean scores were significantly higher in those who were married, who lived in urban areas, who had children aged 0 to 6, who had been diagnosed with Covid-19, who had other individuals infected with COVID-19 at home, and who reportedly had changes in their hygiene habits in the pandemic process. The importance given to hygiene by women was found to increase in the COVID-19 process.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aslan</LastName><ForeName>G&#xfc;lp&#x131;nar</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-1231-4272</Identifier><AffiliationInfo><Affiliation>Department of Midwifery, Agri Ibrahim Cecen University Faculty of Health Sciences, A&#x11f;r&#x131;, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savci Bakan</LastName><ForeName>Ayse Berivan</ForeName><Initials>AB</Initials><Identifier Source="ORCID">0000-0002-0052-9890</Identifier><AffiliationInfo><Affiliation>Department of Nursing, Agri Ibrahim Cecen University Faculty of Health Sciences, A&#x11f;r&#x131;, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Women Health</MedlineTA><NlmUniqueID>7608076</NlmUniqueID><ISSNLinking>0363-0242</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">hygiene</Keyword><Keyword MajorTopicYN="N">women</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36635919</ArticleId><ArticleId IdType="doi">10.1080/03630242.2023.2165600</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36635915</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1705-7051</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres</Title><ISOAbbreviation>Can J Nurs Res</ISOAbbreviation></Journal><ArticleTitle>New Graduate Nurses Navigating Entry to Practice in the Covid-19 Pandemic.</ArticleTitle><Pagination><StartPage>8445621221150946</StartPage><MedlinePgn>8445621221150946</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/08445621221150946</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Covid-19 pandemic has significantly impacted organizational life for nurses, with known physical and psychological impacts. New graduate nurses are a subset of nurses with unique needs and challenges as they transition into their registered nurse roles. However, this subset of nurses has yet to be explored in the context of the Covid-19 pandemic.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To explore the experiences of new graduate nurses entering the profession in Ontario, Canada, during the Covid-19 pandemic approximately one year after entering the profession.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thorne's interpretive description method was utilized.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">All participants identified as completing second entry nursing programs, offering a unique perspective on new graduate nurse transition. Four themes emerged in the data: '<i>Virtual Didn't Cut It,' 'Go Where You Know,' 'Picking Up the Pieces,' and 'Learning When to Say No and Let Go.'</i> Participants felt ill prepared to enter the profession and were cognizant of the various challenges facing the nursing profession, and how these pre-existing challenges were exacerbated by the pandemic. They acknowledged the need to protect themselves against burnout and poor mental health, and as such, made calculated early career decisions - demonstrating strong socio-political knowing. Half of the participants had already left their first nursing job; citing unmet orientation, mental health, and wellbeing needs. However, all participants were steadfast in remaining in the nursing profession.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Second entry new graduate nurses remain a unique subset of nurses that require more scholarly attention as their transition experiences may differ from the traditional trajectory of new graduate nurses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Kim</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-3752-3505</Identifier><AffiliationInfo><Affiliation>School of Nursing, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akoo</LastName><ForeName>Chaman</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0325-9272</Identifier><AffiliationInfo><Affiliation>School of Nursing, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catigbe-Cates</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Nursing, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Nurs Res</MedlineTA><NlmUniqueID>8910581</NlmUniqueID><ISSNLinking>0844-5621</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Covid-19</Keyword><Keyword MajorTopicYN="N">education</Keyword><Keyword MajorTopicYN="N">new graduate nurse</Keyword><Keyword MajorTopicYN="N">nursing</Keyword><Keyword MajorTopicYN="N">socio-political knowledge</Keyword><Keyword MajorTopicYN="N">transition</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36635915</ArticleId><ArticleId IdType="doi">10.1177/08445621221150946</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36635909</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-3659</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>Social studies of science</Title><ISOAbbreviation>Soc Stud Sci</ISOAbbreviation></Journal><ArticleTitle>Scientific conferences, socialization, and the Covid-19 pandemic: A conceptual and empirical enquiry.</ArticleTitle><Pagination><StartPage>3063127221138521</StartPage><MedlinePgn>3063127221138521</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/03063127221138521</ELocationID><Abstract><AbstractText>Since the 1970s social analysts have seen communication between scientists not solely as information exchange (the algorithmical model), but as a process of socialization into overlapping and mutually embedded scientific domains (the enculturational model). Under the algorithmical model, the impact of the Covid-19 shutdown on travel would be easily remedied by replacing face-to-face communication with online platforms. Conferences and similar gatherings are costly, elitist, and environmentally damaging, but under the enculturational model abandoning them could be disastrous for science, which depends on the development of cross-national trust and mutual agreements through face-to-face interaction and, in turn, disastrous for science's role in democracy. We explore the problem theoretically and empirically, arguing against recent proposals from some scientists for the wholesale and permanent replacement of conferences with remote communication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Harry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Social Sciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leonard-Clarke</LastName><ForeName>Willow</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Social Sciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason-Wilkes</LastName><ForeName>Will</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-8648-6205</Identifier><AffiliationInfo><Affiliation>Institute for STEMM in Culture and Society, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Soc Stud Sci</MedlineTA><NlmUniqueID>7506743</NlmUniqueID><ISSNLinking>0306-3127</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Covid-19 pandemic</Keyword><Keyword MajorTopicYN="N">algorithmical model</Keyword><Keyword MajorTopicYN="N">enculturational model</Keyword><Keyword MajorTopicYN="N">face-to-face communication in science</Keyword><Keyword MajorTopicYN="N">remote conferences</Keyword><Keyword MajorTopicYN="N">science and democracy</Keyword><Keyword MajorTopicYN="N">scientific conferences</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>0</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36635909</ArticleId><ArticleId IdType="doi">10.1177/03063127221138521</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36635906</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-6697</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>Current computer-aided drug design</Title><ISOAbbreviation>Curr Comput Aided Drug Des</ISOAbbreviation></Journal><ArticleTitle>Identification of Kaempferol as viral entry inhibitor and DL-Arginine as viral replication inhibitor from selected plants of Indian traditional medicine against COVID-19: An in silico guided in vitro approach.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2174/1573409919666230112123213</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Indian traditional medicinal plants are known for their great potential in tackling viral diseases. Previously, we reported a systematic review approach of seven plausible traditional Indian medicinal plants against SARS CoV 2.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Molecular docking was conducted with Biovia Discovery Studio. Three binding domains for Spike glycoprotein (PDB IDs: 6LZG, 6M17, 6M0J) and one binding domain of RdRp (PDB ID: 7BTF) were used. Among 100 phytoconstituents listed from seven plants by IMPPAT Database used for virtual screening, the best six compounds were again filtered using Swiss ADME prediction and Lipinski's rule. Additionally, a Pseudovirion assay was performed to study the interaction of SARS CoV 2 S1-protein with the ACE 2 receptor for further confirming the effect.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Chebulagic acid (52.06 Kcal/mol) and Kaempferol (48.84 Kcal/mol) showed an increased interaction energy compared to Umifenovir (33.68 Kcal/mol) for the 6LZG binding domain of Spike glycoprotein. Epicatechin gallate (36.95 Kcal/mol) and Arachidic acid (26.09 Kcal/mol) showed equally comparable interaction energy compared to Umifenovir (38.20 Kcal/mol) for 6M17 binding domain of Spike glycoprotein. Trihydroxychalcone (35.23 Kcal/mol) and Kaempferol (36.96 Kcal/mol) showed equally comparable interaction energy with Umifenovir (36.60 Kcal/mol) for 6M0J binding domain of Spike glycoprotein. On analyzing the phytoconstituents against RdRp binding domain, DL-Arginine (41.78 Kcal/mol) showed comparable results with the positive control Remdesivir (47.61 Kcal/mol). ADME analysis performed using Swiss ADME revealed that Kaempferol and DL Arginine show drug-like properties with appropriate pharmacokinetic parameters. Further in vitro analysis of Kaempferol by Pseudo virion assay confirmed an acceptable decrease of the lentiviral particles on transfected HEK293T-hACE2 cells.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The study highlights that Kaempferol and DL-Arginine could be the significant molecules to exhibit potent action against SARS CoV 2 and its variants.</AbstractText><CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>J</LastName><ForeName>Adithya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Amrita School of Pharmacy Department of Pharmacognosy Kochi India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murali</LastName><ForeName>Maneesha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Amrita School of Pharmacy Department of Pharmacognosy Kochi India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>Bhagyalakshmi</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Amrita School of Pharmacy Department of Pharmacognosy Kochi India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benny</LastName><ForeName>Feby</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Amrita School of Pharmacy Department of Pharmacognosy Kochi India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P M</LastName><ForeName>Rajalakshmi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Amrita School of Pharmacy Department of Pharmacognosy Kochi India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suresh</LastName><ForeName>Darshana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Amrita School of Pharmacy Department of Pharmacognosy Kochi India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P</LastName><ForeName>Aneesh T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Amrita School of Pharmacy Department of Pharmaceutical Chemistry and Analysis Kochi India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nisthul</LastName><ForeName>Amrutha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Kannur University, Dr. Janaki Ammal Campus Department of Biotechnology and Microbiology kochi India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nath</LastName><ForeName>Lekshmi R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Amrita School of Pharmacy Department of Pharmacognosy Kochi India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Comput Aided Drug Des</MedlineTA><NlmUniqueID>101265750</NlmUniqueID><ISSNLinking>1573-4099</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ayurveda</Keyword><Keyword MajorTopicYN="N">DL- Arginine</Keyword><Keyword MajorTopicYN="N">In silico studies</Keyword><Keyword MajorTopicYN="N">Kaempferol</Keyword><Keyword MajorTopicYN="N">Molecular docking</Keyword><Keyword MajorTopicYN="N">SARS CoV 2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>0</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36635906</ArticleId><ArticleId IdType="doi">10.2174/1573409919666230112123213</ArticleId><ArticleId IdType="pii">CAD-EPUB-128795</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36635863</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1937-710X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>American journal of critical care : an official publication, American Association of Critical-Care Nurses</Title><ISOAbbreviation>Am J Crit Care</ISOAbbreviation></Journal><ArticleTitle>Brief Narrative Writing Program Implemented in a Neurosurgical Intensive Care Unit During the COVID-19 Pandemic.</ArticleTitle><Pagination><StartPage>e1</StartPage><EndPage>e5</EndPage><MedlinePgn>e1-e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4037/ajcc2023700</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The COVID-19 pandemic has substantially affected health care professionals. Health care professionals have noted increased distress, psychiatric symptoms, and feelings of burnout during this time. Implementation of brief, easy-to-access psychosocial interventions might help health care professionals process stressful events, thus bolstering mental health. One such approach is the narrative expressive writing program, a 5-session cognitive behavioral writing intervention.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The narrative expressive writing program was instituted in a neurosurgical intensive care unit during the COVID-19 pandemic. The program was delivered online and guided by a licensed mental health professional.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Health care professionals completed measures of anxiety, depression, burnout, resilience, and perceived stress before and after completing the narrative expressive writing program. Fifty-eight health care professionals initiated the program; 31 (53% of initiators) completed it.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Health care professionals who completed the narrative expressive writing program experienced significant reductions in depressive symptoms and perceived stress (P &lt; .05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Preliminary data show that narrative expressive writing is an easy-to-access intervention that has the potential to decrease stress and depressive symptoms. Additional research on tailoring or augmenting the narrative expressive writing program may facilitate health care professionals' engagement and address other mental health domains (eg, burnout).</AbstractText><CopyrightInformation>&#xa9;2023 American Association of Critical-Care Nurses.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holliday</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ryan Holliday is a clinical research psychologist at the Rocky Mountain Mental Illness Research, Education, and Clinical Center for Suicide Prevention, Aurora, Colorado, and an assistant professor at University of Colorado Anschutz Medical Campus, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricke</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>David J. Ricke is a nurse manager at University of Colorado Hospital, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricklefs</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Claudia Ricklefs is program administrative support at University of Colorado Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mealer</LastName><ForeName>Meredith</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Meredith Mealer is a psychiatric mental health nurse practitioner at the Rocky Mountain Mental Illness Research, Education, and Clinical Center for Suicide Prevention and an associate professor at University of Colorado Anschutz Medical Campus.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Crit Care</MedlineTA><NlmUniqueID>9211547</NlmUniqueID><ISSNLinking>1062-3264</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>0</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36635863</ArticleId><ArticleId IdType="doi">10.4037/ajcc2023700</ArticleId><ArticleId IdType="pii">31954</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36635846</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0250-3301</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>08</Day></PubDate></JournalIssue><Title>Huan jing ke xue= Huanjing kexue</Title><ISOAbbreviation>Huan Jing Ke Xue</ISOAbbreviation></Journal><ArticleTitle>[Migration, Transformation, and Toxicity of Quaternary Ammonium Antimicrobial Agents in the Environment].</ArticleTitle><Pagination><StartPage>583</StartPage><EndPage>592</EndPage><MedlinePgn>583-592</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.13227/j.hjkx.202202165</ELocationID><Abstract><AbstractText>Quaternary ammonium compounds (QACs) are one type of widely used cationic biocide, and their usage amount is growing rapidly due to the flu and COVID-19 pandemic. Many QACs were released into the environment in or after the course of their use, and thus they were widely detected in water, sediment, soil, and other environmental media. QACs have stronger surface activity and non-specific biotoxicity, which poses a potential threat to the ecosystem. In this study, the environmental fate and potential toxicity of QACs were documented in terms of their migration and transformation process, biological toxicity effects, and the main mechanisms of bacterial resistance to QACs. Aerobic biodegradation was the main natural way of eliminating QACs in the environment, and the reaction was mainly initiated by the hydroxylation of C atoms at different positions of QACs and finally mineralized to CO<sub>2</sub>and H<sub>2</sub>O through decarboxylation, demethylation, and &#x3b2;-oxidation reaction. Toxicological studies showed that QACs at environmental concentrations could not pose acute toxicity to the selected biotas but threatened the growth and reproduction of aquatic organisms like <i>Daphnia magna</i>. Their toxicity effects depended on their molecular structure, the tested species, and the exposed durations. Additionally, our team first investigated the toxicity effects and mechanisms of QACs toward <i>Microcystis aeruginosa</i>, which showed that QACs depressed the algae growth through the denaturation of photosynthetic organelles, suppression of electron transport, and then induction of cell membrane damage. In the environment, the concentrations of QACs were always lower than their bactericidal concentrations, and their degradation could induce the formation of a concentration gradient, which facilitated microbes resistant to QACs. The known resistance mechanisms of bacteria to QACs mainly included the change in cell membrane structure and composition, formation of biofilm, overexpression of the efflux pump gene, and acquisition of resistance genes. Due to the similar targets and mechanisms, QACs could also induce the occurrence of antibiotic resistance, mainly through co-resistance and cross-resistance. Based on the existing data, future research should emphasize the toxicity effect and the potential QACs resistance mechanism of microorganisms in real environmental conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li-Lan</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Key Laboratory of Three Gorges Reservoir Region's Eco-environment, Ministry of Education, Chongqing University, Chongqing 400044, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Coal Mine Disaster Dynamics and Control, Chongqing University, Chongqing 400044, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Cun-Li</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Key Laboratory of Three Gorges Reservoir Region's Eco-environment, Ministry of Education, Chongqing University, Chongqing 400044, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Three Gorges Reservoir Region's Eco-environment, Ministry of Education, Chongqing University, Chongqing 400044, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Mei-Ling</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Key Laboratory of Three Gorges Reservoir Region's Eco-environment, Ministry of Education, Chongqing University, Chongqing 400044, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Huan Jing Ke Xue</MedlineTA><NlmUniqueID>8405344</NlmUniqueID><ISSNLinking>0250-3301</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">co-resistance</Keyword><Keyword MajorTopicYN="N">mechanism of resistance</Keyword><Keyword MajorTopicYN="N">migration and transformation</Keyword><Keyword MajorTopicYN="N">quaternary ammonium compounds (QACs)</Keyword><Keyword MajorTopicYN="N">toxic effects</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>12</Day><Hour>23</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36635846</ArticleId><ArticleId IdType="doi">10.13227/j.hjkx.202202165</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36635794</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0250-3301</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>08</Day></PubDate></JournalIssue><Title>Huan jing ke xue= Huanjing kexue</Title><ISOAbbreviation>Huan Jing Ke Xue</ISOAbbreviation></Journal><ArticleTitle>[Numerical Response Analysis of PM<sub>2.5</sub>-O<sub>3</sub> Compound Pollution in Beijing].</ArticleTitle><Pagination><StartPage>48</StartPage><EndPage>57</EndPage><MedlinePgn>48-57</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.13227/j.hjkx.202203185</ELocationID><Abstract><AbstractText>The multi-scale variation trend of PM<sub>2.5</sub>-O<sub>3</sub> compound pollution events was analyzed based on air quality data, meteorological data, and COVID-19 data in Beijing from 2015 to 2020. For the threshold of compound pollution, a compound pollution index was proposed, and the numerical response trend was evaluated based on the generalized additive model. A distributed lag nonlinear model was introduced to analyze the risk response relationship between compound pollution and influencing factors. The results showed that the events of PM<sub>2.5</sub>-O<sub>3</sub> compound pollution in Beijing decreased annually. At the same time, due to the influence of pollutant emissions and meteorological conditions, there were obvious seasonal effects, week effects, holiday effects, and epidemic effects. The composite pollution index had no correlation with rainfall but had a linear positive correlation with O<sub>3</sub> and air temperature and a nonlinear correlation with other explanatory variables. Air pollutants and meteorological conditions had obvious lag effects on the composite pollution index, and the lag effects were mainly concentrated in 1-3 d. PM<sub>2.5</sub>, PM<sub>10</sub>, O<sub>3</sub>, SO<sub>2</sub>, and air temperature in high-value areas significantly increased the risk of compound pollution. The CO (1-6 mg&#xb7;m<sup>-3</sup>), NO<sub>2</sub> (38-118 &#x3bc;g&#xb7;m<sup>-3</sup>), and relative humidity (54%-87%) in the median section would also increase the risk of compound pollution, as would low wind speed. The compound pollution events showed a trend of multi-day continuous pollution in the numerical response. Compared with PM<sub>2.5</sub> and PM<sub>10</sub>, compound pollution events were more dependent on O<sub>3</sub>, and the compound pollution rate in high-value areas was 30.7%-47.5%. CO and relative humidity had little effect on compound pollution events. The air temperature had the greatest impact, and 84.7% of the composite pollution incidents occurred at 20-30&#x2103;.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Tian-Qiang</ForeName><Initials>TQ</Initials><AffiliationInfo><Affiliation>Key Laboratory of Earth Exploration and Information Technology, Ministry of Education, College of Geophysics, Chengdu University of Technology, Chengdu 610059, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Huan Jing Ke Xue</MedlineTA><NlmUniqueID>8405344</NlmUniqueID><ISSNLinking>0250-3301</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PM2.5</Keyword><Keyword MajorTopicYN="N">compound pollution</Keyword><Keyword MajorTopicYN="N">delayed response</Keyword><Keyword MajorTopicYN="N">numerical response</Keyword><Keyword MajorTopicYN="N">ozone(O3)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>12</Day><Hour>23</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36635794</ArticleId><ArticleId IdType="doi">10.13227/j.hjkx.202203185</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36635766</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2052-3211</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of pharmaceutical policy and practice</Title><ISOAbbreviation>J Pharm Policy Pract</ISOAbbreviation></Journal><ArticleTitle>Polypharmacy and potentially inappropriate medications among hospitalized older adults with COVID-19 in Malaysian tertiary hospitals.</ArticleTitle><Pagination><StartPage>2</StartPage><MedlinePgn>2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40545-022-00504-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Older adults are among the most vulnerable groups during the COVID-19 epidemic, contributing to a large proportion of COVID-19-related death. Medication review and reconciliation by pharmacist can help reduce the number of potentially inappropriate medications but these services were halted during COVID-19.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To assess the prevalence and factors associated with inappropriate medicine use among older populations with COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a cross-sectional, retrospective analysis of medications among hospitalized older adults with COVID-19. Potentially inappropriate medication use was categorized using the Beer's and STOPP criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Combining both criteria, 181 (32.7%) of the 553 patients were identified to have used at least one or more potentially inappropriate medication. A marginally higher number of inappropriate medications was documented using the Beers 2019 criteria (151 PIM in 124 patients) compared to STOPP criteria (133 PIMS in 104 patients). The long-term use of proton pump inhibitors (n&#x2009;=&#x2009;68; 12.3%) and drugs which increases the risk of postural hypotension were the most commonly reported PIM (n&#x2009;=&#x2009;41; 7.4%). Potentially inappropriate medication use was associated with previous history of hospital admission in the past 12&#xa0;months (Odds ratio [OR]: 2.27; 95% CI 1.29-3.99) and higher number of discharge medications.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Nearly, one in three older adults with COVID-19 had been prescribed a PIM, and the proportion of older adults with polypharmacy increased after discharge. This highlights the importance of having clinical pharmacist conducting medication reviews to identify PIMs and ensure medication appropriateness.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chee-Tao</ForeName><Initials>CT</Initials><Identifier Source="ORCID">0000-0002-9263-446X</Identifier><AffiliationInfo><Affiliation>Clinical Research Centre (CRC) HRPB Ipoh, Hospital Raja Permaisuri Bainun, Ministry of Health Malaysia, Ipoh, Malaysia. davidcct.crc@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmacy, Monash University Malaysia, Subang Jaya, Malaysia. davidcct.crc@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohd Shariff</LastName><ForeName>Siti Mallissa</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Sungai Buloh, Ministry of Health Malaysia, Sungai Buloh, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abu Bakar</LastName><ForeName>Nur Suriana</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Sungai Buloh, Ministry of Health Malaysia, Sungai Buloh, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramzuzzaman</LastName><ForeName>Nasiha Sufina</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Sungai Buloh, Ministry of Health Malaysia, Sungai Buloh, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Chun Kiat</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Sungai Buloh, Ministry of Health Malaysia, Sungai Buloh, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Eddy Yew Joe</ForeName><Initials>EYJ</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Sungai Buloh, Ministry of Health Malaysia, Sungai Buloh, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Peng Seng</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Pulau Pinang, Ministry of Health Malaysia, George Town, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jie Min</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Pulau Pinang, Ministry of Health Malaysia, George Town, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Aie Yen</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Sultan Ismail, Ministry of Health Malaysia, Johor Bahru, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamis</LastName><ForeName>Siti Fatimah</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Sultan Ismail, Ministry of Health Malaysia, Johor Bahru, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liew</LastName><ForeName>Wei Mun</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Raja Permaisuri Bainun, Ministry of Health Malaysia, Ipoh, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Low</LastName><ForeName>Yuet Man</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Raja Permaisuri Bainun, Ministry of Health Malaysia, Ipoh, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>George</LastName><ForeName>Doris</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Raja Permaisuri Bainun, Ministry of Health Malaysia, Ipoh, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voo</LastName><ForeName>James Yau Hon</ForeName><Initials>JYH</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Duchess of Kent, Ministry of Health Malaysia, Sandakan, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Hoo Seng</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Duchess of Kent, Ministry of Health Malaysia, Sandakan, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajan</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Research Centre (CRC) HRPB Ipoh, Hospital Raja Permaisuri Bainun, Ministry of Health Malaysia, Ipoh, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Shaun Wen Huey</ForeName><Initials>SWH</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Monash University Malaysia, Subang Jaya, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Pharm Policy Pract</MedlineTA><NlmUniqueID>101627192</NlmUniqueID><ISSNLinking>2052-3211</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hospital</Keyword><Keyword MajorTopicYN="N">Malaysia</Keyword><Keyword MajorTopicYN="N">Older adults</Keyword><Keyword MajorTopicYN="N">Polypharmacy</Keyword><Keyword MajorTopicYN="N">Potentially inappropriate medications</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>12</Day><Hour>23</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36635766</ArticleId><ArticleId IdType="doi">10.1186/s40545-022-00504-1</ArticleId><ArticleId IdType="pii">10.1186/s40545-022-00504-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rochon PA, et al. Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens. Lancet Healthy Longev. 2021;2(5):e290-300. https://doi.org/10.1016/S2666-7568(21)00054-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(21)00054-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C-T, Ang J-Y, Islam MA, Chan H-K, Cheah W-K, Gan SH. Prevalence of drug-related problems and complementary and alternative medicine use in Malaysia: a systematic review and meta-analysis of 37,249 older adults. Pharmaceuticals. 2021;14(3):187. https://doi.org/10.3390/ph14030187 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14030187</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahine B. Potentially inappropriate medications prescribing to elderly patients with advanced chronic kidney by using 2019 American Geriatrics Society Beers Criteria. Health Sci Rep. 2020;3(4): e214. https://doi.org/10.1002/hsr2.214 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hsr2.214</ArticleId></ArticleIdList></Reference><Reference><Citation>Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716&#x2013;24. https://doi.org/10.1001/archinte.163.22.2716 . (Erratum in: Arch Intern Med. 2004 Feb 9;164(3):298).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.163.22.2716</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher PF, O&#x2019;Connor MN, O&#x2019;Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011;89(6):845&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2011.44</ArticleId></ArticleIdList></Reference><Reference><Citation>Holt S, Schmiedl S, Th&#xfc;rmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010;107(31&#x2013;32):543&#x2013;51. https://doi.org/10.3238/arztebl.2010.0543 . (Epub 2010 Aug 9).</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2010.0543</ArticleId></ArticleIdList></Reference><Reference><Citation>Kua KP, Hamzah NN, Lee SWH. Potentially inappropriate medication prescribed among older patients in a primary care setting in Malaysia. Pharmacoepidemiol Drug Saf. 2020;29(3):363&#x2013;4. https://doi.org/10.1002/pds.4945 . (Epub 2019 Dec 9).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4945</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahrni ML, Azmy MT, Usir E, Aziz NA, Hassan Y. Inappropriate prescribing defined by STOPP and START criteria and its association with adverse drug events among hospitalized older patients: a multicentre, prospective study. PLoS ONE. 2019;14(7): e0219898. https://doi.org/10.1371/journal.pone.0219898 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0219898</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew NY, Chong YY, Yeow SH, Kua KP, Saw PS, Lee SWH. Prevalence of potentially inappropriate medications among geriatric residents in nursing care homes in Malaysia: a cross-sectional study. Int J Clin Pharm. 2019;41(4):895&#x2013;902. https://doi.org/10.1007/s11096-019-00843-1 . (Epub 2019 May 9).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-019-00843-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S, Beh L, Nordin RB. Health care delivery in Malaysia: changes, challenges and champions. J Public Health Afr. 2011;2(2): e23. https://doi.org/10.4081/jphia.2011.e23 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/jphia.2011.e23</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim BLH, et al. Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: a nationwide observational study. Lancet Regional Health Western Pac. 2020;4:100055. https://doi.org/10.1016/j.lanwpc.2020.100055 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2020.100055</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi H, Darvishi N, Salari N, et al. Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies. Trop Med Health. 2022;50:60. https://doi.org/10.1186/s41182-022-00456-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41182-022-00456-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha Y, et al. The association of medication complexity with COVID-19 severity and its impact on pharmacotherapy evaluation. J Young Pharm. 2022;14(3):322&#x2013;6. https://doi.org/10.5530/jyp.2022.14.63 .</Citation><ArticleIdList><ArticleId IdType="doi">10.5530/jyp.2022.14.63</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj A, Shoma M. COVID-19 impact on the prevalence of PIMS in elderly patients according to STOPP/START criteria: a record base study. Int J Basic Clin Pharmacol. 2022;11(5):38&#x2013;45. https://doi.org/10.18203/2319-2003.ijbcp20222140 .</Citation><ArticleIdList><ArticleId IdType="doi">10.18203/2319-2003.ijbcp20222140</ArticleId></ArticleIdList></Reference><Reference><Citation>Mafi JN, et al. Low-value proton pump inhibitor prescriptions among older adults at a large academic health system. J Am Geriatr Soc. 2019;67(12):2600&#x2013;4. https://doi.org/10.1111/jgs.16117 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.16117</ArticleId></ArticleIdList></Reference><Reference><Citation>Boghossian TA, Rashid F, Thompson W, Welch V, Moayyedi P, Rojas-Fernandez C, Pottie K, Farrell B. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017. https://doi.org/10.1002/14651858.CD011969.pub2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD011969.pub2</ArticleId></ArticleIdList></Reference><Reference><Citation>Chock YL, Wee YL, Gan SL, Teoh KW, Ng KY, Lee SWH. How willing are patients or their caregivers to deprescribe: a systematic review and meta-analysis. J Gen Intern Med. 2021;36(12):3830&#x2013;40. https://doi.org/10.1007/s11606-021-06965-5 . (Epub 2021 Jun 25).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-021-06965-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa S, Rom&#xe3;o M, Mendes M, Horta MR, Rodrigues AT, Carneiro AV, Martins AP, Mallarini E, Naci H, Babar ZU. Pharmacy interventions on COVID-19 in Europe: mapping current practices and a scoping review. Res Social Adm Pharm. 2022;18(8):3338&#x2013;49. https://doi.org/10.1016/j.sapharm.2021.12.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sapharm.2021.12.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukhari N, Rasheed H, Nayyer B, Babar ZU. Pharmacists at the frontline beating the COVID-19 pandemic. J Pharm Policy Pract. 2020;20(13):8. https://doi.org/10.1186/s40545-020-00210-w .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40545-020-00210-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Thong KS, Selvaratanam M, Tan CP, et al. Pharmacy preparedness in handling COVID-19 pandemic: a sharing experience from a Malaysian tertiary hospital. J of Pharm Policy Pract. 2021;14:61. https://doi.org/10.1186/s40545-021-00343-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40545-021-00343-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong WY, Chang CT, Chew CC, Khoo TE. Interactive virtual medication counselling in outpatient pharmacy: an accessible and safe patient counselling method during the COVID-19 pandemic. Res Social Adm Pharm. 2021;17(10):1860&#x2013;2. https://doi.org/10.1016/j.sapharm.2021.07.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sapharm.2021.07.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo YL, Chang CT, Chew CC, Rama S. Contactless medicine lockers in outpatient pharmacy: A safe dispensing system during the COVID-19 pandemic. Res Social Adm Pharm. 2021;17(5):1021&#x2013;3. https://doi.org/10.1016/j.sapharm.2020.11.011 . (Epub 2020 Nov 17).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sapharm.2020.11.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CT, Ong SY, Lim XJ, et al. Managing nirmatrelvir/ritonavir during COVID-19: pharmacists&#x2019; experiences from the Perak state of Malaysia. J of Pharm Policy and Pract. 2022;15:70. https://doi.org/10.1186/s40545-022-00469-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40545-022-00469-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kua KP, Lee SWH. The coping strategies of community pharmacists and pharmaceutical services provided during COVID-19 in Malaysia. Int J Clin Pract. 2021;75(12): e14992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14992</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36635758</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1752-1947</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of medical case reports</Title><ISOAbbreviation>J Med Case Rep</ISOAbbreviation></Journal><ArticleTitle>Diagnostic and treatment dilemma during the coronavirus disease 2019 pandemic: a primary pulmonary lymphoma presenting as a cavitary mass in a patient with coronavirus disease 2019: a case report.</ArticleTitle><Pagination><StartPage>12</StartPage><MedlinePgn>12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13256-022-03745-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A radiological finding of a cavitary pulmonary lesion in a patient acutely infected with severe acute respiratory syndrome coronavirus-2 early during the coronavirus disease 2019 pandemic created a diagnostic and treatment dilemma, as invasive procedures with bronchoscopy and percutaneous needle lung biopsy posed an infection hazard to healthcare workers due to the associated risk of viral aerosolization. Available guidelines recommended delay of non-emergent procedures, but timely proceeding with those deemed urgent provided appropriate personal protective equipment and negative pressure isolation were available and exposure risk was not excessive. Thoughtful consideration by clinicians was required to avoid delay in diagnosis of a potential new malignancy and prevent unnecessary healthcare worker exposure to the virus. Additionally, acute severe acute respiratory syndrome coronavirus-2 infection in patients with malignancy complicated timing of oncologic treatment.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 26-year-old otherwise healthy Caucasian male initially presented with an enlarging right upper lobe cavitary pulmonary lesion despite antimicrobial therapy. During his hospitalization and evaluation, the patient was found to be acutely infected with severe acute respiratory syndrome coronavirus-2 without hypoxia or viral pneumonia. Bronchoscopy was deemed too high risk for viral aerosolization and healthcare worker infection. He underwent computed-tomography-guided percutaneous needle biopsy of the lesion by interventional radiology while on mechanical ventilation after elective intubation by anesthesiology. Biopsy revealed classic Hodgkin lymphoma consistent with primary pulmonary Hodgkin lymphoma. After collaboration with oncology, his treatment with combined chemotherapy and immunotherapy was delayed for 3&#xa0;weeks following diagnosis to allow for viral clearance.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A careful multidisciplinary strategy is required to expeditiously diagnose and treat aggressive cancers of the respiratory tract in patients acutely infected with severe acute respiratory syndrome coronavirus-2 while observing practices to prevent healthcare worker infection during the ongoing coronavirus disease 2019 pandemic.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Fatima</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Graduate School of Medicine, University of Tennessee Health Sciences Center Knoxville, Knoxville, TN, USA. fjwong2181@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doyle-McClam</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Graduate School of Medicine, University of Tennessee Health Sciences Center Knoxville, Knoxville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pugh</LastName><ForeName>Spencer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Graduate School of Medicine, University of Tennessee Health Sciences Center Knoxville, Knoxville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dudney</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Graduate School of Medicine, University of Tennessee Health Sciences Center Knoxville, Knoxville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCormack</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Graduate School of Medicine, University of Tennessee Health Sciences Center Knoxville, Knoxville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kravitz</LastName><ForeName>Jared</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Graduate School of Medicine, University of Tennessee Health Sciences Center Knoxville, Knoxville, TN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Med Case Rep</MedlineTA><NlmUniqueID>101293382</NlmUniqueID><ISSNLinking>1752-1947</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bronchoscopy</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">Cavitary pulmonary lesion</Keyword><Keyword MajorTopicYN="N">Hodgkin lymphoma</Keyword><Keyword MajorTopicYN="N">Percutaneous needle biopsy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>12</Day><Hour>23</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36635758</ArticleId><ArticleId IdType="doi">10.1186/s13256-022-03745-5</ArticleId><ArticleId IdType="pii">10.1186/s13256-022-03745-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chetty R, Slavin JL, O&#x2019;Leary JJ, Ansari NA, Gatter KC. Primary Hodgkin&#x2019;s disease of the lung. Pathology. 1995;27:111&#x2013;4.</Citation></Reference><Reference><Citation>Grunzke M, Hayes K, Bourland W, Garrington T. Diffuse cavitary lung lesions. Pediatr Ragiol. 2010;40:215&#x2013;8.</Citation></Reference><Reference><Citation>Shanbhag S, Ambinder R. Hodgkin Lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21438</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberle FC, Mani H, Jaffe ES. Histopathology of Hodgkin&#x2019;s Lymphoma. Cancer J. 2009;15(2):129&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PPO.0b013e31819e31cf</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Wang Y, Zhao H, Liu S, Li Q, Lin L, Yue Y, Wang X, Zhao Z, Yu Y, Zhang Y. Clinical characteristics of 26 patients with pulmonary extranodal Hodgkin lymphoma. Int J Clin Exp Pathol. 2014;7(8):5045&#x2013;50.</Citation></Reference><Reference><Citation>Wang HW, Balakrishna JP, Pittaluga S, Jaffe ES. Diagnosis of Hodgkin lymphoma in the modern era. Br J Haematol. 2019;184(1):45&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.15614</ArticleId></ArticleIdList></Reference><Reference><Citation>Schild MH, Wong WW, Valdez R, Leis JF. Primary pulmonary classical Hodgkin lymphoma: a case report. J Surg Oncol. 2014;110:341&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jso.23624</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooksley N, Judge DJ, Brown J. Primary pulmonary Hodgkin&#x2019;s lymphoma and a review of the literature since 2006. BMJ Case Rep. 2014;2014:bcr2014204020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2014-204020</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha A, Patti R, Singh P, Solomon W, Kupfer Y. A diagnostic surprise: primary Hodgkin&#x2019;s lymphoma of the lung. J Investig Med High Impact Case Rep. 2017;5(4):2324709617734247.</Citation></Reference><Reference><Citation>Lluch-Garcia R, Gomez AB, Castellano EM, Sanchez-Toril F, Lopez A, Brotons B. Primary pulmonary Hodgkin&#x2019;s lymphoma. Can Respir J. 2010;17(6):e106-108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2010/252746</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzi D, Dini C, Mungai F, Puccini B, Rigacci L, Miele V. Primary pulmonary lymphoma: imaging findings in 30 cases. Radiol Med (Torino). 2019;124:1262&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11547-019-01091-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Binesh F, Halvani H, Taghipour S, Navabii H. Primary pulmonary classic Hodgkin&#x2019;s lymphoma. BMJ Case Rep. 2011. https://doi.org/10.1136/bcr.03.2011.3955 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr.03.2011.3955</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern W, Crepeau A, Jones J. Primary Hodgkin&#x2019;s disease of the lung: report of 4 cases and review of literature. Cancer. 1961;14(6):1151&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0142(196111/12)14:6&lt;1151::AID-CNCR2820140604&gt;3.0.CO;2-1</ArticleId></ArticleIdList></Reference><Reference><Citation>El Hage H, Hossri S, Samra B, El-Sayegh D. Primary pulmonary Hodgkin&#x2019;s lymphoma: a rare etiology of a cavitary lung mass. Cureus. 2017;9(8): e1620.</Citation></Reference><Reference><Citation>Tanveer S, El Damati A, El Baz A, Alsayyah A, ElSharkawy T, Regal M. Primary pulmonary Hodgkin lymphoma. Rare Tumors. 2015;7(4):5968.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/rt.2015.5968</ArticleId></ArticleIdList></Reference><Reference><Citation>Aljehani Y, Al-Saif H, Al-Osail A, Al-Osail E. Multiloculated cavitary primary pulmonary Hodgkin lymphoma: case series. Case Rep Oncol. 2018;11:90&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000486824</ArticleId></ArticleIdList></Reference><Reference><Citation>Soliman M, Neemuchwala F, Sankar A, Jasty R, Rabah R, Popova AP, Newman EA. Multiple cavitary lung lesions in an adolescent: case report of a rare presentation of nodular lymphocyte predominant Hodgkin lymphoma. J Pediatr Hematol Oncol. 2018;40(7):e454-457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPH.0000000000001260</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahidi MM, Shojaee S, Lamb CR, et&#xa0;al. The use of bronchoscopy during the COVID-19 pandemic: CHEST/AABIP guideline and expert panel report. Chest. 2020;158(3):1268&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.04.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchett MA, Oberg CL, Belanger A, De Cardenas J, Cheng G, Nacheli GC, Franco-Paredes C, Singh J, Toth J, Zgoda M, Folch E. Society for advanced bronchoscopy consensus statement and guidelines for bronchoscopy and airway management amid the COVID-19 pandemic. J Thorac Dis. 2020;12(5):1781&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd.2020.04.32</ArticleId></ArticleIdList></Reference><Reference><Citation>Mossa-Basha M, Azadi J, Ko J, Klein J, Meltzer C, RSNA COVID-19 Task Force: Best Practices for Radiology Departments during COVID-19. COVID-19 Task Force: April 27, 2020. rsna.org/COVID-19.</Citation></Reference><Reference><Citation>Singhania N, Bansal S, Nimmatoori DP, Ejaz AA, McCullough PA, Singhania G. Current overview on hypercoagulability in COVID-19. Am J Cardiovasc Drugs. 2020;20(5):393&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40256-020-00431-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: a systematic review of current evidence. Crit Rev Oncol Hematol. 2020;150: 102979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2020.102972</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Chen Y, Peng P, Zhang P, Chu Q, Shen Q, Wang Y, Xu SY, Zhao P, Zhou M. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2020.03.296</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A. Case fatality rate of cancer patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020;10:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-0516</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Shamsi H, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Meyers BM, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID19) pandemic: an international collaborative group. Oncologist. 2020;25:e936&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2020-0213</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Quteimat OM, Amer AM. The impact of the COVID-19 pandemic on cancer patients. Am J Clin Oncol. 2020;43(6):452&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/COC.0000000000000712</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>